Genetics and Etiology of Down Syndrome by unknown
Genetics and Etiology of 
Down Syndrome
Edited by Subrata Dey
Edited by Subrata Dey
Photo by Pixtum / iStock
This book provides a concise yet comprehensive source of current information on 
Down syndrome. Research workers, scientists, medical graduates and paediatricians 
will find it an excellent source for reference and review. This book has been divided 








GENETICS AND ETIOLOGY 
OF DOWN SYNDROME 
 




GENETICS AND ETIOLOGY 
OF DOWN SYNDROME 
 




Genetics and Etiology of Down Syndrome
http://dx.doi.org/10.5772/736
Edited by Subrata Dey
Contributors
Ahmed Khocht, Myungshin Kim, Jong Chul Shin, In Yang Park, Véronique-Aurelie Bricout, Thomas Eggermann, Gesa 
Schwanitz, Carlos Ortez-González, Andrés Nascimento, Subrata Kumar Dey, Sujoy Ghosh, Randall J. Roper, Samantha 
L. Deitz, Joshua D. Blazek, Jeffrey P. Solzak, Radek Vrtel, Radek Vodicka, Jana Bohmova, Romana Kratochvilova, 
Ladislav Dusek, Jiri Santavy, Ishraq Dhaifalah, JJ Domingues-Cruz, Maria Bueno-Delgado, Érika Cristina Pavarino, Bruna 
Lancia Zampieri, Joice Matos Biselli, Eny Maria Goloni Bertollo, George Grouios, Antonia Ypsilanti, Volney Sheen, Jie 
Lu, Takashi Minami, Narihito Seki, Nouval Shahab, Brian R. Wamhoff, Monica Y. Lee, Ksenija Gersak, Maja Pohar-
Perme, Darija Mateja Strah, Pavel V. V. Belichenko, Alexander M. M. Kleschevnikov, Huntington Potter
© The Editor(s) and the Author(s) 2011
The moral rights of the and the author(s) have been asserted.
All rights to the book as a whole are reserved by INTECH. The book as a whole (compilation) cannot be reproduced, 
distributed or used for commercial or non-commercial purposes without INTECH’s written permission.  
Enquiries concerning the use of the book should be directed to INTECH rights and permissions department 
(permissions@intechopen.com).
Violations are liable to prosecution under the governing Copyright Law.
Individual chapters of this publication are distributed under the terms of the Creative Commons Attribution 3.0 
Unported License which permits commercial use, distribution and reproduction of the individual chapters, provided 
the original author(s) and source publication are appropriately acknowledged. If so indicated, certain images may not 
be included under the Creative Commons license. In such cases users will need to obtain permission from the license 
holder to reproduce the material. More details and guidelines concerning content reuse and adaptation can be 
foundat http://www.intechopen.com/copyright-policy.html.
Notice
Statements and opinions expressed in the chapters are these of the individual contributors and not necessarily those 
of the editors or publisher. No responsibility is accepted for the accuracy of information contained in the published 
chapters. The publisher assumes no responsibility for any damage or injury to persons or property arising out of the 
use of any materials, instructions, methods or ideas contained in the book.
First published in Croatia, 2011 by INTECH d.o.o.
eBook (PDF) Published by  IN TECH d.o.o.
Place and year of publication of eBook (PDF): Rijeka, 2019.
IntechOpen is the global imprint of IN TECH d.o.o.
Printed in Croatia
Legal deposit, Croatia: National and University Library in Zagreb
Additional hard and PDF copies can be obtained from orders@intechopen.com
Genetics and Etiology of Down Syndrome
Edited by Subrata Dey
p. cm.
ISBN 978-953-307-631-7
eBook (PDF) ISBN 978-953-51-6460-9
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
4,000+ 




Contributors from top 500 universities








the world’s leading publisher of 
Open Access books




Subrata  Dey was born in India and grew up in the state 
of Assam. He received his Ph.D. from the University 
of Kalyani, West Bengal. He joined the faculty of West 
Bengal University of Technology as Professor of Bio-
technology in 2005. In 2006 he became the Director of 
the   School of Biotechnology and Biological Sciences. 
His laboratory has long been involved in research on 
Genetics of Down syndrome & other congenital disorders, Genetics of 
Alzheimer’s disease, radiation induced genomic instability, radioprotec-
tion by antioxidants & stem cell biology. He has been teaching courses in 
Genetics, Molecular Biology, Evolution & Developmental Biology for more 
than thirty years. Prof. Dey received golden jubilee award of excellence 
from Presidency College (Presidency University), Kolkata, in recognition 
of his contributions to undergraduate and post graduate teaching. He is 
also the founder Director of the Centre for Genetic Counselling. Prof. Dey 
is the author of many scientific papers resulting from research funded by 
University Grants Commission, Council of Scientific & Industrial Research, 












Part 1 Genetics and Etiology 1 
Chapter 1 Genetics of Down Syndrome 3 
Thomas Eggermann and Gesa Schwanitz 
Chapter 2 Etiology of Down Syndrome:  
Risk of Advanced Maternal Age  
and Altered Meiotic Recombination  
for Chromosome 21 Nondisjunction 23 
Subrata Kumar Dey and Sujoy Ghosh 
Chapter 3 Combinatorial Gene Effects  
on the Neural Progenitor Pool  
in Down Syndrome 37 
Jie Lu and Volney Sheen  
Chapter 4 Down Syndrome: A Complex  
and Interactive Genetic Disorder 65 
Samantha L. Deitz, Joshua D. Blazek,  
Jeffrey P. Solzak and Randall J. Roper 
Chapter 5 Abnormal Folate Metabolism  
and Maternal Risk for Down Syndrome 97 
Érika Cristina Pavarino, Bruna Lancia Zampieri, 
Joice Matos Biselli and Eny Maria Goloni Bertollo 
Chapter 6 Down Syndrome Expressed Protein;  
DSCR-1 Deters Cancer and Septic Inflammation 121 
Takashi Minami 
Chapter 7 Down Syndrome and Vascular Disease:  
DSCR1 and NFAT Signaling 137 
Monica Y. Lee and Brian R. Wamhoff 
Contents 
Preface XI 
Part 1 Genetics and Etiology 1 
Chapter 1 Genetics of Down Syndrome 3 
Thomas Eggermann and Gesa Schwanitz 
Chapter 2 Etiology of Down Syndrome: 
Risk of Advanced Maternal Age  
and Altered Meiotic Recombination  
for Chromosome 21 Nondisjunction 23 
Subrata Kumar Dey and Sujoy Ghosh 
Chapter 3 Combinatorial Gene Effects 
on the Neural Progenitor Pool 
in Down Syndrome 37 
Jie Lu and Volney Sheen  
Chapter 4 Down Syndrome: A Complex 
and Interactive Genetic Disorder 65 
Samantha L. Deitz, Joshua D. Blazek,  
Jeffrey P. Solzak and Randall J. Roper 
Chapter 5 Abnormal Folate Metabolism 
and Maternal Risk for Down Syndrome 97 
Érika Cristina Pavarino, Bruna Lancia Zampieri, 
Joice Matos Biselli and Eny Maria Goloni Bertollo 
Chapter 6 Down Syndrome Expressed Protein; 
DSCR-1 Deters Cancer and Septic Inflammation 121 
Takashi Minami 
Chapter 7 Down Syndrome and Vascular Disease: 
DSCR1 and NFAT Signaling 137 
Monica Y. Lee and Brian R. Wamhoff 
X Contents
Part 2 Down Syndrome Models 157 
Chapter 8 Down Syndrome Model of Alzheimer’s Disease: 
Beyond Trisomy 21Nondisjunction 159 
Antoneta Granic and Huntington Potter 
Chapter 9 Deficiency of Adult Neurogenesis 
in the Ts65Dn Mouse Model of Down Syndrome 177 
Pavel V. Belichenko and Alexander M. Kleschevnikov 
Part 3 Neurologic, Urologic, Dental and Allergic Disorders 193 
Chapter 10 Dermatological Manifestations of Down Syndrome 195 
Dominguez-Cruz JJ and Bueno Delgado MA 
Chapter 11 Down Syndrome and Periodontal Disease 209 
Ahmed Khocht 
Chapter 12 Dysfunctional Voiding of Non-Neurogenic 
Neurogenic Bladder: A Urological Disorder 
Associated with Down Syndrome 231 
Narihito Seki and Nouval Shahab 
Chapter 13 Down Syndrome and Epilepsy 241 
A. Nascimento and C. Ortez-González 
Chapter 14 Endocrine and Autonomic Nervous Adaptations 
during Physical Exercise in Down Syndrome 259 
Véronique ~ Aurélie Bricout 
Chapter 15 Language and Visuospatial Abilities in Down Syndrome 
Phenotype: A Cognitive Neuroscience Perspective 275 
George Grouios and Antonia Ypsilanti 
Part 4 Prenatal Diagnosis and Screening 287 
Chapter 16 Prenatal Diagnosis of Down Syndrome 289 
Myungshin Kim, Jong Chul Shin and In Yang Park 
Chapter 17 First Trimester Screening for Trisomy 21 
by Maternal Age, Nuchal Translucency  
and Fetal Nasal Bone in Unselected Pregnancies 301 
Ksenija Gersak, Maja Pohar-Perme and Darija M. Strah 
Chapter 18 Noninvasive Prenatal Nucleic Acid 
Diagnostics of Down Syndrome 313 
Radek Vodicka, Radek Vrtel, Jana Böhmova, Romana  
Kratochvilova, Ladislav Dusek, Ishraq Dhaifalah and Jiri Santavy 
Preface 
This  book provides the recent developments and advances in research on Down 
syndrome. It also  covers a wide range of topics, including investigations on 
neurologic, urologic, dental and allergic disorders in Down syndrome. Chromosomal 
aneuploidy is the leading cause of fetal death in our species and the information about 
chromosomal nondisjunction in man largely comes from studies in trisomy 21 or 
Down syndrome, the most frequent of the autosomal trisomies in liveborns. The cause 
of nondisjunction of chromosome 21 remains largely unknown. Accurate 
investigations on meiotic nondisjunction have been made possible in recent years by 
the development and utilization of microsatellite markers. Although several 
hypotheses have been put forward, it is still unclear as to whether particular gene loci 
on chromosome 21 are sufficient to cause Down syndrome and its associated features. 
For over two decades trisomy 21 has represented a prototype disorder for the study of 
human aneuploidy and copy-number variation, but the genes responsible for most 
Down syndrome phenotypes are still unknown. The genetic mechanism by which 
wide variability in the phenotypes arise is not understood, additional complexity may 
exist due to possible epigenetic changes that may act differently on Down syndrome. 
Consequently, gene-disease links have often been based on indirect evidence from 
cellular or animal models. Numerous mouse models with features reminiscent of those 
seen in individuals with Down syndrome have been produced and studied in some 
depth, and these have added considerable insight into possible genetic mechanisms by 
which trisomy 21 leads to Down syndrome. 
The book is organized into four sections. All sections include chapters on recent 
advances in Down syndrome research.   
Section I deals with our present knowledge on the genetics and etiology of Down 
syndrome. 
Section II discusses the utility of using mouse model for in depth study of Down 
syndrome. Down syndrome could be used as model for understanding the genetics of 
Alzheimer’s disease.  
Section III describes the etiology and clinical aspects of some common disorders of 
Down syndrome patients such as neurologic, urologic, dental and allergic disorders. 
X Preface 
 
Section IV focuses on prenatal diagnosis and screening of Down syndrome. 
This book provides a concise yet comprehensive source of current information on 
Down syndrome. Research workers, scientists, medical graduates and paediatricians 
will find it an excellent source for reference and review. 
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Part 1 
Genetics and Etiology 
 1 
Genetics of Down Syndrome 
Thomas Eggermann1 and Gesa Schwanitz2 
1Institute of Human Genetics, RWTH Aachen 




According to the International System for Human Cytogenetic Nomenclature (ISCN) human 
chromosomes (2n=46) are divided into two groups (Shaffer et al., 2009). These are the two 
sex chromosomes or gonosomes (X,Y) and the 44 non-sex chromosomes or autosomes, 
respectively. Chromosomes of the latter group are numbered as 1 to 22, according to their 
decreasing size. Autosomes in somatic cells are comprised of two homologous, genetically 
identical chromosomes. 
The time of the first conference for nomenclature in 1959 is called the pre-banding area. 
Individual chromosomes could not yet be ascertained beyond reasonable doubt. Thus it 
happened that the second smallest chromosome, chromosome 21, which had been analysed 
three times in the patient’s karyotype, was believed to cause Down Syndrome (DS). Later 
studies showed that DS is trisomic in the smallest chromosome. To avoid conflict between 
previous and subsequent publications, the position of the two smallest chromosomes (21 
and 22) was switched, resulting in the definition of DS as trisomy 21. 
The relative length of chromosome 21 is 1.9 ± 0.17 % of the total length of the human 
genome, and its size is approximately 60 Mb. Chromosome 21 belongs to the acrocentric 
chromosomes, i.e. the centromere is localised closer to the end of the short arm (p). The short 
arm 21p is heterochromatic but consists of different types of repetitive DNA (Figure 
1)(Wyandt and Tonk, 2004). 
The relative length of the short arm of chromosome 21 comprises 30 % of its total length 
(Figure 1). Variants in brilliant fluorescence after QFQ-staining are diagnosed in 2.0 % of band 
p11.2 and 10.0 % of band p13. Duplications in p12 show a frequency of 0.7-1.3 % and 0.1 % in 
the satellites of p13. Deletions in all three regions (p11.2, p12, p13) are rare (Kalz et al., 2004). 
These frequencies are derived from population studies based on Europeans. Significant 
differences in comparison to other ethnic groups have been observed (Kalz et al., 2005). The 
polymorphic regions in the short arm of chromosome 21 allowed the first studies on the 
parental origin of trisomy 21 (Mikkelsen et al., 1980).  
The long arm (q) of chromosome 21 is euchromatic, with the exception of the peri-
centromeric region q11.1 and the distal telomere.  
Chromosomes are usually presented and analysed in the metaphase of mitosis after in vitro 
cultivation, which is not identical to their appearance in vivo. Among the differentiated cells,   
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Fig. 1. Structure and morphology of chromosome 21. Ideogram according to the ISCN 
(Shaffer et al., 2009). 
only some (i.e. T-lymphocytes in a blood sample) can be stimulated in vitro to enter the cell 
cycle again and thus represent a selected cell population. In addition, cells are treated with 
colcemid. This substance arrests the chromosomes in the c-metaphase of mitosis and, at the 
same time, increases the contraction of chromosomes, rendering the centromeres and the 
fissure between the two chromatids visible (Figure 2a).  
1.2 Structure 
The central part of the centromere of chromosome 21 consists of α-satellite DNA that is 
almost identical to the centromere of chromosome 13 (homology 99.7%)(Figure 1). On both 
sides α-satellite DNA is flanked by β-satellite DNA. These two non-coding regions can vary 
significantly in size through duplication or deletion. They are irrelevant for the carrier, 
unless their length is less than 20 % of the average length of the region and thus prevents the 
normal development of the kinetochores. This would result in the failure of exact separation 
of the chromatids in the anaphase of mitosis (Waye et al., 1989; Mitchell et al., 1992).  
Distal of the β-satellite DNA, satellite DNA class III is situated on the short arm (p11.2). 
Significantly varying in size, this band shows a specific absorption of DNA-dyes. Therefore, 
it is defined as a polymorphic region.  It is followed in the short arm by the band p12, which 
is also named the nucleolus organising region (NOR) and contains the ribosomal RNA-
genes. It is characterised by its slightly lateral expansion (satellite stalks). It is polymorphic 
and can be deleted or amplified (Tagarro et al., 1994a). The most distal regions of the short 
arms are the satellites (p13 or s), consisting of Sat I DNA with the telomeres at the ends 
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(Tagarro et al., 1994b). Satellites are also polymorphic varying in size and staining 
characteristics. They also have the ability to duplicate. 
In describing the structure of the short arm of chromosome 21, only the main components of 
the different bands are mentioned. Especially p11.1, p11.2, and p13 contain further 
subgroups of repetitive DNA. 
 
 
a)      b) 
Fig. 2. Routine diagnostic workup for identification of trisomy 21. a) Standard karyotype 
(47,XY,+21) by GTG banding (by kind courtesy of U. Mau-Holzmann, Tübingen). b) 
Interphase FISH showing three signals of chromosome 21 and two of chromosome 13 
(LSI21:21q22.13q22.2; AneuVysion multicolor DNA probe Kit, Vysis). 
According to the literature, the proximal heterochromatic region of the long arm (q11.1) of 
chromosome 21 consists of β-satellite DNA boarding the central α-satellite DNA and 
followed distal by Sat I DNA (Waye et al., 1989; Mitchell et al., 1992; Tagarro et al., 1994a, 
1994b). The main part of the long arm is euchromatic. AT- and GC-rich bands have 
characteristic sequences and can be differentiated by their typical staining features (figure 
1). These bands of single copy DNA are interspersed by non-coding repetitive DNA (SINEs 
and LINEs).  
1.3 Aneuploidy and gene content 
A complete or partially aneuploid chromosome is associated with a pathologic phenotype in 
the carrier, the expression of which depends on the type and amount of the aberrant genetic 
material. 
In contrast to chromosome 22, chromosome 21 consists of a high number of AT sequences 
which contain a smaller amount of vitality-determining genes than the GC-rich ones. 
GC-rich or housekeeping genes are expressed in most cell types. They lead to proteins that 
carry out various metabolic and structural functions. In contrast, the AT-rich genes are 
tissue-specific and are only active in certain cell types while being inactivated in others by 
methylation. This gene inactivation is accompanied by a more condensed structure of the 
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chromatin and, consequently, the DNA of these genes is not accessible to the transcription 
factors. These AT-rich DNA regions show a higher staining intensity and can thus be 
localised by chromosome analysis.  
Because of its high content of AT-rich regions, trisomy 21 is compatible with life, and in the 
majority of cases, leads only to retardation in the development of the carrier and not, as in 
trisomy 22, to lethality.  
The gene map of chromosome 21 was initially constructed by combining the analyses of 
small structural aberrations with the results of different gene product analyses (dosage 
effect). Chromosome 21 was sequenced in 2000 (Hattori et al., 2000), and 225 loci (genes) 
were identified, which was less than expected. This might explain the relatively mild 
phenotype of the carriers.  
In the following years, a high number of small regions in 21q has been analysed in order to 
localise the DS critical region (Figure 3)(Wong, 2011), but recent investigations revealed in 
contrast to the first assumptions that a direct genotype-phenotype correlation does not exist, 
since a large number of gene products from chromosome 21 also influences gene products 
and their function on heterologous chromosomes (Gardner and Sutherland, 2004; 
Weinhaeusel et al., 2011). 
 
 
(AMKL acute megakaryocytic leukemia; TMD transient myeloproliferative disorder; DST duodenal 
stenosis; IA inperforate anus; HSCR Hirschsprung disease) 
Fig. 3. Genotype-phenotype correlation in trisomy 21 based on partial trisomy 21 cases (from 
Korbel et al., 2009). (with kind permission of J.R. Korenberg) 
2. Historic development of the cytogenetics of DS 
DS was the first malformation complex that could be delineated as a chromosome 
abnormality in 1959. This was enabled by the new technology to prepare chromosomes in 
Bayesian Probabilities for Gene Contribution in a set of Segmental Trisomies 
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the metaphase of mitosis. In the early years, mitoses were analysed after direct preparations 
of bone marrow cells and long term cell cultures of tissue biopsies. Starting in 1960, the 
lymphocyte culture of peripheral blood was established. Thereby screening of handicapped 
persons on a large scale became possible. At the beginning of the 1980s, prenatal diagnoses 
were started for high-risk groups. 
Any extension of the spectrum of investigations, any more precise definition of the 
localisation of the aberration and characterisation of the patients´ symptoms were combined 
with an improvement of the investigation methods. 
The direct preparation of meristematic somatic cells was followed by long-term and short-
term cell cultures of differentiated somatic cells removed postpartum, by the culture of 
amniotic fluid specimen and biopsy of chorionic villi, as well as the analysis of germ cells 
and their precursor stages in certain special cases, of polar bodies and early postzygotic 
stages like morula and gastrula in preimplantation diagnostics.  
Initially, the presentation of chromosomes was only possible through homogeneous 
staining, which was succeeded by application of radioactive markers and subsequently of 
the differentiated characterisation of the chromosomal banding patterns (GTG, GAG, QFQ, 
RBG, RBA, CBG, and others). 
Today, a necessary requirement in diagnostic investigations is a high differentiation of the 
euchromatin (usually 550 bands per genome). By that way, structural aberrations of 
chromosome 21 can be safely detected microscopically, starting with a minimal length of 5 
Mb. In the 1980s, fluorescence-in-situ hybridisation (FISH) as a new technique was 
introduced (Figure 2b). By FISH the characterisation of either the entire euchromatin or the 
centromeric areas or selected euchromatic bands with specific DNA-probes became possible. 
Simultaneously, this allowed the analysis of cells in interphase and the rapid investigation 
of larger amounts of cells without cell culture. This so-called rapid aneuploidy testing is 
especially important for prenatal diagnostics. 
Further improvement of the investigation spectrum provided the development of the 
comparative genomic hybridisation (CGH) with the advancement to the microarray, which 
has been depicting an improvement and specification of diagnostics on the molecular-
genetic level through development of specific tiling arrays. 
The newest development is next-generation sequencing. This method is still known to be in 
trial tests, and its establishment in diagnostics is to be expected. 
The various methods of investigation are often combined to improve diagnostics. 
3. Types and frequencies of chromosome 21 aberrations 
In addition to the predominance of standard trisomy 21 as the cause of DS, further types of 
aberrations exist. They differ in relation to the type of abnormality, and they lead to 
different prognoses as to the chances of development of the carrier and recurrence risks for 
the relatives of a carrier. 
Therefore, the indication for a chromosome analysis is always given in the presence of the 
distinct phenotype of DS. 
3.1 Standard trisomy 21 
In this type of aberration, the carrier has 47 chromosomes, including three chromosomes 21. 
It accounts for nearly 90% of DS cases. Standard trisomy 21 typically occurs sporadically, 
therefore the recurrence risk is low.  
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(AMKL acute megakaryocytic leukemia; TMD transient myeloproliferative disorder; DST duodenal 
stenosis; IA inperforate anus; HSCR Hirschsprung disease) 
Fig. 3. Genotype-phenotype correlation in trisomy 21 based on partial trisomy 21 cases (from 
Korbel et al., 2009). (with kind permission of J.R. Korenberg) 
2. Historic development of the cytogenetics of DS 
DS was the first malformation complex that could be delineated as a chromosome 
abnormality in 1959. This was enabled by the new technology to prepare chromosomes in 
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the metaphase of mitosis. In the early years, mitoses were analysed after direct preparations 
of bone marrow cells and long term cell cultures of tissue biopsies. Starting in 1960, the 
lymphocyte culture of peripheral blood was established. Thereby screening of handicapped 
persons on a large scale became possible. At the beginning of the 1980s, prenatal diagnoses 
were started for high-risk groups. 
Any extension of the spectrum of investigations, any more precise definition of the 
localisation of the aberration and characterisation of the patients´ symptoms were combined 
with an improvement of the investigation methods. 
The direct preparation of meristematic somatic cells was followed by long-term and short-
term cell cultures of differentiated somatic cells removed postpartum, by the culture of 
amniotic fluid specimen and biopsy of chorionic villi, as well as the analysis of germ cells 
and their precursor stages in certain special cases, of polar bodies and early postzygotic 
stages like morula and gastrula in preimplantation diagnostics.  
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staining, which was succeeded by application of radioactive markers and subsequently of 
the differentiated characterisation of the chromosomal banding patterns (GTG, GAG, QFQ, 
RBG, RBA, CBG, and others). 
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centromeric areas or selected euchromatic bands with specific DNA-probes became possible. 
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of larger amounts of cells without cell culture. This so-called rapid aneuploidy testing is 
especially important for prenatal diagnostics. 
Further improvement of the investigation spectrum provided the development of the 
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genetic level through development of specific tiling arrays. 
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3.1 Standard trisomy 21 
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therefore the recurrence risk is low.  
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The majority of free trisomy 21 cases (85-90%) originates from errors in maternal meiosis. In 
particular, maternal meiosis I is the most frequently affected stage of nondisjunction (>75%), 
whereas maternal meiosis II errors account for >20%. In 5% of free trisomy 21, paternal 
meiotic errors can be observed, here meiosis II nondisjunction is more frequent than meiosis 
I errors. In addition, postzygotic mitotic errors have also been reported (5%). The 
predominant influence of disturbed maternal meiosis is reflected by the decreased number 
of of chiasmata in meiosis I increasing with maternal age. Indeed, the reason for this 
association is unknown, however numerous hypotheses have been proposed (for review: 
Hultén et al., 2010). 
3.2 Robertsonian translocations 
Trisomy 21 due to an unbalanced translocation of chromosome 21 with a hetero- or 
homologous acrocentric, satellite-bearing chromosome (13, 14, 15, 21, 22) is called a 
Robertsonian translocation. However, the frequency of translocation partners varies and is a 
result of homologies in the heterochromatin of the short arm, thus leading to failures in the 
pairing of meisosis I. The resulting fusion products can be monocentric or dicentric with an 
inactive centromere.  
In monocentric translocation chromosomes, the centromere can derive from each of the two 
partners or can be a hybrid structure originating from both of them. 
Robertsonian translocations involve about 5% of the cases of trisomy 21. Approximately 75% 
are formed de-novo in the carrier , and 25% are familial ( for review: Gardner and Sutherland, 
2004). Among these, translocation 21/21 is an unusual rearrangement, but in the majority of 
cases, it is not a fusion of homologous but the formation of an isochromosome. 
In general rule, carriers of the balanced Robertsonian translocation display only 45 
chromosomes, the unbalanced ones show 46, as in the majority of carriers, and two short-
arm regions are lost. The loss of two NOR-regions does not lead to clinical symptoms in the 
carriers of balanced translocations.  
Among the different heterologous translocations of the acrocentric chromosomes with 
chromosome 21, the combination with chromosome 14 (rob(14q21q)) is the most frequent 
one with about 60%. This is followed by the translocation rob(21q21q) or by the formation of 
isochromosome i(21q21q), respectively, in 35% of the cases. The other translocations are rare 
and do not exceed 5%. (for review: Gardner and Sutherland, 2004) 
Current studies of meiosis are leading to new insights on frequency of formation and 
postzygotic selection of Robertsonian translocations in familial cases. These studies are largely 
based on analyses of translocation rob(14q21q) as the most common subgroup. According to 
these, women with a balanced translocation have an aberrant karyotype in about 20 % of their 
polar bodies as well as in the oocytes and men in 10-15% of their sperms. These frequencies 
decrease postzygotically in the course of the development of the embryo, therefore the risk of a 
child with heterologous translocation trisomy 21 amounts to only 8% if the mother is the 
carrier and to 4 % with the father (for review: Gardner and Sutherland, 2004). 
It is noticeable that in families with translocations, children with a normal phenotype carry a 
balanced translocation more often than the normal karyotype if the origin is maternal 
(60:40), while the ratio is equal with paternal origin (50:50).  
3.3 Reciprocal translocations 
Reciprocal translocations are caused by the exchange of euchromatic regions of chromosome 
21 with the euchromatin of different autosomes or gonosomes. In addition to trisomic 
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regions in various length and location of chromosome 21, unbalanced forms at the same 
time show partial monosomy for the exchanged regions of the second translocation 
chromosome. As a result, the phenotype in the carriers of unbalanced translocations is not 
consistent. 
Caused by the rare occurrence of these translocations, there are no reliable data for their 
incidence, a frequency of less than 1:1000 standard trisomies can be assumed. According to 
the literature, the most common partners for a reciprocal translocation seem to be the 
chromosomes 18 and 22 (Schinzel, 2001). 
3.4 Duplications 
This type of aberration is always formed de-novo in carriers with a noticeable pathologic 
phenotype. If the duplicated segment is only of small size or originated from a 
postzygotic mosaic, the impairment of the carrier may be mild, and he might have an 
almost unrestricted life opening the possibility of inheriting the duplication to his 
offsprings.  
A duplication in the cells of the carrier can be caused by an unequal pairing of homologous 
chromosomes in the pachytene of meiosis I and an aberrant crossing-over as the 
consequence. 
A paracentric inversion in the long arm of a parental chromosome 21 may present an 
increased risk for the formation of a duplication. According to published cases, the size of 
the duplicated region can vary significantly, and so far, no preferential sites for the exchange 
have been documented. With the few existing case reports, no data concerning the 
frequency of duplications can be given. 
3.5 Submicroscopic aberrations 
Investigations with FISH probes and applications of molecular-genetic methods for small 
euchromatic regions enabled the detection of structural aberrations in chromosome 21 in a 
size of less than 5 Mb.  The amount of disorders that can be attributed to small duplications 
and deletions of chromosome 21 therefore has risen significantly within the last years. The 
phenotype of the carriers is predominantly not characteristic for the DS. 
3.6 Gene mutations 
Meanwhile, extensive genotype-phenotype correlations on the basis of structural aberrations 
of chromosome 21 have been reported, which help to narrow down the DS critical regions 
(Figures 3, 4)(for review: Korbel et al., 2009). A small number of genes has been proposed to 
cause the specific DS features, and among them are: DSCR1, DYRK1A or APP (for further 
details see other chapters of this book). 
3.7 Mosaicism 
The frequency of trisomy 21 mosaics after chromosomal analysis is about 3-5 %. This 
number is most likely too small since tissue-specific mosaics cannot always be detected. 
Mosaics always originate from mitotic aberrations during the early postzygotic 
development of the conceptus. Their formation may be caused by an aberrant zygote 
loosing one of the three chromosomes 21 of a standard trisomy in a portion of the cells. 
Alternatively, the zygote can have a normal karyotype, but in a postzygotic mitosis, 
nondisjunction of chromosomes 21 takes place. 
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regions in various length and location of chromosome 21, unbalanced forms at the same 
time show partial monosomy for the exchanged regions of the second translocation 
chromosome. As a result, the phenotype in the carriers of unbalanced translocations is not 
consistent. 
Caused by the rare occurrence of these translocations, there are no reliable data for their 
incidence, a frequency of less than 1:1000 standard trisomies can be assumed. According to 
the literature, the most common partners for a reciprocal translocation seem to be the 
chromosomes 18 and 22 (Schinzel, 2001). 
3.4 Duplications 
This type of aberration is always formed de-novo in carriers with a noticeable pathologic 
phenotype. If the duplicated segment is only of small size or originated from a 
postzygotic mosaic, the impairment of the carrier may be mild, and he might have an 
almost unrestricted life opening the possibility of inheriting the duplication to his 
offsprings.  
A duplication in the cells of the carrier can be caused by an unequal pairing of homologous 
chromosomes in the pachytene of meiosis I and an aberrant crossing-over as the 
consequence. 
A paracentric inversion in the long arm of a parental chromosome 21 may present an 
increased risk for the formation of a duplication. According to published cases, the size of 
the duplicated region can vary significantly, and so far, no preferential sites for the exchange 
have been documented. With the few existing case reports, no data concerning the 
frequency of duplications can be given. 
3.5 Submicroscopic aberrations 
Investigations with FISH probes and applications of molecular-genetic methods for small 
euchromatic regions enabled the detection of structural aberrations in chromosome 21 in a 
size of less than 5 Mb.  The amount of disorders that can be attributed to small duplications 
and deletions of chromosome 21 therefore has risen significantly within the last years. The 
phenotype of the carriers is predominantly not characteristic for the DS. 
3.6 Gene mutations 
Meanwhile, extensive genotype-phenotype correlations on the basis of structural aberrations 
of chromosome 21 have been reported, which help to narrow down the DS critical regions 
(Figures 3, 4)(for review: Korbel et al., 2009). A small number of genes has been proposed to 
cause the specific DS features, and among them are: DSCR1, DYRK1A or APP (for further 
details see other chapters of this book). 
3.7 Mosaicism 
The frequency of trisomy 21 mosaics after chromosomal analysis is about 3-5 %. This 
number is most likely too small since tissue-specific mosaics cannot always be detected. 
Mosaics always originate from mitotic aberrations during the early postzygotic 
development of the conceptus. Their formation may be caused by an aberrant zygote 
loosing one of the three chromosomes 21 of a standard trisomy in a portion of the cells. 
Alternatively, the zygote can have a normal karyotype, but in a postzygotic mitosis, 
nondisjunction of chromosomes 21 takes place. 
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Structural aberrations of chromosome 21 as mosaics are always caused by postzygotic 
rearrangements. Carriers of mosaics with the aberrant cells occuring only in the gonads 
have an increased risk compared to the general population of the same age for the birth of a 
child with the aberration in all cells. 
The risk of mosaic carriers for a retardation or affected offspring can not be specified because 
of the different types of aberrant karyotypes and their unequal distribution in the organism. 
If the percentage of trisomic cells in all somatic tissues is small (0.5 – 5 %), the phenotype of 
the carrier can be normal.  
Carriers with mosaics have a better prognosis than carriers of non-mosaic trisomies, but 
there is always a risk of uneven distribution of pathologic cells in the various tissues. 
Therefore, only the analyses of cells type stemming from different germ layers can lead to a 
reliable prognosis concerning the development of the patient.  
3.8 Tetrasomy 21 
A specific type of hyperploidy 21 is the tetrasomy where the chromosome 21 is present for  
four times. In the literature, only single cases have been published (Gardner and Sutherland, 
2004). This abnormality can either consist of four free chromosomes 21 or of two normal 
chromosomes and in addition an isochromosome 21. The aberration is usually lethal in the 
conceptus in early pregnancy, but a mosaic constitution has been diagnosed in patients 
postnatally. 
4. Techniques for DS testing 
Many different cytogenetic as well as molecular-genetic techniques have been developed in 
the past to detect standard trisomy 21 and structural aberrations of chromosome 21. 
Whereas the “simple” detection of genomic imbalances can be performed with numerous 
molecular techniques (short tandem repeat typing, MLPA, molecular karyotyping), 
information on structural rearrangements is usually up till now achieved by classical 
microscopic methods, e.g. chromosome analysis and FISH. In future the development of high 
resolution next generation sequencing techniques will allow a nearly complete overview on all 
numerical and unbalanced structural rearrangements in one molecular assay. 
4.1 Chromosome analyses 
Chromosome investigation is the conventional cytogenetic method based on cells 
undergoing mitosis to obtain metaphase spreads. The chromosomes can be pre-treated and 
stained according to different protocols to induce specific banding patterns. By karyotyping, 
the specifically banded chromosomes can be arranged into seven groups (A to G) based on 
descending order of size and of the position of the centromere. According to the type of 
induced banding pattern, two subtypes can be defined: a) those resulting in bands 
distributed along the length of the whole chromosome, such as G-, Q- and R-bands, and b) 
those that stain specific chromosome structures (e.g. C-bands, nucleolus organizing regions, 
telomeric bands)(Shaffer et al., 2009). 
The advantage of classical cytogenetics is that both unbalanced as well as balanced 
chromosomal aberrations are detectable. However, the technique is limited by the microscopic 
solution. Therefore, imbalances <5 Mb are not analysable by routine cytogenetics. Another 
disadvantage is that the majority of cell types has  to be cultured in vitro either as a short-term 
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or long-term culture. The long culture times bear the risk of in-vitro chromosomal changes. The 
direct preparation of mitoses is only possible when analysing meristematic cells (bone marrow 
biopsies, trophoblast cells, germ cells and their precursors). This mehtod has the advantage 
that the chromosomal analysis reflects the situation in-vivo. 
Chromosome analyses are mainly done after lymphocyte culture from peripheral blood 
samples. The cells are easily obtained and stimulated to mitosis, and the time of cultivation 
is only 48-72h.  
The chromosomes are arranged in a formal karyotype, according to their size, centromere 
position, and banding pattern (Figure 2a) following the International System for Human 
Cytogenetic Nomenclature (ISCN; Shaffer et al. 2009). 
4.2 Fluorescence-in-situ-hybridization (FISH) 
FISH is a widely used method to analyse different target DNA sequences by supplying specific 
DNA - probes. It combines cytogenetic and molecular genetic techniques. The principle of 
FISH is the interaction of a labelled single-stranded DNA with a denatured metaphase or 
interphase.  
Since a much higher resolution than chromosome analysis, FISH is used to identify and 
characterise small structural chromosome aberrations in clinical cytogenetics, including 
microdeletions and microduplications. A precise and detailed breakpoint analysis is possible. 
However, a FISH investigation is only applicable if the aberration in question is suspected. 
At first this technique was restricted to metaphase analysis, meanwhile, it has gained 
importance in interphase diagnostics as well. In particular the latter procedure is extremely 
helpful to detect low-level mosaicism. Furthermore, it has enabled rapid prenatal testing for 
the frequent aneuploidies in the fetus, including trisomy 21 (for review: Caine et al., 2005). 
4.3 Microsatellite typing 
Short tandem repeat markers (STRs, microsatellites) are highly informative molecular 
markers which are easy to handle. STRs have been described as an abundant class of DNA - 
polymorphisms in the human genome, consisting of highly repetitive short DNA - 
sequences. They can be typed by using PCR and single-copy primers flanking the repeats, 
followed by denaturing on a high resolution gel or by capillary electrophoresis. In 1991, 
Petersen and co-workers were the first to describe the application of these markers in order 
to determine the parental origin of the extra chromosome in families with a trisomy 21 
patient. Meanwhile, numerous studies on the origin of unbalanced chromosomal 
aberrations have been published. 
It is the advantage of microsatellite analysis that it needs only minimal amounts of genomic 
DNA. Furthermore, it is a fast and simple method which is widely established. It is therefore 
not amazing that this technique is one of the most frequently used methods for rapid 
prenatal aneuploidy testing (Mann et al., 2004). It circumvents time-consuming cell 
cultivation and needs approximately 6-8 h from taking the sample to final report. In 
addition, the comparison of the allelic distribution of a fetus and his parents allows the 
exclusion of a maternal contamination in fetal DNA - samples. 
However, the technique does not allow the detection of balanced rearrangements. 
Furthermore, a reduced informativity of microsatellite markers might hamper the 
interpretation. In particular in case of parental consanguinity,  the informativity might be 
reduced. 
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Genetics and Etiology of Down Syndrome 
 
12
4.4 Multiplex Ligation-dependent Probe Amplification (MLPA) 
Multiplex Ligation-dependent Probe Amplification (MLPA) is a simple, high  throughput   
method that allows detection of DNA copy number changes of up to 40 sequences in a 
single reaction. It is based on the semi-quantitative polymerase chain reaction principle and 
can be applied for detecting copy number changes and has been developed by MRC 
Holland (http://www.mlpa.com/). MLPA has rapidly gained acceptance in genetic 
diagnostic laboratories due to its simplicity compared to other methods, its relatively low 
costs, the capacity for high throughput, and its robustness. Typical for the MLPA is that not 
target sequences are amplified but MLPA probes that hybridise to the target sequence. In 
contrast to a standard multiplex PCR, a single pair of PCR primers is used for MLPA 
amplification. The resulting amplification products of an MLPA assay range between 130 
and 480 nucleotides in length and can be analysed by capillary electrophoresis. By 
comparing the peak pattern obtained to that of reference samples it can be delineated which 
sequences have aberrant copy numbers. The MLPA reaction can be divided into five major 
steps: 1) DNA denaturation and hybridisation of MLPA probes; 2) ligation reaction; 3) PCR 
reaction; 4) separation of amplification products by electrophoresis; and 5) data analysis. For 
trisomy 21 and further frequent aneuploidies (trisomies 13 and 18), an aneuploidy MLPA kit 
is commercially available. 
The advantage of MLPA is indeed the low amount of genomic DNA needed for genotyping 
and the fact that that parental samples are not necessary for comparison. However, the 
procedure is time-consuming and needs at least two days. 
4.5 Array analysis 
Molecular karyotyping is meanwhile a well established method to identify genomic 
imbalances. In particular the resolution is much better than that of conventional 
cytogenetics. While chromosome analysis detects imbalances (deletions and duplications) >5 
Mb, array typing has a resolution of <100 kb (figure 4). Microarray analysis allows the 
identification of any type of segmental imbalance by virtue of its design, but it does not 
allow the identification of balanced rearrangements or small mosaics. 
 
 
Fig. 4. Example of Micro-array based characterisation of a partial trisomy 21 in a patient 
affected by Silver-Russell syndrome (Eggermann et al., 2010). The patient did not exhibit 
any symptoms of DS, thus the trisomic region could be excluded to be involved in the 
specific phenotypic expression of DS. 
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As a large number of strategies and platforms are commercially available and cannot be 
covered here, we strongly emphasize checking the updated literature. Dependent on the 
array type, molecular karyotyping allows the detection of imbalances with a size of a few 
kb. And thus the detection rate for chromosomal aberrations in patients with mental 
retardation could be increased impressively (for review: Shaffer and Bejjani, 2010). 
However, the interpretation of microarray data is currently hampered by the large genomic 
instability mainly in non-coding regions, resulting in the analysis of a growing number of 
copy number variations (CNVs).  
Nevertheless, first guidelines for molecular karyotyping have recently been published 
(Vermeesch et al., 2010).  
4.6 Next generation sequencing 
Due to the development of genome-wide sequencing (next generation sequencing) the cheap 
and accurate characterisation of whole genomes in a short time has become possible. Indeed, 
the methods and applications are extremely manifold and can be merely covered in this short 
paragraph (for review: Metzker, 2010). Of course, it is too early to apply this complex 
technology for characterisation of whole chromosome aberrations like trisomy 21. However, 
target assays will be developed, and it has to be considered that next generation sequencing 
will allow to rapidly identify and reliably characterise genomic disturbances – balanced as well 
as unbalanced – and breakpoints in cases of structural rearrangements. 
5. Probability for the birth of a child with DS 
As the clinical symptoms of a child with the phenotype of DS cannot be considered as a 
reliable classification, the diagnosis must always be accompanied by a chromosome analysis. 
The occurrence of trisomy 21 in young mothers lead to screening investigations to ascertain 
whether exogeneous factors might play a role in the aetiology of trisomy 21 besides the well-
known genetic risk factors. 
5.1 Subjects for discussion on exogeneous risk factors 
Different substances known as mutagens, co-mutagens, and teratogens have been 
investigated in detail. 
The atomic bomb blasts in Japan at the end of the World War Two and the explosion of the 
atomic reactor in Chernobyl in 1986 are well-known examples of exposures and have been 
thoroughly explored. However, they did not lead to an increased birth of children with DS 
(Dean et al., 2000).  
Furthermore, neither contact with different organic substances or heavy metals nor an 
increased consumption of caffeine, alcohol, or nicotine could be shown to increase the 
number of births of children with trisomy 21 or other chromosome aberrations. 
5.2 Endogeneous risk factors 
This group encloses carriers of balanced and unbalanced chromosome 21 aberrations and 
includes the risk of advanced maternal age at pregnancy as well. 
5.2.1 Carriers of standard trisomy 21 
Adequate therapy has increased the life expectancy of carriers of trisomy 21 significantly 
within the last decades. Furthermore, a largerly normal life by a specific support of motor and 
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4.4 Multiplex Ligation-dependent Probe Amplification (MLPA) 
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Mb, array typing has a resolution of <100 kb (figure 4). Microarray analysis allows the 
identification of any type of segmental imbalance by virtue of its design, but it does not 
allow the identification of balanced rearrangements or small mosaics. 
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mental abilities has become possible for many DS individuals. This leads to pregnancies in DS 
women and makes adequate genetic counselling necessary. The theoretical risk for a woman 
with trisomy 21 to have a child with trisomy 21 is 50%, but it is reduced by the high amount of 
abortions in early pregnancy. An empirical risk of 30-40% can therefore be delineated. 
However, genetic counselling has also   to take into account the risks of a pregnancy in a DS 
woman suffering from malformations such as heart defects or kidney anomalies. Males with 
a trisomy 21 are usually sterile. 
5.2.2 Recurrence risk in carriers of mosaic trisomy 21 
In mosaic cases, the risk of a female or male in rare cases carrier to have a child with full trisomy 
21 cannot be estimated precisely, because only the amount of trisomic cells in the somatic 
tissues can be analysed but not the one in the gonads. The ratio of trisomic cells may even be 
100% in the ovaries and testes, leading to the same risk factor as in carriers with a full trisomy. 
A special situation is given if the carrier has a normal karyotype in all somatic cells 
investigated, and the trisomic cells are restricted to the gonads (parental germline 
mosaicism). In these cases the empiric recurrence risk is delineated as 1-2%, but in two cases 
of two or more pregnancies with trisomy 21 it is estimated to be much higher (empirical 
value of more than 10%) (Warburton et al., 2001). 
Mosaics are usually found in free trisomy 21 but mosaicism of translocation trisomy 21 has 
also been observed. 
5.2.3 Carriers of a balanced heterologous Robertsonian translocation 
Significant differences concerning risk factors have been observed   for female and male 
carriers of heterologous translocations. In female carriers, the empiric risk of having a child 
with an unbalanced translocation is about 10%, and in males it is only 1-2% (Ferguson-Smith, 
1983; Daniel et al., 1989). In both sexes, the translocations rob(14q21q) and rob(15q21q) harbour 
the additional risk of uniparental disomy 14 or 15 as a consequence of trisomic rescue (Kotzot 
and Utermann, 2005) which is  associated with specific clinical syndromes. 
5.2.4 Robertsonian translocation rob(21q21q) and isochromosome 21 
Balanced carriers of these two types of rearrangements have a risk of 100% that the offspring 
will inherit a translocation trisomy 21, regardless of the sex. 
5.2.5 Parents with a balanced reciprocal translocation 
In the rare group of parents carrying a balanced chromosome rearrangement affecting 
whole or partial 21q, the risk of having a child with a complete or partial trisomy 21 is 
relatively high, with about 20% in females and 10% in males. If the translocation 
chromosomes and their normal homologous show pairing difficulties in meiosis I, the 
additional risk of a 3:1 segregation has to be taken into account, leading to a recurrence risk 
of up to 30%. Offspring with an unbalanced translocation show monosomy of the 
heterologous chromosomal segment, in addition to the complete or partial trisomy 21. As a 
result, the phenotype will be complex and heterogeneous, depending on the origin of the 
second translocation chromosome. 
5.2.6 Parents with normal karyotype having a child with DS 
This is the main group of consultants. The maternal age at pregnancy is significantly 
elevated in the majority of cases, and therefore, an increased risk for elder women can be 
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delineated (risk of 1:1667 at 20 years and 1:32 at 45 years (Morris et al., 2002). There is a 
second slight increase of risk in very young mothers (1:1000 at 15 years). The probability for 
a child with DS is not correlated with paternal age.  
However, in a small cohort of families an age independent high risk for pregnancies with 
different trisomies has been observed (Munné et al., 2004; Baart et al., 2006). 
Molecular investigations made it probable that in these cases the increased aneuploidy rate 
is caused by an autosomal recessive mutation. To identify this group of carriers a thorough 
pedigree analysis is necessary, cytogenetic karyotyping is indicated for the consultants and 
their offspring – children and miscarriages. Failures from pregnancy induction by IVF (in-
vitro fertilisation) have to be included in the risk estimation. These couples are usually 
recommended to a special IVF program for   a further pregnancy, and preimplantation-
testing procedures might be considered (Stumm et al., 2006). 
5.2.7 Siblings and 3rd degree relatives of a patient with DS 
Healthy relatives of a patient with a free trisomy 21 have no increased risk for the birth of a 
child with trisomy 21 when compared to the average population of the same age.  
Relatives of a proband with DS caused by an unbalanced structural rearrangement have an 
increased risk if they are balanced carriers of the translocation (see above). The risk factor 
depends on the type of rearrangement and on the sex of the carrier. 
5.2.8 Prenatal findings of symptoms characteristic for DS detectable by ultrasound 
At the end of the first trimester of pregnancy (10th to 12th week,) ultrasound investigations 
are routinely recommended. At that age, the majority of  fetuses with trisomy 21 show a 
number of characteristic features. These  include nuchal translucency, absence of nasal bone, 
heart defect and growth retardation. In the second trimester, the main symptoms detectable 
by ultrasonography are a flat occiput, a flat profile of the face, small nose, dysmorphic and 
deep seated ears, receding chin and short neck,  malformations of the internal organs, and 
growth retardation. 
These observations by ultrasound are an indication for prenatal chromosome analysis either 
by chorionic villi sampling (CVS) or by amniocentesis (AC). 
5.2.9 Comparison of invasive and non-invasive prenatal investigations 
Non-invasive methods 
The main technique in prenatal diagnostics is ultrasound. In Germany, it is usually applied 
three times during pregnancy. Ultrasound can meanwhile be regarded as a prerequisite for 
CVS, AC, or fetal blood sampling (FBS) since morphologic abnormalities are caused by a 
pathologic karyotype in 20-50% of the cases (personal observation).  
A second group of non-invasive parameters   are specific biochemical factors (AFP, β-HCG, 
estriol) analysed from maternal blood. They are combined with the risk delineated from the 
given maternal age. If the result differs from expectation and corresponds to an increased risk 
for DS, invasive methods to determine the karyotype are applied. 
A third possibility for non-invasive investigations in pregnancy is the analysis of fetal cells 
and fetal DNA in the maternal blood. By   special procedures, fetal DNA can be isolated and 
enriched from maternal blood, however, this method is still under development and is 
currently not applied in routine prenatal testing. 
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Invasive prenatal investigations 
Three different methods are usually applied: CVS in the first trimester, AC in the second, 
and AC, FBS, and placenta biopsy in the third. 
All three methods generally include an investigation risk of about 1%. Therefore, these 
methods should only be applied if the genetic risk is higher than the risk of investigation. 
Sometimes different methods have to be combined to receive a diagnosis. However, this 
increases the time of investigation and prolongs the psychological stress of the parents 
(Geskas et al., 2011).  
Usually, a reliable, final diagnosis can only be achieved by invasive investigations but the 
non-invasive methods enable the investigator to get information of an increased or 
decreased  extent of the pre-existing risk in the individual pregnancy. 
6. Comparison of type and contretype of DS 
As a full monosomy 21 is lethal in life-born children and also exceedingly rare in 
spontaneous abortions, the phenotype of carriers of this aberration is delineated from 
mosaic cases and partial deletions. The clinical findings revealed a number of symptoms, 
especially facial dysmorphic features that can be defined as opposite type  or “contretype”  
to patients with trisomy 21 (Table 1). 
 
Trisomy 21 Partial monosomy 21 
Muscular hypotonia Muscular hypertonia 
Overextension of joints Spasticity 
Hyperflexible fingers Camptodactyly 
Flat occiput Protuberant occiput 
Upslanting palpebral fissures Downslanting palpebral fissures 
Small round ears Large ears 
Aplastic nasal bridge Protuberant nasal bridge 
Table 1. Phenotypes of trisomy and (partial or mosaic) monosomy 21. (Schinzel, 2001) 
7. DS and uniparental disomy 
As trisomic rescue is the most frequent way of uniparental disomy formation, this type of 
cytogenetic aberration has to be discussed in context with trisomy 21. Uniparental disomy 
(UPD) is the inheritance of both homologous of a chromosome pair from only one parent. 
The concept of UPD was first postulated to cause specific phenotypes in the eighties (Engel, 
1980). This hypothesis was then confirmed by UPD of different chromosomes in association 
with typical syndromes. The best examples of this type of aberration are maternal UPD15 
(upd(15)mat) in Prader-Willi and paternal UPD15 (upd(15)pat) in Angelman syndrome.  
Different mechanisms may lead to UPD (Spence et al., 1988): each of them includes at least 
two errors either during meiosis or in postzygotic mitoses. During meiosis, a nondisjunction 
of two homologous chromosomes occurs, which leads to a trisomy in the zygote. In most 
cases, this zygote will not be viable, unless a correction or a “trisomic rescue” happens. 
Statistically, in one third of cases, the chromosome of the parent who did not contribute to 
the trisomy is lost, thus resulting in UPD.  
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A cytogenetic hint for a trisomy rescue is the confined placental mosaicism (CPM), which 
describes the presence of a partial chromosomal aberration (usually a trisomy mosaic) in the 
placenta but not in the fetus. This constitution can be diagnosed in approximately 1-2% of 
chorionic villous samples (Kalousek et al., 1989). CPM can have relevant clinical 
consequences since it may lead to placental insufficiency and then induces intrauterine 
growth retardation.  
Clinical features in context with UPD can be caused by: 
a. hidden chromosomal mosaicism originating by the UPD formation via trisomy rescue; 
b. by the imbalanced expression of imprinted genes in the respective chromosomal region 
resulting in a specific imprinting disorder; 
c. homozygosity for recessive mutations. Interestingly, this phenomenon led to the 
detection of the first case of UPD. Spence et al. (1988) reported a patient suffering from 
cystic fibrosis who was homozygous for the mutation F508del in the CFTR gene. Only 
his mother was a heterozygous carrier for F508del transmitting the mutant gene copy 
twice to her child. Therefore, UPD always involves the usually unpredictable risk for 
homozygosity of mutant genes in addition to imprinted gene effects.  
Due to the frequency of trisomy 21, UPD of this chromosome should be a well-known 
aberration. Indeed, maternal as well as paternal UPD21 (upd(21)mat, upd(21)pat) have been 
reported for several times (for review: Kotzot and Utermann, 2005), including healthy 
carriers. Based on the latter finding, it can be decided that the clinical course of upd(21)mat 
or upd(21)pat carriers is rather caused by a hidden chromosomal mosaicism which can be 
delineated from the UPD formation mechanism or by homozygosity of a recessive allele 
than by the UPD itself. Imprinted genes involved in the aetiology of imprinting disorders 
are not localised on chromosome 21. A different epigenetic effect was shown by recent 
investigations. 
It could be demonstrated that trisomy 21 affects the methylation pattern of different 
heterologous chromosomes by decreasing their extent of methylation (Weinhaeusel et al., 
2011) and thus leas to clinical abnormalitiesof the carrier. 
8. The simultaneous occurrence of trisomy 21 and other chromosomal 
aberrations 
This group of combined aberrations comprises numerical and structural abnormalities which 
present as pathologic karyotype in all cells of an organism or as different types of mosaicism. 
Investigations usually rely on conventional chromosome analyses of spontaneous abortions 
as in this group the frequency among conceptus with pathological karyotype is about 25% 
compared to life-born children with 0.2% (own investigations and findings from the 
literature). 
8.1 Double aneuploidies 
Trisomy 21 can be combined with aneuploidies of different heterologous chromosomes 
(Micale et al., 2010). The maternal age of a pregnancy with a conceptus showing a double 
aneuploidy is on average higher than that with a single trisomy. The life expectance of the 
carrier is lower in prenatal and postnatal period than in single trisomies. Double trisomies of 
autosomes show a higher lethality than combinations of autosomes and gonosomes. 
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carriers. Based on the latter finding, it can be decided that the clinical course of upd(21)mat 
or upd(21)pat carriers is rather caused by a hidden chromosomal mosaicism which can be 
delineated from the UPD formation mechanism or by homozygosity of a recessive allele 
than by the UPD itself. Imprinted genes involved in the aetiology of imprinting disorders 
are not localised on chromosome 21. A different epigenetic effect was shown by recent 
investigations. 
It could be demonstrated that trisomy 21 affects the methylation pattern of different 
heterologous chromosomes by decreasing their extent of methylation (Weinhaeusel et al., 
2011) and thus leas to clinical abnormalitiesof the carrier. 
8. The simultaneous occurrence of trisomy 21 and other chromosomal 
aberrations 
This group of combined aberrations comprises numerical and structural abnormalities which 
present as pathologic karyotype in all cells of an organism or as different types of mosaicism. 
Investigations usually rely on conventional chromosome analyses of spontaneous abortions 
as in this group the frequency among conceptus with pathological karyotype is about 25% 
compared to life-born children with 0.2% (own investigations and findings from the 
literature). 
8.1 Double aneuploidies 
Trisomy 21 can be combined with aneuploidies of different heterologous chromosomes 
(Micale et al., 2010). The maternal age of a pregnancy with a conceptus showing a double 
aneuploidy is on average higher than that with a single trisomy. The life expectance of the 
carrier is lower in prenatal and postnatal period than in single trisomies. Double trisomies of 
autosomes show a higher lethality than combinations of autosomes and gonosomes. 
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8.1.1 Combinations with gonosome aberrations 
Gonosomal aneuploidies in patients with an additional trisomy 21 were diagnosed in the 
four possible combinations with monosomy X, XXY, XYY and XXX. The most frequent 
gonosome aberration in this context is XXY. Monosomy X often presents as mosaic. 
The phenotype of the patients usually corresponds to that of trisomy 21. The reason might 
be the inactivation of more than one X chromsome and the low number of genes on the Y 
chromosome. The combinations of these double aneuploidies are more frequent than the 
total amount of the two single trisomies, or the trisomy combined with that of monosomy X. 
8.1.2 Combinations with heterologous autosome aberrations 
In life-born children, only three combinations of trisomy 21 with additional heterologous 
chromosomes have been observed: +8, +13, +18, and trisomy 8 is always occurring as 
mosaic. The double trisomy 21 and 18 seems to be the most frequent combination with an 
average of 1:1000 among trisomy 21 carriers. The frequency of this combination is much 
higher in spontaneous abortions with about 2.5 in 100 trisomies. This is explained by the 
high and early lethality of conceptus with a double autosomal trisomy. 
Clinical investigations reveal a heterogenous picture: The carrier can show the phenotype of 
one of the 2 trisomies or a combination of both. The majority of double trisomies presents as 
a mosaic with one or two trisomic cell lines. 
8.2 Trisomy 21 in combination with structural aberrations 
The most frequent aberration is a trisomy 21 in combination with a balanced Robertsonian 
translocation rob(13q14q). It has been hypothesized that a familial translocation  rob(13q14q) 
induces frequently errors of pairing of heterologous chromosomes in the prophase of 
meiosis I leading to an aneuploid gamete (interchromosomal effect). Recent investigations 
could not prove this hypothesis. It is nowadays assumed that the reduced fertility of the 
translocation carriers is the reason for pregnancies at increased maternal age, which leads to 
an elevated risk for pregnancies with trisomy 21. 
Further single cases of trisomy 21 combined with structural aberrations comprise 
unbalanced and balanced reciprocal translocations, deletions, and sub-microscopic 
aberrations. 
9. Differential diagnoses 
Carriers of trisomy 21 are characterised by a number of clinical symptoms caused by 
disturbances during early embryonic development. This abnormal course of differentiation 
can also occur in other syndromes based on an aberrant embryogenesis.  
These syndromes can be caused by other chromosome abnormalities, by monogenic 
mutations, and by exogeneous factors or teratogenic agents. 
Chromosome syndromes with a phenotype that, especially in early childhood, resembles 
that of children with trisomy 21 are the two poly-X syndromes, penta-X syndrome in the 
female, and XXXXY in the male.  
A monogenic disease with a phenotype similar to that of trisomy 21 is hypothyroidism. 
The best-known differential diagnosis to trisomy 21 though, is fetal alcohol syndrome. 
The similarity between them is so high and the facial dysmorphic features are so 
characteristic for both that even in the general population the typical phenotype is well-
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known but often misinterpreted. Therefore, it may happen that a child with DS is wrongly 
mistaken as one with fetal alcohol syndrome and which can lead to discrimination of the 
family. 
The possibility that the phenotype of DS may be caused by other diseases than trisomy 21 
makes it necessary for all patients with the clinical diagnosis of DS to be investigated 
cytogenetically because otherwise prognosis, therapy, and estimation of recurrence risk 
might not be correct. 
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1. Introduction 
Down Syndrome (DS) is the most frequent live born aneuploidy and recognizable form of 
mental retardation among all the ethnic groups of human population across the globe. The 
overwhelming majority of this birth defect is caused by trisomy 21 due to nondisjunction 
(NDJ), i.e., failure of chromosomes to separate properly during meiosis at parental 
gametogenesis and the fact was initially reported by Lejeune et al. (1959). Since that time 
attempts were made to explore the etiologic factors that are associated with the underlying 
mechanism of NDJ of chromosome 21(Ch21). Like that of other autosomal aneuploidy, the 
errors during maternal oogenesis accounts for about 90% of DS births (Antonarakis, 1991; 
Freeman et al. 2007), of which majority occurs at first meiotic division(MI) (Antonarakis et 
al. 1992; Yoon et al. 1996). In searching the maternal risk factors for DS birth, researchers 
have identified advanced maternal age (Hassold and Chiu, 1985) and altered meiotic 
recombination (Warren at al. 1987; Sherman et al. 1991) as two strong correlates associated 
with underlying mechanism of Ch21 NDJ in oocyte and the risk factors are preferentially 
present in oocyte due to its mode of development in the lifetime of women.  
The meiosis in fetal ovary initiates at about 11-12 weeks of gestation (Gondos et al. 1986) and 
becomes arrested at late prophase I following pairing, synapsis and recombination. The 
process resumes at the onset of puberty after the follicle receives proper hormonal signal 
and immediately completes the MI and progress through metaphase of meiosis II (MII) 
where it pauses until it is fertilized and the meiosis is then completed. Thus the individual 
oocyte remains arrested in prophase I for 10 to 50 years, depending on the time of ovulation 
in reproductive life. This protracted event of oocyte growth includes three distinct error 
prone phases (Hassold et al., 2007). First, the prophase event in fetal ovary, at which change 
in usual pattern of recombination might lead to subsequent aneuploid oocyte formation. 
The second risk prone phase is the follicular growth during which the meiosis remains 
arrested and the genetic and environmental challenges get chance to accumulate in ovarian 
milieu. The third and the final risk phase is the maturation of oocyte which is associated 
with the adverse effect of advancing maternal age on protein components involved in 
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chromosome separation system and rapidly deteriorating endocrine environments. In 
contrast, spermatogenesis begins at puberty and spermatogonial cells complete both MI and 
MII without any delay (Sherman et al. 2007). 
As mentioned earlier, the overwhelming majority of Ch21 NDJ is maternal in origin among 
all the ethnic varieties of human population studied to date. Based on results from the US 
(Allen et al. 2009) and other population-based studies (Mikkelsen et al., 1995; Gomez et al., 
2000), it has now been estimated that over 90% of NDJ errors leading to trisomy 21 arise in 
the oocyte and the majority of those occur at MI.  
We carried out similar study on Indian trisomy 21 samples, particularly from eastern part 
of the country and obtained strong replication of those observations (Table 1). This study 
was started from the year 2001 and till date we included about 400 families having free 
trisomy21 child. Our STR(short tandem repeat)-PCR analyses estimated over 88% maternal 
errors with majority of cases (~77%) having NDJ events at MI. The paternal errors account   
for about 10 % with almost equal distribution of MI and MII NDJ events. The post zygotic 
mitotic error was estimated about 2%. Very concordant results were also reported for 
Ukraine and Russian cohorts (Machatkova et al. 2005), and Spanish cohort (Gomez et al. 
2000).  Little difference among these datasets that does exist is probably due to sampling 
variation. In this article we discuss the maternal stress factors responsible for the origin of 
nondisjunction. 
2. Effect of advanced maternal age 
The effect of ‘maternal age’ remains as ‘black-box’ for DS birth. Initially Penrose identified 
that advanced maternal age as risk for DS birth (Penrose 1933, 1934) and postulated that the 
maternal age dependent increase in birth rate of DS is in some way associated with the NDJ 
mechanism. But this effect is restricted only to NDJ that occur in the oocyte (Antonarakis et 
al., 1992; Ballesta et al., 1999; Muller et al., 2000; Sherman et al., 2005). That is, adverse effect 
of advanced maternal age is not evident among mothers whose offspring received an extra 
copy of chromosome 21 as a result of: (1) a NDJ error in spermatogenesis i.e., paternal errors 
(Yoon et al., 1996; Sherman et al., 2005), (2) a post zygotic mitotic error (Antonarakis et al., 
1993; Sherman et al., 2005), or (3) a translocation (inherited or de novo) (Hook, 1983).  
The results of earlier studies (Antonarakis et al. 1992; Ballesta et al. 1999; Muller et al. 2000), 
revealed that the average age of mother at the time of conception of a fetus with DS is 
significantly higher than that of mothers with normal euploid baby. This observation was 
confirmed further in the population based study in the Atlanta Down syndrome project 
(Allen et al. 2009) for US population and recently by us (Ghosh et al. 2010a) for Indian 
population. All these reports suggest that the advanced maternal age is risk factor for both 
the MI and MII errors and both  types of error are potentially related in respect to their 
association with risk factors. Further, Atlanta Down syndrome project suggests (Allen et al. 
2009) that maternal age specific incidence rate for live birth with free trisomy 21 may differ 
between MI and MII errors: the increasing risk for MII errors is shifted to the older maternal 
ages compared with MI errors. Interestingly, the women with MII errors are in average 
older than mothers with MI errors, as evident in both US (Allen et al. 2009) and Indian 
cohorts (Table 1). All these observations led the workers to propose several hypotheses to 
explain the intriguing association between advanced maternal age and an increasing chance 
of Ch21 nondisjunction. 
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Table 1. Origin of Trisomy 21 in Indian Cohort and Parental Age at conception of Trisomy 
Foetus 
3. Biological aging hypothesis 
The hypothesis was originally proposed by Brook et al (1984). The central idea of this 
hypothesis is that the increasing rate of meiotic errors and subsequent aneuploid birth is 
related to ‘biological aging’ of ovary not to the chronological age of women. Two different 
views do exist about how the biological aging is implicated for increased incidence of 
trisomic birth. The first view relates the suboptimal level of hormonal signal with higher 
rate of meiotic errors in aging ovary. The number of antral follicle at various stages of 
development also declines with increasing maternal age as the fact has been confirmed in 
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several studies (Reuss et al. 1996; Gougeon 1998; Scheffer et al. 1999; Kline et al. 2004). This 
decline in antral follicle count, together with the accompanying decrease in total oocyte pool 
generates an imbalance in the hormonal environment in ovary (Warburton, 2005) which 
predisposes the women for aneuploid conception. Support to this postulate came from the 
studies on human and mouse (Freeman et al., 2000; Roberts et al. 2005). Alternate to this 
concept has been proposed by Warburton (1989) in her “limited oocyte pool” hypothesis 
which suggests a more direct effect of antral oocyte pool size on the risk of aneuploidy. 
Among older women available antral follicles are limited and ovary has to compromise in 
selecting a suboptimal or erroneous oocyte for ovulation.  
The ‘biological aging’ can also be interpreted in term of senescence associated degradation 
of ovarian protein components that are implicated in chromosome separation system in 
oocyte (Sherman 2005).  Interestingly, level of hundred of transcripts, including cell cycle 
genes have been reported to decrease with increased maternal age in mice and women 
(Hamatani et al., 2004; Steuerwald et al., 2007). 
4. Genetic aging hypothesis 
We proposed ‘genetic aging’ hypothesis (Ghosh et al. 2010b), which states that some of the 
mothers who have DS baby are genetically older than the mothers of same chronological age 
who have euploid  baby (Ghosh et al. 2010b) and this genetic aging is the underlying cause 
of biological aging in ovary. In this analyses we estimated the telomere length (TL) of age 
matched controls and cases to get insight into the state of molecular aging, stratifying the 
mothers by stage of NDJ and their age of conception (young ,<29 years; middle ,29-35 years; 
and old ,>35 years). Our results showed that all three groups(M1,MII & control) have similar 
TL on average for younger mothers. As age increases, all groups show telomere loss, but 
that loss is largest in the meiosis II mother group and smallest in the euploid mother group 
with the meiosis I mother group in the middle(Figure 1). Our results do not support the 
theory that younger women who have babies with Down syndrome do so because they are 
‘genetically older’ than their chronological age, but we proposed that older mothers who have 
DS baby are “genetically older” than controls, who have euploid babies at the same age. This 
finding, however, is consistent with the previous result (Dorland et al. 1998), showing no 
difference in genetic age among young DS mothers and young controls. 
The fact of telomere shortening among women with DS child can be explained in several 
ways. Apparently, the result suggests a possible functional link between telomere 
maintenance system and chromosome segregating apparatus at molecular level. 
Degradation of this possible ‘molecular link’ with age may affect the both system 
simultaneously. In this regard BubR1 is most promising candidate as mutation in this gene 
causes rapid senescence and high rate of aneuploidy in mouse (Baker et al., 2004) and the 
protein shows rapid fall with age. Alternatively, the environmental factor that induces rapid 
telomere loss at advanced reproductive age might simultaneously affect the chromosome 
separation system in oocyte. (Chen et al.,2007; Sebastián et al., 2009; Eichenlaub-Ritter et al,. 
2007; Susiarjo et al., 2007).   
5. Reduced meiotic recombination and its interaction with maternal age 
Aside from maternal age, only single factor that has been identified unambiguously to be 
associated with maternal NDJ is altered pattern of meiotic recombination. The first evidence 
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for association of reduced recombination with the events of NDJ of Ch21 was provided by 
Warren et al. (1987). Chiasmata are physical connections between homologous 
chromosomes at the site of recombination and they function to stabilize the paired 
homologues or tetrad at MI along with sister chromatids and centromere cohesion. It aids in 
proper chromosome orientation on the meiotic spindle (Carpenter 1994) and ensure their 
proper segregation to opposite poles. Absence of chiasma formation left the homologous 
pair free to drift randomly to the poles and if they move together to same pole aneuploidy 
results. As far as chromosome 21 NDJ is concerned, achiasmate meiosis is the major cause of 
reduction in recombination frequency (Lamb et al., 2005a, 2005b), although fall in double 
exchange frequency was reported too (Hawley et al. 1994).  
In our analysis of etiology of DS birth in Indian cohort, we recorded only ~22% detectable 
crossover on MI nondisjoined chromosome in maternal meiosis (Ghosh et al., 2009). This 
observation was very consistent with the previous observation by Sherman et al. (2007), who 
reported 45% achiasmate meiosis associated with MI NDJ of Ch 21 in US population.  
Sherman and her co-workers constructed the linkage map of nondisjoined Ch21 (1994) and 
estimated 55% reduction in map length than the control CEPH map (39.4cM in contrast to 
72.1cM). With similar approach for Indian DS population (Ghosh et al. 2010a), we scored 
30.8cM map length of  maternal MI nondisjoined Ch 21, which further confirmed the fact 
that reduced recombination due to absence of chiasma or less recombination frequency in 
some way increases the risk of  NDJ. 
In elucidation of the relationship between reduced recombination and maternal age, 
Sherman et al. (1994) hypothesized that the trisomy 21 conception at advanced maternal age 
is strongly associated with reduction in recombination frequency. The authors estimated 
shorter map length of Ch21 for mothers of >35 years with their linkage analysis approach. 
Very recently, Oliver et al. (2008) also reported a highest occurrence of non-exchange Ch21 
pair among the old age (>34 years) women in compare to young (<29 yrs) and middle (29-35 
yrs.), although the frequency of non-exchange tetrads remain most frequent among all the 
risk factors when only young mothers (<29 years) were considered. The authors proposed a 
model for explaining the risk of Ch21 NDJ in relation to maternal age categories. Among the 
young mothers risks related to aging is minimum and therefore absence of recombination 
becomes the predominant cause of NDJ in total risk scenario. If this remains true, then lack 
of recombination is an age-independent risk factor for Ch21 NDJ. This hypothesis was 
supported by our previous studies (Ghosh et al. 2009; 2010a) in which we estimated about 
80% of younger mothers with achiasmate Ch21 who had NDJ at MI.  
The highest frequency of non-exchange Ch 21 among older mothers is difficult to explain as 
the events of chiasma formation and recombination take place in foetal ovary. The fact led 
workers (Oliver et al. 2008; Ghosh et al. 2009) to speculate presence of maternal age 
dependent NDJ mechanism which gains support from the studies on model organisms. 
Mutation in the gene nod (no distributive disjunction) in Drosphila causes high frequency of 
NDJ of non-exchange chromosome (Knowles and Hawley, 1991) and it suggests existence of 
the genetic component that acts as surveillance system to ensure proper segregation of non-
exchange meiotic chromosomes. Presence of such ‘back-up system’ is also evident in yeast in 
which, the gene Mad3 performs the same function (Gillett et al. 2004). Interestingly, proteins 
with similar function in human have been shown to be down regulated with increasing 
ovarian age (Baker et al. 2004; Steuerwald et al. 2001). Thus, age-dependent down-regulation 
of these essential proteins may lead to the decreased ability to segregate properly the non-
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exchange chromosomes in aging oocyte. However, more direct evidence is needed to 
establish this speculation as fact.   
6. Susceptible chiasma formation and its interaction with maternal age 
Aside reduced recombination, unusual chiasma placement is another risk for Ch21 NDJ. 
Chiasma formation usually takes place at the middle of normally disjoining chromosomes 
(Lynn et al. 2000). This medially placed chiasma probably maintains the proper balance by 
counteracting the pull from opposite poles which is needed for proper segregation of 
chromosomes. But a chiasma  close to centromere or close to telomere seems to confer 
instability and makes the Ch21 susceptible for random segregation and subsequent NDJ 
(Lamb et al. 1996; 2005a, 2005b). The increased risk of NDJ due to sub-optimally placed 
chiasma on the chromosome is also evident in model organisms such as Drosophila (Rasooly 
et al.1991; Moore et al. 1994; Koehler et al. 1996a), yeast (Sears et al. 1995;Krawchuk and 
Wahls,1999) and Caenorhabditis elegans (Zetka and Rose, 1995). The study of Lamb et al. 
(1996), suggested for the first time that a single telomeric chiasma is a risk for 
malsegregation of Ch21 at MI in oocyte in contrast to single pericentromeric chiasma which 
increases risk of MII NDJ.  
Very recently, Oliver et al.(2008) and we (Ghosh et al.2009) independently conducted 
population based studies on US and Indian DS populations respectively to get an insight 
into the interaction between susceptible chiasma configuration on Ch21 in oocyte and 
maternal age. In doing so we used family linkage approach to detect exchange pattern on 
nondisjoined Ch21, using set of microsatellite markers and all the analyses were done by 
stratifying the participating mothers into three age groups:young (>29 yrs.), middle (29-34 
yrs) and old (>34 yrs). Surprisingly, the two sets (US set and Indian set) of results were very 
concordant and revealed that single telomeric exchange is prevalent among younger 
mothers whose Ch21 nondisjoined at MI. In contrary, single centromeric chiasma is risk for 
MII NDJ, particularly at older age. For Indian DS sample, we recorded susceptible single 
chiasma within the 3.1Mb peri-telomeric and 4Mb peri-centromeric segment of 21q for MI 
younger and MII older categories, respectively (unpublished data). These observations led 
us (Oliver et al. 2008; Ghosh et al. 2009) to propose a hypothesis which states that maternal 
age independent risk factor is one which affects all the age groups equally and be detected 
in highest frequency among younger mothers for whom aging related risk factors are 
minimum. Alternately, age-dependent risk factors usually intensify with advancing age and 
so one would expect highest frequency of such factors among older age group (Figure 2). If 
our prediction is true, the telomeric single chiasma is maternal age independent risk, 
whereas, the single peri-centromeric chiasma is maternal age dependent factor. 
The relationship between centromeric exchange and advancing maternal age can be 
interpreted in two different ways: 1) pericentromeric exchange set up a sub-optimal 
configuration that initiates or exacerbates the susceptibility to maternal age-related risk 
factors, or 2) a pericentromeric exchange protect the bivalent against age related risk factor 
allowing proper segregation of homologues, but not the sister chromatids at MII (Oliver et 
al., 2008). A chiasma very close to centromere may cause ‘chromosomal entanglement’ at 
MI, with the bivalent being unable to separate, passing intact to MII metaphase plate (Lamb 
et al.1996). Upon MII division, the bivalent divides reductionally, resulting in disomic 
gamete with identical centromeres. In this manner, proximal pericentromeric exchange, 
which occurred during MI, is resolved and visualized as MII error. According to an 
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alternate model, studied in Drosophila (Koehler et al. 1996b), proximal chiasma lead to 
premature sister chromatid separation just prior to anaphase I. Resolution of chiasma 
requires the release of sister chromatid cohesion distal to the site of exchange (Hawley et al., 
1994). Attempt to resolve chiasmata that are very near to centromere could result in 
premature separation of chromatids. If  the sister  chromatids  migrate to a common pole at 
MI, they have 50% probability to move randomly into the same pole  at MII, resulting in an 
apparent MII NDJ. Similar observation is evident in yeast in which centromere-proximal 
crossover promotes local loss of sister-chromatid cohesion (Rockmill et al., 2006). One of the 
members of centromeric cohesion complex shugoshin, when down regulated due to aging 
shows high frequency of MII NDJ of bivalent with peri-centromeric exchange (Marston et al. 
2004). Alternatively, a pericentromeric exchange may protect the bivalent from maternal age 
related risk factors. The effect of degradation of centromere or sister chromatid cohesion 
complexes or of spindle proteins with age of oocyte may lead to premature sister chromatid 
separation. Perhaps the pericentromeric exchanges help to stabilize the compromised tetrad 
through MI. This would lead to an enrichment of MII errors among the older oocytes. 
Although there is no specific model system in favor of this mechanism, but some findings in 






























Fig. 1. Telomere length (Kbp) among control and meiotic outcome groups stratified by age 
categories. 
A telomeric chiasma imparts its susceptibility for MI NDJ probably due to recruitment of 
minimal amount of sister chromatid cohesion complex remaining distal to the exchange 
event (Orr-Weaver, 1996). Specifically, when the exchange is too far from kinetochore, this 
could prevent the bi-orientation of the homologues on the meiotic spindle (Nicklas 1974; 
Hawley et al.1994; Koehler et al.1996b). Alternatively, the integrity of chiasma may be 
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compromised when a minimum amount of cohesin remains to hold homologue together. 
Thus bivalent may act as pair of functional univalents during MI, as has been evident in 
human oocyte (Angell 1994, 1995). 
 
 
Fig. 2. Risk factor model for Down syndrome birth showing consistent presence of maternal 
age independent risk factors (Age Indepnt) among all the ages and gradual increased 
incidence of age dependent risk factors (Age Depnt) with increasing age. 
Further, we evaluated the interaction between maternal age and multiple chiasmata on MI 
nondisjoined Ch21 and found that there is a linear increase in multiple chiasama frequency 
with advancing age (Ghosh et al.2010a). Interestingly, similar trend is also evident for 
chromosome 15, 18 and X chromosome (Robinson et al. 1998; Thomas et al. 2001; Bugge et 
al.1998). This finding suggests two important possibilities. The first one is that the multiple 
chiasmata might be protective and chromosomes with multiple recombinants probably 
more resistant to NDJ at least at MI because of an increase in bivalent stability. Secondly, 
instead of enjoying multiple recombinations some bivalents segregate improperly, 
particularly in older oocyte, which suggests presence of some aging associated factors that 
impart risk to these otherwise recombination perfect chromosomes.  
7. Summary and conclusion 
We have paved half of a century after the initial discovery of cause of DS, but we are still in 
dark regarding etiology of DS. Although advanced maternal age has been identified 
unambiguously as risk, its molecular relation with chromosome separation  system  is 
enigmatic. It is still elusive whether or not some women are genetically predisposed to 
altered meiotic recombination and subsequent chromosomal NDJ. Very recently, the gene 
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PRDM9 has drawn the interest. The gene controls the recombination hotspot of meiotic 
homologues (Parvanov et al. 2010). The variant of this gene has been reported to make the 
women susceptible for recurrent miscarriages, infertility and aneuploid pregnancy (Cheung 
et al. 2010). So PRDM9 is prospective candidate gene whose altered functional state might 
increase susceptibility of Ch21 NDJ. Similarly, genetic variant of any component of meiotic 
chromosome separation system could increase the risk  for chromosome missegregation in 
oocyte.   Intuitively, the gene BubR1 is of special interest as it is a member of centromere 
cohesion complex and also known for its role in cellular aging (Baker et al. 2004). In 
Drosophila hypomorphic bubR1 causes high rate of NDJ at MII due to premature sister 
chromatid separation and these nondisjoined chromosome exhibited centromeric exchange. 
All these findings suggest the possibility of BubR1 to be a ‘missing link’ between the 
molecular mechanism of cellular aging and higher incidence of chromosomal NDJ at 
advanced age.  
The effect of environmental agents on chromosome segregation, particularly in connection 
with maternal age and recombination remains unexplored. As environmental aneugens 
have great opportunity to become accumulated within the ovarian microenvironment 
during protracted oocyte growth phase, their probable effects cannot be underestimated. 
Although epidemiologic association of some environmental agents with DS birth have been 
identified, their influence on meiotic recombination and aging is intriguing. The 
periconceptional smoking and contraceptive use have been identified as potential risk for 
Ch21 NDJ (Yang et al. 1999), but this observation needs further confirmation. We conducted 
an epidemiological study on the risk of chewing tobacco and contraceptive use among 
mothers having DS baby and found some association of chewing tobacco with MI NDJ and 
contraceptive for both MII and MI (unpublished data). Moreover, the fetal incidence of 
chiasma formation and recombination make us curious to the probable ‘grand maternal’ 
influence on DS birth. Presently we are in position to realize at least that the risk factors 
associated with DS birth is multidimensional and several mechanisms are involved for 
chromosome 21 NDJ in women. At this point, it is worth mentioning that the etiology of  
maternal Ch21 NDJ and subsequent DS birth may be similar across the human population 
divides irrespective of ethnic and socio-cultural differences. The future investigations 
should be focused to resolve all these pending issues so that we could move towards 
complete understanding of risk factors associated with DS birth. 
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1. Introduction 
Down syndrome (DS) arises from triplication of genes on chromosome 21 (HSA21) and is 
characterized by neurological complications including cognitive dysfunction, epilepsy, and 
early onset Alzheimer’s disease (AD). At the histological and cellular level, DS brains show 
prolongation in the cell cycle length of neural progenitors, increased oxidative stress, and 
mitochondrial dysfunction. These pathological processes likely contribute to the observed 
decrease in neurogenesis, increased neuronal cell death, enhanced gliosis in the cortex, and a 
corresponding decrease in both neuronal glutamatergic and GABAergic expression. 
With recent advances in molecular biology and human genetics, many HSA21 genes have 
been identified, putative functions assigned to these genes and network analyses used to 
predict interconnecting, functional gene pathways. Interactions at this level are further 
complicated by gene regulatory mechanisms such as DNA methylation, histone acetylation 
and microRNA. In this respect, the neurological phenotypes seen in DS are not merely due 
to genomic imbalance from triplication of HSA21 genes, but also additive effects due to 
influences on associated genes within a given network or pathway and modification of gene 
expression due to epigenetic factors. 
The development of stem cell technologies has provided the opportunity to isolate human 
neural progenitors (HNPs) and induced pluripotent stem cells (iPS) from patients with 
known neurological disorders. These reagents are also used as tools to study molecular 
mechanisms and pharmacological therapies in various human diseases. They provide a 
means by which an understanding is established for interactions between various genes 
causal for a human disorder, especially in contiguous gene syndromes that are difficult to 
faithfully replicate in animal models. We have focused on the study of DS HNPs in relation 
to neurological phenotypes in the early onset of DS in these individuals. 
In the current review, we summarize the approaches taken, recent progress and insights 
gained from studies of DS during neural development, incorporating insights gained from 
the use of human DS neural progenitors.  
2. Down syndrome phenotype and genotype during neurodevelopment 
The most prominent neurological phenotypes in DS include mental retardation (MR), 
epilepsy, and dementia (early onset AD). Individuals with DS generally have mild to 
moderate MR with average intelligence quotient (IQ) among children at 50, as compared 
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with normal children at an IQ of 100. Children with DS generally exhibit better visual motor 
skills (such as drawing) than auditory and linguistic skills, which typically lead to a delay in 
language skill development. MR can also be accompanied by behavioural issues such as 
attention-deficit disorder (sometimes with hyperactivity) and autistic behaviour, especially 
in those with severe intellectual disability. The onset of seizures tends to occur in a bimodal 
distribution. At early ages, individuals with DS are susceptible to infantile spasms and tonic 
clonic seizures with myoclonus. These epilepsies are associated with MR and likely due to 
early impairments in brain development. Individuals with DS in the third decade of life are 
more prone to developing simple partial or complex partial seizures in addition to tonic-
clonic seizures. These focal epilepsies are likely associated with the increasing burden of 
parenchymal damage sustained from the progressive neuronal degeneration. It is estimated 
that 46% of Down's patients over the age of 50 have a diagnosis of epilepsy. Finally, AD is 
generally considered a neurodegenerative disorder that affects the elderly at 60 years of age 
and over. Premature AD is seen in DS in the early 40s (Arya et al., 2011; Contestabile et al., 
2010; Lott and Dierssen, 2010; Menendez, 2005) 
The clinical phenotypes in DS correlate with functional changes seen at the histological and 
cellular levels in DS brain. DS cortex shows increased simplified gyral patterning and 
delayed myelination (Banik et al., 1975; Cragg, 1975; Koo et al., 1992; Wisniewski, 1990; 
Wisniewski and Schmidt-Sidor, 1989). Neuronal loss has been seen in DS brain both during 
development, following differentiation and aging (Becker et al., 1991; Benda, 1947; Colon, 
1972; Davidoff, 1928; Golden and Hyman, 1994; Guidi et al., 2008; Ross et al., 1984; 
Wisniewski et al., 1984). Histological evidence of neurofibrillary plaques and tangles can be 
seen in the DS brain, consistent with the premature onset of AD (Motte and Williams, 1989). 
Changes in dendritic branching as well as neurotransmitter levels have also been reported 
in the DS brain tissue and likely correlate with the behavioural and cognitive difficulties 
seen in these individuals (Reynolds and Warner, 1988; Ross et al., 1984). At the cellular level, 
DS progenitors have prolonged cell cycle lengths, thereby impairing neurogenesis 
(Chakrabarti et al., 2007; Contestabile et al., 2007; Guidi et al., 2008). Neuronal numbers 
further decline presumably through increased levels of reactive oxygen  species (ROS), 
mitochondrial dysfunction and increased cell death in mature neurons (Busciglio et al., 2002; 
Guidi et al., 2008; Seidl et al., 2001). Following differentiation, neurons also show an 
imbalance of excitatory-inhibitory neurotransmission (Bhattacharyya et al., 2009), with 
reduced dendritic branching and spine density (Benavides-Piccione et al., 2004). Overall, 
these changes could all contribute to the MR, epilepsy and AD phenotypes seen in DS.  
Various neurological features in DS have been attributed to over-expression of individual 
genes on HSA21, and several of these genes might contribute to a final common pathway. For 
example, APP has been shown to promote neuronal degeneration and oxidative stress. Similar 
functions have been implicated in other HSA21 genes including BACH1, SOD1, and S100B, 
raising a possible role in AD.  Other HSA21 genes (TIAM1, SYNJ1, ITSN1, DSCR1) have been 
associated with synaptic dysfunction (suggestive of a pathological role in MR and epilepsy). 
Individual HSA21 genes with proposed neurological functions are summarized in Table 1. 
3. Identification of genes and pathways responsible for AD or MR 
Although HSA21 is a relatively small chromosome and single candidate genes have been 
shown to mimic certain DS features, the combinatorial effects of contiguous genes on  
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with normal children at an IQ of 100. Children with DS generally exhibit better visual motor 
skills (such as drawing) than auditory and linguistic skills, which typically lead to a delay in 
language skill development. MR can also be accompanied by behavioural issues such as 
attention-deficit disorder (sometimes with hyperactivity) and autistic behaviour, especially 
in those with severe intellectual disability. The onset of seizures tends to occur in a bimodal 
distribution. At early ages, individuals with DS are susceptible to infantile spasms and tonic 
clonic seizures with myoclonus. These epilepsies are associated with MR and likely due to 
early impairments in brain development. Individuals with DS in the third decade of life are 
more prone to developing simple partial or complex partial seizures in addition to tonic-
clonic seizures. These focal epilepsies are likely associated with the increasing burden of 
parenchymal damage sustained from the progressive neuronal degeneration. It is estimated 
that 46% of Down's patients over the age of 50 have a diagnosis of epilepsy. Finally, AD is 
generally considered a neurodegenerative disorder that affects the elderly at 60 years of age 
and over. Premature AD is seen in DS in the early 40s (Arya et al., 2011; Contestabile et al., 
2010; Lott and Dierssen, 2010; Menendez, 2005) 
The clinical phenotypes in DS correlate with functional changes seen at the histological and 
cellular levels in DS brain. DS cortex shows increased simplified gyral patterning and 
delayed myelination (Banik et al., 1975; Cragg, 1975; Koo et al., 1992; Wisniewski, 1990; 
Wisniewski and Schmidt-Sidor, 1989). Neuronal loss has been seen in DS brain both during 
development, following differentiation and aging (Becker et al., 1991; Benda, 1947; Colon, 
1972; Davidoff, 1928; Golden and Hyman, 1994; Guidi et al., 2008; Ross et al., 1984; 
Wisniewski et al., 1984). Histological evidence of neurofibrillary plaques and tangles can be 
seen in the DS brain, consistent with the premature onset of AD (Motte and Williams, 1989). 
Changes in dendritic branching as well as neurotransmitter levels have also been reported 
in the DS brain tissue and likely correlate with the behavioural and cognitive difficulties 
seen in these individuals (Reynolds and Warner, 1988; Ross et al., 1984). At the cellular level, 
DS progenitors have prolonged cell cycle lengths, thereby impairing neurogenesis 
(Chakrabarti et al., 2007; Contestabile et al., 2007; Guidi et al., 2008). Neuronal numbers 
further decline presumably through increased levels of reactive oxygen  species (ROS), 
mitochondrial dysfunction and increased cell death in mature neurons (Busciglio et al., 2002; 
Guidi et al., 2008; Seidl et al., 2001). Following differentiation, neurons also show an 
imbalance of excitatory-inhibitory neurotransmission (Bhattacharyya et al., 2009), with 
reduced dendritic branching and spine density (Benavides-Piccione et al., 2004). Overall, 
these changes could all contribute to the MR, epilepsy and AD phenotypes seen in DS.  
Various neurological features in DS have been attributed to over-expression of individual 
genes on HSA21, and several of these genes might contribute to a final common pathway. For 
example, APP has been shown to promote neuronal degeneration and oxidative stress. Similar 
functions have been implicated in other HSA21 genes including BACH1, SOD1, and S100B, 
raising a possible role in AD.  Other HSA21 genes (TIAM1, SYNJ1, ITSN1, DSCR1) have been 
associated with synaptic dysfunction (suggestive of a pathological role in MR and epilepsy). 
Individual HSA21 genes with proposed neurological functions are summarized in Table 1. 
3. Identification of genes and pathways responsible for AD or MR 
Although HSA21 is a relatively small chromosome and single candidate genes have been 
shown to mimic certain DS features, the combinatorial effects of contiguous genes on  
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Table 1. HSA21 genes implicated in neurodevelopment 
particular DS phenotypes are not known. Several approaches have been used to ascertain 
HSA21 genotype phenotype contributions: analyses of gene clusters based on their physical 
linkage, common function/ interactions and/or temporal-spatial distribution of expression.  
3.1 Structure-based clusters 
Genes that are physically linked based on their location within the same region are usually 
active together and often contribute to the same phenotype. Based on these structure-based 
clusters, comparison of full trisomy 21 and partial trisomy 21 genotypes provide some 
insight between contiguous genes and DS phenotypes. One such region includes APP, 
which is positioned between 27.25 to 27.54Mb on the long arm of HSA21. Five families with 
various segmental trisomies that range from 0.58 to 6.37Mb in length and contain APP were 
all shown to have abundant parenchymal and vascular deposits of beta amyloid without 
MR on brain autopsy, strongly linking APP to AD (Rovelet-Lecrux et al., 2006).  
 
 
Fig. 1. APP is positioned between 27.25 to 27.54Mb on the long arm of HSA21. 
Furthermore, a DS patient with duplication of the distal last 12Mb of HSA21 (a fragment 
that does not include APP) did not develop typical AD pathology (Prasher et al., 1998). 
Recently, Korbel et al. analyzed 30 patients carrying rare segmental trisomies of various 
regions of HSA21 and identified discrete regions between 1.8-16.3Mb in length that were 
likely to be involved in 8 DS CNS and non-CNS phenotypes including MR and AD (Korbel 
et al., 2009). They described a patient with a duplication of 18.8 Mb (28.12-telo) without APP, 
who did not have dementia and had no amyloid accumulation by fMRI. Conversely, several 
patients with segmental trisomies containing APP did show AD characteristics in the 
absence of severe MR, which supports the involvement of APP in AD but not MR. These 
authors were able to narrow down a 1.95Mb interval including APP responsible for the AD 
phenotype, that excludes genes located distal to 28.12 Mb on HSA21q, including BACH1 
and SOD1. These genes were previously suggested to play important roles in the 
development of AD and MR in DS (Ferrando-Miguel et al., 2003; Lott et al., 2006). 
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Table 1. HSA21 genes implicated in neurodevelopment 
particular DS phenotypes are not known. Several approaches have been used to ascertain 
HSA21 genotype phenotype contributions: analyses of gene clusters based on their physical 
linkage, common function/ interactions and/or temporal-spatial distribution of expression.  
3.1 Structure-based clusters 
Genes that are physically linked based on their location within the same region are usually 
active together and often contribute to the same phenotype. Based on these structure-based 
clusters, comparison of full trisomy 21 and partial trisomy 21 genotypes provide some 
insight between contiguous genes and DS phenotypes. One such region includes APP, 
which is positioned between 27.25 to 27.54Mb on the long arm of HSA21. Five families with 
various segmental trisomies that range from 0.58 to 6.37Mb in length and contain APP were 
all shown to have abundant parenchymal and vascular deposits of beta amyloid without 
MR on brain autopsy, strongly linking APP to AD (Rovelet-Lecrux et al., 2006).  
 
 
Fig. 1. APP is positioned between 27.25 to 27.54Mb on the long arm of HSA21. 
Furthermore, a DS patient with duplication of the distal last 12Mb of HSA21 (a fragment 
that does not include APP) did not develop typical AD pathology (Prasher et al., 1998). 
Recently, Korbel et al. analyzed 30 patients carrying rare segmental trisomies of various 
regions of HSA21 and identified discrete regions between 1.8-16.3Mb in length that were 
likely to be involved in 8 DS CNS and non-CNS phenotypes including MR and AD (Korbel 
et al., 2009). They described a patient with a duplication of 18.8 Mb (28.12-telo) without APP, 
who did not have dementia and had no amyloid accumulation by fMRI. Conversely, several 
patients with segmental trisomies containing APP did show AD characteristics in the 
absence of severe MR, which supports the involvement of APP in AD but not MR. These 
authors were able to narrow down a 1.95Mb interval including APP responsible for the AD 
phenotype, that excludes genes located distal to 28.12 Mb on HSA21q, including BACH1 
and SOD1. These genes were previously suggested to play important roles in the 
development of AD and MR in DS (Ferrando-Miguel et al., 2003; Lott et al., 2006). 
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Collectively, these studies conclude a small-segment containing APP as the basis for AD 
phenotype, with multiple focal regions contributing to MR.   
Through segmental trisomy analyses, the primary features of DS have previously been 
ascribed to the Down syndrome critical region (DSCR). This interval spans about 5Mb around 
21q22.12-q22.2 and contains about 33 conserved genes, including DSCR1 (35.88-35.99 Mb), 
SIM2 (38.07-38.13 Mb), DYRK1A (38.74-38.89), KCNJ6 (38.99-39.29Mb), ETS2 (40.18-40.2Mb), 
PCP4 (41.24-41.3Mb) and DSCAM (41.38-42.22Mb). The contiguous genes are thought to be 
sufficient to replicate the DS features including craniofacial abnormalities, short stature, joint 
hyperlaxity, hypotonia and mental retardation (Delabar et al., 1993; Korenberg, 1990; 
Korenberg, 1993; McCormick et al., 1989; Olson et al., 2004a; Rahmani et al., 1989). Further 
studies suggest that DSCR1 and DYRA1A cooperatively destabilize NFATC and induce DS 
features (Arron et al., 2006; de la Luna and Estivill, 2006). However, several genotype-
phenotype correlation studies argue against this hypothesis, given that other patients with 
partial trisomy 21 that do not include DSCR1, DSCAM or genes within the DSCR have severe 
DS features including MR (Korbel et al., 2009; Lyle et al., 2009; Ronan et al., 2007).  
3.2 Function-based clusters 
Microarray expression profiling and sequencing of the human genome have allowed for 
data analyses and interconnection of functional pathways responsible for various human 
disorders. By comparing differentially expressed genes between normal and pathological 
samples, function-based clusters can be generated and attributed to certain disease 
pathways. We have used this approach in the study of DS human neural progenitors 
(HNPs) at 18 weeks gestation age (Esposito et al., 2008a). Through pairwise comparison of 
mRNA expression levels for approximately 54,000 probes in the HU133 plus 2.0 Affymetrix 
microarray, we observed that some 1900 transcripts (3.8%) were significantly different 
between WT and DS samples, and that these transcripts were distributed across every 
chromosome – not just HSA21. Moreover, of these 1900 transcripts, only 330 transcripts 
(0.07%) were at least 1.5 to 2 fold in excess/deficit on pairwise comparison. These transcripts 
could then be grouped into specific functional networks, including gene clusters involved in 
cell cycle (proliferation), cell compromise (cell death, oxidative stress), cell signalling (stress 
kinases) and cell function and maintenance (differentiation and survival).  For example, 
HSA21 genes such as S100B and amyloid precursor protein (APP) were constitutively over-
expressed in DS HNPs along with various stress related kinases and the water channel 
aquaporin 4 (AQP4). These dysregulated genes comprised a cell signaling functional cluster, 
whereby HSA21 associated S100B and APP led to increased ROS formation, activation of 
stress response kinases, and compensatory AQP4 expression. siRNA inhibition of AQP4 
resulted in elevated levels of ROS following S100B exposure whereas loss of AQP4 
expression led to increased programmed cell death. Results from these studies support the 
hypothesis that HSA21 gene overdose lead to profound disruption of the entire 
transcriptome, but presumably in fairly specific functional groups (FitzPatrick et al., 2002; 
Saran et al., 2003; Tang et al., 2004).  
Using a similar strategy, Bhattacharyya et al. compared the differential expression of genes 
in DS versus WT HNPs at 13 weeks gestation age. Within these earlier aged progenitors, 
they observed similar functional clusters involved in cell death, cell cycle/ proliferation, and 
cell fate/ neuronal development. These studies focused on impairments in interneuron 
neurogenesis, perhaps related to increased expression of gliocentric genes such as Olig1, 
Olig2, OMG and COUP-TF1/NR2F1 and downregulation of the interneuron related genes 
DLX1, DLX2 and DLX5. 
 




Fig. 2. Constitutively overexpressed genes on HSA21 (S100B & APP) and AQP4 (shown by 
red arrows) are predicted to form tight interrelationships within known cell signaling 
pathways shown in the networks pooled out from many differentially expressed genes in 
DS HNPs with microarray. 
In another report, Canzonetta used differential expression analyses following microarray 
profiling of normal and trsisomy 21 mouse ES cells and pooled the differentially expressed 
genes into endodermal, mesodermal or ectodermal subgroups. They found reduced 
expression of stem cell genes controlling pluripotency such as Nanog and Sox2; increased 
expression of endodermal genes such as Gata4, Gata6 and Foxa2; increased expression of 
mesodermal genes such as Snail1 and Pitx2 and reduced expression of neuroectodermal 
genes, such as Nestin, Tubb3, Map2 in trisomy 21 ES cells (Canzonetta et al., 2008). More 
pervasively, they observed a decrease in Nrsf/Rest, a key regulator of neuronal 
differentiation and pluripotency. Quantitative linkage analysis (QTL) mapped the REST 
level change to a 3Mb region of HSA21 containing DYRK1A, suggesting that dysregulation 
of this HSA21 gene was an early regulator of various embryonic lineages. 
3.3 Temporal-spatial mapping-based clusters 
Although structure and function cluster approaches provide correlation between DS 
genotype-phenotypes, temporal and spatial distribution of gene expression further refines 
the contribution of individual HSA21 genes in DS neural development and later maturation. 
Previous reports analyzing human trisomy 21 tissue or cells have shown that 
overexpression of different chromosome 21 genes is cell type and developmental time 
specific (Ait Yahya-Graison et al., 2007; Chung et al., 2005; Giannone et al., 2004; Gross et al., 
2002; Li et al., 2006; Lubec and Sohn, 2003; Mao et al., 2005; Mao et al., 2003; Rozovski et al., 
2007). For example, by RNA whole-mount in situ hybridization, gene expression maps of 
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Collectively, these studies conclude a small-segment containing APP as the basis for AD 
phenotype, with multiple focal regions contributing to MR.   
Through segmental trisomy analyses, the primary features of DS have previously been 
ascribed to the Down syndrome critical region (DSCR). This interval spans about 5Mb around 
21q22.12-q22.2 and contains about 33 conserved genes, including DSCR1 (35.88-35.99 Mb), 
SIM2 (38.07-38.13 Mb), DYRK1A (38.74-38.89), KCNJ6 (38.99-39.29Mb), ETS2 (40.18-40.2Mb), 
PCP4 (41.24-41.3Mb) and DSCAM (41.38-42.22Mb). The contiguous genes are thought to be 
sufficient to replicate the DS features including craniofacial abnormalities, short stature, joint 
hyperlaxity, hypotonia and mental retardation (Delabar et al., 1993; Korenberg, 1990; 
Korenberg, 1993; McCormick et al., 1989; Olson et al., 2004a; Rahmani et al., 1989). Further 
studies suggest that DSCR1 and DYRA1A cooperatively destabilize NFATC and induce DS 
features (Arron et al., 2006; de la Luna and Estivill, 2006). However, several genotype-
phenotype correlation studies argue against this hypothesis, given that other patients with 
partial trisomy 21 that do not include DSCR1, DSCAM or genes within the DSCR have severe 
DS features including MR (Korbel et al., 2009; Lyle et al., 2009; Ronan et al., 2007).  
3.2 Function-based clusters 
Microarray expression profiling and sequencing of the human genome have allowed for 
data analyses and interconnection of functional pathways responsible for various human 
disorders. By comparing differentially expressed genes between normal and pathological 
samples, function-based clusters can be generated and attributed to certain disease 
pathways. We have used this approach in the study of DS human neural progenitors 
(HNPs) at 18 weeks gestation age (Esposito et al., 2008a). Through pairwise comparison of 
mRNA expression levels for approximately 54,000 probes in the HU133 plus 2.0 Affymetrix 
microarray, we observed that some 1900 transcripts (3.8%) were significantly different 
between WT and DS samples, and that these transcripts were distributed across every 
chromosome – not just HSA21. Moreover, of these 1900 transcripts, only 330 transcripts 
(0.07%) were at least 1.5 to 2 fold in excess/deficit on pairwise comparison. These transcripts 
could then be grouped into specific functional networks, including gene clusters involved in 
cell cycle (proliferation), cell compromise (cell death, oxidative stress), cell signalling (stress 
kinases) and cell function and maintenance (differentiation and survival).  For example, 
HSA21 genes such as S100B and amyloid precursor protein (APP) were constitutively over-
expressed in DS HNPs along with various stress related kinases and the water channel 
aquaporin 4 (AQP4). These dysregulated genes comprised a cell signaling functional cluster, 
whereby HSA21 associated S100B and APP led to increased ROS formation, activation of 
stress response kinases, and compensatory AQP4 expression. siRNA inhibition of AQP4 
resulted in elevated levels of ROS following S100B exposure whereas loss of AQP4 
expression led to increased programmed cell death. Results from these studies support the 
hypothesis that HSA21 gene overdose lead to profound disruption of the entire 
transcriptome, but presumably in fairly specific functional groups (FitzPatrick et al., 2002; 
Saran et al., 2003; Tang et al., 2004).  
Using a similar strategy, Bhattacharyya et al. compared the differential expression of genes 
in DS versus WT HNPs at 13 weeks gestation age. Within these earlier aged progenitors, 
they observed similar functional clusters involved in cell death, cell cycle/ proliferation, and 
cell fate/ neuronal development. These studies focused on impairments in interneuron 
neurogenesis, perhaps related to increased expression of gliocentric genes such as Olig1, 
Olig2, OMG and COUP-TF1/NR2F1 and downregulation of the interneuron related genes 
DLX1, DLX2 and DLX5. 
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red arrows) are predicted to form tight interrelationships within known cell signaling 
pathways shown in the networks pooled out from many differentially expressed genes in 
DS HNPs with microarray. 
In another report, Canzonetta used differential expression analyses following microarray 
profiling of normal and trsisomy 21 mouse ES cells and pooled the differentially expressed 
genes into endodermal, mesodermal or ectodermal subgroups. They found reduced 
expression of stem cell genes controlling pluripotency such as Nanog and Sox2; increased 
expression of endodermal genes such as Gata4, Gata6 and Foxa2; increased expression of 
mesodermal genes such as Snail1 and Pitx2 and reduced expression of neuroectodermal 
genes, such as Nestin, Tubb3, Map2 in trisomy 21 ES cells (Canzonetta et al., 2008). More 
pervasively, they observed a decrease in Nrsf/Rest, a key regulator of neuronal 
differentiation and pluripotency. Quantitative linkage analysis (QTL) mapped the REST 
level change to a 3Mb region of HSA21 containing DYRK1A, suggesting that dysregulation 
of this HSA21 gene was an early regulator of various embryonic lineages. 
3.3 Temporal-spatial mapping-based clusters 
Although structure and function cluster approaches provide correlation between DS 
genotype-phenotypes, temporal and spatial distribution of gene expression further refines 
the contribution of individual HSA21 genes in DS neural development and later maturation. 
Previous reports analyzing human trisomy 21 tissue or cells have shown that 
overexpression of different chromosome 21 genes is cell type and developmental time 
specific (Ait Yahya-Graison et al., 2007; Chung et al., 2005; Giannone et al., 2004; Gross et al., 
2002; Li et al., 2006; Lubec and Sohn, 2003; Mao et al., 2005; Mao et al., 2003; Rozovski et al., 
2007). For example, by RNA whole-mount in situ hybridization, gene expression maps of 
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HSA21 orthologues in various aged embryonic or newborn mouse brain have been reported 
(Gitton et al., 2002; Reymond et al., 2002). Of the 158 orthologous genes examined in 
postnatal day 2 mouse brain, 41% were expressed in new cortex, 25% in hippocampus and 
25% in cerebellum. The transcripts expressed in neocortex represent a pool of candidate 
genes for MR of DS, and include DSCAM, SYNJ1 and TIAM1. These genes are implicated in 
synaptic function, axonal guidance, cell migration and neurite outgrowth (Leeuwen et al., 
1997; Saito et al., 2000; Yamakawa et al., 1998).  
While several studies have used human cortical progenitors to identify changes in 
expression profiling, the findings of gene expression levels vary between studies. The 
temporal-spatial variations in DS HNPs may account for these differences.  For example, the 
REST/NRSF transcription factor was previously reported to be selectively repressed in the 
DS HNPs (Bahn et al., 2002). These changes were not seen in our studies or those of others 
(Bhattacharyya et al., 2009; Esposito et al., 2008a). However, this discrepancy could be due to 
the fact that the gestational ages of the euploid and DS fetal tissues used in these differential 
expression studies were not the same.  Similarly, our observations of increased S100B and 
aquaporin 4 levels in 19 week gestational age DS HNPs were not appreciated in 13 week 
gestational age HNPs. This difference would be consistent with the previous notion that 
HNPs mimic normal developmental patterns such that later generated or propagated HNPs 
generate fewer neurons than HNPs harvested at an earlier age. Given that S100B and AQP4 
are associated with more gliocentric phenotypes, upregulation of these genes would be 
expected in later gestational aged HNPs. Similar differences appear to exist with other 
HSA21 genes such as Olig1/2 and DNMT3L (unpublished observations).  
4. Characterization of endophenotypes for AD or MR 
Endophenotypes are pathological changes observed at the histological, cellular or molecular 
levels, which provide an association between candidate genes and the clinical symptoms. 
Clinical neurological symptoms of DS include early onset AD, mental retardation and 
seizures. Histological changes such as increased cell death, gliosis, demyelination, loss in 
neuronal numbers, and gyral simplification are thought to contribute to AD and/or MR in 
DS brain. At the cellular level, DS cells show impairments in mitochondrial function, 
increased levels of oxidative stress, and changes in proliferative rates. An imbalance in 
excitatory-inhibitory neurotransmission, expression changes of genes that affect cell 
fate/differentiation, proliferation/cell cycle and cell injury have been observed at the 
molecular level.  
4.1 Mitochondrial dysfunction and apoptosis 
Oxidative stress is increased in DS brain and the imbalance of reactive oxygen species (ROS) 
metabolism may be the key component giving rise to DS pathogenesis- namely neuronal 
degeneration (Brooksbank and Balazs, 1984; Busciglio and Yankner, 1995). The 
mitochondrial respiratory system is the primary source of ROS, and dysregulation of the 
redox states may induce sequential apoptosis. Several lines of evidence implicate multiple 
HSA21 genes in mitochondrial dysfunction and DS/AD neuropathology. APP is a 
membrane protein associated with neuronal survival and overexpression of APP and its 
products Abeta has been attributed to neurodegeneration in DS and AD (Conti et al., 2010; 
Isacson et al., 2002; Salehi et al., 2006). APP and Abeta are located in mitochondria (Devi and 
Anandatheerthavarada, 2010; Manczak et al., 2006). Abeta peptides induce mitochondrial 
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dysfunction and oxidative stress in astrocytes leading to cell death in neurons (Abramov et 
al., 2004). Impairments in mitochondrial function in astrocytes also alter metabolism and 
secretion of neuroprotective APP and increase neuronal vulnerability (Busciglio et al., 2002). 
Mitochondrial dysfunction, however, does not require aberrant APP and Abeta processing 
specifically. The Ts1Cje DS mouse model, whose partial trisomy 16 does not include the 
APP gene, also exhibits diminished mitochondrial activity (Shukkur et al., 2006). These mice 
show decreased mitochondrial membrane potential and ATP production, increased ROS, 
and increased GSK3ß and JNK/SAPK activities. GSK3ß preserves mitochondrial function, 
and inhibits Ca(2+)-induced mitochondrial permeability (Mio et al., 2009). In addition to 
GSK3ß, several other genes within the Ts1Cje trisomic segment are thought to be involved 
in mitochondrial function. DSCR1 has been reported to be located in the mitochondria and 
to play a critical role in mitochondrial function (Chang and Min, 2005). DYRK1A can 
phosphorylate tau and APP (Park et al., 2007; Woods et al., 2001), and the transcription 
factor ETS-2 increases APP production and promotes the activation of a mitochondrial death 
pathway in DS neurons (Helguera et al., 2005; Wolvetang et al., 2003a; Wolvetang et al., 
2003b). S100B is another HSA21 gene that can increase ROS, it is a calcium binding protein 
that affects calcium-dependent signals, targeting mitochondrial proteins such as p53 and 
ATPase ATAD3A, thereby assisting the cytoplasmic processing of proteins for proper 
folding and subcellular localization. S100B overexpression can also lead to p53 inactivation 
(Donato, 2003; Gilquin et al., 2010; Leclerc et al., 2010; Lin et al., 2001; Mihara et al., 2003). 
Finally, similar mechanisms involving mitochondrial dysfunction have been proposed with 
other HSA21 genes including SOD1 and BATCH1 (Arbuzova et al., 2002; Ferrando-Miguel 
et al., 2003; Furuta et al., 1995; Harris-Cerruti et al., 2004; Iannello et al., 1999; Lott et al., 
2006; Shim et al., 2003). The added, combinatorial effects of these various HSA21 genes in 
oxidative stress, apoptosis in neurons and neuronal progenitors are not known. 
While mitochondrial dysfunction, oxidative stress, and subsequent apoptosis have been well 
appreciated in neurons, only recently changes have been reported in DS HNPs. We have 
shown that upregulation of glial-associated proteins such as S100B lead to tau and GSK3ß 
hyperphosphorylation, suggesting loss of mitochondrial function (Esposito et al., 2008a; 
Esposito et al., 2008b). HNPs over-express the HSA21-localized S100B, leading to increased 
ROS formation such as hydrogen peroxide and nitric oxide, activation of stress response 
kinase pathways (JNK/STAT), and the upregulation of the glial-associated water channel 
AQP4 (Esposito et al., 2008a). This same functional network also predicts an added 
contribution through HSA21 localized APP. Both APP and S100B are upregulated in DS 
HNPs, they reciprocally enhance the expression of one another, have an additive effect on 
increasing hydrogen peroxide, decreasing mitochondrial membrane potential and 
increasing apoptosis (unpublished data). The co-localization of APP and S100B within the 
same HNPs along VZ of cortex may make progenitors even more vulnerable to oxidative 
stress, which is supported by the fact that increased progenitor cell death is seen at nano or 
pico level of S100B or Abeta stimulation (unpublished observations). These same doses are 
neuroprotective in more mature neurons (Lambert et al., 1998; Van Eldik and Wainwright, 
2003; Yankner and Lu, 2009). The additive effects from S100B and APP may depend upon 
their common activation through the extracellular RAGE receptor which has been shown to 
regulate intracellular mitochondrial function (Devi and Anandatheerthavarada, 2010; 
Donato, 2003; Leclerc et al., 2010; Manczak et al., 2006). The in vitro observations from DS 
HNPs are consistent with in vivo observations in polytransgenic mice. S100B/APP double 
transgenic (Tg2576/APP-huS100B) mice display augmented reactive astrocytosis and 
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HSA21 orthologues in various aged embryonic or newborn mouse brain have been reported 
(Gitton et al., 2002; Reymond et al., 2002). Of the 158 orthologous genes examined in 
postnatal day 2 mouse brain, 41% were expressed in new cortex, 25% in hippocampus and 
25% in cerebellum. The transcripts expressed in neocortex represent a pool of candidate 
genes for MR of DS, and include DSCAM, SYNJ1 and TIAM1. These genes are implicated in 
synaptic function, axonal guidance, cell migration and neurite outgrowth (Leeuwen et al., 
1997; Saito et al., 2000; Yamakawa et al., 1998).  
While several studies have used human cortical progenitors to identify changes in 
expression profiling, the findings of gene expression levels vary between studies. The 
temporal-spatial variations in DS HNPs may account for these differences.  For example, the 
REST/NRSF transcription factor was previously reported to be selectively repressed in the 
DS HNPs (Bahn et al., 2002). These changes were not seen in our studies or those of others 
(Bhattacharyya et al., 2009; Esposito et al., 2008a). However, this discrepancy could be due to 
the fact that the gestational ages of the euploid and DS fetal tissues used in these differential 
expression studies were not the same.  Similarly, our observations of increased S100B and 
aquaporin 4 levels in 19 week gestational age DS HNPs were not appreciated in 13 week 
gestational age HNPs. This difference would be consistent with the previous notion that 
HNPs mimic normal developmental patterns such that later generated or propagated HNPs 
generate fewer neurons than HNPs harvested at an earlier age. Given that S100B and AQP4 
are associated with more gliocentric phenotypes, upregulation of these genes would be 
expected in later gestational aged HNPs. Similar differences appear to exist with other 
HSA21 genes such as Olig1/2 and DNMT3L (unpublished observations).  
4. Characterization of endophenotypes for AD or MR 
Endophenotypes are pathological changes observed at the histological, cellular or molecular 
levels, which provide an association between candidate genes and the clinical symptoms. 
Clinical neurological symptoms of DS include early onset AD, mental retardation and 
seizures. Histological changes such as increased cell death, gliosis, demyelination, loss in 
neuronal numbers, and gyral simplification are thought to contribute to AD and/or MR in 
DS brain. At the cellular level, DS cells show impairments in mitochondrial function, 
increased levels of oxidative stress, and changes in proliferative rates. An imbalance in 
excitatory-inhibitory neurotransmission, expression changes of genes that affect cell 
fate/differentiation, proliferation/cell cycle and cell injury have been observed at the 
molecular level.  
4.1 Mitochondrial dysfunction and apoptosis 
Oxidative stress is increased in DS brain and the imbalance of reactive oxygen species (ROS) 
metabolism may be the key component giving rise to DS pathogenesis- namely neuronal 
degeneration (Brooksbank and Balazs, 1984; Busciglio and Yankner, 1995). The 
mitochondrial respiratory system is the primary source of ROS, and dysregulation of the 
redox states may induce sequential apoptosis. Several lines of evidence implicate multiple 
HSA21 genes in mitochondrial dysfunction and DS/AD neuropathology. APP is a 
membrane protein associated with neuronal survival and overexpression of APP and its 
products Abeta has been attributed to neurodegeneration in DS and AD (Conti et al., 2010; 
Isacson et al., 2002; Salehi et al., 2006). APP and Abeta are located in mitochondria (Devi and 
Anandatheerthavarada, 2010; Manczak et al., 2006). Abeta peptides induce mitochondrial 
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dysfunction and oxidative stress in astrocytes leading to cell death in neurons (Abramov et 
al., 2004). Impairments in mitochondrial function in astrocytes also alter metabolism and 
secretion of neuroprotective APP and increase neuronal vulnerability (Busciglio et al., 2002). 
Mitochondrial dysfunction, however, does not require aberrant APP and Abeta processing 
specifically. The Ts1Cje DS mouse model, whose partial trisomy 16 does not include the 
APP gene, also exhibits diminished mitochondrial activity (Shukkur et al., 2006). These mice 
show decreased mitochondrial membrane potential and ATP production, increased ROS, 
and increased GSK3ß and JNK/SAPK activities. GSK3ß preserves mitochondrial function, 
and inhibits Ca(2+)-induced mitochondrial permeability (Mio et al., 2009). In addition to 
GSK3ß, several other genes within the Ts1Cje trisomic segment are thought to be involved 
in mitochondrial function. DSCR1 has been reported to be located in the mitochondria and 
to play a critical role in mitochondrial function (Chang and Min, 2005). DYRK1A can 
phosphorylate tau and APP (Park et al., 2007; Woods et al., 2001), and the transcription 
factor ETS-2 increases APP production and promotes the activation of a mitochondrial death 
pathway in DS neurons (Helguera et al., 2005; Wolvetang et al., 2003a; Wolvetang et al., 
2003b). S100B is another HSA21 gene that can increase ROS, it is a calcium binding protein 
that affects calcium-dependent signals, targeting mitochondrial proteins such as p53 and 
ATPase ATAD3A, thereby assisting the cytoplasmic processing of proteins for proper 
folding and subcellular localization. S100B overexpression can also lead to p53 inactivation 
(Donato, 2003; Gilquin et al., 2010; Leclerc et al., 2010; Lin et al., 2001; Mihara et al., 2003). 
Finally, similar mechanisms involving mitochondrial dysfunction have been proposed with 
other HSA21 genes including SOD1 and BATCH1 (Arbuzova et al., 2002; Ferrando-Miguel 
et al., 2003; Furuta et al., 1995; Harris-Cerruti et al., 2004; Iannello et al., 1999; Lott et al., 
2006; Shim et al., 2003). The added, combinatorial effects of these various HSA21 genes in 
oxidative stress, apoptosis in neurons and neuronal progenitors are not known. 
While mitochondrial dysfunction, oxidative stress, and subsequent apoptosis have been well 
appreciated in neurons, only recently changes have been reported in DS HNPs. We have 
shown that upregulation of glial-associated proteins such as S100B lead to tau and GSK3ß 
hyperphosphorylation, suggesting loss of mitochondrial function (Esposito et al., 2008a; 
Esposito et al., 2008b). HNPs over-express the HSA21-localized S100B, leading to increased 
ROS formation such as hydrogen peroxide and nitric oxide, activation of stress response 
kinase pathways (JNK/STAT), and the upregulation of the glial-associated water channel 
AQP4 (Esposito et al., 2008a). This same functional network also predicts an added 
contribution through HSA21 localized APP. Both APP and S100B are upregulated in DS 
HNPs, they reciprocally enhance the expression of one another, have an additive effect on 
increasing hydrogen peroxide, decreasing mitochondrial membrane potential and 
increasing apoptosis (unpublished data). The co-localization of APP and S100B within the 
same HNPs along VZ of cortex may make progenitors even more vulnerable to oxidative 
stress, which is supported by the fact that increased progenitor cell death is seen at nano or 
pico level of S100B or Abeta stimulation (unpublished observations). These same doses are 
neuroprotective in more mature neurons (Lambert et al., 1998; Van Eldik and Wainwright, 
2003; Yankner and Lu, 2009). The additive effects from S100B and APP may depend upon 
their common activation through the extracellular RAGE receptor which has been shown to 
regulate intracellular mitochondrial function (Devi and Anandatheerthavarada, 2010; 
Donato, 2003; Leclerc et al., 2010; Manczak et al., 2006). The in vitro observations from DS 
HNPs are consistent with in vivo observations in polytransgenic mice. S100B/APP double 
transgenic (Tg2576/APP-huS100B) mice display augmented reactive astrocytosis and 
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microgliosis, increased levels of pro-inflammatory cytokines and enhanced apoptosis (Mori 
et al., 2010). The double transgenic (mutant APP (mAPP)/RAGE) mice demonstrate 
increased activation of stress pathways (phosphorylation of p38 and JNK) and altered 
expression of markers of synaptic plasticity (MAP kinases), leading to early abnormalities in 
spatial learning/memory (Arancio et al., 2004).  
4.2 Gliosis and inflammatory changes  
Increased astrocytes and gliosis have previously been reported in DS brain (Guidi et al., 
2008).  Altered redox states and mitochondrial compromise leading to cell death are thought 
to promote these inflammatory changes in mature DS brain (Griffin et al., 1989). In DS the 
increase in the glial marker S100B could be explained, in part, by a gene dosage effect and in 
part by reactive gliosis (Selinfreund et al., 1991).  
A shift in the DS progenitor pool may contribute to the neuronal reduction and increase in 
glial cells within the mature trisomy 21 brain.  Some studies have suggested impairments in 
interneuron neurogenesis within the DS HNP pool, possibly due to over-expression of the 
transcription factor COUP-TF1/NR2F1 (Bhattacharyya et al., 2009). Increased levels of 
COUP-TF1/NR2F1 cause increases in the generation of earlier born neurons and depletion 
of later born interneurons. Alternatively, other reports suggest that HSA21 associated 
DYRK1A causes a skewed ratio of primitive endoderm at the expense of neuroectodermal 
progenitors, leading to a reduction in neurogenesis (Canzonetta et al., 2008). Mensah also 
reported an inhibition of neuroectodermal differentiation in a teratoma model transplanted 
with mouse ES cells injected with HSA21 (Mensah et al., 2007). Our prior studies of DS 
HNPs had demonstrated a constitutive increase in the glial and HSA21 associated S100B 
protein, which in turn, enhanced expression of another glial-associated protein, the water 
channel AQP4. Aquaporins can partially mitigate damage due to ROS, such that glial 
progenitors are more resistant to oxidative damage (Esposito et al., 2008a).  In this setting 
endogenous overexpression of a glial-associated gene S100B might drive gliogenic 
progenitors, while the inflammatory changes from oxidative stressors would further 
promote a gliocentric progenitor pool. Other candidate genes such as HSA21-localized Olig1 
and Olig2 are basic helix-loop-helix (bHLH) transcription factors essential for development 
of oligodendrocytes (Jakovcevski and Zecevic, 2005; Lu et al., 2002; Takebayashi et al., 2002; 
Zhou and Anderson, 2002) or astrocytes (Cai et al., 2007; Marshall et al., 2005; Ono et al., 
2008); and SYNJ1 could increase astrogliosis (Herrera et al., 2009).  The number of 
Olig1/Olig2(+) progenitors increases in the injured CNS (Arnett et al., 2004), and Olig2(+) 
cells preferentially differentiate into GFAP-expressing astrocytes, the main contributors to 
glial scars which further secrete S100B (Chen et al., 2008; Tatsumi et al., 2008). S100B also 
contributes to oligodendrocyte progenitor cells (OPC) differentiation in response to 
demyelinating insults (Deloulme et al., 2004). In addition to transcription factors, epigenetic 
regulation can also control the cell fate changes within progenitors. One possible candidate 
gene in DS is HSA21 associated DNMT3L. DNMT3L is a DNA methyltransferase like gene 
playing a role in DNA methylation by activating DNMT3A or DNMT3B (Jia et al., 2007; Ooi 
et al., 2007; Suetake et al., 2004). It also represses transcription by recruiting histone 
deacetylase (HDAC) (Aapola et al., 2002; Deplus et al., 2002). Hypomethylation in neural 
progenitors leads to precocious astroglial differentiation and perturbed neuronal maturation 
in DNMT1 or DNMT3A knockout mice (Fan et al., 2005; Hutnick et al., 2009), whereas 
HDAC activation increases oligodendrocytes differentiation (Hsieh et al., 2004; Liu et al., 
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2009; Liu and Casaccia, 2010; Shen et al., 2005; Ye et al., 2009). Again the combinatorial 
effects from these various HSA21 genes associated with cell fate changes are not known.  
4.3 Prolonged cell cycle and reduced proliferation 
Proliferation changes during development have been thought to contribute to the decreased 
neuronal numbers and reduced cortical volume in DS brains. Recent studies demonstrated 
impairments in proliferation within both hippocampus and neocortical germinal matrix of 
17 weeks to 21 weeks gestation age fetal DS brains (Contestabile et al., 2007; Guidi et al., 
2008).  The DS progenitor cell cycle is prolonged with more cells remaining in G2 phase, 
thereby causing a reduction in neurogenesis and presumptive increase in astrocytosis. 
Similar endophenotypes are also found in animal models, which show a reduced progenitor 
pool and neurogenesis in ventricular zone or dentate gyrus (Contestabile et al., 2009; 
Haydar et al., 2000; Lorenzi and Reeves, 2006; Moldrich et al., 2009).  The molecular 
mechanisms behind G2 phase prolongation are not known although many genes on HSA21 
can cause proliferation changes.  Overexpression of APP would antagonistically compete 
with the APP-BP1, which is required for the cell cycle progression from G1 to S phase. This 
change would lead to a  predicted slowing in proliferation but at the G1 to S phase (Joo et 
al., 2010). Overexpression of S100B could promote p53 nuclear accumulation and inhibit 
proliferation (Scotto et al., 1999).  Olig2 overexpression has been shown to increase CDK 
inhibitor p27, leading to decreased proliferation (Tabu et al., 2006). Presumably, various 
HSA21 genes may directly act in a combinatorial fashion to affect progenitor proliferation.   
Studies from human DS HNPs raise another potential explanation for altered progenitor 
proliferative rates. Consistent with previous reports, we have also found reduced 
proliferation in HNPs, localized along the ventricular zone of DS cortex, and within DS 
HNPs cultured in vitro. However, characterization of these progenitors have shown that 
these progenitors, while retaining neural progenitor markers, are more gliocentric in their 
expression profile. Some preliminary studies suggest that the DS HNPs have reduced 
voltage gated, outward rectifying potassium channel activity, which correlated to decreased 
proliferation. Increased potassium channel activity has been correlated with increased 
proliferation, whereas decreased channel activity coincides with oligodendrocyte 
differentiation (Chittajallu et al., 2002). Taken in this context, changes in progenitor cell fates 
(due to such HSA21 genes as S100B, APP, and Olig2) may in part explain the reduction in 
cell proliferation. 
4.4 Imbalance of excitatory-inhibitory neurotransmission 
The balance of neurotransmission is important for maintaining normal physiology and 
behavior. Imbalance of excitatory-inhibitory neurotransmission could contribute to the MR 
phenotypes seen in DS. Prior studies have shown decreased excitatory and increased 
inhibitory activities in DS neurons or Trisomy 16 mice. The excitatory neurotransmitter 
glutamate and inhibitory neurotransmitter GABA are both decreased in DS fetal brain 
(Reynolds and Warner, 1988; Risser et al., 1997; Smigielska-Kuzia et al., 2010; Whittle et al., 
2007). Ts65Dn mice show increased inhibitory synapses and decreased excitatory synapses 
in the hippocampus (Belichenko et al., 2009; Belichenko et al., 2004; Kurt et al., 2000; Perez-
Cremades et al., 2010). Excessive GABA inhibition also alters LTP in the hippocampus 
(Costa and Grybko, 2005; Kleschevnikov et al., 2004; Siarey et al., 1997). Likewise, Ts1Cje 
mice show a shortened long term potentiation and an increase in long term depression, as 
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microgliosis, increased levels of pro-inflammatory cytokines and enhanced apoptosis (Mori 
et al., 2010). The double transgenic (mutant APP (mAPP)/RAGE) mice demonstrate 
increased activation of stress pathways (phosphorylation of p38 and JNK) and altered 
expression of markers of synaptic plasticity (MAP kinases), leading to early abnormalities in 
spatial learning/memory (Arancio et al., 2004).  
4.2 Gliosis and inflammatory changes  
Increased astrocytes and gliosis have previously been reported in DS brain (Guidi et al., 
2008).  Altered redox states and mitochondrial compromise leading to cell death are thought 
to promote these inflammatory changes in mature DS brain (Griffin et al., 1989). In DS the 
increase in the glial marker S100B could be explained, in part, by a gene dosage effect and in 
part by reactive gliosis (Selinfreund et al., 1991).  
A shift in the DS progenitor pool may contribute to the neuronal reduction and increase in 
glial cells within the mature trisomy 21 brain.  Some studies have suggested impairments in 
interneuron neurogenesis within the DS HNP pool, possibly due to over-expression of the 
transcription factor COUP-TF1/NR2F1 (Bhattacharyya et al., 2009). Increased levels of 
COUP-TF1/NR2F1 cause increases in the generation of earlier born neurons and depletion 
of later born interneurons. Alternatively, other reports suggest that HSA21 associated 
DYRK1A causes a skewed ratio of primitive endoderm at the expense of neuroectodermal 
progenitors, leading to a reduction in neurogenesis (Canzonetta et al., 2008). Mensah also 
reported an inhibition of neuroectodermal differentiation in a teratoma model transplanted 
with mouse ES cells injected with HSA21 (Mensah et al., 2007). Our prior studies of DS 
HNPs had demonstrated a constitutive increase in the glial and HSA21 associated S100B 
protein, which in turn, enhanced expression of another glial-associated protein, the water 
channel AQP4. Aquaporins can partially mitigate damage due to ROS, such that glial 
progenitors are more resistant to oxidative damage (Esposito et al., 2008a).  In this setting 
endogenous overexpression of a glial-associated gene S100B might drive gliogenic 
progenitors, while the inflammatory changes from oxidative stressors would further 
promote a gliocentric progenitor pool. Other candidate genes such as HSA21-localized Olig1 
and Olig2 are basic helix-loop-helix (bHLH) transcription factors essential for development 
of oligodendrocytes (Jakovcevski and Zecevic, 2005; Lu et al., 2002; Takebayashi et al., 2002; 
Zhou and Anderson, 2002) or astrocytes (Cai et al., 2007; Marshall et al., 2005; Ono et al., 
2008); and SYNJ1 could increase astrogliosis (Herrera et al., 2009).  The number of 
Olig1/Olig2(+) progenitors increases in the injured CNS (Arnett et al., 2004), and Olig2(+) 
cells preferentially differentiate into GFAP-expressing astrocytes, the main contributors to 
glial scars which further secrete S100B (Chen et al., 2008; Tatsumi et al., 2008). S100B also 
contributes to oligodendrocyte progenitor cells (OPC) differentiation in response to 
demyelinating insults (Deloulme et al., 2004). In addition to transcription factors, epigenetic 
regulation can also control the cell fate changes within progenitors. One possible candidate 
gene in DS is HSA21 associated DNMT3L. DNMT3L is a DNA methyltransferase like gene 
playing a role in DNA methylation by activating DNMT3A or DNMT3B (Jia et al., 2007; Ooi 
et al., 2007; Suetake et al., 2004). It also represses transcription by recruiting histone 
deacetylase (HDAC) (Aapola et al., 2002; Deplus et al., 2002). Hypomethylation in neural 
progenitors leads to precocious astroglial differentiation and perturbed neuronal maturation 
in DNMT1 or DNMT3A knockout mice (Fan et al., 2005; Hutnick et al., 2009), whereas 
HDAC activation increases oligodendrocytes differentiation (Hsieh et al., 2004; Liu et al., 
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2009; Liu and Casaccia, 2010; Shen et al., 2005; Ye et al., 2009). Again the combinatorial 
effects from these various HSA21 genes associated with cell fate changes are not known.  
4.3 Prolonged cell cycle and reduced proliferation 
Proliferation changes during development have been thought to contribute to the decreased 
neuronal numbers and reduced cortical volume in DS brains. Recent studies demonstrated 
impairments in proliferation within both hippocampus and neocortical germinal matrix of 
17 weeks to 21 weeks gestation age fetal DS brains (Contestabile et al., 2007; Guidi et al., 
2008).  The DS progenitor cell cycle is prolonged with more cells remaining in G2 phase, 
thereby causing a reduction in neurogenesis and presumptive increase in astrocytosis. 
Similar endophenotypes are also found in animal models, which show a reduced progenitor 
pool and neurogenesis in ventricular zone or dentate gyrus (Contestabile et al., 2009; 
Haydar et al., 2000; Lorenzi and Reeves, 2006; Moldrich et al., 2009).  The molecular 
mechanisms behind G2 phase prolongation are not known although many genes on HSA21 
can cause proliferation changes.  Overexpression of APP would antagonistically compete 
with the APP-BP1, which is required for the cell cycle progression from G1 to S phase. This 
change would lead to a  predicted slowing in proliferation but at the G1 to S phase (Joo et 
al., 2010). Overexpression of S100B could promote p53 nuclear accumulation and inhibit 
proliferation (Scotto et al., 1999).  Olig2 overexpression has been shown to increase CDK 
inhibitor p27, leading to decreased proliferation (Tabu et al., 2006). Presumably, various 
HSA21 genes may directly act in a combinatorial fashion to affect progenitor proliferation.   
Studies from human DS HNPs raise another potential explanation for altered progenitor 
proliferative rates. Consistent with previous reports, we have also found reduced 
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HNPs cultured in vitro. However, characterization of these progenitors have shown that 
these progenitors, while retaining neural progenitor markers, are more gliocentric in their 
expression profile. Some preliminary studies suggest that the DS HNPs have reduced 
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(due to such HSA21 genes as S100B, APP, and Olig2) may in part explain the reduction in 
cell proliferation. 
4.4 Imbalance of excitatory-inhibitory neurotransmission 
The balance of neurotransmission is important for maintaining normal physiology and 
behavior. Imbalance of excitatory-inhibitory neurotransmission could contribute to the MR 
phenotypes seen in DS. Prior studies have shown decreased excitatory and increased 
inhibitory activities in DS neurons or Trisomy 16 mice. The excitatory neurotransmitter 
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2007). Ts65Dn mice show increased inhibitory synapses and decreased excitatory synapses 
in the hippocampus (Belichenko et al., 2009; Belichenko et al., 2004; Kurt et al., 2000; Perez-
Cremades et al., 2010). Excessive GABA inhibition also alters LTP in the hippocampus 
(Costa and Grybko, 2005; Kleschevnikov et al., 2004; Siarey et al., 1997). Likewise, Ts1Cje 
mice show a shortened long term potentiation and an increase in long term depression, as 
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well as a decrease in the evoked field excitatory postsynaptic potentials- all consistent with 
impairments in short and long term plasticity (Siarey et al., 2005).  
Various HSA21 genes could theoretically affect synaptic function and thereby alter memory 
and learning. TINM1, SYNJ1 and ITSN1 are thought to play some role in synaptic plasticity, 
KCNJ6, KCNJ15, KCNE1 and KCNE2 would alter channel activity, whereas NRIP1, ETS2, 
PCP4, DSCR1, DYRK1A, S100B and APP have some role in affecting neurotransmitter 
receptors or intracellular signaling. Another more closely scrutinized HSA21 gene GIRK2 
(KCNJ6), an inwardly rectifying K channel, could contribute to synaptic inhibition. GIRK2 
channels are overexpressed in Ts65Dn hippocampus and frontal cortex (Harashima et al., 
2006). The overexpression leads to a significant increase in GABAB-mediated GIRK current 
in primary cultured hippocampal neurons, and likely affects the balance between excitatory 
and inhibitory neuronal transmission (Best et al., 2007). Pharmacological treatment of the 
trisomy 16 mice with GABAA antagonists at non-epileptic doses causes a persistent post-
drug recovery of cognition and LTP (Fernandez et al., 2007). Interestingly, treatment of these 
same mice with the uncompetitive NMDAR antagonist memantine rescues the performance 
deficits on a fear-conditioning test (Costa et al., 2008). Memantine mimics calcineurin action 
and the HSA21 DSCR1 gene inhibits calcineurin activity. This raises the hypothesis that 
DSCR1 overexpression produces a pathological increase in NMDAR activity.  
Earlier developmental changes in DS HNPs could also contribute to the imbalance of 
excitatory and inhibitory neurotransmission. Alterations in cell fate through genes such as 
Olig1 and Olig2 could lead to an abnormal ratio or distribution of excitatory and inhibitory 
neurons. Overexpression of HSA21 located Olig1 and Olig2 have been shown to increase 
GABAergic interneuron neurogenesis in Ts65Dn mice, and the dysregulation of excitatory-
inhibitory imbalance could be rescued by knocking down the extra copy of these two genes 
(Chakrabarti et al., 2010). This phenotype contrasts with our observations and those from 
other groups, who have observed a reduction of interneurons in DS HNPs at the expense of 
increasing oligodendrocytes (Bhattacharyya et al., 2009). We see a shift from neuronal to 
gliocentric progenitors with overexpression of S100B (Esposito et al., 2008a) and APP 
(unpublished observations), which would potentially further compromise the interneuron 
population.  This decline in interneuron neuronal production is consistent with the loss in 
GABA-ergic interneurons, as opposed to total neuronal numbers, reported in the DS cortex, 
further reiterating differences between the mouse and human disorders (Golden and 
Hyman, 1994; Ross et al., 1984; Weitzdoerfer et al., 2001). 
5. Combinatorial gene effects in DS HNPs contribute to the DS phenotype  
HSA21 associated genes which are implicated in cell death and oxidative stress could 
contribute to the later endophenotypes seen in DS. To identify functional modules of gene 
expression and interacting partners relevant to DS HNPs, we had applied network-based 
analyses through the Ingenuity Pathways Knowledge Base (IPA) (Calvano et al., 2005). 
Among 1902 genes that were significantly different on pairwise comparison between WT-
DS expression profiling of HNPs, 334 genes were shown to interact within 46 functional 
networks (Esposito et al., 2008a). The top four interactive networks incorporated 93 
dysregulated genes involved in cell cycle, cell death, oxidative stress and several canonical 
signal transduction pathways. These findings would suggest that genes involved in these 
primary functional clusters might later contribute to the observed DS endophenotypes.  
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To understand the role of HSA21 genes in progenitor cell death and changes in redox state, 
we first focused on HSA21 genes APP and S100B. These molecules were included in one of 
the top functional clusters and were associated with other cell signaling molecules, 
including JAK/STAT and MAPK, which have been implicated in the stress response 
pathway, inflammation and potentially gliosis. Using this potential pathway, we found that 
upregulation of S100B activated the JAK/STAT MAPK pathway through the RAGE 
receptor. RAGE receptor activation induced mitochondrial disruption and oxidative stress. 
Activation of this pathway enhanced progenitor cell death and likely gliosis, as suggested 
by increased expression of glial associated water channel AQP4 (Esposito et al., 2008a). We 
have also been able to observe a S100B-mediated induction of tau protein 
hyperphosphorylation via Dickopff-1 up-regulation and disruption of the Wnt pathway, 
suggesting a shared common final pathway with APP (Esposito et al., 2008b).  
Although APP and S100B have previously been implicated in oxidative stress and cell death, 
constitutive over-expression of these and other HSA21 genes would also predict 
upregulation of inflammatory responses (astrocytosis), leading to a skewed gliocentric 
progenitor phenotype.  The ongoing cell death and inflammation from APP and S100B 
promote reactive astrocytosis and astrocytes secrete S100B, causing further cell injury and 
death (Li et al., 2011). This same mechanism of injury in the mature brain could also take 
place within the progenitor population during development. Additionally, the transcription 
factors Olig1/2 increase oligodendroglial progenitor numbers and would likely augment any 
gliocentric shift. Similarly, the HSA21 DNA methylthansferase like DNMT3L gene recruits 
HDACs, which compete with beta catenin to regulate TCF4 dependent transcriptional 
inhibition of neuronal progenitor proliferation and activation of oligoprogenitor phenotypes 
(Aapola et al., 2002; Deplus et al., 2002; Liu et al., 2009; Ye et al., 2009).   
A gliocentric shift in the progenitor pool could alter rates of proliferation and create an 
imbalance in excitatory-inhibitory transmission. Gliocentric progenitors would be predicted 
to demonstrate reduced voltage gated, outward rectifying potassium channel activity, and 
consequent slower rates of proliferation. Moreover, the ongoing neural progenitor cell death 
from oxidative stress enhances gliocentric progenitor characteristics at the expense of 
neuronal progenitor phenotypes. This shift becomes more prominent later in cortical 
development when the cyclical and synergistic roles played by such inflammatory 
mediators such as S100B and APP become more pronounced. Under this paradigm, the loss 
in neuronogenic progenitors would manifest later in development and thereby affect 
interneuron production. 
These observations raise a hypothetical paradigm whereby several specific HSA21-localized 
genes promote a deleterious, cyclical pathway involving ROS, hypersecretion of S100B, APP 
overproduction and proliferation of gliocentric progenitors. A gliocentric shift in the 
progenitor pool would provide a potential explanation for the predominant 
endophenotypes seen in the DS brain.  
6. Pharmacological approach using DS HNPs 
From a translational standpoint, human neurally-derived reagents will be useful to identify 
pathological mechanisms and address the efficacy of pharmacotherapeutics. Given that DS 
is a contiguous gene syndrome, multiple genes on HSA21 will interact, share substrates, 
and/or influence the same processes or pathways relevant to neural function. Our ongoing 
work demonstrates that some genes such as S100B and APP are over-expressed from 
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development into adulthood and would therefore have potentially cumulative effects over 
time. In this respect, treatment directed toward correcting aberrant pathways regulated by 
these genes may require early and ongoing management to achieve efficacy.  Other genes 
which might also contribute to gliocentric phenotypes and which reside on HSA21 such as 
Olig1/2 appear to be more temporally restricted (personal observations, Lu and Sheen) and 
therefore might be more amenable to a finite pharmacological approach. It remains to be 
seen to what extent the observations made from various treatment modalities for trisomy 
mouse models and/or DS HNPs are faithfully replicated in actual individuals with DS. That 
said, the use of DS HNPs would provide another measure of validation for 
pharmocotherapies devised in treatment of these disorders. 
7. Conclusion 
DS is a contiguous gene syndrome giving rise to MR, dementia, and seizures. These clinical 
outcomes are mirrored by endophenotypes including mitochondrial dysfunction, oxidative 
stress, cell death, gliosis, inflammation, prolonged cell cycle, reduction in proliferation and 
imbalances in excitatory and inhibitory neurotransmission. While these characteristics have 
largely been observed in neurons in the mature brain, function based cluster analyses of 
pair-wise comparisons between normal and DS human neural progenitors suggest that 
similar changes are ongoing during development. Moreover, these endophenotypes likely 
arise from the integration of various genetic and epigenetic factors on chromosome 21 such 
as APP, S100B, Olig1/2 and DNMT3L. The ongoing disruption of mitochondrial redux 
states and inflammation promote early gliocentric phenotypes in the progenitor pool, which 
would alter progenitor proliferative rates and contribute to a decline in interneuron 
production. Overall, early developmental changes in the progenitor population could 
promote many of the deleterious changes seen later in the mature DS brain. 
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1. Introduction 
1.1 Trisomy 21 causes phenotypes associated with Down syndrome  
Down syndrome (DS) occurs in approximately 1 out of 700 live births and most commonly 
results from three copies of human chromosome 21 (Hsa21) (Christianson, 2006). DS is a 
multifaceted disorder with over 80 clinically defined phenotypes including those affecting 
the central nervous system, heart, gastrointestinal tract, skeleton and immune system 
(Epstein, 2001; Van Cleve and Cohen, 2006). Phenotypes associated with individuals with 
DS vary in both incidence and severity, leading to a vast array of phenotypic combinations 
among those with Trisomy 21 (Ts21) (Deutsch et al., 2005; Epstein, 2001; Van Cleve et al., 
2006; Van Cleve and Cohen, 2006). For example, cognitive impairment, hypotonia and 
craniofacial features are universal phenotypes, whereas cardiac abnormalities only affect 
approximately half of individuals with DS. Individual phenotypes similar to those seen in 
DS have been documented in individuals without Ts21, but a general higher incidence and 
severity of these phenotypes in individuals with DS suggests that trisomy plays an 
important role in initiating or modifying these features  (Epstein, 2001; Roper and Reeves, 
2006). Although it has been suggested that common mechanisms may be involved in similar 
phenotypes seen in individuals with and without Ts21, common pathophysiology must be 
proven for each individual phenotype. 
A chromosomal basis for DS was postulated as early as 1932 (Patterson and Costa, 2005). 
After Jerome Lejeune established that DS was caused by an extra Hsa21, he studied the 
metabolic pathways associated with Ts21 phenotypes in an attempt to cure DS (Neri and 
Opitz, 2009). Alternate causes of DS, including translocations and mosaicism of extra 
material from Hsa21, were established shortly after the chromosomal basis of DS had been 
discovered (Patterson and Costa, 2005). These early genetic findings set the stage for current 
paradigms and research surrounding the gene-phenotype relationships in DS.  
Although ~95% of the incidence of DS is due to trisomy of the entire Hsa21, DS also results 
from extra genetic material from Hsa21 translocated to other chromosomes. Additionally, 
some individuals with DS phenotypes have Ts21 in only a portion of their cells (mosaicism). 
Differences in genetic and cellular composition of the trisomy may lead to the observed 
differences in DS phenotypic incidence and severity. Genotypic and phenotypic variations 
have also been used to hypothesize about trisomic genes or chromosomal regions that may 
cause or significantly alter DS phenotypes. Such genotype-phenotype correlations are 
important in defining the etiology of traits associated with DS as well as suggesting possible 
therapeutic mechanisms to overcome deficits seen in individuals with DS.  
 
Genetics and Etiology of Down Syndrome 
 
64
Yankner, B. A., and Lu, T. (2009). Amyloid beta-protein toxicity and the pathogenesis of 
Alzheimer disease. J Biol Chem 284, 4755-4759. 
Ye, F., Chen, Y., Hoang, T., Montgomery, R. L., Zhao, X. H., Bu, H., Hu, T., Taketo, M. M., 
van Es, J. H., Clevers, H., et al. (2009). HDAC1 and HDAC2 regulate 
oligodendrocyte differentiation by disrupting the beta-catenin-TCF interaction. Nat 
Neurosci 12, 829-838. 
Yu, Y., Chu, P. Y., Bowser, D. N., Keating, D. J., Dubach, D., Harper, I., Tkalcevic, J., 
Finkelstein, D. I., and Pritchard, M. A. (2008). Mice deficient for the chromosome 21 
ortholog Itsn1 exhibit vesicle-trafficking abnormalities. Hum Mol Genet 17, 3281-
3290. 
Zhou, Q., and Anderson, D. J. (2002). The bHLH transcription factors OLIG2 and OLIG1 




Down Syndrome: A Complex and  
Interactive Genetic Disorder 
 Samantha L. Deitz, Joshua D. Blazek, Jeffrey P. Solzak and Randall J. Roper 
Indiana University-Purdue University Indianapolis 
United States of America 
1. Introduction 
1.1 Trisomy 21 causes phenotypes associated with Down syndrome  
Down syndrome (DS) occurs in approximately 1 out of 700 live births and most commonly 
results from three copies of human chromosome 21 (Hsa21) (Christianson, 2006). DS is a 
multifaceted disorder with over 80 clinically defined phenotypes including those affecting 
the central nervous system, heart, gastrointestinal tract, skeleton and immune system 
(Epstein, 2001; Van Cleve and Cohen, 2006). Phenotypes associated with individuals with 
DS vary in both incidence and severity, leading to a vast array of phenotypic combinations 
among those with Trisomy 21 (Ts21) (Deutsch et al., 2005; Epstein, 2001; Van Cleve et al., 
2006; Van Cleve and Cohen, 2006). For example, cognitive impairment, hypotonia and 
craniofacial features are universal phenotypes, whereas cardiac abnormalities only affect 
approximately half of individuals with DS. Individual phenotypes similar to those seen in 
DS have been documented in individuals without Ts21, but a general higher incidence and 
severity of these phenotypes in individuals with DS suggests that trisomy plays an 
important role in initiating or modifying these features  (Epstein, 2001; Roper and Reeves, 
2006). Although it has been suggested that common mechanisms may be involved in similar 
phenotypes seen in individuals with and without Ts21, common pathophysiology must be 
proven for each individual phenotype. 
A chromosomal basis for DS was postulated as early as 1932 (Patterson and Costa, 2005). 
After Jerome Lejeune established that DS was caused by an extra Hsa21, he studied the 
metabolic pathways associated with Ts21 phenotypes in an attempt to cure DS (Neri and 
Opitz, 2009). Alternate causes of DS, including translocations and mosaicism of extra 
material from Hsa21, were established shortly after the chromosomal basis of DS had been 
discovered (Patterson and Costa, 2005). These early genetic findings set the stage for current 
paradigms and research surrounding the gene-phenotype relationships in DS.  
Although ~95% of the incidence of DS is due to trisomy of the entire Hsa21, DS also results 
from extra genetic material from Hsa21 translocated to other chromosomes. Additionally, 
some individuals with DS phenotypes have Ts21 in only a portion of their cells (mosaicism). 
Differences in genetic and cellular composition of the trisomy may lead to the observed 
differences in DS phenotypic incidence and severity. Genotypic and phenotypic variations 
have also been used to hypothesize about trisomic genes or chromosomal regions that may 
cause or significantly alter DS phenotypes. Such genotype-phenotype correlations are 
important in defining the etiology of traits associated with DS as well as suggesting possible 
therapeutic mechanisms to overcome deficits seen in individuals with DS.  
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1.2 Hypotheses regarding genotype-phenotype correlation in DS 
Early investigations into the genotype-phenotype relationship drew upon information from 
individuals with partial Ts21. By examining these individuals, determining the extra 
chromosomal material and corresponding phenotypes, an early causal hypothesis linked DS 
to trisomy of the distal end of Hsa21 (Patterson and Costa, 2005). A reductionist variation of 
this hypothesis later stated that individual phenotypes and features could be mapped to 
specific regions of the genome, and the addition of these regions with their respective 
phenotypes would cause the multitude of traits associated with DS (Neri and Opitz, 2009). 
Others had a more global or genomic view of the genotype-phenotype relationship and 
hypothesized that DS phenotypes were due to a general genomic imbalance initiated by 
Ts21. Many new ideas have extended or combined previous hypotheses as well as proposed 
novel views about the correlation between genes and phenotypes in DS, especially with an 
increased ability to precisely define the genotypes and phenotypes associated with DS. Yet, 
the exact mechanisms of how the triplication of genes on Hsa21, the smallest and least gene 
dense of the autosomes, causes one of the myriad phenotypes associated with DS have still 
largely not been established. One or more of the hypothesized mechanisms may be correct 
for a single phenotype associated with DS, yet it is unlikely that a single overriding 
mechanism would describe the etiology of all Ts21 phenotypes (Epstein, 2001). 
1.2.1 Gene dosage imbalance hypothesis 
The “gene dosage imbalance” hypothesis suggests that an increased dosage or copy number 
of genes on Hsa21 would lead to an increase in gene expression and protein product in the 
individual (Antonarakis et al., 2004; Epstein, 2001; Pritchard and Kola, 1999). In essence, 
overexpression of the products of dosage sensitive genes on Hsa21 would lead to DS 
phenotypes. This hypothesis has been extended to include the possibility that specific genes 
or subsets of genes may control specific DS phenotypes (Patterson, 2007). Most studies have 
concluded that three copies of Hsa21 genes leads to an average 50% higher expression of 
trisomic genes as compared to euploid (normal chromosomal complement) individuals 
(Gardiner et al., 2010). As additional high throughput analyses are performed, however it is 
becoming increasingly clear that the gene expression changes may be specific to a group of 
genes in a particular tissue at a precise developmental or mature stage. Additionally, some 
trisomic gene expression changes may overlap with normal expression of these genes in the 
euploid chromosomal component (Ait Yahya-Graison et al., 2007; Prandini et al., 2007; 
Wiseman et al., 2009).  
1.2.2 Amplified developmental instability hypothesis 
The “amplified developmental instability” hypothesis states that a non-specific dosage of a 
number of trisomic genes leads to a genetic imbalance that causes a large impact on the 
expression and regulation of many genes throughout the genome (Pritchard and Kola, 1999; 
Shapiro, 1983). This disruption in genetic homeostasis or more generalized change in gene 
expression throughout the genome would affect signaling pathways and lead to phenotypes 
associated with DS. Therefore, it has been hypothesized that traits in individuals with DS 
are not caused by the altered expression of a particular gene, but rather the general changes 
in expression throughout the genome caused by trisomy that lead to DS traits (Patterson, 
2009). An additional premise of this hypothesis is that the larger the number of trisomic 
genes, the higher the incidence and severity of DS phenotypes due to increased genetic 
instability. An extension of this hypothesis is that some phenotypic changes associated with 
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DS may not be attributable to specific genetic changes but rather to changes in the 
expression of the entire chromosomal domain (Gardiner et al., 2010). 
1.2.3 Critical region(s) hypothesis   
Phenotypic analyses conducted on individuals with partial trisomy for Hsa21 led to a 
hypothesis that only one or a few small chromosomal regions, termed “Down syndrome 
critical regions” (DSCR), contain genes responsible for the majority of DS phenotypes 
(Delabar et al., 1993; Korenberg et al., 1990). It has been suggested that DS (including many 
of the major, most well defined phenotypes) was caused by one specific DSCR (Epstein, 
2001). Even before the identification of specific genes on Hsa21, a region of 1.6-2.5 Mb on 
Hsa21was thought to be responsible and sufficient to cause most DS phenotypes (Dahmane 
et al., 1998; Ohira et al., 1996). The sequencing of Hsa21 proved to be an important factor in 
the progression of DS research (Hattori et al., 2000) and led to further insight into genotype-
phenotype correlations associated with DS and precise characterizations of DSCR regions 
(Patterson, 2009). A region of 3.8-6.5 Mb on 21q21.22 containing approximately 30 genes has 
been traditionally identified as the DSCR, although recent studies have demonstrated that 
this DSCR is not sufficient for all major DS phenotypes, though its inclusive genes may be 
relevant for some individual phenotypes (Delabar et al., 1993; Lyle et al., 2009). A current 
hypothesis states that certain chromosomal regions may contain a significant gene or genes 
necessary for the development or maintenance of specific but not all DS phenotypes (Korbel 
et al., 2009; Lyle et al., 2009; Olson et al., 2007).  
1.2.4 Other genetic, epigenetic and environmental considerations 
The hypotheses of how genetic mechanisms control DS phenotypes are not mutually 
exclusive, may include a combination of different mechanisms and may be unique for each 
particular phenotype. It is now believed that contributions to phenotypes associated with 
DS are likely to come from a number of genes. Variability in genomes may also come from 
allelic heterogeneity or other differences in the genetic architecture (Antonarakis et al., 
2004). There may be genes that have a larger effect on certain phenotypes (Epstein, 2001; 
Patterson, 2009), or genetic contributions may be additive, subtractive, or epistatic (Gardiner 
et al., 2010). Recently it has been shown that epigenetic modifications and allelic differences 
also play a significant role in the development of these phenotypes, not just the simple 
presence of the chromosomal imbalance (Belichenko et al., 2009; Elton et al., 2010). Other 
factors including environmental influences and stochastic events also add to the differential 
manifestation of phenotypes. 
1.2.5 Dosage compensation 
Extra copies of genes may be found as a result of a number of duplication events, yet many 
of the resultant trisomies may be difficult to detect or have subtle phenotypes. Though there 
may be an extra copy of a gene, and even alterations in gene expression with the resultant 
protein product, dosage imbalance for a specific gene may have no effect on a phenotype. 
Such genes have been “dosage compensated” by some mechanism (Antonarakis et al., 2004). 
Gene expression experiments of cells with Ts21 have shown that a high percentage of three 
copy genes may undergo dosage compensation (Ait Yahya-Graison et al., 2007). This 
compensation could be accomplished by gene regulatory networks or negative feedback 
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DS may not be attributable to specific genetic changes but rather to changes in the 
expression of the entire chromosomal domain (Gardiner et al., 2010). 
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2001). Even before the identification of specific genes on Hsa21, a region of 1.6-2.5 Mb on 
Hsa21was thought to be responsible and sufficient to cause most DS phenotypes (Dahmane 
et al., 1998; Ohira et al., 1996). The sequencing of Hsa21 proved to be an important factor in 
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2004). There may be genes that have a larger effect on certain phenotypes (Epstein, 2001; 
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presence of the chromosomal imbalance (Belichenko et al., 2009; Elton et al., 2010). Other 
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Extra copies of genes may be found as a result of a number of duplication events, yet many 
of the resultant trisomies may be difficult to detect or have subtle phenotypes. Though there 
may be an extra copy of a gene, and even alterations in gene expression with the resultant 
protein product, dosage imbalance for a specific gene may have no effect on a phenotype. 
Such genes have been “dosage compensated” by some mechanism (Antonarakis et al., 2004). 
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loops. Dosage compensation may be tissue or time dependent and may play an important 
role in the development and progression of DS phenotypes.  
1.3 Mouse models of DS to understand genotype-phenotype correlation 
In addition to being valuable tools for better understanding Ts21 and DS phenotypes, DS 
mouse models have also been utilized as predictive models of novel DS phenotypes (Baxter 
et al., 2000). Mice provide access to all tissues at all developmental stages, the ability to 
understand genetic and cellular mechanisms caused by trisomy, and a resource to 
understand potential treatments for phenotypes. Genes found on Hsa21 are highly 
conserved in order and homology on three different mouse chromosomes: mouse 
chromosome (Mmu)16, 17, and 10. Several DS mouse models have been created with 
segmental trisomy for different regions of the distal portion Mmu16, that contains nearly 
half the gene homologs found on Hsa21 (Hattori et al., 2000; Pletcher et al., 2001). The 
Ts65Dn mouse is the most commonly used DS model with segmental trisomy for the distal 
portion of Mmu16. Three copies of the region between Mrpl39 and Znf295 spanning 13.6 Mb 
on Mmu16 and containing over 100 Hsa21 gene homologs results in  several DS-like 
phenotypes (Reeves et al., 1995). The Ts1Cje mouse contains segmental trisomy for 
approximately 78% (Sod1-Znf295 excluding Sod1) of the triplicated genes in the Ts65Dn 
model (Olson et al., 2004b; Sago et al., 1998). Both Ts65Dn and Ts1Cje mice contain three 
copies of the putative DSCR region and exhibit a significant amount of phenotypic similarity 
to humans with DS. The Ts1Rhr/Ms1Rhr mouse models were created by generating a 3.9 
Mb reciprocal duplication/deletion containing 33 genes (Cbr1-Orf9) homologous to those 
found in the most commonly defined human DSCR (Olson et al., 2004a). The 
transchromosomal Tc1 mouse model of DS has a copy of Hsa21 in its cells, though there are 
some deletions of Hsa21 regions and significant mosaicism in this model (O'Doherty et al., 
2005). The Ts1Yey model contains the entire region of Hsa21 homology on Mmu16 from 
D930038D03Rik-Znf295 duplicated on one Mmu16 and results in trisomy for this region in 
the mouse model (Li et al., 2007) (See Table 1). 
More recently, mouse models of DS have been made that contain small regions of homology 
from chromosomes other than Mmu16. The Ts1Yah model contains a duplication of Mmu17 
from Abcg1-U2af1 with homology to Hsa21 (Pereira et al., 2009). The Ts2Yey model has a 
duplication of the entire region of Mmu10 homologous to Hsa21 (Prmt2-Pdxk). The Ts3Yey 
mouse has a duplication of the entire Mmu17 chromosomal region that corresponds to 
Hsa21 (Abcg1-Rrp1b) (Yu et al., 2010). Mice containing entire regions of homology to Hsa21 
are being generated to examine DS phenotypes. Mouse models of DS may exhibit certain 
DS-like phenotypes with differing severity, but phenotypes may not be conserved across 
models, thus adding to the usefulness of the models for understanding the genotype-
phenotype relationships associated with DS. 
1.4 Using modern genetic and genomic tools to understand genotype-phenotype 
correlation in DS 
Because DS and its resultant phenotypes are caused by trisomy, the gene-phenotype 
correlation (the genes responsible for the cellular or developmental changes) is of great 
importance in understanding DS. DS may be viewed as a chromosomal disorder due to 
three copies of Hsa21, a genetic disorder resulting from the altered expression of trisomic 
genes, or a disorder that results from alterations in gene expression and pathways  
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Common 
Name 
Genetic triplication Number of triplicated 
genes 
Ts65Dn Ts(1716)65Dn 104 (Mmu 16) 
Ts1Rhr Dp(16Cbr1-Orf9)1Rhr 33 (Mmu 16) 
Ts1Cje Ts(1216C-tel)1Cje 81 (Mmu16) 




Ts2Yey Dp(10Prmt2-Pdxk)2Yey Mmu 10 
Ts3Yey Dp(17Abcg1-Rrp1b)3Yey Mmu 17 
Table 1. Common DS mouse models with defined trisomic regions.   
throughout the entire genome. Several studies have documented differential gene 
expression in tissues originating from varying spatial and developmental environments in 
attempts to determine genetic mechanisms affecting DS phenotypes (Conti et al., 2007; 
Lintas et al., 2010; Lyle et al., 2004; Moldrich et al., 2007). High throughput analysis utilizing 
tools such as microarray analysis, qPCR (quantitative polymerase chain reaction) and SAGE 
(serial analysis of gene expression) not only allow for a better understanding of gene 
expression aberrations in a spatiotemporal sense, but also permit for a better understanding 
of gene interactions within the context of natural physiological conditions. Though 
disparities exist between tissues and developmental time points, such analyses have 
provided insight into genes that appear to be critical to the development of specific DS 
phenotypes. New genetic information, coupled with precisely defined cellular and 
molecular phenotypes, (often using mouse models), has allowed the testing of multiple 
hypotheses concerning the gene-phenotype relationship. Functional groupings of 
dysregulated genes may add additional mechanistic insight into the origin of DS 
phenotypes, and such groupings may transcend both time and tissue type. The intersection 
of genetic and functional information may lead to new insights into the gene-phenotype 
relationship and the mechanisms leading to the development of DS phenotypes. With 
increasing ability to assess large scale gene expression, the importance of both trisomic and 
non-trisomic genes and genetic pathways utilizing gene products from the entire genome 
has been investigated. Instead of a simple notion of trisomy for Hsa21 causing a disorder or 
trisomic expression of specific genes on Hsa21 causing a disorder, current technologies and 
techniques now suggest that DS, with its myriad phenotypes, is a complex disorder with 
many interactions on genetic and mechanistic levels.  
2. Trisomic and non-trisomic genes 
2.1 The importance of trisomic and non-trisomic genes 
Numerous gene expression studies have been performed on an assortment of tissues from 
individuals with DS as well as mouse models of DS (Tables 2 and 3). Although these assays 
vary widely in technique and scope, they have generally focused on the altered expression 
of trisomic genes. A strict interpretation of the gene dosage hypothesis suggests that all 
trisomic genes theoretically exhibit a 1.5 fold upregulation in every tissue and cell when 
compared to normal subjects, and nearly all studies use this expected fold change as a 
standard for expression analysis (Giannone et al., 2004; Mao et al., 2003). Interestingly, in 
studies that have analyzed both trisomic and disomic (non-trisomic) gene expression in 
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loops. Dosage compensation may be tissue or time dependent and may play an important 
role in the development and progression of DS phenotypes.  
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In addition to being valuable tools for better understanding Ts21 and DS phenotypes, DS 
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understand genetic and cellular mechanisms caused by trisomy, and a resource to 
understand potential treatments for phenotypes. Genes found on Hsa21 are highly 
conserved in order and homology on three different mouse chromosomes: mouse 
chromosome (Mmu)16, 17, and 10. Several DS mouse models have been created with 
segmental trisomy for different regions of the distal portion Mmu16, that contains nearly 
half the gene homologs found on Hsa21 (Hattori et al., 2000; Pletcher et al., 2001). The 
Ts65Dn mouse is the most commonly used DS model with segmental trisomy for the distal 
portion of Mmu16. Three copies of the region between Mrpl39 and Znf295 spanning 13.6 Mb 
on Mmu16 and containing over 100 Hsa21 gene homologs results in  several DS-like 
phenotypes (Reeves et al., 1995). The Ts1Cje mouse contains segmental trisomy for 
approximately 78% (Sod1-Znf295 excluding Sod1) of the triplicated genes in the Ts65Dn 
model (Olson et al., 2004b; Sago et al., 1998). Both Ts65Dn and Ts1Cje mice contain three 
copies of the putative DSCR region and exhibit a significant amount of phenotypic similarity 
to humans with DS. The Ts1Rhr/Ms1Rhr mouse models were created by generating a 3.9 
Mb reciprocal duplication/deletion containing 33 genes (Cbr1-Orf9) homologous to those 
found in the most commonly defined human DSCR (Olson et al., 2004a). The 
transchromosomal Tc1 mouse model of DS has a copy of Hsa21 in its cells, though there are 
some deletions of Hsa21 regions and significant mosaicism in this model (O'Doherty et al., 
2005). The Ts1Yey model contains the entire region of Hsa21 homology on Mmu16 from 
D930038D03Rik-Znf295 duplicated on one Mmu16 and results in trisomy for this region in 
the mouse model (Li et al., 2007) (See Table 1). 
More recently, mouse models of DS have been made that contain small regions of homology 
from chromosomes other than Mmu16. The Ts1Yah model contains a duplication of Mmu17 
from Abcg1-U2af1 with homology to Hsa21 (Pereira et al., 2009). The Ts2Yey model has a 
duplication of the entire region of Mmu10 homologous to Hsa21 (Prmt2-Pdxk). The Ts3Yey 
mouse has a duplication of the entire Mmu17 chromosomal region that corresponds to 
Hsa21 (Abcg1-Rrp1b) (Yu et al., 2010). Mice containing entire regions of homology to Hsa21 
are being generated to examine DS phenotypes. Mouse models of DS may exhibit certain 
DS-like phenotypes with differing severity, but phenotypes may not be conserved across 
models, thus adding to the usefulness of the models for understanding the genotype-
phenotype relationships associated with DS. 
1.4 Using modern genetic and genomic tools to understand genotype-phenotype 
correlation in DS 
Because DS and its resultant phenotypes are caused by trisomy, the gene-phenotype 
correlation (the genes responsible for the cellular or developmental changes) is of great 
importance in understanding DS. DS may be viewed as a chromosomal disorder due to 
three copies of Hsa21, a genetic disorder resulting from the altered expression of trisomic 
genes, or a disorder that results from alterations in gene expression and pathways  
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Genetic triplication Number of triplicated 
genes 
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Table 1. Common DS mouse models with defined trisomic regions.   
throughout the entire genome. Several studies have documented differential gene 
expression in tissues originating from varying spatial and developmental environments in 
attempts to determine genetic mechanisms affecting DS phenotypes (Conti et al., 2007; 
Lintas et al., 2010; Lyle et al., 2004; Moldrich et al., 2007). High throughput analysis utilizing 
tools such as microarray analysis, qPCR (quantitative polymerase chain reaction) and SAGE 
(serial analysis of gene expression) not only allow for a better understanding of gene 
expression aberrations in a spatiotemporal sense, but also permit for a better understanding 
of gene interactions within the context of natural physiological conditions. Though 
disparities exist between tissues and developmental time points, such analyses have 
provided insight into genes that appear to be critical to the development of specific DS 
phenotypes. New genetic information, coupled with precisely defined cellular and 
molecular phenotypes, (often using mouse models), has allowed the testing of multiple 
hypotheses concerning the gene-phenotype relationship. Functional groupings of 
dysregulated genes may add additional mechanistic insight into the origin of DS 
phenotypes, and such groupings may transcend both time and tissue type. The intersection 
of genetic and functional information may lead to new insights into the gene-phenotype 
relationship and the mechanisms leading to the development of DS phenotypes. With 
increasing ability to assess large scale gene expression, the importance of both trisomic and 
non-trisomic genes and genetic pathways utilizing gene products from the entire genome 
has been investigated. Instead of a simple notion of trisomy for Hsa21 causing a disorder or 
trisomic expression of specific genes on Hsa21 causing a disorder, current technologies and 
techniques now suggest that DS, with its myriad phenotypes, is a complex disorder with 
many interactions on genetic and mechanistic levels.  
2. Trisomic and non-trisomic genes 
2.1 The importance of trisomic and non-trisomic genes 
Numerous gene expression studies have been performed on an assortment of tissues from 
individuals with DS as well as mouse models of DS (Tables 2 and 3). Although these assays 
vary widely in technique and scope, they have generally focused on the altered expression 
of trisomic genes. A strict interpretation of the gene dosage hypothesis suggests that all 
trisomic genes theoretically exhibit a 1.5 fold upregulation in every tissue and cell when 
compared to normal subjects, and nearly all studies use this expected fold change as a 
standard for expression analysis (Giannone et al., 2004; Mao et al., 2003). Interestingly, in 
studies that have analyzed both trisomic and disomic (non-trisomic) gene expression in 
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trisomic compared to normal individuals, a significant number of non-trisomic genes have 
been found to be dysregulated in association with DS phenotypes (Table 4) (Lockstone et al., 
2007; Rozovski et al., 2007; Slonim et al., 2009). 
 
Study Strain Age Tissue Platform 
Chrast et al. 2000 Ts65Dn Adult Brain SAGE 
Saran et al. 2003 Ts65Dn 3-4 months Cerebellum Microarray 
Amano et al. 2004 Ts1Cje Postnatal 0 Brain Microarray 
Lyle et al. 2004 Ts65Dn Adult Brain, Heart, Kidney, Liver, 
Lung, Muscle 
qPCR 
Dauphinot et al. 2005 Ts1Cje Postnatal 0, 15, 30 Cerebellum Microarray 
Kahlem et al 2007 Ts65Dn 3-4 months Lung, Skeletal Muscle, 
Midbrain, Cerebellum, 
Cortex, Testis, Liver, Heart, 
Kidney 
Microarray 
Sultan et al. 2007 Ts65Dn 13-26 weeks Cerebellum, Midbrain, 
Cortex 
qPCR 
Laffaire et al. 2009 Ts1Cje Postnatal 0, 3, 7, 10 Cerebellum, Granule Cell 
Layer 
Microarray 
Moldrich et al. 2009 Ts1Cje E14 Neural Progenitor Cells Microarray 
Hewitt et al. 2010 Ts1Cje Adult Neural Stem Cells Microarray, 
qPCR 
Table 2. Features of gene expression assays performed in mice.  
 
Study Age Tissue Platform 
Gross et al. 2002 Gest. 16-24 weeks Placenta Microarray 
FitzPatrick et al. 2002 Fetal Amniocytes Microarray, qPCR 
Mao et al. 2003 Gest. 17-21 weeks Cerebral cortex, astrocytes Microarray 
Giannone et al. 2004 Adult T lymphocytes Microarray 
Tang et al. 2004 Adult Blood Microarray 
Chung et al. 2005 Fetal Amniocytes Microarray 
Deutsch et al. 2005 Adult Lymphoblastoids qPCR 
Mao et al. 2005 Fetal Cerebellum, heart Microarray 
Li et al. 2006 Gest. 15-23 weeks Heart, fibroblasts Microarray, qPCR 
Ait Yahya-Graison  
et al. 2007 
Adult Lymphoblasts Microarray 
Altug-Teber et al. 2007 Fetal Amniocytes,  
Chorionic Villus Cells 
Microarray 
Conti et al. 2007 Gest. 18-22 weeks Heart Microarray 
Lockstone et al. 2007 47-76 years Brain Microarray 
Prandini et al. 2007 25 years Lymphoblasts, Fibroblasts qPCR 
Rozovski et al. 2007 Fetal Placenta Microarray, qPCR 
Chou et al. 2008 Gest. 16-21 weeks Amniocytes Microarray 
Esposito et al. 2008 Gest. 19-21 weeks Frontal cortex Microarray 
Sommer et al. 2008 







    
Table 3. Features of gene expression assays from human derived tissues.  
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The number and variety of genes found to be dysregulated in response to trisomy seems to 
vary greatly in a spatiotemporal dependent manner, and provide evidence against the idea 
of a specific 1.5 fold dysregulation of trisomic genes in all tissue types (Mao et al., 2005; 
Potier et al., 2006; Sultan et al., 2007). Additionally, much of the variation in both trisomic 
and disomic gene expression in subjects with trisomy overlaps with the variation observed 
among normal individuals, which may limit the number of trisomic genes found to be 
differentially expressed (Prandini et al., 2007), and contribute to the variable phenotypes 
associated with DS (Chou et al., 2008). We therefore hypothesize that both trisomic and non-
trisomic genes are important for the origin and development of DS phenotypes.  
2.2 Gene expression studies in humans and mouse models of DS  
2.2.1 Altered expression of trisomic genes and the gene dosage hypothesis 
The gene dosage hypothesis and the proposed 1.5 fold increase in all trisomic gene expression 
have motivated much of the gene expression research of DS phenotypes. Assessment of gene 
expression in human fetal brain tissue and astrocyte cell lines taken at 17-20 weeks gestation 
revealed a general upregulation of trisomic gene expression, and seemed to agree with the 1.5 
fold change hypothesis (Mao et al., 2003). Analysis of brain tissue isolated from 13-16 week old 
Ts65Dn mice also identified a global upregulation of trisomic genes in the cerebellum, cortex, 
and midbrain, and the average fold changes of trisomic gene expression were 1.44, 1.37, and 
1.39, respectively, in Ts65Dn mice (Sultan et al., 2007). 
Yet, other studies suggest the global upregulation of trisomic genes in agreement with the 
gene-dosage hypothesis is likely not occurring in DS. Many studies indicate that not all 
trisomic genes are dysregulated in all trisomic tissues. Furthermore, several studies on 
trisomic tissues have demonstrated expression levels significantly different from the 
expected 1.5 fold increase, indicating that having three copies of a gene does not necessarily 
confer a 1.5 fold upregulation. For example, expression analysis of 99 genes in 6 different 
tissues (brain, heart, lung, kidney, liver, and muscle) in P30 and 11 month old Ts65Dn mice 
revealed that 37% of the trisomic genes were expressed at a 1.5 fold increase, 45% were <1.5 
increase, 18% >1.5 increase, and 9% were not significantly different from normal mice (Lyle 
et al., 2004). Additionally, only 15% and 29% of tested trisomic genes were found to be 
overexpressed in DS fetal hearts and cultured fibroblasts, respectively (Li et al., 2006). Of 134 
differentially expressed genes assessed in lymphoblastoid cell lines (LCLs), 58/134 had 
overexpression greater than 1, (1.25-2.27), and 86/134 exhibited fold changes significantly 
different from 1.5 (9 were greater than 1.5 fold (1.64-2.27) and 77 were less than 1.5 (0.74-
1.4)) (Ait Yahya-Graison et al., 2007). Of 117 trisomic genes in LCLs and 114 trisomic genes 
in fibroblasts, only 39% and 62% respectively were found to have significant expression 
differences from euploid cells (Prandini et al., 2007). Based on these data, four classes of 
genes in trisomic tissues have been suggested: those that exhibit expression significantly 
different from 1 but not different from 1.5 fold, amplified genes (expression significantly 
greater than 1.5 fold), compensated genes (expression significantly less than 1.5 fold), and 
the genes with expression differences not different from 1 or 1.5 fold (Ait Yahya-Graison et 
al., 2007; Prandini et al., 2007). These extensive studies indicate that a global 1.5 fold 
upregulation of all trisomic genes in DS tissues is unlikely and suggest that mechanisms in 
addition to trisomy are also affecting gene regulation. Although the expression levels of 
some trisomic genes fit within the theoretical 50% upregulation, trisomic genes in several 
tissues at different time points exhibit expression levels much different from the expected 
1.5 fold increase.  
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trisomic compared to normal individuals, a significant number of non-trisomic genes have 
been found to be dysregulated in association with DS phenotypes (Table 4) (Lockstone et al., 
2007; Rozovski et al., 2007; Slonim et al., 2009). 
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The number and variety of genes found to be dysregulated in response to trisomy seems to 
vary greatly in a spatiotemporal dependent manner, and provide evidence against the idea 
of a specific 1.5 fold dysregulation of trisomic genes in all tissue types (Mao et al., 2005; 
Potier et al., 2006; Sultan et al., 2007). Additionally, much of the variation in both trisomic 
and disomic gene expression in subjects with trisomy overlaps with the variation observed 
among normal individuals, which may limit the number of trisomic genes found to be 
differentially expressed (Prandini et al., 2007), and contribute to the variable phenotypes 
associated with DS (Chou et al., 2008). We therefore hypothesize that both trisomic and non-
trisomic genes are important for the origin and development of DS phenotypes.  
2.2 Gene expression studies in humans and mouse models of DS  
2.2.1 Altered expression of trisomic genes and the gene dosage hypothesis 
The gene dosage hypothesis and the proposed 1.5 fold increase in all trisomic gene expression 
have motivated much of the gene expression research of DS phenotypes. Assessment of gene 
expression in human fetal brain tissue and astrocyte cell lines taken at 17-20 weeks gestation 
revealed a general upregulation of trisomic gene expression, and seemed to agree with the 1.5 
fold change hypothesis (Mao et al., 2003). Analysis of brain tissue isolated from 13-16 week old 
Ts65Dn mice also identified a global upregulation of trisomic genes in the cerebellum, cortex, 
and midbrain, and the average fold changes of trisomic gene expression were 1.44, 1.37, and 
1.39, respectively, in Ts65Dn mice (Sultan et al., 2007). 
Yet, other studies suggest the global upregulation of trisomic genes in agreement with the 
gene-dosage hypothesis is likely not occurring in DS. Many studies indicate that not all 
trisomic genes are dysregulated in all trisomic tissues. Furthermore, several studies on 
trisomic tissues have demonstrated expression levels significantly different from the 
expected 1.5 fold increase, indicating that having three copies of a gene does not necessarily 
confer a 1.5 fold upregulation. For example, expression analysis of 99 genes in 6 different 
tissues (brain, heart, lung, kidney, liver, and muscle) in P30 and 11 month old Ts65Dn mice 
revealed that 37% of the trisomic genes were expressed at a 1.5 fold increase, 45% were <1.5 
increase, 18% >1.5 increase, and 9% were not significantly different from normal mice (Lyle 
et al., 2004). Additionally, only 15% and 29% of tested trisomic genes were found to be 
overexpressed in DS fetal hearts and cultured fibroblasts, respectively (Li et al., 2006). Of 134 
differentially expressed genes assessed in lymphoblastoid cell lines (LCLs), 58/134 had 
overexpression greater than 1, (1.25-2.27), and 86/134 exhibited fold changes significantly 
different from 1.5 (9 were greater than 1.5 fold (1.64-2.27) and 77 were less than 1.5 (0.74-
1.4)) (Ait Yahya-Graison et al., 2007). Of 117 trisomic genes in LCLs and 114 trisomic genes 
in fibroblasts, only 39% and 62% respectively were found to have significant expression 
differences from euploid cells (Prandini et al., 2007). Based on these data, four classes of 
genes in trisomic tissues have been suggested: those that exhibit expression significantly 
different from 1 but not different from 1.5 fold, amplified genes (expression significantly 
greater than 1.5 fold), compensated genes (expression significantly less than 1.5 fold), and 
the genes with expression differences not different from 1 or 1.5 fold (Ait Yahya-Graison et 
al., 2007; Prandini et al., 2007). These extensive studies indicate that a global 1.5 fold 
upregulation of all trisomic genes in DS tissues is unlikely and suggest that mechanisms in 
addition to trisomy are also affecting gene regulation. Although the expression levels of 
some trisomic genes fit within the theoretical 50% upregulation, trisomic genes in several 
tissues at different time points exhibit expression levels much different from the expected 
1.5 fold increase.  
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Table 4. Significant trisomic and disomic genes highlighted by gene expression studies. 
Common genes of interest were selected from studies that stated more than three genes. 
N/A= not applicable or available. 
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2.2.2 Altered expression of non-trisomic genes 
While many gene expression studies have focused on expression levels of genes in three 
copies, increasingly the expression of non-trisomic genes has also been analyzed. Two early 
microarray studies using amniotic fluid and placenta found extreme variation associated 
with the genes on Hsa21, however both of these studies showed that disomic genes also 
contained high variation in expression in trisomic tissue (Chung et al., 2005; Deutsch et al., 
2005). It was observed that two-copy genes were downregulated implying that Ts21 was 
affecting genes on other chromosomes (Chung et al., 2005). An additional microarray 
analysis on cells derived from DS fetal placenta found 750 genes were overexpressed with 
the majority located on chromosomes other than 21, implicating non-trisomic genes as 
significant contributors to DS phenotypes (Rozovski et al., 2007). Adult human DS brains 
exhibited 400 differentially expressed genes when compared to normal individuals and 
approximately 350 of these were not found on Hsa21 (Lockstone et al., 2007). Expression 
analyses conducted on uncultured DS amniotic fluid cells identified a total of 414 
dysregulated genes with only five located on Hsa21 (Slonim et al., 2009). Two recent 
analyses of cells from developing Ts1Cje brains have also indicated a large number of 
dysregulated non-trisomic genes in addition to significantly dysregulated trisomic genes 
(Laffaire et al., 2009; Moldrich et al., 2009). Additionally, 6.5% of all disomic genes were 
found to be dysregulated in the primary neural progenitor cells isolated from the brains of 
adult DS mice (Hewitt et al., 2010). Based on these findings, it has been suggested that 
trisomy causes a disruption in gene regulation throughout the entire genome and not just of 
the genes in three copies. Despite these findings, the phenotypic effects of altered disomic 
gene expression in DS is highly debated and not well understood (Lyle et al., 2004; Mao et 
al., 2005; Saran et al., 2003). 
2.3 Measuring gene regulation with tissue and age specificity  
The most tissue-specific developmental microarray research in mouse models of DS has 
focused on the developing cerebellum, which continues to develop after birth. Extensive 
microarray analyses of the hypocellular cerebellum in adult and early postnatal trisomic 
mice have revealed dysregulation of both trisomic and non-trisomic genes. For example, 
microarray analyses were performed on the entire cerebellum during postnatal days 0, 15, 
and 30 (P0, P15, P30) in the Ts1Cje model of DS. Though genes present in three copies had 
an average relative expression of about 1.5 fold, only five (P0), nine (P15), and seven (P30) 
three copy genes of the 63 trisomic genes tested were expressed at levels >2 or <1.2. 
Additionally, 406 of 8250 two copy (non-trisomic) genes examined had ratios comparing 
trisomic and euploid expression that were significantly different from 1 (Dauphinot et al., 
2005). Three trisomic genes were dysregulated at all developmental time points. 
Interestingly, changes in development influenced gene expression differences between 
stages more than between trisomy and euploid animals (Dauphinot et al., 2005; Potier et al., 
2006). As these studies showed, gene expression can vary greatly in one tissue from early in 
development to adulthood. Because individual genes are shown to have variation in 
expression throughout development, certain genes may be relevant to a particular 
phenotype at one time point and unrelated at another. 
2.4 Gene expression variation in response to Trisomy 21 
In addition to the importance of understanding the temporal and spatial relationships 
associated with trisomic gene expression, variation in gene expression of both disomic and 
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Table 4. Significant trisomic and disomic genes highlighted by gene expression studies. 
Common genes of interest were selected from studies that stated more than three genes. 
N/A= not applicable or available. 
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2.2.2 Altered expression of non-trisomic genes 
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contained high variation in expression in trisomic tissue (Chung et al., 2005; Deutsch et al., 
2005). It was observed that two-copy genes were downregulated implying that Ts21 was 
affecting genes on other chromosomes (Chung et al., 2005). An additional microarray 
analysis on cells derived from DS fetal placenta found 750 genes were overexpressed with 
the majority located on chromosomes other than 21, implicating non-trisomic genes as 
significant contributors to DS phenotypes (Rozovski et al., 2007). Adult human DS brains 
exhibited 400 differentially expressed genes when compared to normal individuals and 
approximately 350 of these were not found on Hsa21 (Lockstone et al., 2007). Expression 
analyses conducted on uncultured DS amniotic fluid cells identified a total of 414 
dysregulated genes with only five located on Hsa21 (Slonim et al., 2009). Two recent 
analyses of cells from developing Ts1Cje brains have also indicated a large number of 
dysregulated non-trisomic genes in addition to significantly dysregulated trisomic genes 
(Laffaire et al., 2009; Moldrich et al., 2009). Additionally, 6.5% of all disomic genes were 
found to be dysregulated in the primary neural progenitor cells isolated from the brains of 
adult DS mice (Hewitt et al., 2010). Based on these findings, it has been suggested that 
trisomy causes a disruption in gene regulation throughout the entire genome and not just of 
the genes in three copies. Despite these findings, the phenotypic effects of altered disomic 
gene expression in DS is highly debated and not well understood (Lyle et al., 2004; Mao et 
al., 2005; Saran et al., 2003). 
2.3 Measuring gene regulation with tissue and age specificity  
The most tissue-specific developmental microarray research in mouse models of DS has 
focused on the developing cerebellum, which continues to develop after birth. Extensive 
microarray analyses of the hypocellular cerebellum in adult and early postnatal trisomic 
mice have revealed dysregulation of both trisomic and non-trisomic genes. For example, 
microarray analyses were performed on the entire cerebellum during postnatal days 0, 15, 
and 30 (P0, P15, P30) in the Ts1Cje model of DS. Though genes present in three copies had 
an average relative expression of about 1.5 fold, only five (P0), nine (P15), and seven (P30) 
three copy genes of the 63 trisomic genes tested were expressed at levels >2 or <1.2. 
Additionally, 406 of 8250 two copy (non-trisomic) genes examined had ratios comparing 
trisomic and euploid expression that were significantly different from 1 (Dauphinot et al., 
2005). Three trisomic genes were dysregulated at all developmental time points. 
Interestingly, changes in development influenced gene expression differences between 
stages more than between trisomy and euploid animals (Dauphinot et al., 2005; Potier et al., 
2006). As these studies showed, gene expression can vary greatly in one tissue from early in 
development to adulthood. Because individual genes are shown to have variation in 
expression throughout development, certain genes may be relevant to a particular 
phenotype at one time point and unrelated at another. 
2.4 Gene expression variation in response to Trisomy 21 
In addition to the importance of understanding the temporal and spatial relationships 
associated with trisomic gene expression, variation in gene expression of both disomic and 
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trisomic genes may contribute to DS phenotypes. Expression studies conducted on fibroblasts 
and LCLs identified large gene expression variation between cell lines as well as between 
individual genes (Ait Yahya-Graison et al., 2007; Deutsch et al., 2005; Prandini et al., 2007). It 
was suggested that high levels of gene expression variation could explain why the majority of 
Hsa21 genes were not significantly upregulated and the variability in DS phenotypes. The 
latter is explained by the level of overlap between gene expression in trisomic and euploid 
individuals. Genes with distinct expression profiles may be candidates for the constant 
features of DS, whereas the genes that exhibit overlapping expression profiles may be 
responsible for the variable DS phenotypes (Prandini et al., 2007). 
Studies conducted in Ts65Dn mice also exhibited differing levels of variable gene 
expression. Sultan et al. showed that 31 out of 33 trisomic genes were upregulated in the 
Ts65Dn brain. Of these 31 genes, 24 genes exhibited a small amount of variation (coefficient 
of variation of <0.2) and seven genes exhibited high variation. These authors suggested that 
the level of variation in gene expression indicated how tightly the genes were being 
regulated in the brain tissue of Ts65Dn animals.  
Understanding gene expression variation in trisomic tissues is a key component in the study 
of DS gene-phenotype relationships. This expression variation may influence the results of 
microarray and qPCR studies and lead to the false identification/exclusion of candidate 
genes for specific phenotypes. Additionally the phenotypic variability observed in 
individuals with DS may be attributed to trisomic gene expression variation in different 
tissues, and it is likely that the level of variation within an individual gene is directly related 
to how tightly that particular gene is regulated. Further research is needed to identify the 
exact role expression variation plays in the development of DS phenotypes. 
2.5 Summary 
Gene expression assays in DS are an essential tool for understanding the mechanisms 
behind Ts21. While the gene dosage hypothesis may be applicable to specific genes with  
spatiotemporal specific expression, gene expression analyses suggest that not all trisomic 
genes are dysregulated at a 1.5 fold ratio, the expression of some trisomic genes is similar to 
euploid, and variation in gene expression plays a significant role in influencing phenotypic 
development. Differences in developmental stages as well as particular tissue types may 
contribute to some of the variable findings across studies. Additionally, the level of gene 
expression variation differs between individuals of the same genotype, adding to the 
complexity of understanding expression analyses. Though trisomic genes are important and 
are the likely initiators of DS phenotypes, disomic genes are also dysregulated suggesting 
that both trisomic and disomic genes can influence the DS phenotype.  
3. Complex genotype-phenotype relationships 
Characterization of certain DS phenotypes along with the genetic analysis of individuals 
with partial trisomies led to a hypothesis of the “Down syndrome critical or chromosomal 
region” (DSCR) believed to contain the genes necessary for the development of the most 
common phenotypes observed in individuals with DS (Delabar et al., 1993; Korenberg et al., 
1990). The sequencing of Hsa21 and mapping of specific genes in the putative DSCR further 
defined the genetic content of the region and allowed for a more detailed trisomic gene-
phenotype correlation. More recent analyses of critical regions using mouse models of DS as 
well as samples from individuals with partial trisomies have questioned the validity of the 
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original DSCR hypothesis of a single region or gene important for most of the common DS 
traits (Korbel et al., 2009; Lyle et al., 2009; Olson et al., 2004a). Current data suggest a single 
critical region or critical gene is not sufficient to cause multiple characteristic DS 
phenotypes. Rather, specific genes within susceptibility regions may play important roles in 
the establishment and maintenance of specific, but not all, DS phenotypes.  
3.1 Origins of the Down syndrome critical region hypothesis 
The DSCR was originally hypothesized based on the assessment of a family with partial 
Hsa21 trisomy and the variable expression of several of the characteristic physical features 
of DS. A “critical region” within 21q22 was believed to be responsible for several DS 
phenotypes including craniofacial abnormalities, congenital heart defects of the endocardial 
cushions, clinodactyly of the fifth finger and mental retardation  (Niebuhr, 1974). Soon after 
the DSCR hypothesis, genetic analyses of the Hsa21 DNA revealed several gene-rich 
segments located within 21q22 and placed further emphasis on this region as critical to the 
development of DS phenotypes (Brahe et al., 1990).  
The hypothesis of a DSCR shifted the focus of many in the DS research community toward 
understanding how these genomic regions could correlate with the development of DS 
phenotypes. Regions linked to congenital heart defects (CHD), duodenal stenosis and 
craniofacial abnormalities in individuals with DS were identified through further analyses 
(Korenberg et al., 1992). An analysis of ten patients with partial trisomy for different 
segments of Hsa21 led to the mapping of 24 DS phenotypes to six chromosomal regions. Of 
these 24 phenotypes, 13 were mapped to 21g22.2 – proximal 21q22.3 region and six were 
linked to the D21S55-MX1 region (Delabar et al., 1993). CHD was not included in the 
phenotypes associated with the D21S55-MX1 region, and a later assessment of 19 
individuals led to the mapping of CHD to a region outside of the D21S55-MX1 region on 
21q22.3 including DSCAM, a gene known to be involved in cell adhesion and expressed in 
the heart during development (Barlow et al., 2001a). A similar experiment comparing gene 
overlap regions with the phenotypic traits of 16 individuals with partial Ts21 along with the 
phenotypic variability observed in DS led to the hypothesis that factors in addition to 
trisomic genes both within and outside the DSCR likely contribute to most DS phenotypes, 
as opposed to a single critical region (Korenberg et al., 1994). Several additional genetic 
aspects including allelic heterogeneity, epistatic interactions, imprinting effects, 
uncharacterized epigenetic modifications and environmental events as well as the general 
variability observed in non-affected individuals were also suggested to have an impact on 
phenotypic variability (Korenberg et al., 1994).  
The DSCR hypothesis, derived from analyses of the shortest region of overlap in individuals 
with partial Ts21, paved the way for the establishment of gene-phenotype relationships 
associated with DS. However, the high variability in phenotypic expression caused by an array 
of trisomic genetic consequences severely restricts the resolution of the gene-phenotype 
relationships associated with DS. The sequencing of Hsa21 as well as the development of 
several mouse models of DS provided further insight into the DSCR hypothesis.  
3.2 Disproving the DSCR with mouse models 
Unlike the analyses of partial trisomy in humans, comparisons of DS mouse models with 
differing segmental aneuploidies (both on their own and crossed between each other) has 
allowed for a systematic and meticulous analysis of the relationship between certain 
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trisomic genes may contribute to DS phenotypes. Expression studies conducted on fibroblasts 
and LCLs identified large gene expression variation between cell lines as well as between 
individual genes (Ait Yahya-Graison et al., 2007; Deutsch et al., 2005; Prandini et al., 2007). It 
was suggested that high levels of gene expression variation could explain why the majority of 
Hsa21 genes were not significantly upregulated and the variability in DS phenotypes. The 
latter is explained by the level of overlap between gene expression in trisomic and euploid 
individuals. Genes with distinct expression profiles may be candidates for the constant 
features of DS, whereas the genes that exhibit overlapping expression profiles may be 
responsible for the variable DS phenotypes (Prandini et al., 2007). 
Studies conducted in Ts65Dn mice also exhibited differing levels of variable gene 
expression. Sultan et al. showed that 31 out of 33 trisomic genes were upregulated in the 
Ts65Dn brain. Of these 31 genes, 24 genes exhibited a small amount of variation (coefficient 
of variation of <0.2) and seven genes exhibited high variation. These authors suggested that 
the level of variation in gene expression indicated how tightly the genes were being 
regulated in the brain tissue of Ts65Dn animals.  
Understanding gene expression variation in trisomic tissues is a key component in the study 
of DS gene-phenotype relationships. This expression variation may influence the results of 
microarray and qPCR studies and lead to the false identification/exclusion of candidate 
genes for specific phenotypes. Additionally the phenotypic variability observed in 
individuals with DS may be attributed to trisomic gene expression variation in different 
tissues, and it is likely that the level of variation within an individual gene is directly related 
to how tightly that particular gene is regulated. Further research is needed to identify the 
exact role expression variation plays in the development of DS phenotypes. 
2.5 Summary 
Gene expression assays in DS are an essential tool for understanding the mechanisms 
behind Ts21. While the gene dosage hypothesis may be applicable to specific genes with  
spatiotemporal specific expression, gene expression analyses suggest that not all trisomic 
genes are dysregulated at a 1.5 fold ratio, the expression of some trisomic genes is similar to 
euploid, and variation in gene expression plays a significant role in influencing phenotypic 
development. Differences in developmental stages as well as particular tissue types may 
contribute to some of the variable findings across studies. Additionally, the level of gene 
expression variation differs between individuals of the same genotype, adding to the 
complexity of understanding expression analyses. Though trisomic genes are important and 
are the likely initiators of DS phenotypes, disomic genes are also dysregulated suggesting 
that both trisomic and disomic genes can influence the DS phenotype.  
3. Complex genotype-phenotype relationships 
Characterization of certain DS phenotypes along with the genetic analysis of individuals 
with partial trisomies led to a hypothesis of the “Down syndrome critical or chromosomal 
region” (DSCR) believed to contain the genes necessary for the development of the most 
common phenotypes observed in individuals with DS (Delabar et al., 1993; Korenberg et al., 
1990). The sequencing of Hsa21 and mapping of specific genes in the putative DSCR further 
defined the genetic content of the region and allowed for a more detailed trisomic gene-
phenotype correlation. More recent analyses of critical regions using mouse models of DS as 
well as samples from individuals with partial trisomies have questioned the validity of the 
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original DSCR hypothesis of a single region or gene important for most of the common DS 
traits (Korbel et al., 2009; Lyle et al., 2009; Olson et al., 2004a). Current data suggest a single 
critical region or critical gene is not sufficient to cause multiple characteristic DS 
phenotypes. Rather, specific genes within susceptibility regions may play important roles in 
the establishment and maintenance of specific, but not all, DS phenotypes.  
3.1 Origins of the Down syndrome critical region hypothesis 
The DSCR was originally hypothesized based on the assessment of a family with partial 
Hsa21 trisomy and the variable expression of several of the characteristic physical features 
of DS. A “critical region” within 21q22 was believed to be responsible for several DS 
phenotypes including craniofacial abnormalities, congenital heart defects of the endocardial 
cushions, clinodactyly of the fifth finger and mental retardation  (Niebuhr, 1974). Soon after 
the DSCR hypothesis, genetic analyses of the Hsa21 DNA revealed several gene-rich 
segments located within 21q22 and placed further emphasis on this region as critical to the 
development of DS phenotypes (Brahe et al., 1990).  
The hypothesis of a DSCR shifted the focus of many in the DS research community toward 
understanding how these genomic regions could correlate with the development of DS 
phenotypes. Regions linked to congenital heart defects (CHD), duodenal stenosis and 
craniofacial abnormalities in individuals with DS were identified through further analyses 
(Korenberg et al., 1992). An analysis of ten patients with partial trisomy for different 
segments of Hsa21 led to the mapping of 24 DS phenotypes to six chromosomal regions. Of 
these 24 phenotypes, 13 were mapped to 21g22.2 – proximal 21q22.3 region and six were 
linked to the D21S55-MX1 region (Delabar et al., 1993). CHD was not included in the 
phenotypes associated with the D21S55-MX1 region, and a later assessment of 19 
individuals led to the mapping of CHD to a region outside of the D21S55-MX1 region on 
21q22.3 including DSCAM, a gene known to be involved in cell adhesion and expressed in 
the heart during development (Barlow et al., 2001a). A similar experiment comparing gene 
overlap regions with the phenotypic traits of 16 individuals with partial Ts21 along with the 
phenotypic variability observed in DS led to the hypothesis that factors in addition to 
trisomic genes both within and outside the DSCR likely contribute to most DS phenotypes, 
as opposed to a single critical region (Korenberg et al., 1994). Several additional genetic 
aspects including allelic heterogeneity, epistatic interactions, imprinting effects, 
uncharacterized epigenetic modifications and environmental events as well as the general 
variability observed in non-affected individuals were also suggested to have an impact on 
phenotypic variability (Korenberg et al., 1994).  
The DSCR hypothesis, derived from analyses of the shortest region of overlap in individuals 
with partial Ts21, paved the way for the establishment of gene-phenotype relationships 
associated with DS. However, the high variability in phenotypic expression caused by an array 
of trisomic genetic consequences severely restricts the resolution of the gene-phenotype 
relationships associated with DS. The sequencing of Hsa21 as well as the development of 
several mouse models of DS provided further insight into the DSCR hypothesis.  
3.2 Disproving the DSCR with mouse models 
Unlike the analyses of partial trisomy in humans, comparisons of DS mouse models with 
differing segmental aneuploidies (both on their own and crossed between each other) has 
allowed for a systematic and meticulous analysis of the relationship between certain 
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chromosomal regions and DS phenotypes. The Ts1Rhr/Ms1Rhr mouse model was created 
by generating a 3.9 Mb reciprocal duplication/deletion containing 33 genes (Cbr1-Orf9) 
homologous to those found in the most commonly recognized putative human DSCR 
(Olson et al., 2004a). Human DS-like phenotypes documented in Ts65Dn and Ts1Cje mice, 
which contain larger segmental trisomies, and the creation of Ts1Rhr and Ms1Rhr mice, 
established a system suitable to test the DSCR hypothesis in mice. Ts65Dn mice are smaller 
in size with shorter femurs and exhibit craniofacial abnormalities including smaller skulls 
and mandible bones, as well as brachycephaly when compared to euploid littermates—
defects  also found in humans with DS and previously attributed to the DSCR (Delabar et 
al., 1993; Richtsmeier et al., 2000). Analysis of Ts1Rhr mice revealed significant increases in 
overall size, length of femur, and mandible size when compared to euploid littermates and 
an absence of brachycephaly, indicating major differences between Ts1Rhr and Ts65Dn or 
Ts1Cje phenotypes (Olson et al., 2004a). Mice generated from a cross between Ts65Dn and 
Ms1Rhr mice (removing triplication of the DSCR in the Ts65Dn mouse) exhibited 
craniofacial phenotypes similar to those observed in Ts65Dn mice (Olson et al., 2004a). 
Comparison of the craniofacial phenotypes observed in Ts1Rhr and Ts65Dn/Ms1Rhr mice 
indicated that the DSCR is not sufficient to produce these phenotypes in DS mouse models, 
but may still contribute in the genetic context of the phenotypes observed in Ts65Dn mice 
through genetic interactions.  
In addition to the studies conducted on craniofacial skeletal abnormalities, DS-associated 
brain phenotypes have also been compared in DS mouse models. Ts65Dn mice exhibit a 
similar sized brain and hippocampus but smaller cerebellum and reductions in granule and 
Purkinje cell density when compared to euploid littermates (Baxter et al., 2000). Ts1Cje and 
Ms1Cje/Ts65Dn mice exhibit similar but less severe defects to those observed in Ts65Dn 
mice (Olson et al., 2004b). Analysis of Ts1Rhr mice revealed a similar sized brain and 
hippocampus when compared to euploid littermates, analogous to what was observed in 
Ts65Dn and Ts1Cje mouse models. The cerebellum of Ts1Rhr mice exhibited a small but 
significant reduction in size compared to euploid mice, but no differences were found in 
granule or Purkinje cell density, suggesting that trisomy for the DSCR is not sufficient to 
produce some brain phenotypes associated with DS (Olson et al., 2007). 
Furthermore, studies have shown that Ts65Dn mice exhibit impairment of hippocampal 
function similar to that observed in individuals with DS (Holtzman et al., 1996; Reeves et al., 
1995). Based on the DSCR hypothesis, genes within this region control the cognitive 
impairment phenotype associated with DS. If this were true, Ts1Rhr mice should exhibit 
similar deficits to Ts65Dn mice in hippocampal function. In contrast to Ts65Dn mice, Ts1Rhr 
exhibited normal hippocampal function in the Morris water maze test and normal induction 
of  long term potentiation (LTP) in the CA1 suggesting the DSCR is not sufficient to cause 
the cognitive impairment associated with DS (Aldridge et al., 2007; Olson et al., 2007). 
Interestingly, when three copies of the DSCR were reduced to two, Ts65Dn/Ms1Rhr mice 
performed similarly to euploid animals in the water maze test suggesting that although the 
DSCR is not sufficient on its own to cause cognitive impairment, it is necessary for the 
phenotype to occur (Olson et al., 2007).  
It is important to note that there are background differences between Ts65Dn, Ts1Cje, Ms1Rhr, 
and Ts1Rhr mice utilized in the studies described above. Inbreeding strategies for Ts65Dn 
and Ms1Rhr mice have not been successful, and these mice are maintained on an ~50% B6 and 
50% C3H advanced intercross genetic background. The majority of studies previously 
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documented in Ts1Rhr mice used a mixed background of approximately 50% B6, 25% 129 and 
25% C3H (except for the Morris water maze and LTP study where Ts1Rhr were on a B6 
background) and it is possible that background differences may cloud direct comparisons 
between these mouse models. Behavioral and neurophysiologic phenotypes were assessed in 
Ts1Rhr mice maintained on a ~50% B6 and 50% C3H background to mimic the same genetic 
background as Ts65Dn mice. In contrast to what was observed in Ts1Rhr mice on other 
backgrounds, these mice exhibited several (20 of 48) similar neurologic phenotypes as Ts65Dn 
mice suggesting that the DSCR may be sufficient to confer some characteristic DS cognitive 
and brain abnormalities (Belichenko et al., 2009). The differences in neurological phenotypes in 
Ts1Rhr mice on different genetic backgrounds suggest the importance of understanding the 
complex genetic interactions associated with DS. Although evidence in mouse models implies 
that there is no single region critical to the majority of DS phenotypes, it is apparent that a gene 
or genes within this region are important in certain phenotypes and these phenotypes may be 
dependent on genetic background. Either allelic differences associated with trisomic genes or 
other two-copy genes in the genome may be responsible for the differences observed between 
trisomies with different genetic backgrounds. 
3.3 New views on the DSCR and additional analyses in humans 
Advancements in DNA technology as well as additional individuals identified with partial 
trisomy have led to more information on the hypothesized DSCR and gene-phenotype 
relationships in individuals with DS. A genotype-phenotype correlation analysis conducted on 
30 individuals with either partial trisomy or partial monosomy for Hsa21 using array 
comparative genome hybridization found that four individuals with partial trisomy for the 
proximal portion of Hsa21 (not including the putative DSCR) exhibited several DS phenotypes 
(Lyle et al., 2009). Additionally, it was shown that there are multiple regions necessary to 
produce the cognitive impairment  and hypotonia associated with DS, as well as a region 
previously identified as a candidate for CHD (D21S3-PFKL) (Barlow et al., 2001a). These new 
results suggest that the concept of one chromosomal region important for the majority of DS 
phenotypes does not exist due to multiple genetic regions critical for DS phenotypes. Due to 
the identification of multiple regions contributing to the same phenotypes, these regions may 
be more aptly termed “susceptibility” regions and may correspond to one or a limited number 
of phenotypes (Lyle et al., 2009). Individuals with triplication of these genes are more likely to 
exhibit the DS phenotypes associated with these regions.  
High-resolution genetic mapping to determine gene involvement of eight specific DS 
phenotypes using 30 individuals with segmental trisomy for Hsa21 also concluded that 
specific genetic regions may be important for certain DS phenotypes. Genomic analysis 
revealed that the interaction of DYRK1A and RCAN1, thought to be involved in many DS 
phenotypes (Arron et al., 2006), were not essential in the development of CHD and mental 
retardation because individuals without trisomy for these genes exhibited severe 
abnormalities (Korbel et al., 2009). Additionally, several DS phenotypes, including transient 
myeloproliferative disorder, AMKL, and cognitive impairment, require triplication of 
multiple Hsa21 regions and genes (Korbel et al., 2009). A combination of data from this 
work and that in mouse models led to the specification of a CHD-causing region smaller 
than but included in a previously defined region for CHD (Barlow et al., 2001a). The newly 
defined region contains only 10 genes including DSCAM, a cell adhesion molecule highly 
expressed in the developing heart, also believed to contribute to the high levels of 
Hirschprung disease associated with DS (Korbel et al., 2009; Korbel et al., 2007).  
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chromosomal regions and DS phenotypes. The Ts1Rhr/Ms1Rhr mouse model was created 
by generating a 3.9 Mb reciprocal duplication/deletion containing 33 genes (Cbr1-Orf9) 
homologous to those found in the most commonly recognized putative human DSCR 
(Olson et al., 2004a). Human DS-like phenotypes documented in Ts65Dn and Ts1Cje mice, 
which contain larger segmental trisomies, and the creation of Ts1Rhr and Ms1Rhr mice, 
established a system suitable to test the DSCR hypothesis in mice. Ts65Dn mice are smaller 
in size with shorter femurs and exhibit craniofacial abnormalities including smaller skulls 
and mandible bones, as well as brachycephaly when compared to euploid littermates—
defects  also found in humans with DS and previously attributed to the DSCR (Delabar et 
al., 1993; Richtsmeier et al., 2000). Analysis of Ts1Rhr mice revealed significant increases in 
overall size, length of femur, and mandible size when compared to euploid littermates and 
an absence of brachycephaly, indicating major differences between Ts1Rhr and Ts65Dn or 
Ts1Cje phenotypes (Olson et al., 2004a). Mice generated from a cross between Ts65Dn and 
Ms1Rhr mice (removing triplication of the DSCR in the Ts65Dn mouse) exhibited 
craniofacial phenotypes similar to those observed in Ts65Dn mice (Olson et al., 2004a). 
Comparison of the craniofacial phenotypes observed in Ts1Rhr and Ts65Dn/Ms1Rhr mice 
indicated that the DSCR is not sufficient to produce these phenotypes in DS mouse models, 
but may still contribute in the genetic context of the phenotypes observed in Ts65Dn mice 
through genetic interactions.  
In addition to the studies conducted on craniofacial skeletal abnormalities, DS-associated 
brain phenotypes have also been compared in DS mouse models. Ts65Dn mice exhibit a 
similar sized brain and hippocampus but smaller cerebellum and reductions in granule and 
Purkinje cell density when compared to euploid littermates (Baxter et al., 2000). Ts1Cje and 
Ms1Cje/Ts65Dn mice exhibit similar but less severe defects to those observed in Ts65Dn 
mice (Olson et al., 2004b). Analysis of Ts1Rhr mice revealed a similar sized brain and 
hippocampus when compared to euploid littermates, analogous to what was observed in 
Ts65Dn and Ts1Cje mouse models. The cerebellum of Ts1Rhr mice exhibited a small but 
significant reduction in size compared to euploid mice, but no differences were found in 
granule or Purkinje cell density, suggesting that trisomy for the DSCR is not sufficient to 
produce some brain phenotypes associated with DS (Olson et al., 2007). 
Furthermore, studies have shown that Ts65Dn mice exhibit impairment of hippocampal 
function similar to that observed in individuals with DS (Holtzman et al., 1996; Reeves et al., 
1995). Based on the DSCR hypothesis, genes within this region control the cognitive 
impairment phenotype associated with DS. If this were true, Ts1Rhr mice should exhibit 
similar deficits to Ts65Dn mice in hippocampal function. In contrast to Ts65Dn mice, Ts1Rhr 
exhibited normal hippocampal function in the Morris water maze test and normal induction 
of  long term potentiation (LTP) in the CA1 suggesting the DSCR is not sufficient to cause 
the cognitive impairment associated with DS (Aldridge et al., 2007; Olson et al., 2007). 
Interestingly, when three copies of the DSCR were reduced to two, Ts65Dn/Ms1Rhr mice 
performed similarly to euploid animals in the water maze test suggesting that although the 
DSCR is not sufficient on its own to cause cognitive impairment, it is necessary for the 
phenotype to occur (Olson et al., 2007).  
It is important to note that there are background differences between Ts65Dn, Ts1Cje, Ms1Rhr, 
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50% C3H advanced intercross genetic background. The majority of studies previously 
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documented in Ts1Rhr mice used a mixed background of approximately 50% B6, 25% 129 and 
25% C3H (except for the Morris water maze and LTP study where Ts1Rhr were on a B6 
background) and it is possible that background differences may cloud direct comparisons 
between these mouse models. Behavioral and neurophysiologic phenotypes were assessed in 
Ts1Rhr mice maintained on a ~50% B6 and 50% C3H background to mimic the same genetic 
background as Ts65Dn mice. In contrast to what was observed in Ts1Rhr mice on other 
backgrounds, these mice exhibited several (20 of 48) similar neurologic phenotypes as Ts65Dn 
mice suggesting that the DSCR may be sufficient to confer some characteristic DS cognitive 
and brain abnormalities (Belichenko et al., 2009). The differences in neurological phenotypes in 
Ts1Rhr mice on different genetic backgrounds suggest the importance of understanding the 
complex genetic interactions associated with DS. Although evidence in mouse models implies 
that there is no single region critical to the majority of DS phenotypes, it is apparent that a gene 
or genes within this region are important in certain phenotypes and these phenotypes may be 
dependent on genetic background. Either allelic differences associated with trisomic genes or 
other two-copy genes in the genome may be responsible for the differences observed between 
trisomies with different genetic backgrounds. 
3.3 New views on the DSCR and additional analyses in humans 
Advancements in DNA technology as well as additional individuals identified with partial 
trisomy have led to more information on the hypothesized DSCR and gene-phenotype 
relationships in individuals with DS. A genotype-phenotype correlation analysis conducted on 
30 individuals with either partial trisomy or partial monosomy for Hsa21 using array 
comparative genome hybridization found that four individuals with partial trisomy for the 
proximal portion of Hsa21 (not including the putative DSCR) exhibited several DS phenotypes 
(Lyle et al., 2009). Additionally, it was shown that there are multiple regions necessary to 
produce the cognitive impairment  and hypotonia associated with DS, as well as a region 
previously identified as a candidate for CHD (D21S3-PFKL) (Barlow et al., 2001a). These new 
results suggest that the concept of one chromosomal region important for the majority of DS 
phenotypes does not exist due to multiple genetic regions critical for DS phenotypes. Due to 
the identification of multiple regions contributing to the same phenotypes, these regions may 
be more aptly termed “susceptibility” regions and may correspond to one or a limited number 
of phenotypes (Lyle et al., 2009). Individuals with triplication of these genes are more likely to 
exhibit the DS phenotypes associated with these regions.  
High-resolution genetic mapping to determine gene involvement of eight specific DS 
phenotypes using 30 individuals with segmental trisomy for Hsa21 also concluded that 
specific genetic regions may be important for certain DS phenotypes. Genomic analysis 
revealed that the interaction of DYRK1A and RCAN1, thought to be involved in many DS 
phenotypes (Arron et al., 2006), were not essential in the development of CHD and mental 
retardation because individuals without trisomy for these genes exhibited severe 
abnormalities (Korbel et al., 2009). Additionally, several DS phenotypes, including transient 
myeloproliferative disorder, AMKL, and cognitive impairment, require triplication of 
multiple Hsa21 regions and genes (Korbel et al., 2009). A combination of data from this 
work and that in mouse models led to the specification of a CHD-causing region smaller 
than but included in a previously defined region for CHD (Barlow et al., 2001a). The newly 
defined region contains only 10 genes including DSCAM, a cell adhesion molecule highly 
expressed in the developing heart, also believed to contribute to the high levels of 
Hirschprung disease associated with DS (Korbel et al., 2009; Korbel et al., 2007).  
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Additional evidence against the synergy of DYRK1A and RCAN1 in causing craniofacial and 
cardiac abnormalities associated with DS (Arron et al., 2006; Richtsmeier et al., 2000) came 
from a family with a 4.3 Mb duplication of chromosome 21q22 (including DYRK1A but not 
RCAN1 or DSCAM). Individuals with the duplication presented with severe DS-like 
craniofacial abnormalities, but other malformations including cardiac defects were not 
observed. Based on these observations, the authors suggested two distinct regions important 
for these DS phenotypes with the distal region containing the genes including DYRK1A  
associated with craniofacial abnormalities and the proximal region (including RCAN1 and 
DSCAM) associated with cardiac abnormalities (Ronan et al., 2007).  
Interestingly, studies of individuals without DS provide evidence against the theory of only 
these distal and proximal specific regions associated with DS phenotypes. A patient with 
Silver-Russell syndrome, which has little similarity with DS, and his healthy father 
displayed a 0.46 Mb duplication of 21q22 including the RCAN1 gene. No DS-associated 
phenotypes were documented in either individual suggesting that RCAN1 alone is not 
sufficient to produce DS phenotypes (Eggermann et al., 2010). Furthermore, a child with a 
non-mosaic ring chromosome 21 duplication containing most of the long arm of Hsa21 
including the hypothesized DSCR was found to have several characteristic DS phenotypes 
including cardiac and gastrointestinal defects but lacked the usual facial features associated 
with DS (Crombez et al., 2005).  
Taken together, these studies provide evidence against the original DSCR hypothesis. It has 
been shown that genes and regions of genes located both within and outside of the 
hypothesized DSCR are critical to the initiation and severity of specific DS phenotypes. 
Studies conducted on humans with DS, DS mouse models, and other transgenic models 
have uncovered that several genes found within the putative DSCR are known to have a 
major effect on DS phenotypes. Thus, although the DSCR concept as traditionally defined 
does not seem to be correct, there are critical genes within this region that have a major 
impact on specific DS phenotypes. 
3.4 Individual genes associated with the DSCR 
Although it is evident the DSCR does not contribute to all of the phenotypes associated with 
DS, because the DSCR has been heavily studied, several genes found within this region have 
been implicated as candidate genes for individual DS phenotypes. The most extensively 
studied genes found within this region are Regulator of calcineurin1 (RCAN1/DSCR1) and 
dual specificity tyrosine-phosphorylation kinase 1a (DYRK1A), which are hypothesized to 
play important roles in several developmental pathways, including CNS, craniofacial 
skeletal and cardiac (Arron et al., 2006; Park et al., 2009; Richtsmeier et al., 2000). DYRK1A 
and RCAN1 are both involved in the regulation of NFAT, a critical transcription factor 
necessary for the processes of vertebrate development and organogenesis (Graef et al., 2001). 
Transgenic Nfatc mutant mice exhibit several characteristics similar to DS mouse models as 
well as humans with DS including cognitive impairment and craniofacial and cardiac 
abnormalities. Mice with overexpression of Dyrk1a and Rcan1 exhibited similar phenotypes 
to Nfatc mutants, suggesting that these genes are likely playing a part in the development of 
DS phenotypes (Arron et al., 2006).  
In addition to DYRK1A and RCAN1, Down syndrome cell adhesion molecule (DSCAM) has 
been suggested to play a critical role in the developing brain and has also been identified as 
a candidate gene for the increased levels of CHD observed in DS individuals (Alves-
Sampaio et al., 2010; Barlow et al., 2001a; Barlow et al., 2002). DSCAM is a critical factor in 
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neural differentiation, axon guidance, and the establishment of neural networks and it has 
been suggested that the disruption of these processes contributes to the DS neurocognitive 
phenotype (Agarwala et al., 2001; Barlow et al., 2001b; Yamakawa et al., 1998). A recent 
study found that Dscam was overexpressed in hippocampal neurons of the Ts1Cje mouse 
model. Overexpression of Dscam impaired dendritic branching leading to an inhibitory 
effect on synaptogenesis and neurite outgrowth, further implicating the role of Dscam in the 
development of the DS brain phenotype (Alves-Sampaio et al., 2010).  
Also found within the DSCR, ETS2 is a transcription factor known to be involved in the 
regulation of cellular proliferation, differentiation, transformation and apoptosis (Seth and 
Watson, 2005). Extensive studies on Ets2 in transgenic and DS mouse models have revealed 
that the gene may play a role in the neuronal, tumor suppressive, and craniofacial 
phenotypes associated with DS (Hill et al., 2009; Sussan et al., 2008; Wolvetang et al., 2003). 
Additionally, KCNJ6/GIRK2 overexpression in the hippocampus of Ts65Dn mice has been 
shown to cause an abnormal balance between inhibitory and excitatory synapses, 
implicating the gene in the DS-brain phenotype (Best et al., 2007). Additionally, this 
overexpression was also implicated in the reduced cerebellar size and alterations in granule 
cell neuron differentiation observed in the weaver mouse (Patil et al., 1995). 
3.5 Gene(s)-phenotype relationships 
The establishment of a specific phenotype requires the successful coordination of a number 
of genetic interactions. In many human disorders a single gene or gene network is 
responsible for causing the associated phenotypes. However, evidence from both humans 
and mouse models of DS suggests that specific DS phenotypes are influenced by genetic 
aberrations in multiple genes as opposed to a single gene. The most glaring case of multiple 
genes affecting a phenotype comes from the study of cognitive impairment through the 
analysis of human and mouse DS brains. DYRK1A, RCAN1, and DSCAM have all been 
shown to regulate the stages of neuronal cell maturation (proliferation, differentiation, and 
apoptosis) in the developing brain (Agarwala et al., 2001; Barlow et al., 2001b; Park et al., 
2010; Sun et al., 2011). Triplication of Olig1, Olig2, and Kcnj6, leads to significant changes in 
the ratio of inhibitory to excitatory neurons in the Ts65Dn forebrain (Best et al., 2007; 
Chakrabarti et al., 2010) and DSCAM regulates dendritic branching and neuronal network 
establishment (Alves-Sampaio et al., 2010), suggesting that increased inhibitory activity and 
the inability to form neuronal networks are also contributing to the cognitive impairment 
phenotype. In addition to cognitive impairment, an AD-like phenotype is apparent in most 
adult individuals with DS. Dysregulation of DYRK1A, RCAN1, and/or Ets2 lead to an 
increase in the number of neurofibrillary tangles and β-amyloid plaques in the brains of 
humans and mice (Ermak et al., 2001; Ryoo et al., 2008; Sun et al., 2011), respectively, 
indicating that multiple genes are contributing to the DS-AD phenotype. 
3.6 Summary 
Based on thorough analyses of studies on humans and DS mouse models, it is evident that 
there is not a single critical region of genes sufficient to cause all DS phenotypes. 
Alternatively, it is likely that there are multiple critical regions or critical genes contributing 
to a respective phenotype or group of phenotypes associated with DS (Lyle et al., 2009). 
Although studies conducted regarding the DSCR have provided a wealth of evidence 
refuting the idea, it is important to understand that several genes within this region have 
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Additional evidence against the synergy of DYRK1A and RCAN1 in causing craniofacial and 
cardiac abnormalities associated with DS (Arron et al., 2006; Richtsmeier et al., 2000) came 
from a family with a 4.3 Mb duplication of chromosome 21q22 (including DYRK1A but not 
RCAN1 or DSCAM). Individuals with the duplication presented with severe DS-like 
craniofacial abnormalities, but other malformations including cardiac defects were not 
observed. Based on these observations, the authors suggested two distinct regions important 
for these DS phenotypes with the distal region containing the genes including DYRK1A  
associated with craniofacial abnormalities and the proximal region (including RCAN1 and 
DSCAM) associated with cardiac abnormalities (Ronan et al., 2007).  
Interestingly, studies of individuals without DS provide evidence against the theory of only 
these distal and proximal specific regions associated with DS phenotypes. A patient with 
Silver-Russell syndrome, which has little similarity with DS, and his healthy father 
displayed a 0.46 Mb duplication of 21q22 including the RCAN1 gene. No DS-associated 
phenotypes were documented in either individual suggesting that RCAN1 alone is not 
sufficient to produce DS phenotypes (Eggermann et al., 2010). Furthermore, a child with a 
non-mosaic ring chromosome 21 duplication containing most of the long arm of Hsa21 
including the hypothesized DSCR was found to have several characteristic DS phenotypes 
including cardiac and gastrointestinal defects but lacked the usual facial features associated 
with DS (Crombez et al., 2005).  
Taken together, these studies provide evidence against the original DSCR hypothesis. It has 
been shown that genes and regions of genes located both within and outside of the 
hypothesized DSCR are critical to the initiation and severity of specific DS phenotypes. 
Studies conducted on humans with DS, DS mouse models, and other transgenic models 
have uncovered that several genes found within the putative DSCR are known to have a 
major effect on DS phenotypes. Thus, although the DSCR concept as traditionally defined 
does not seem to be correct, there are critical genes within this region that have a major 
impact on specific DS phenotypes. 
3.4 Individual genes associated with the DSCR 
Although it is evident the DSCR does not contribute to all of the phenotypes associated with 
DS, because the DSCR has been heavily studied, several genes found within this region have 
been implicated as candidate genes for individual DS phenotypes. The most extensively 
studied genes found within this region are Regulator of calcineurin1 (RCAN1/DSCR1) and 
dual specificity tyrosine-phosphorylation kinase 1a (DYRK1A), which are hypothesized to 
play important roles in several developmental pathways, including CNS, craniofacial 
skeletal and cardiac (Arron et al., 2006; Park et al., 2009; Richtsmeier et al., 2000). DYRK1A 
and RCAN1 are both involved in the regulation of NFAT, a critical transcription factor 
necessary for the processes of vertebrate development and organogenesis (Graef et al., 2001). 
Transgenic Nfatc mutant mice exhibit several characteristics similar to DS mouse models as 
well as humans with DS including cognitive impairment and craniofacial and cardiac 
abnormalities. Mice with overexpression of Dyrk1a and Rcan1 exhibited similar phenotypes 
to Nfatc mutants, suggesting that these genes are likely playing a part in the development of 
DS phenotypes (Arron et al., 2006).  
In addition to DYRK1A and RCAN1, Down syndrome cell adhesion molecule (DSCAM) has 
been suggested to play a critical role in the developing brain and has also been identified as 
a candidate gene for the increased levels of CHD observed in DS individuals (Alves-
Sampaio et al., 2010; Barlow et al., 2001a; Barlow et al., 2002). DSCAM is a critical factor in 
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neural differentiation, axon guidance, and the establishment of neural networks and it has 
been suggested that the disruption of these processes contributes to the DS neurocognitive 
phenotype (Agarwala et al., 2001; Barlow et al., 2001b; Yamakawa et al., 1998). A recent 
study found that Dscam was overexpressed in hippocampal neurons of the Ts1Cje mouse 
model. Overexpression of Dscam impaired dendritic branching leading to an inhibitory 
effect on synaptogenesis and neurite outgrowth, further implicating the role of Dscam in the 
development of the DS brain phenotype (Alves-Sampaio et al., 2010).  
Also found within the DSCR, ETS2 is a transcription factor known to be involved in the 
regulation of cellular proliferation, differentiation, transformation and apoptosis (Seth and 
Watson, 2005). Extensive studies on Ets2 in transgenic and DS mouse models have revealed 
that the gene may play a role in the neuronal, tumor suppressive, and craniofacial 
phenotypes associated with DS (Hill et al., 2009; Sussan et al., 2008; Wolvetang et al., 2003). 
Additionally, KCNJ6/GIRK2 overexpression in the hippocampus of Ts65Dn mice has been 
shown to cause an abnormal balance between inhibitory and excitatory synapses, 
implicating the gene in the DS-brain phenotype (Best et al., 2007). Additionally, this 
overexpression was also implicated in the reduced cerebellar size and alterations in granule 
cell neuron differentiation observed in the weaver mouse (Patil et al., 1995). 
3.5 Gene(s)-phenotype relationships 
The establishment of a specific phenotype requires the successful coordination of a number 
of genetic interactions. In many human disorders a single gene or gene network is 
responsible for causing the associated phenotypes. However, evidence from both humans 
and mouse models of DS suggests that specific DS phenotypes are influenced by genetic 
aberrations in multiple genes as opposed to a single gene. The most glaring case of multiple 
genes affecting a phenotype comes from the study of cognitive impairment through the 
analysis of human and mouse DS brains. DYRK1A, RCAN1, and DSCAM have all been 
shown to regulate the stages of neuronal cell maturation (proliferation, differentiation, and 
apoptosis) in the developing brain (Agarwala et al., 2001; Barlow et al., 2001b; Park et al., 
2010; Sun et al., 2011). Triplication of Olig1, Olig2, and Kcnj6, leads to significant changes in 
the ratio of inhibitory to excitatory neurons in the Ts65Dn forebrain (Best et al., 2007; 
Chakrabarti et al., 2010) and DSCAM regulates dendritic branching and neuronal network 
establishment (Alves-Sampaio et al., 2010), suggesting that increased inhibitory activity and 
the inability to form neuronal networks are also contributing to the cognitive impairment 
phenotype. In addition to cognitive impairment, an AD-like phenotype is apparent in most 
adult individuals with DS. Dysregulation of DYRK1A, RCAN1, and/or Ets2 lead to an 
increase in the number of neurofibrillary tangles and β-amyloid plaques in the brains of 
humans and mice (Ermak et al., 2001; Ryoo et al., 2008; Sun et al., 2011), respectively, 
indicating that multiple genes are contributing to the DS-AD phenotype. 
3.6 Summary 
Based on thorough analyses of studies on humans and DS mouse models, it is evident that 
there is not a single critical region of genes sufficient to cause all DS phenotypes. 
Alternatively, it is likely that there are multiple critical regions or critical genes contributing 
to a respective phenotype or group of phenotypes associated with DS (Lyle et al., 2009). 
Although studies conducted regarding the DSCR have provided a wealth of evidence 
refuting the idea, it is important to understand that several genes within this region have 
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been identified as key contributors to more specific DS phenotypes. Furthermore, both non-
trisomic genes and trisomic genes located outside of the hypothesized DSCR have also been 
implicated in the development of specific DS phenotypes and in some cases may be linked 
with DSCR associated genes. It is evident that DS phenotypes are influenced by a multitude 
of complex genetic interactions and it seems likely that multiple genes and gene networks 
will be involved in the development of most DS phenotypes. Important genes or regions of 
genes contributing to specific DS phenotypes should be defined as susceptibility genes or 
regions, as opposed to defining a single Down syndrome critical region or single gene-
phenotype relationship (Lyle et al., 2009).  
4. Functional analysis of genes 
4.1 Introduction 
Although hypotheses have been developed concerning cellular and developmental 
mechanisms relating to DS phenotypes, no conclusive evidence exists for a single 
mechanism likely responsible for the majority of DS phenotypes. Instead, multiple common 
mechanisms may be responsible for individual phenotypes in specific tissues or at precise 
developmental stages and groups of genes with related functions may also be dysregulated 
in DS pathology. Functional databases provide the foundation for elucidating gene-
phenotype relationships by clustering dysregulated genes with common functions. These 
clusters identify potential cellular, developmental and biological functions, as well as the 
number of genes in each cluster and significance of those categories. Depending on the 
functional annotation tool, relevant pathways, molecules for potential pharmacological 
interventions or insight into genetic mechanisms may be suggested. The use of functional 
databases extends the value of high throughput arrays and tests hypotheses that specific 
groups of genes with related function may be dysregulated in DS. Rather than a simple 
dosage increase of Hsa21 genes, it has been hypothesized that trisomy has a more global 
dysregulational effect on the genome, though developmental changes and tissue type do 
maintain a significant role (Altug-Teber et al., 2007; Dauphinot et al., 2005; Sommer et al., 
2008). We hypothesize that the interaction between trisomic and disomic genes have a 
significant effect on the way DS phenotypes arise, manifest and progress. 
Several studies have documented differential gene expression in unique spatial and 
developmental environments to determine mechanisms affecting DS phenotypes (Conti et 
al., 2007; Lyle et al., 2004; Moldrich et al., 2007). Other studies often concentrate on the 
cellular or developmental mechanisms as a causative factor of DS phenotypes (Chakrabarti 
et al., 2007; Contestabile et al., 2009; Cooper et al., 2001; Roper et al., 2006; Roper et al., 2009). 
High throughput analyses are important for investigating gene-phenotype relationships in 
analyses of various tissue and cell types from individuals with DS, mouse models of DS, and 
cell lines previously derived from individuals with DS or engineered to contain this extra 
genetic material. We hypothesize that a single generalized pathway or mechanism does not 
underlie the phenotypes of DS, but rather several pathways and mechanisms contribute to 
the phenotypes of DS, though some functional groups may cluster together in certain tissues 
or within phenotypes. Assessment of the gene-phenotype relationships in high throughput 
meta-analysis provides novel information regarding the importance of developmental 
processes in the DS pathophysiology. 
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4.2 Previously established functional analyses 
Studies of DS have utilized high throughput analysis on several tissues including cultured 
DS neural progenitor cells and tissue samples from DS amniocytes, hearts, cerebra and 
cerebella and cultured Ts1Cje neural progenitor cells (NPCs). Though differences are 
present between developmental time points and tissues, genes involved with cellular 
cycling, cell adhesion, signal transduction, DNA and RNA metabolism and binding, gene 
expression regulation and transcription, mitochondrial function and oxidative 
phosphorylation, kinase activity, and ECM production and maintenance were the most 
highly dysregulated and common categories observed, as well as maintain the ability to 
transcend time and tissue differences (Table 5). More specifically, certain cell types of 
representative models of DS or from individuals with DS share multiple common 
annotation results. We suggest a similar phenomenon may regulate multiple DS phenotypes 
in which dysregulated mechanisms affect the same tissue in order to produce a phenotype 
(Figure 1).  
4.2.1 Cell cycle alterations contribute to neurological phenotypes  
NPCs display altered gene expression related to cell cycling, proliferation, signaling, 
transcription and metabolism of chromosomal material. It is well established that deficits in 
proliferation and mitotic activity of specific cellular populations in the DS brain exist, 
including areas of the cerebellum and multiple areas of the cerebrum (Baxter et al., 2000; 
Chakrabarti et al., 2007; Gardiner et al., 2010; Roper et al., 2006). Additionally, impairment of 
proliferation in the cerebellum of fetuses with DS has also been reported (Guidi et al., 2010) 
as well as in the Ts65Dn neonate peripheral tissues and fibroblasts, suggesting a general 
deficit in proliferation as a mechanism for multiple DS abnormalities (Contestabile et al., 
2009). Individuals born with DS have reduced brain weights coupled with a smaller, 
dysmorphic skull and multiple cellular abnormalities within the brain including reduction 
in the number of neurons in the cerebral cortex as well as cellular deficiencies in multiple 
other structures (Aylward et al., 1997; Fink et al., 1975; Wisniewski, 1990). Therefore, these 
phenotypic deficits may be caused by a similar mechanism. However, downregulation of 
genes with proliferation-promoting function or upregulation of genes involved in the arrest 
of proliferation could equally, if not synergistically, contribute to the general proliferation 
deficit hypothesized to occur in several DS phenotypes. Overexpression of Dyrk1a in mouse 
NPCs was recently found to inhibit proliferation and stimulate precocious neuronal 
differentiation (Park et al., 2010; Yabut et al., 2010). DYRK1A has previously been implicated 
in the physiopathology of the cognitive impairment observed in individuals with DS 
(Altafaj et al., 2001; Smith et al., 1997) and is overexpressed approximately 1.5 fold in the DS 
and Ts65Dn brain (Dowjat et al., 2007; Guimera et al., 1999), suggesting upregulation of 
DYRK1A in concert with other Hsa21 and disomic genes in the DS brain may lead to deficits 
that underlie both cognitive phenotypes and other cellular phenotypes of DS. 
4.2.2 Changes in cell adhesion contribute to DS phenotypes  
In addition to brain, other tissues appear to be affected by alterations in cell homeostasis. 
Because cell cycling, cell adhesion, signal transduction, and ECM production all display 
dysregulation in DS fetal amniocytes, heart, cerebra and cerebella, one cannot conclude that 
a simple deficit in proliferation, such as that observed in DS skin fibroblasts (Kimura et al., 
2005), is sufficient to result in the DS phenotypes observed. While the DS brain is reduced in 
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been identified as key contributors to more specific DS phenotypes. Furthermore, both non-
trisomic genes and trisomic genes located outside of the hypothesized DSCR have also been 
implicated in the development of specific DS phenotypes and in some cases may be linked 
with DSCR associated genes. It is evident that DS phenotypes are influenced by a multitude 
of complex genetic interactions and it seems likely that multiple genes and gene networks 
will be involved in the development of most DS phenotypes. Important genes or regions of 
genes contributing to specific DS phenotypes should be defined as susceptibility genes or 
regions, as opposed to defining a single Down syndrome critical region or single gene-
phenotype relationship (Lyle et al., 2009).  
4. Functional analysis of genes 
4.1 Introduction 
Although hypotheses have been developed concerning cellular and developmental 
mechanisms relating to DS phenotypes, no conclusive evidence exists for a single 
mechanism likely responsible for the majority of DS phenotypes. Instead, multiple common 
mechanisms may be responsible for individual phenotypes in specific tissues or at precise 
developmental stages and groups of genes with related functions may also be dysregulated 
in DS pathology. Functional databases provide the foundation for elucidating gene-
phenotype relationships by clustering dysregulated genes with common functions. These 
clusters identify potential cellular, developmental and biological functions, as well as the 
number of genes in each cluster and significance of those categories. Depending on the 
functional annotation tool, relevant pathways, molecules for potential pharmacological 
interventions or insight into genetic mechanisms may be suggested. The use of functional 
databases extends the value of high throughput arrays and tests hypotheses that specific 
groups of genes with related function may be dysregulated in DS. Rather than a simple 
dosage increase of Hsa21 genes, it has been hypothesized that trisomy has a more global 
dysregulational effect on the genome, though developmental changes and tissue type do 
maintain a significant role (Altug-Teber et al., 2007; Dauphinot et al., 2005; Sommer et al., 
2008). We hypothesize that the interaction between trisomic and disomic genes have a 
significant effect on the way DS phenotypes arise, manifest and progress. 
Several studies have documented differential gene expression in unique spatial and 
developmental environments to determine mechanisms affecting DS phenotypes (Conti et 
al., 2007; Lyle et al., 2004; Moldrich et al., 2007). Other studies often concentrate on the 
cellular or developmental mechanisms as a causative factor of DS phenotypes (Chakrabarti 
et al., 2007; Contestabile et al., 2009; Cooper et al., 2001; Roper et al., 2006; Roper et al., 2009). 
High throughput analyses are important for investigating gene-phenotype relationships in 
analyses of various tissue and cell types from individuals with DS, mouse models of DS, and 
cell lines previously derived from individuals with DS or engineered to contain this extra 
genetic material. We hypothesize that a single generalized pathway or mechanism does not 
underlie the phenotypes of DS, but rather several pathways and mechanisms contribute to 
the phenotypes of DS, though some functional groups may cluster together in certain tissues 
or within phenotypes. Assessment of the gene-phenotype relationships in high throughput 
meta-analysis provides novel information regarding the importance of developmental 
processes in the DS pathophysiology. 
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4.2 Previously established functional analyses 
Studies of DS have utilized high throughput analysis on several tissues including cultured 
DS neural progenitor cells and tissue samples from DS amniocytes, hearts, cerebra and 
cerebella and cultured Ts1Cje neural progenitor cells (NPCs). Though differences are 
present between developmental time points and tissues, genes involved with cellular 
cycling, cell adhesion, signal transduction, DNA and RNA metabolism and binding, gene 
expression regulation and transcription, mitochondrial function and oxidative 
phosphorylation, kinase activity, and ECM production and maintenance were the most 
highly dysregulated and common categories observed, as well as maintain the ability to 
transcend time and tissue differences (Table 5). More specifically, certain cell types of 
representative models of DS or from individuals with DS share multiple common 
annotation results. We suggest a similar phenomenon may regulate multiple DS phenotypes 
in which dysregulated mechanisms affect the same tissue in order to produce a phenotype 
(Figure 1).  
4.2.1 Cell cycle alterations contribute to neurological phenotypes  
NPCs display altered gene expression related to cell cycling, proliferation, signaling, 
transcription and metabolism of chromosomal material. It is well established that deficits in 
proliferation and mitotic activity of specific cellular populations in the DS brain exist, 
including areas of the cerebellum and multiple areas of the cerebrum (Baxter et al., 2000; 
Chakrabarti et al., 2007; Gardiner et al., 2010; Roper et al., 2006). Additionally, impairment of 
proliferation in the cerebellum of fetuses with DS has also been reported (Guidi et al., 2010) 
as well as in the Ts65Dn neonate peripheral tissues and fibroblasts, suggesting a general 
deficit in proliferation as a mechanism for multiple DS abnormalities (Contestabile et al., 
2009). Individuals born with DS have reduced brain weights coupled with a smaller, 
dysmorphic skull and multiple cellular abnormalities within the brain including reduction 
in the number of neurons in the cerebral cortex as well as cellular deficiencies in multiple 
other structures (Aylward et al., 1997; Fink et al., 1975; Wisniewski, 1990). Therefore, these 
phenotypic deficits may be caused by a similar mechanism. However, downregulation of 
genes with proliferation-promoting function or upregulation of genes involved in the arrest 
of proliferation could equally, if not synergistically, contribute to the general proliferation 
deficit hypothesized to occur in several DS phenotypes. Overexpression of Dyrk1a in mouse 
NPCs was recently found to inhibit proliferation and stimulate precocious neuronal 
differentiation (Park et al., 2010; Yabut et al., 2010). DYRK1A has previously been implicated 
in the physiopathology of the cognitive impairment observed in individuals with DS 
(Altafaj et al., 2001; Smith et al., 1997) and is overexpressed approximately 1.5 fold in the DS 
and Ts65Dn brain (Dowjat et al., 2007; Guimera et al., 1999), suggesting upregulation of 
DYRK1A in concert with other Hsa21 and disomic genes in the DS brain may lead to deficits 
that underlie both cognitive phenotypes and other cellular phenotypes of DS. 
4.2.2 Changes in cell adhesion contribute to DS phenotypes  
In addition to brain, other tissues appear to be affected by alterations in cell homeostasis. 
Because cell cycling, cell adhesion, signal transduction, and ECM production all display 
dysregulation in DS fetal amniocytes, heart, cerebra and cerebella, one cannot conclude that 
a simple deficit in proliferation, such as that observed in DS skin fibroblasts (Kimura et al., 
2005), is sufficient to result in the DS phenotypes observed. While the DS brain is reduced in 
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size overall, it is also dysmorphic, pointing to both a decrease in proliferation, but perhaps 
also altered cell cycling, changes in the migratory pattern of progenitor cells and even the 
decreased founder population of these cells due to decreases in neurogenesis, implicating a 
complex interaction of mechanisms in the DS neurological phenotype (Bhattacharyya et al., 
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Table 5. Published functional analysis data for phenotypes of DS. Functional annotations 
were selected by lowest p-values for the categories established by the investigators and of 
specific interest to the authors. Studies are listed by tissue type and annotations are listed by 
most common to least common categories horizontally. Analysis tool abbreviations: G: 
GeneOntology (www.geneontology.org), I: Ingenuity Pathway Analysis 
(www.ingenuity.com), O: OntoExpress (vortex.cs.wayne.edu/projects.htm), N: NetAffex 
(www.affymetrix.com/analysis/index.affx), D: DAVID (david.abcc.ncifcrf.gov). 
In addition, approximately 50% of newborns with DS display a congenital heart defect, most 
of which involve septal and canal defects (Pediatrics, 2001). Previous studies have 
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established a link between DS atrioventricular septal defects (AVSDs) and the importance of 
collagen VI in developing endocardial cushions (Baptista et al., 2000; Davies et al., 1995). 
Characterization of the involvement of collagen VI in cardiac development was later 
established when investigators observed altered collagen VI expression in AV endocardial 
cushions in the DS heart (Gittenberger-de Groot et al., 2003). Interestingly, genes encoding 
collagen VI are found on Hsa21 and its role as an extracellular matrix (ECM) component 
makes its presence ubiquitous throughout the body (Aumailley et al., 1991). A similar idea 
has recently been proposed in which atrioventricular canal (AVC) defects, which comprise 
the majority of congenital heart defects observed in DS, are a result of increased cell 
adhesion. Deficits in cell adhesion may lead to decreased cell migration to the ventricular 
canal because of changes in the ECM, leading to alterations in epithelial-mesenchymal 
transformations (Delom et al., 2009). Using a transchromosomic model of DS, investigators 
found both decreased cell migration and an increased affinity for adhesion to collagen VI 
(Delom et al., 2009). Importantly, differences in Hsa21 genes or groups of genes causing 
aberrations in both cellular properties may act in concert to lead to the development of AVC 
defects. It is therefore plausible that cell adhesion complexes coupled with ECM component 
alterations significantly contribute to congenital heart abnormalities in DS.  
In addition to congenital heart defects, individuals with DS are at an increased risk for 
dermatological disorders such as atopic dermatitis, causing susceptibility toward 
opportunistic infections (Madan et al., 2006). Studies utilizing DS skin fibroblasts have 
shown that these cells display an increased adhesion to collagen VI, likely leading to 
aberrant migration of these cells to target areas of the body (Jongewaard et al., 2002). This 
decreased migration would leave a smaller population of cells to make up an epidermal 
barrier and thus would compromise the integrity of the skin. Dysregulation of genes 
involved in cell adhesion may also lead to changes in junctional complexes that are found to 
be altered in functional analyses, and these changes may contribute to atypical migration of 
the cells with which they interact. 
4.2.3 Changes in DNA and RNA metabolism may lead to transcription and translation 
dysregulation 
Genes involved with the metabolism and expression of nucleic acids are highly 
dysregulated in multiple DS tissue types (brain, heart, trophoblasts) and time points in 
multiple functional analyses. The observed dysregulation of the genome due to the presence 
of the extra chromosomal material and its interaction with the rest of the genome is likely 
directed by multiple types of regulation. It may be that fewer transcripts are formed given a 
higher rate of metabolism of genetic material. The reduced transcripts directing cellular 
proliferation, migration or an anti-apoptotic state could lead to the smaller or altered 
structures observed in DS.  
In particular, changes in metabolism of genetic transcripts have been documented in the 
expression of multiple genes in both DS-related and unrelated tissues. Several studies 
sampling multiple DS-derived tissues have described the transcriptional alterations of 
Hsa21 genes, including two genes involved in nucleic acid metabolism: GART (purine 
metabolism) and ZNF294 (transcriptional regulation) (Lintas et al., 2010). DNA and RNA 
binding and metabolism may also be related to transcription factor activity, dysregulating 
genes downstream of these alterations. Alterations of transcription factors such as NFAT, as 
a result of dysregulation of DYRK1A and DSCR1, have the potential to lead to DS 
developmental phenotypes (Arron et al., 2006). The dysregulation of NFAT may initiate a 
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size overall, it is also dysmorphic, pointing to both a decrease in proliferation, but perhaps 
also altered cell cycling, changes in the migratory pattern of progenitor cells and even the 
decreased founder population of these cells due to decreases in neurogenesis, implicating a 
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established when investigators observed altered collagen VI expression in AV endocardial 
cushions in the DS heart (Gittenberger-de Groot et al., 2003). Interestingly, genes encoding 
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canal because of changes in the ECM, leading to alterations in epithelial-mesenchymal 
transformations (Delom et al., 2009). Using a transchromosomic model of DS, investigators 
found both decreased cell migration and an increased affinity for adhesion to collagen VI 
(Delom et al., 2009). Importantly, differences in Hsa21 genes or groups of genes causing 
aberrations in both cellular properties may act in concert to lead to the development of AVC 
defects. It is therefore plausible that cell adhesion complexes coupled with ECM component 
alterations significantly contribute to congenital heart abnormalities in DS.  
In addition to congenital heart defects, individuals with DS are at an increased risk for 
dermatological disorders such as atopic dermatitis, causing susceptibility toward 
opportunistic infections (Madan et al., 2006). Studies utilizing DS skin fibroblasts have 
shown that these cells display an increased adhesion to collagen VI, likely leading to 
aberrant migration of these cells to target areas of the body (Jongewaard et al., 2002). This 
decreased migration would leave a smaller population of cells to make up an epidermal 
barrier and thus would compromise the integrity of the skin. Dysregulation of genes 
involved in cell adhesion may also lead to changes in junctional complexes that are found to 
be altered in functional analyses, and these changes may contribute to atypical migration of 
the cells with which they interact. 
4.2.3 Changes in DNA and RNA metabolism may lead to transcription and translation 
dysregulation 
Genes involved with the metabolism and expression of nucleic acids are highly 
dysregulated in multiple DS tissue types (brain, heart, trophoblasts) and time points in 
multiple functional analyses. The observed dysregulation of the genome due to the presence 
of the extra chromosomal material and its interaction with the rest of the genome is likely 
directed by multiple types of regulation. It may be that fewer transcripts are formed given a 
higher rate of metabolism of genetic material. The reduced transcripts directing cellular 
proliferation, migration or an anti-apoptotic state could lead to the smaller or altered 
structures observed in DS.  
In particular, changes in metabolism of genetic transcripts have been documented in the 
expression of multiple genes in both DS-related and unrelated tissues. Several studies 
sampling multiple DS-derived tissues have described the transcriptional alterations of 
Hsa21 genes, including two genes involved in nucleic acid metabolism: GART (purine 
metabolism) and ZNF294 (transcriptional regulation) (Lintas et al., 2010). DNA and RNA 
binding and metabolism may also be related to transcription factor activity, dysregulating 
genes downstream of these alterations. Alterations of transcription factors such as NFAT, as 
a result of dysregulation of DYRK1A and DSCR1, have the potential to lead to DS 
developmental phenotypes (Arron et al., 2006). The dysregulation of NFAT may initiate a 
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cascade of events affecting multiple downstream targets. Many of these genes may also be 
involved with cell cycling and maintenance as well as DNA and RNA binding and 
metabolism. Such studies, however, remain to be performed. 
4.2.4 Mitochondrial changes penetrate neurological and metabolic phenotypes 
The high incidence of mitochondria-related dysregulation in DS hearts, lymphocytes, and 
trophoblasts coupled with the increased prevalence of biomarkers of reactive oxygen species 
(ROS) in individuals with DS (Jovanovic et al., 1998) is an interesting and well-studied 
paradigm. Mitochondrial impairment in fetal hearts suggested by the downregulation of 
genes from five mitochondrial complexes, as well as the cerebellum and other brain regions, 
platelets, astrocytes and cultured fibroblasts suggests pervasive impairment of mitochondria 
in individuals with DS (Arbuzova et al., 2002; Busciglio et al., 2002; Conti et al., 2007; Kim et 
al., 2001; Kim et al., 2000; Prince et al., 1994). Interestingly, this mitochondrial impairment 
may affect other DS pathophysiology. Dysregulation of  the mitochondria has the ability to 
cause alterations in ATP synthesis, electron transport, monovalent cation transporter 
activity, oxidative phosphorylation, and general changes in physical components (Conti et 
al., 2007) (all found as dysregulated functional groups in Table 5). Furthermore, changes in 
membrane potential caused by this dysregulation may lead to increased mitochondrial 
susceptibility to other insults, leading to a constant feedback in the balance of genetic 
regulation (Roat et al., 2007). Two genes in particular located on Hsa21, SOD1 and BACH1, 
have been implicated the generation of ROS due to elevated H2O2 levels and decreased 
transcriptional activity, respectively. Elevated levels of SOD1 have been implicated in 
deposition of β amyloid and BACH1 downregulation has been proposed as a contributing 
mechanism to the development of Alzheimer disease neuropathology (Percy et al., 1990; 
Shim et al., 2003). High levels of oxidative stress in the brains of individuals with DS may 
indicate that dysregulation of normal processes in the mitochondria lead to anomalies 
including Alzheimer pathology (de Haan et al., 1997; Lockstone et al., 2007). A 
disproportionate number of ROS, caused by mitochondrial and other changes, combined 
with altered metabolism and feedback mechanisms suggest the complexity of  the 
interacting mechanisms involved in DS phenotypes affecting the brain, heart and skin 
(Busciglio and Yankner, 1995; Li et al., 2006; Sinha, 2005).  
4.3 DAVID analysis of trisomic genes in humans with DS and DS mouse models  
DS mouse models have the ability to predict phenotypes not previously observed in 
individuals with DS (Baxter et al., 2000; Pennington et al., 2003). We hypothesized that by 
analyzing the genes trisomic genes on Hsa21 as well as their homologs in two DS mouse 
models, we would observe common mechanisms as found by functional analysis of altered 
gene expression. Using DAVID (http://david.abcc.ncifcrf.gov/) we analyzed trisomic genes 
from Hsa21 and the Ts1Rhr and Ts65Dn mouse models 
(http://chr21.molgen.mpg.de/HSA21db.html). Functional annotations were obtained using 
the protocol described by Huang et al. 2009.  
Our analyses of Hsa21 genes revealed dysregulation of functional annotations including 
keratin, intermediate filament/cytoskeleton digestion, protein dimerization, interferon 
receptor activity, cytokine receptor activity, multiple junctions, cell adhesion, ionic channels 
and ECM (Table 6). Analysis of the genes triplicated in Ts65Dn mice revealed dysregulation 
of genes involved in ion transport, voltage-gated channels,  ionic channels, monovalent 
inorganic cation transport, tight junctions, calcium dependent cell-cell adhesion, regulation 
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of transcription, DNA binding, behavior, neuron development, neuron differentiation and 
synaptic transmission and cell-cell signaling. Analysis of genes in three copies from the 
Ts1Rhr mouse model identified functions integral to binding and related to regulation of 
transcription factor activity, transcription and DNA binding as the most enriched categories 
with the lowest p-values.  
As predicted, some, but not all functional groups found in previous analyses were also seen 
in our DAVID analysis. Data compiled using DAVID analysis of Hsa21 and two DS mouse 
models provide insight into what mechanisms appear to be generally dysregulated when 
trisomy for these regions occurs. Ts65Dn mice display many similarities to individuals with 
DS with regard to general brain, behavior, stature, heart and craniofacial phenotypes. 
Interestingly, a high level of overlap in functional categories also exists between the two 
analyses. For example, our analysis of Hsa21 and Ts65Dn revealed dysregulation of genes 
involved in cell adhesion, tight junctions and ionic transport. Ts65Dn mice replicate some of 
the heart defects observed in DS, and aberrant cell adhesion and migration have been 
implicated in these defects (Delom et al., 2009; Moore, 2006; Williams et al., 2008). Ts1Rhr 
and Ts65Dn triplicated genes led to functional hits in transcription, transcription factor 
activity, and RNA/DNA binding. While Ts1Rhr and Ts65Dn mice display some similar 
phenotypes, Ts1Rhr mice exhibit a number of phenotypes contrary to those seen in DS. It is 
noteworthy, though, that though these functional groups are dysregulated, they may be 
regulated in a manner divergent from one another, such as higher levels of transcription and 
RNA/DNA binding in Ts1Rhr than Ts65Dn, leading to the exaggerated phenotypes which 
Ts1Rhr mice display. Interestingly, no functional groups overlapped between the Hsa21 and 
Ts1Rhr analyses and this result provides additional evidence for the different phenotypes 
observed between humans with DS and this mouse model. Clearly, the involvement of other 
trisomic genes as well as disomic genes plays an important role in the identification of 
functional categories. Given that our analyses only included trisomic genes, it seems 
plausible that significant overlap between the past and current studies was not found. 
   
 
Table 6. DAVID analysis of trisomic genes from Hsa21 and Ts65Dn and Ts1Rhr mice. 
Functional annotations are listed in columns by most common dysregulated annotations, 
then by highest to lowest enrichment score and smallest to largest p-value in succession for 
each category. 
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4.4 Summary 
Functional analyses of genetic information for DS have the potential to revolutionize our 
understanding about the gene-phenotype relationships in DS (Ait Yahya-Graison et al., 
2007; Gardiner, 2010). Our meta-analysis of current functional analyses has indicated that 
cell cycling, maintenance, function, and adhesion, as well as DNA and RNA metabolism and 
binding and mitochondrial function are leading common mechanisms underlying DS 
phenotypes. The combination of multiple genes to produce specific disorder-related 
phenotypes appears to be a common theme in DS phenotypes. Groups of genes may act in 
concert to produce one or more phenotypes, or contribute a key factor in the development 
or maintenance of a phenotype. In many cases, functional groups and mechanisms overlap 
between tissues of different origins, but no general mechanism appears to be ubiquitously 





























Fig. 1. Overlap of dysregulated functional groups occurs between multiple tissues, but no 
single mechanism appears to be dysregulated among all tissues studied. 
5. Conclusions 
Although the initial genetic insult is known and the phenotypes related to DS have been 
characterized, the relationship between genes and phenotypes has not been well 
distinguished for most DS phenotypes. Though phenotypes associated with DS must be 
caused by Ts21, high throughput gene expression analyses demonstrate the dysregulation of 
both trisomic and non-trisomic genes in tissues that are important for traits associated with 
Ts21. Hypotheses concerning critical regions and genes, thought to be important in most of 
 
Down Syndrome: A Complex and Interactive Genetic Disorder 87 
the major phenotypes associated with DS, have been disproved. Instead, it is postulated that 
a region of Hsa21 may be critical for a specific phenotype and a genomic region may contain 
a gene that is important (but not exclusive) for the causation of the trait. Moreover, there 
may be singular genes that are important in many, but not all, phenotypes associated with 
DS. Functional analyses of differentially expressed genes and genes in three copies may be 
used to further understand the relationships between genes and phenotypes. A number of 
differentially expressed genes may be tied into a mechanism and there may be mechanisms 
that are critical to a number of phenotypes. Thus, more accurate genotyping, large scale 
gene expression meta-analysis and functional mechanism investigations are helping to 
define gene-phenotype relationships in this complex and interactive disorder.  
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1. Introduction 
Down syndrome (DS) or trisomy 21 (MIM 190685) is the most common genetic disorder 
with a prevalence of 1 in 660 live births (Jones, 2006). DS is the leading cause of genetically-
defined intellectual disability (Contestabile et al., 2010) and its phenotype is complex and 
variable among individuals, who may present with a combination of dysmorphic features 
(Ahmed et al., 2005; Pavarino-Bertelli et al., 2009), congenital heart disease (Abbag, 2006), 
neurological abnormalities such as early manifestations of Alzheimer’s disease (Lott & 
Head, 2005), immunological  impairments (Ram & Chinen, 2011), elevated risk of specific 
types of leukemia (Hasle et al., 2000), and other clinical complications (Venail et al., 2004). 
Trisomy 21 can be caused by three types of chromosomal abnormalities: free trisomy, 
translocation, or mosaicism. Mosaicism accounts for the minority of DS cases (about 1%) 
and is characterized by some cells containing 46 chromosomes and others, 47 chromosomes. 
Translocations are attributed to 3-4% of the cases, with Robertsonian translocation involving 
chromosomes 14 and 21 being the most common type. Finally, free trisomy occurs in about 
95% of cases (Ahmed et al., 2005; J.M. Biselli et al., 2008b) and is characterized by the 
presence of three complete copies of chromosome 21. 
Free trisomy, the main chromosomal abnormality leading to DS, is caused by the failure of 
normal chromosome 21 segregation during meiosis (meiotic nondisjunction) (Hassold & 
Hunt, 2000). The parental origin of the extra chromosome 21 is maternal in about 80% of 
cases (Jyothy et al., 2001), and most (about 77%) occur during the first maternal meiotic 
division in the maturing oocyte, before conception (Antonarakis et al., 1992). 
2. Meiosis and chromosomal segregation 
Faithful transmission of a genome from one generation to another depends on the 
mechanism of cell division in which each pair of replicated chromosomes is separated and 
equally distributed to mother and daughter cells. Meiosis generates haploid gametes 
through a specialized cell division process that consists of one round of DNA replication 
followed by two cell divisions. The first division, meiosis I (MI), involves the segregation of 
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defined intellectual disability (Contestabile et al., 2010) and its phenotype is complex and 
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(Ahmed et al., 2005; Pavarino-Bertelli et al., 2009), congenital heart disease (Abbag, 2006), 
neurological abnormalities such as early manifestations of Alzheimer’s disease (Lott & 
Head, 2005), immunological  impairments (Ram & Chinen, 2011), elevated risk of specific 
types of leukemia (Hasle et al., 2000), and other clinical complications (Venail et al., 2004). 
Trisomy 21 can be caused by three types of chromosomal abnormalities: free trisomy, 
translocation, or mosaicism. Mosaicism accounts for the minority of DS cases (about 1%) 
and is characterized by some cells containing 46 chromosomes and others, 47 chromosomes. 
Translocations are attributed to 3-4% of the cases, with Robertsonian translocation involving 
chromosomes 14 and 21 being the most common type. Finally, free trisomy occurs in about 
95% of cases (Ahmed et al., 2005; J.M. Biselli et al., 2008b) and is characterized by the 
presence of three complete copies of chromosome 21. 
Free trisomy, the main chromosomal abnormality leading to DS, is caused by the failure of 
normal chromosome 21 segregation during meiosis (meiotic nondisjunction) (Hassold & 
Hunt, 2000). The parental origin of the extra chromosome 21 is maternal in about 80% of 
cases (Jyothy et al., 2001), and most (about 77%) occur during the first maternal meiotic 
division in the maturing oocyte, before conception (Antonarakis et al., 1992). 
2. Meiosis and chromosomal segregation 
Faithful transmission of a genome from one generation to another depends on the 
mechanism of cell division in which each pair of replicated chromosomes is separated and 
equally distributed to mother and daughter cells. Meiosis generates haploid gametes 
through a specialized cell division process that consists of one round of DNA replication 
followed by two cell divisions. The first division, meiosis I (MI), involves the segregation of 
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homologous chromosomes from each other, whereas meiosis II (MII) involves the 
segregation of the sister chromatids (Hassold & Hunt, 2000).  
Timing of chromosome attachment and loss of cohesion is essential to faithful chromosome 
segregation. During MI, the cohesion between sister chromatid arms assures physical 
attachment by the chiasmata of homologous chromosomes, ensuring their alignment on the 
meiosis-I spindle, and maintains them at the site of recombination. Chiasmata are resolved 
at anaphase I by the loss of cohesion between the arms of sister chromatids in the 
homologous chromosomes; the chromosomes then segregate to opposite poles of the cell. 
Cohesion, however, must be maintained at centromeres between sister chromatids beyond 
meiosis I to prevent premature chromatid separation (predivision) and ensure proper 
attachment of the sister chromatids to opposite spindle poles in meiosis II (Barbero, 2011; 
Sakuno & Watanabe, 2009; Vogt et al., 2008). 
The centromeric cohesion during meiosis I results from the attachment of kinetochores of sister 
chromatids to only one spindle pole (Sakuno & Watanabe, 2009). Kinetochores are situated on 
opposite sides of the centromeric heterochromatin at the centromeres of each sister chromatid 
and they capture and stabilize microtubules for the formation of kinetochore fibers, only then 
they are capable of chromosome bi-orientation during the metaphase and chromosome 
segregation during the anaphase of meiosis (Vogt et al., 2008). 
During cell division, several chromosomal mal-segregation mechanisms can occur. Classical 
nondisjunction is due to the failure to resolve chiasmata between homologous chromosomes, 
whereby both homologues segregate together. In addition, premature resolution of chiasmata 
or the failure to establish a chiasma between a pair of homologues results in the independent 
segregation of homologues at MI, which leads to an error if both segregate to the same pole of 
the MI spindle. A MI error can also involve the segregation of sister chromatids, rather than 
homologous chromosomes, whereby the premature separation of sister chromatids at MI can 
result in the segregation of a whole chromosome and a single chromatid to one of the poles. At 
MII, errors result from the failure of sister chromatid separation (Hassold & Hunt, 2000). 
3. The origin of maternal chromosome 21 nondisjunction 
The molecular mechanisms involved in meiotic nondisjunction leading to trisomy 21 are still 
poorly understood and the only well-established risk factor for DS is advanced maternal age at 
conception (35 years or older) (Allen et al., 2009; Jyothy et al., 2001; Lamb et al., 2005). Studies 
have suggested many explanations for the maternal age-associated increase in aneuploidy. 
One model attributes the effect of advanced maternal age to the uterine environment, 
indicating that there might be an age-related decline in the ability to recognize and then abort 
trisomic fetuses (Aymé & Lippman-Hand, 1982; Stein et al., 1986). However, the observation 
that the advanced maternal age effect is restricted to chromosome 21 nondisjunction of 
maternal origin, but not associated with cases resulting from sperm or post-zygotic mitotic 
errors, suggests that the uterus is the source of the age effect (Allen et al., 2009). 
On the other hand, Zheng & Byers (1993) proposed that age-dependent trisomy 21 results 
primarily from a mechanism that favors maturation and utilization of euploid oocytes over 
the pre-existing aneuploid products of mitotic (premeiotic) nondisjunction at an early stage 
of the reproductive lifespan. In addition, decreased expression of checkpoint proteins in 
aging oocytes (Vogt et al., 2008) and failure to effectively replace cohesion proteins that are 
lost from chromosomes during aging (Chiang et al., 2010) also are pointed out as risk factors 
for predisposing oocytes to errors in chromosome segregation. 
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A link between altered recombination and maternal age-related nondisjunction has been 
described. It was observed that recombination is reduced among nondisjoined 
chromosomes 21 at MI, and this reduction seems to be age-related (Sherman et al., 1994). 
Lamb et al. (1996) proposed that at least two “hits” are required for chromosome 21 
nondisjuntion: (1) the establishment in the fetal ovary of a susceptible pattern of meiotic 
recombination, and (2) the abnormal processing of susceptible chromosomes in the adult 
ovary. The second “hit” would involve degradation of a meiotic process (e.g., a spindle 
component, a sister chromatid cohesion protein, a meiotic motor protein, a checkpoint 
control protein) that increases the risk of improper segregation for these susceptible 
bivalents (Hassold & Sherman, 2000). Further studies have shown susceptible patterns of 
chromosome 21 meiotic recombination, including pericentromeric and telomeric exchanges, 
described as maternal risk factors for DS even in young DS mothers (Gosh et al., 2009; Lamb 
et al., 2005). 
Besides advanced maternal age, the age of the maternal grandmother at the time of birth of 
the mother has also been pointed out as a risk factor for the occurrence of DS. At an 
advanced age, the grandmother's reproductive system may fail to make the essential 
proteins needed for proper meiotic segregation in the germ cells of her daughter, leading to 
nondisjunction of chromosome 21 during the embryogenesis of DS child’s mother when she 
was in the grandmother's womb (Malini & Ramachandra, 2006). However, more recent 
studies failed to support the suggestion that advanced age of the DS grandmother is 
responsible for meiotic disturbances in her daughter (Allen et al., 2009; Kovaleva et al., 
2010). 
Although the risk of bearing a child with DS increases substantially with increasing 
maternal age, many DS children are born to mothers aged less than 35 years-old, suggesting 
other risk factors influencing DS etiology. In 1999, James et al. produced the first evidence 
that the occurrence of DS independent of maternal age is associated with DNA 
hypomethylation due to impairments in folate metabolism. 
4. Folate metabolism 
Folate represents an essential nutrition component in the human diet, and is involved in many 
metabolic pathways, mainly the folate metabolism, i.e., a single-carbon transfer from one 
molecule to another through a series of interconnected biochemical reactions. Folate is a 
generic term for a family of compounds present in most foods, e.g., legumes, leafy greens, 
some fruits, vegetables (e.g.,  spinach, broccoli, asparagus, and lettuce), liver, milk, and dairy 
products (Lin & Young, 2000). Humans, as all mammals, are unable to synthesize folate, thus 
its ingestion, either from normal diet or nutritional supplements, is very important. After 
intestinal absorption, natural folate, known as polyglutamate, requires reduction into 
monoglutamate by conjugases in the small intestine before it can be absorbed. On the other 
hand, in its synthetic form, folic acid exists as monoglutamate and does not need to be reduced 
for release into the blood and cellular uptake (Bailey & Gregory, 1999; Hall & Solehdin, 1998). 
Another disadvantage of natural  food  folate is its poor stability especially under  typical  
cooking  conditions,  which  can substantially  reduce  the  vitamin  content  before  it  is  even 
ingested, a significant additional factor limiting the ability of natural food folates to  enhance  
folate  status (McNulty & Pentieva, 2004; McNulty & Scott, 2008).  
Folate metabolism is a complex metabolic pathway that involves multiple enzymes and 
water-soluble  B  vitamins such as folate,  vitamin  B6 and  vitamin  B12, that play  key  roles  
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as enzyme cofactors or substrates in this metabolism. It includes two main cycles: purine 
and pyrimidine synthesis, necessary for synthesis and repair of DNA, and DNA 
methylation, an epigenetic process that acts on the control associated with gene expression 
and genomic stability essential for normal cellular methylation reactions (Figure 1). 
 
 
Fig. 1. Folate metabolism. BHMT = Betaine-homocysteine methyltransferase; B6 = vitamin 
B6; B12 = vitamin B12; CβS = Cystathionine β- synthase; CH3 = Methyl; dATP = 
Deoxyadenosine 5’-triphosphate; dGTP = Deoxyguanosine 5’-triphosphate; dTTP = 
Deoxythymidine 5’-triphosphate; DHF = Dihydrofolate; DHFR = Dihydrofolate reductase; 
Hcy = Homocysteine; MTHFD1 = Methylenetetrahydrofolate dehydrogenase 1; MTHFR = 
Methylenetetrahydrofolate reductase; MTR = Methionine synthase; MTRR = Methionine 
synthase reductase; RFC1 = Reduced folate carrier 1; SAH = S-adenosylhomocysteine; SAM 
= S- adenosylmethionine; cSHMT=  Serine hydroxymethyltransferase; TC2 = 
Transcobalamin 2; THF = Tetrahydrofolate.  
Folate requires several transport systems to enter the cells and the one best characterized is 
the reduced folate carrier (RFC1), an enzyme located on intestinal cell membranes that 
carries out the transport of 5-methyltetrahydrofolate (5-methyl-THF) to the interior of a 
variety of cells, representing an important determinant of folate concentration in the interior 
of cells (Nguyen et al., 1997). In addition to the folate transport system, several genes and 
their respective enzymes play important roles in folate metabolism. The Dihydrofolate 
reductase (DHFR) gene encodes an enzyme that catalyzes the conversion of dihydrofolate 
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(DHF) into tetrahydrofolate (THF) (Stanisiawska-Sachadyn et al., 2008), which is then 
converted into the corresponding 10-formyl, 5,10-methenyl, and 5,10-methylene derivatives 
by Methylenetetrahydrofolate dehydrogenase 1 (MTHFD1), a trifunctional nicotinamide 
adenine dinucleotide phosphate-dependent cytoplasmic enzyme. The donor cofactors for de 
novo purine and pyrimidine biosynthesis and, thus, the biosynthesis of DNA (Hum, 1988) 
are 10-formyl-THF and 5,10-methylene-THF. By an alternative route, THF is converted into 
5,10-methylene-THF and glycine by the cytosolic form of the enzyme Serine 
hydroxymethyltransferase (cSHMT) (Steck et al., 2008). 
Methylenetetrahydrofolate reductase (MTHFR) is responsible for the conversion of 5,10-
methylene-THF to 5-methyl-THF, the main circulating form of folate that donates methyl 
groups for homocysteine (Hcy) remethylation into methionine. This latter reaction is catalyzed 
by the enzyme Methionine synthase (MTR), which requires vitamin B12 or cobalamin (Cbl) as 
a cofactor, and results in the formation of S-adenosylmethionine (SAM), the primary methyl 
(CH3) donor for DNA methylation reactions (Finkelstein & Martin, 2000). SAM is 
demethylated to form S-adenosylhomocysteine (SAH) and then hydrolyzed to form adenine 
and Hcy. The DNA methyltransferase (DNMTs) enzymes catalyze the transfer of the methyl 
group, obtained from conversion of SAM into SAH, to position 5’ of cytosine residues located 
mainly in dinucleotide cytosine-guanine (CpG) (Bestor, 2000; DeAngelis et al., 2008).  
Methionine synthase reductase (MTRR), an enzyme codified by the MTRR gene, is 
responsible for the maintenance of the active form of the enzyme MTR. During 
remethylation of Hcy to methionine, a reaction catalyzed by MTR, methylcob(III)alamine 
acts as a methyl donor. In this reaction, the transfer of a methyl group from 
methylcob(III)alamine results in the formation of highly reactive cob(I)alamine, which is 
oxidized into cob(II)alamine, resulting in MTR inactivation (Yamada et al., 2006). In this 
inactivation process, a complex is formed between the enzymes MTR and MTRR, and 
derivative electrons from the oxidation of nicotinamide adenine dinucleotide phosphate 
(NADPH), catalyzed by MTR, are transferred to the inactive form of MTR. This process 
favors the transfer of methyl from the SAM to the MTR enzyme, resulting in 
methylcob(III)alamine, thus reestablishing MTR activity (Leclerc et al., 1999; Olteanu et al., 
2001, 2002).  
Betaine-homocysteine methyltransferase (BHMT) catalyses the conversion of Hcy to 
methionine by an alternative pathway of remethylation using the amino acid bethaine as 
methyl donor. When the Hcy folate-dependent remethylation catalyzed by the MTR enzyme 
is impaired by genetics or environmental factors, the BHMT enzyme plays an important role 
maintaining the homeostasis of Hcy (Pajares & Pérez-Salab, 2006). 
In the transsulfuration cycle, Hcy is converted into cystathionine by Cystathionine β-
synthase (CβS), a vitamin B6-dependent enzyme, and then into cysteine (Kraus et al., 1998). 
Under normal physical conditions, all Hcy is remethylated into methionine or catalyzed into 
cystathionine. The increase of Hcy concentration represents impairment in folate 
metabolism and thus in methylation reactions (Fenech, 2002).  
Besides the enzymes that act directly on folate metabolism, cobalamin-transporting proteins 
also play an important role in this metabolic pathway, since the MTR enzyme is cobalamin-
dependent. The enzyme Transcobalamin 2 (TC2) is synthesized in the intestinal villi and 
binds itself to Cbl in the interstitial fluid. This formed complex goes into the intestinal villi 
microcirculation and then reaches the systemic circulation. This circulation distributes the 
vitamin to all tissues where specific receptors on cell membranes bind and internalize the 
TC2-Cbl complex by endocytosis (Quadros et al., 1999; Seetharam & Li, 2000).  
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5. Folate metabolism, genomic stability, and maternal risk for chromosome 
21 nondisjunction 
Based  on evidence that stable centromeric DNA chromatin may depend on the epigenetic 
inheritance of specific centromeric methylation patterns and on the binding of specific methyl-
sensitive proteins to maintain the higher order DNA architecture necessary for kinetochore 
assembly (Karpen & Allshire, 1997), James et al. (1999) hypothesized that pericentromeric 
hypomethylation, resulting from impaired folate metabolism secondary to polymorphism of 
the MTHFR gene, could impair chromosomal segregation and increase the risk for 
chromosome 21 nondisjunction in young mothers. They observed that the risk of having a 
child with DS was 2.6-fold higher in mothers with 677 C→T substitution in one or both alleles 
of the MTHFR gene than in mothers without the 677 C→T substitution. In addition, DS 
mothers displayed a significant increase in plasma Hcy concentrations and lymphocyte 
methotrexate cytotoxicity, consistent with abnormal folate and methyl metabolism. 
As described above, the MTHFR enzyme plays an important role in regulating DNA 
methylation through the reduction of 5,10-methylene-THF to 5-methyl-THF (Figure 1). The 677 
C→T polymorphism is known to decrease the affinity of the enzyme for the flavin-adenine-
dinucleotide (FAD) cofactor, decreasing enzyme activity (Guenther et al., 1999; Yamada et al., 
2001). The MTHFR 677 CT genotype seems to reduce enzyme activity by about 35% and the 
homozygous TT genotype by 70% (Frosst et al., 1995). Since the study by James et al. (1999), 
polymorphisms in the MTHFR gene are the most frequently investigated in attempt to clarify 
the role of folate and methyl metabolism in the maternal risk for DS (Martínez-Frías et  al.,  
2008). Several  studies  have  associated  the MTHFR 677CT polymorphism and the risk of 
bearing a child with DS (da Silva et al., 2005; Meguid et al., 2008; Sadiq et al., 2011; Wang et al., 
2008) as well as with increasing plasma Hcy concentration (P.M. Biselli et al., 2007; da Silva et 
al., 2005; Narayanan et al., 2004; Ulvik et al., 2007).  
Another common polymorphism in the MTHFR gene, the substitution of alanine for 
cytosine at the 1298 position, was already associated with DS risk and increased plasma Hcy 
concentration (Martínez-Frías et al., 2006; Meguid et al., 2008; Narayanan et al., 2004, Rai et 
al., 2006; Scala et al., 2006; Weisberg et al., 2001). This polymorphism proved to have an 
impact on enzyme activity resulting in an even more pronounced decrease in its activity in 
homozygous 1298 CC compared to the heterozygous individuals (van der Putt et al., 1998). 
In addition to the MTHFR gene, other genetic polymorphisms involved in the folate 
pathway seem to modulate the maternal risk for bearing a child with DS (Bosco et al., 2003; 
J.M. Biselli et al., 2008a; Meguid et al., 2008; Pozzi et al., 2009; Sadiq et al., 2011; Scala et al., 
2006; Wang et al., 2008) as well as the concentrations of metabolites involved in the folate 
pathway (Ananth et al. 2007; Barbosa et al., 2008; Cheng et al., 2010; Devos et al., 2008). The 
MTR 2756 A→G polymorphism has been associated with increased maternal risk  for DS in 
the presence of AG or GG genotypes, as well as when combined with polymorphisms 
MTRR 66 A→G (MTR 2756AG/MTRR 66AG) (Bosco et al., 2003) and MTHFR 677 C→T 
(MTHFR 677TT/MTR 2756AA). In addition, the allele MTR 2756 G proved to be more 
frequent, both in homozygosis and heterozygosis, in DS mothers as compared to mothers of 
individuals without the syndrome (Pozzi et al., 2009). Concerning its influence on Hcy 
concentrations, studies have shown conflicting results, since some have associated the MTR 
2756 A allele to increased Hcy concentration (Fredriksen et al., 2007; Harmon et al., 1999), 
while others found the same association, but with the polymorphic 2756 G alelle (Feix et al., 
2001; Fillon-Emery et al., 2004). 
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As to the MTRR 66 A→G polymorphism, some studies have supported an independent role 
for this polymorphism in the maternal risk for DS in the presence of the homozygous MTRR 
66 GG genotype (Hobbs et al., 2000; Pozzi et al., 2009; Wang et al., 2008). Most of the studies 
have associated this polymorphism with the risk of DS and increased Hcy concentration 
when combined to other polymorphisms, such as MTHFR 677 C→T (Hobbs et al., 2000; 
Martínez-Frías et  al.,  2006; O’Leary et al, 2002; Yang  et  al.,  2008). Additionally, a steady 
state kinetic analysis showed a significantly decreased affinity of MTRR for MTR 
accompanying substitution 66 A→G, revealing a significant difference in the relative 
efficacies of  the  MTRR enzyme (Olteanu et al., 2002). However, several studies have failed 
to find association between DS risk and the MTRR 66 A→G polymorphism, whether alone 
or combined with other genetic variants (Coppedè et al., 2009; Chango et al., 2005; Scala et 
al., 2006). 
The RFC1 gene is polymorphic at nucleotide 80 (A→G), and investigation of the impact of 
this polymorphism on protein function have demonstrated a difference in its affinity for 
subtracts and/or efficiency in transport in comparison with the wild type enzyme 
(Whetstine et al., 2001). Few studies have evaluated the influence of the RFC1  80 A→G 
polymorphism on DS risk (J.M. Biselli, 2008a, 2008c; Chango et al., 2005; Coppedè et al., 
2006). Some studies have found no association between this polymorphism and DS (Chango 
et al. 2005; Fintelman-Rodrigues et al., 2009); however, Coppedè et al. (2006) and J.M. Biselli  
et al. (2008a) suggest a role for this polymorphism when combined with other 
polymorphisms in genes involved in folate metabolism. Supporting this hypothesis, the 
combined RFC1 80 GG/MTHFR 677 TT genotype has been associated with  increased Hcy 
concentration and the RFC1 80 AA/MTHFR 677 CT combined genotype with higher plasma 
folate concentration (Chango et al., 2000). 
A common polymorphism in the CβS gene, 68-base pair (bp) insertion at nucleotide position 
844 (844ins68), is also investigated in the risk for DS, but there is no evidence that this 
variant plays an independent role on this risk (da Silva et al., 2005; Chango et al., 2005; Scala 
et al., 2006). The CβS 844ins68 polymorphism has been associated with reduction of Hcy 
concentration in the presence of the insertion (Tsai et al., 1996; Tsai et al., 1999; Tsai et al., 
2000), and it is believed that this insertion is related to increased enzyme activity (Tsai et al., 
1996, Tsai et al., 1999). This variant is always found to be associated in cis with an additional 
polymorphism in the CβS gene, a thymine-to-cytosine transition at nucleotide position 833, 
which causes a threonine-to-isoleucine amino acid substitution, and is reported, together 
with CβS 844ins68, as a 833 T→C/844ins68 in cis double mutation (Pepe et al., 1999; Vyletal 
et al., 2007). Da Silva et al., (2005) observed that the 844ins68 polymorphism, in association 
with other polymorphisms of the folate pathway, is related to increased risk for DS. 
Concerning its influence on folate metabolite concentrations, such as folate, Hcy, and 
vitamin B12, the CS 844ins68 polymorphism showed no significant association with any of 
the biochemical variables involved in folate metabolism (Bowron et al., 2005; Kumar et al., 
2010; Summers et al., 2008). 
The MTHFD1 gene presents a functional polymorphism, a guanine-to-adenine substitution 
at position 1958 (1958 G→A), that has been shown to reduce the activity and stability of the 
variant enzyme (Christensen et al., 2008). There are only two studies to date on the influence 
of this polymorphism on maternal risk for DS. Scala et al. (2006) showed an association of 
the MTHFD1 1958 AA genotype with DS risk, but only when combined with the RFC1 80 
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5. Folate metabolism, genomic stability, and maternal risk for chromosome 
21 nondisjunction 
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inheritance of specific centromeric methylation patterns and on the binding of specific methyl-
sensitive proteins to maintain the higher order DNA architecture necessary for kinetochore 
assembly (Karpen & Allshire, 1997), James et al. (1999) hypothesized that pericentromeric 
hypomethylation, resulting from impaired folate metabolism secondary to polymorphism of 
the MTHFR gene, could impair chromosomal segregation and increase the risk for 
chromosome 21 nondisjunction in young mothers. They observed that the risk of having a 
child with DS was 2.6-fold higher in mothers with 677 C→T substitution in one or both alleles 
of the MTHFR gene than in mothers without the 677 C→T substitution. In addition, DS 
mothers displayed a significant increase in plasma Hcy concentrations and lymphocyte 
methotrexate cytotoxicity, consistent with abnormal folate and methyl metabolism. 
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polymorphisms in the MTHFR gene are the most frequently investigated in attempt to clarify 
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2008). Several  studies  have  associated  the MTHFR 677CT polymorphism and the risk of 
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al., 2005; Narayanan et al., 2004; Ulvik et al., 2007).  
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al., 2006; Scala et al., 2006; Weisberg et al., 2001). This polymorphism proved to have an 
impact on enzyme activity resulting in an even more pronounced decrease in its activity in 
homozygous 1298 CC compared to the heterozygous individuals (van der Putt et al., 1998). 
In addition to the MTHFR gene, other genetic polymorphisms involved in the folate 
pathway seem to modulate the maternal risk for bearing a child with DS (Bosco et al., 2003; 
J.M. Biselli et al., 2008a; Meguid et al., 2008; Pozzi et al., 2009; Sadiq et al., 2011; Scala et al., 
2006; Wang et al., 2008) as well as the concentrations of metabolites involved in the folate 
pathway (Ananth et al. 2007; Barbosa et al., 2008; Cheng et al., 2010; Devos et al., 2008). The 
MTR 2756 A→G polymorphism has been associated with increased maternal risk  for DS in 
the presence of AG or GG genotypes, as well as when combined with polymorphisms 
MTRR 66 A→G (MTR 2756AG/MTRR 66AG) (Bosco et al., 2003) and MTHFR 677 C→T 
(MTHFR 677TT/MTR 2756AA). In addition, the allele MTR 2756 G proved to be more 
frequent, both in homozygosis and heterozygosis, in DS mothers as compared to mothers of 
individuals without the syndrome (Pozzi et al., 2009). Concerning its influence on Hcy 
concentrations, studies have shown conflicting results, since some have associated the MTR 
2756 A allele to increased Hcy concentration (Fredriksen et al., 2007; Harmon et al., 1999), 
while others found the same association, but with the polymorphic 2756 G alelle (Feix et al., 
2001; Fillon-Emery et al., 2004). 
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As to the MTRR 66 A→G polymorphism, some studies have supported an independent role 
for this polymorphism in the maternal risk for DS in the presence of the homozygous MTRR 
66 GG genotype (Hobbs et al., 2000; Pozzi et al., 2009; Wang et al., 2008). Most of the studies 
have associated this polymorphism with the risk of DS and increased Hcy concentration 
when combined to other polymorphisms, such as MTHFR 677 C→T (Hobbs et al., 2000; 
Martínez-Frías et  al.,  2006; O’Leary et al, 2002; Yang  et  al.,  2008). Additionally, a steady 
state kinetic analysis showed a significantly decreased affinity of MTRR for MTR 
accompanying substitution 66 A→G, revealing a significant difference in the relative 
efficacies of  the  MTRR enzyme (Olteanu et al., 2002). However, several studies have failed 
to find association between DS risk and the MTRR 66 A→G polymorphism, whether alone 
or combined with other genetic variants (Coppedè et al., 2009; Chango et al., 2005; Scala et 
al., 2006). 
The RFC1 gene is polymorphic at nucleotide 80 (A→G), and investigation of the impact of 
this polymorphism on protein function have demonstrated a difference in its affinity for 
subtracts and/or efficiency in transport in comparison with the wild type enzyme 
(Whetstine et al., 2001). Few studies have evaluated the influence of the RFC1  80 A→G 
polymorphism on DS risk (J.M. Biselli, 2008a, 2008c; Chango et al., 2005; Coppedè et al., 
2006). Some studies have found no association between this polymorphism and DS (Chango 
et al. 2005; Fintelman-Rodrigues et al., 2009); however, Coppedè et al. (2006) and J.M. Biselli  
et al. (2008a) suggest a role for this polymorphism when combined with other 
polymorphisms in genes involved in folate metabolism. Supporting this hypothesis, the 
combined RFC1 80 GG/MTHFR 677 TT genotype has been associated with  increased Hcy 
concentration and the RFC1 80 AA/MTHFR 677 CT combined genotype with higher plasma 
folate concentration (Chango et al., 2000). 
A common polymorphism in the CβS gene, 68-base pair (bp) insertion at nucleotide position 
844 (844ins68), is also investigated in the risk for DS, but there is no evidence that this 
variant plays an independent role on this risk (da Silva et al., 2005; Chango et al., 2005; Scala 
et al., 2006). The CβS 844ins68 polymorphism has been associated with reduction of Hcy 
concentration in the presence of the insertion (Tsai et al., 1996; Tsai et al., 1999; Tsai et al., 
2000), and it is believed that this insertion is related to increased enzyme activity (Tsai et al., 
1996, Tsai et al., 1999). This variant is always found to be associated in cis with an additional 
polymorphism in the CβS gene, a thymine-to-cytosine transition at nucleotide position 833, 
which causes a threonine-to-isoleucine amino acid substitution, and is reported, together 
with CβS 844ins68, as a 833 T→C/844ins68 in cis double mutation (Pepe et al., 1999; Vyletal 
et al., 2007). Da Silva et al., (2005) observed that the 844ins68 polymorphism, in association 
with other polymorphisms of the folate pathway, is related to increased risk for DS. 
Concerning its influence on folate metabolite concentrations, such as folate, Hcy, and 
vitamin B12, the CS 844ins68 polymorphism showed no significant association with any of 
the biochemical variables involved in folate metabolism (Bowron et al., 2005; Kumar et al., 
2010; Summers et al., 2008). 
The MTHFD1 gene presents a functional polymorphism, a guanine-to-adenine substitution 
at position 1958 (1958 G→A), that has been shown to reduce the activity and stability of the 
variant enzyme (Christensen et al., 2008). There are only two studies to date on the influence 
of this polymorphism on maternal risk for DS. Scala et al. (2006) showed an association of 
the MTHFD1 1958 AA genotype with DS risk, but only when combined with the RFC1 80 
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GG genotype; however, more recently, Neagos et al. (2010) failed to find association. Thus, 
further investigations are necessary to clarify the role of MTHFD1 1958 G→A in the 
chromosome 21 nondisjunction. 
Johnson et al. (2004) described a 19-base pair (bp) deletion polymorphism in intron-1 of the 
DHFR gene and hypothesized that this polymorphism could be functional since the deletion 
removes a possible transcription factor binding site that affects gene regulation. A study 
with mothers of individuals with spina bifida showed that the expression  of the messenger  
ribonucleic  acid  (mRNA) from the DHFR gene was 50% higher  in  the presence of del/del 
genotype than in the ins/ins genotype (Parle-McDermott  et  al.,  2007). This polymorphism 
has been associated with the modulation of metabolites’ concentrations involved in the 
folate pathway. Gellekink et al. (2007) reported association between the del/del genotype 
and reduction of plasma Hcy concentration, but found no association between this genotype 
and concentrations of serum and erythrocyte folate. Another study found no effect on Hcy 
concentration, but found increased plasma and erythrocyte folate levels in del/del 
individuals (Stanislawska-Sachadyn et al., 2008). The results of the only study that 
investigated the 19-bp deletion polymorphism of DHFR gene in DS mothers did not support 
an association between this variant and the maternal risk for DS. In addition, the 
polymorphism was not associated with variations in serum folate and plasma Hcy and 
methylmalonic acid (MMA) concentrations in the study population (Mendes et al., 2010). 
The TC2 gene, which codifies a transporting protein required for the cellular uptake of 
vitamin B12 (Seetharam &Li, 2000), is polymorphic at nucleotide position 776 (C→G). There is 
evidence that the presence of  the TC2 776 CC genotype may be more efficient in delivering 
vitamin B12 to tissues, resulting in enhanced B12 functional status (Miller et al., 2002; Namour 
et al., 1998). In other studies, the presence of the TC2 776 GG genotype was shown to affect 
negatively the serum concentration of the TC2 protein-vitamin B12 complex (von Castel-
Dunwoody et al., 2005) and was associated with low concentrations of SAM in childbearing-
age women (Barbosa et al., 2008). Considering that SAM is the major methyl donor for DNA 
methylation reactions,  it  was hypothesized that the variant TC2 776 C→G could influence 
the maternal risk for DS by modifying the DNA methylation pattern. This polymorphism 
has only been investigated in DS risk by two groups to date (J.M. Biselli et al., 2008c; 
Fintelman-Rodrigues et al., 2009), but no association has been found. 
The conflicting results shown by literature have raised the suggestion that the presence of 
individual polymorphisms in genes involved in folate metabolism might not increase the 
risk of having a child with DS, although the effect of combined risk genotypes might modify 
their individual effect and increase DS risk (J.M., Biselli et al., 2008a; Brandalize et al., 2010; 
Coppedè et al., 2006; Coppedè et al., 2009; da Silva et al., 2005; Martínez-Frías, et al., 2006; 
Scala et al., 2006; Wang et al., 2008). Moreover, there is evidence that the significance of 
genetic polymorphisms seems to depend on interactions with nutritional factors 
(Papoutsakis et al., 2010; Stover & Caudill, 2008). 
6. Folate metabolism, genomic stability, and genetic polymorphisms 
Both in vitro and in vivo studies have shown that DNA methylation is an important 
mechanism for the maintenance of genomic stability. Literature provides several examples 
that genome-wide DNA hypomethylation enhances the occurrence of aneuploidy and 
chromosomal rearrangements (Herrera et al., 2008), loss of heterozygosity (Matsuzaki et al., 
2005), and chromosome malsegregation (Fenech et al., 2011). Folate and vitamin B12 are 
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among the most important minerals and vitamins required for DNA maintenance and 
prevention of DNA damage that could be induced by inadequate intake of these 
antimutagenic vitamins (Fenech, 2002). In human cells, folate deficiency is associated with 
DNA hypomethylation (Chang et al., 2011; Linhart et al., 2009), DNA instability (strand 
breakage, uracil misincorporation) (Linhart et al., 2009; Williams & Jacobson, 2010), 
aneuploidy of chromosomes 17 and 21 (Beetstra et al., 2005; Wang et al., 2004), apoptosis (Li 
et al., 2003), and necrosis (Beetstra et al., 2005). Low vitamin B12 status is also associated with 
DNA hypomethylation (Brunaud et al., 2003) and genetic instability (Andreassi et al., 2003; 
Botto et al., 2003). 
There is increasing evidence of association between polymorphisms in folate and Hcy 
metabolizing genes and levels of chromosome damage. The MTHFR 677 C→T 
polymorphism is associated with diminished levels of 5-methylcytosine and DNA 
hypomethylation (Chen et al., 2010; Friso et al., 2002; Paz et al., 2002), micronucleus 
formation (Andreassi et al., 2003; Botto et al., 2003), and microsatellite instability 
(Naghibalhossaini et al., 2010) in the presence of the variant T allele. The homozygous 
variant genotype of another polymorphism of the MTHFR gene, 1298 A→C, was more 
frequent in patients with Turner syndrome (de Oliveira et al., 2008), and a higher frequency 
of the C allele was observed in spontaneous abortions with fetal chromosomal aneuploidy 
as compared to those with normal fetal karyotypes (Kim et al., 2011), suggesting its 
involvement in the origin of chromosomal imbalances. The MTR 2756 A→G polymorphism 
was associated  with reduced  number  of  hypermethylated  CpG  islands  of  suppressor  
tumor genes and with higher micronucleus rates in the presence of the MTRR 66 GG variant 
genotype (Botto et al., 2003; Paz et al., 2002; Zijno et al., 2003).  
The polymorphism RFC1 80 A→G has been associated with reduced percentage of 5-
methylcytosine in the DNA of mothers of children with autism in the presence of 
homozygous and heterozygous genotypes for the G allele as compared to AA genotype 
(James et al., 2010); however, the presence of the A allele was recently associated with 
increased oxidative DNA damage, while the cSHMT 1420 C→T polymorphism was 
associated with reduced oxidative DNA damage (CC>CT>TT) (Mohammad et al., 2011). 
Moreover, Piskac-Collier et al. (2011) recently demonstrated that lymphocytes from lung 
cancer patients showed a considerably increased frequency of cytogenetic damage in the 
presence of MTHFR 677 C→T, MTHFR 1298 A→C, and cSHMT 435 C→T allelic variants, 
suggesting that interactions between genetic polymorphisms may also have a significant 
impact on genetic instability. 
7. Predisposition to chromosome malsegregation in young DS mothers and 
its association with folate-metabolizing gene polymorphisms 
Studies with women who have a DS child at a young age have suggested that they present 
genetic predispositions to chromosome malsegregation in both somatic and germ line cells. 
Migliore et al. (2006) observed increased frequency of binucleated-micronucleated 
lymphocytes in women who had a DS child before 35 years of age, and fluorescence in situ 
hybridization analysis revealed that micronuclei were mainly originating from 
chromosomal malsegregation events, including chromosome 21 malsegregation. Further 
studies from their group confirmed increased chromosome damage in blood cells of young 
DS mothers and showed a significant correlation between micronucleated cells and both 
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GG genotype; however, more recently, Neagos et al. (2010) failed to find association. Thus, 
further investigations are necessary to clarify the role of MTHFD1 1958 G→A in the 
chromosome 21 nondisjunction. 
Johnson et al. (2004) described a 19-base pair (bp) deletion polymorphism in intron-1 of the 
DHFR gene and hypothesized that this polymorphism could be functional since the deletion 
removes a possible transcription factor binding site that affects gene regulation. A study 
with mothers of individuals with spina bifida showed that the expression  of the messenger  
ribonucleic  acid  (mRNA) from the DHFR gene was 50% higher  in  the presence of del/del 
genotype than in the ins/ins genotype (Parle-McDermott  et  al.,  2007). This polymorphism 
has been associated with the modulation of metabolites’ concentrations involved in the 
folate pathway. Gellekink et al. (2007) reported association between the del/del genotype 
and reduction of plasma Hcy concentration, but found no association between this genotype 
and concentrations of serum and erythrocyte folate. Another study found no effect on Hcy 
concentration, but found increased plasma and erythrocyte folate levels in del/del 
individuals (Stanislawska-Sachadyn et al., 2008). The results of the only study that 
investigated the 19-bp deletion polymorphism of DHFR gene in DS mothers did not support 
an association between this variant and the maternal risk for DS. In addition, the 
polymorphism was not associated with variations in serum folate and plasma Hcy and 
methylmalonic acid (MMA) concentrations in the study population (Mendes et al., 2010). 
The TC2 gene, which codifies a transporting protein required for the cellular uptake of 
vitamin B12 (Seetharam &Li, 2000), is polymorphic at nucleotide position 776 (C→G). There is 
evidence that the presence of  the TC2 776 CC genotype may be more efficient in delivering 
vitamin B12 to tissues, resulting in enhanced B12 functional status (Miller et al., 2002; Namour 
et al., 1998). In other studies, the presence of the TC2 776 GG genotype was shown to affect 
negatively the serum concentration of the TC2 protein-vitamin B12 complex (von Castel-
Dunwoody et al., 2005) and was associated with low concentrations of SAM in childbearing-
age women (Barbosa et al., 2008). Considering that SAM is the major methyl donor for DNA 
methylation reactions,  it  was hypothesized that the variant TC2 776 C→G could influence 
the maternal risk for DS by modifying the DNA methylation pattern. This polymorphism 
has only been investigated in DS risk by two groups to date (J.M. Biselli et al., 2008c; 
Fintelman-Rodrigues et al., 2009), but no association has been found. 
The conflicting results shown by literature have raised the suggestion that the presence of 
individual polymorphisms in genes involved in folate metabolism might not increase the 
risk of having a child with DS, although the effect of combined risk genotypes might modify 
their individual effect and increase DS risk (J.M., Biselli et al., 2008a; Brandalize et al., 2010; 
Coppedè et al., 2006; Coppedè et al., 2009; da Silva et al., 2005; Martínez-Frías, et al., 2006; 
Scala et al., 2006; Wang et al., 2008). Moreover, there is evidence that the significance of 
genetic polymorphisms seems to depend on interactions with nutritional factors 
(Papoutsakis et al., 2010; Stover & Caudill, 2008). 
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Both in vitro and in vivo studies have shown that DNA methylation is an important 
mechanism for the maintenance of genomic stability. Literature provides several examples 
that genome-wide DNA hypomethylation enhances the occurrence of aneuploidy and 
chromosomal rearrangements (Herrera et al., 2008), loss of heterozygosity (Matsuzaki et al., 
2005), and chromosome malsegregation (Fenech et al., 2011). Folate and vitamin B12 are 
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among the most important minerals and vitamins required for DNA maintenance and 
prevention of DNA damage that could be induced by inadequate intake of these 
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metabolizing genes and levels of chromosome damage. The MTHFR 677 C→T 
polymorphism is associated with diminished levels of 5-methylcytosine and DNA 
hypomethylation (Chen et al., 2010; Friso et al., 2002; Paz et al., 2002), micronucleus 
formation (Andreassi et al., 2003; Botto et al., 2003), and microsatellite instability 
(Naghibalhossaini et al., 2010) in the presence of the variant T allele. The homozygous 
variant genotype of another polymorphism of the MTHFR gene, 1298 A→C, was more 
frequent in patients with Turner syndrome (de Oliveira et al., 2008), and a higher frequency 
of the C allele was observed in spontaneous abortions with fetal chromosomal aneuploidy 
as compared to those with normal fetal karyotypes (Kim et al., 2011), suggesting its 
involvement in the origin of chromosomal imbalances. The MTR 2756 A→G polymorphism 
was associated  with reduced  number  of  hypermethylated  CpG  islands  of  suppressor  
tumor genes and with higher micronucleus rates in the presence of the MTRR 66 GG variant 
genotype (Botto et al., 2003; Paz et al., 2002; Zijno et al., 2003).  
The polymorphism RFC1 80 A→G has been associated with reduced percentage of 5-
methylcytosine in the DNA of mothers of children with autism in the presence of 
homozygous and heterozygous genotypes for the G allele as compared to AA genotype 
(James et al., 2010); however, the presence of the A allele was recently associated with 
increased oxidative DNA damage, while the cSHMT 1420 C→T polymorphism was 
associated with reduced oxidative DNA damage (CC>CT>TT) (Mohammad et al., 2011). 
Moreover, Piskac-Collier et al. (2011) recently demonstrated that lymphocytes from lung 
cancer patients showed a considerably increased frequency of cytogenetic damage in the 
presence of MTHFR 677 C→T, MTHFR 1298 A→C, and cSHMT 435 C→T allelic variants, 
suggesting that interactions between genetic polymorphisms may also have a significant 
impact on genetic instability. 
7. Predisposition to chromosome malsegregation in young DS mothers and 
its association with folate-metabolizing gene polymorphisms 
Studies with women who have a DS child at a young age have suggested that they present 
genetic predispositions to chromosome malsegregation in both somatic and germ line cells. 
Migliore et al. (2006) observed increased frequency of binucleated-micronucleated 
lymphocytes in women who had a DS child before 35 years of age, and fluorescence in situ 
hybridization analysis revealed that micronuclei were mainly originating from 
chromosomal malsegregation events, including chromosome 21 malsegregation. Further 
studies from their group confirmed increased chromosome damage in blood cells of young 
DS mothers and showed a significant correlation between micronucleated cells and both 
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MTHFR   677C→T   and  1298A→C polymorphisms. The mean frequency of binucleated-
micronucleated cells increased significantly with the increasing number of MTHFR 677 T 
alleles, and MTHFR 1298 AA women have significantly higher binucleated-micronucleated 
cells frequency than do MTHFR 1298 AC + CC carriers (Coppedè et al., 2007; Coppedè, 
2009). In addition, mothers who had a DS child at a young age showed increased frequency 
(of about 5-fold) of Alzheimer’s disease (AD) (Schupf, et al., 2001). A unifying hypothesis 
trying to relate DS, trisomy 21, and AD has proposed that trisomy 21 mosaicism at the germ 
cell level or in brain cells could account for the familial aggregation of AD and DS (Potter, 
1991). Together, these results suggest that young DS mothers are more prone to 
chromosome malsegregation, which could be true both for somatic (peripheral blood 
lymphocytes, brain) and for germ cells and, importantly, folate-metabolizing gene 
polymorphisms seem to play an important role on this susceptibility to aneuploidy. 
8. Folate supplementation and DS prevention 
Two important emerging areas of nutrition science are nutrigenomics, which refers to the 
effect of diet on DNA stability, and nutrigenetics, which refers to the impact of genetic 
differences between individuals on their response to a specific dietary pattern, functional 
food, or supplement for a specific health outcome. On these terms, two premises are 
important: (a) inappropriate nutrient supply can cause considerable levels of genome 
mutation and alter the expression of genes required for  genome  maintenance, and  (b)  
common  genetic  polymorphisms may alter the activity of genes that affect the 
bioavailability  of  micronutrients  and/or  the  affinity  for micronutrient cofactors in key 
enzymes involved in DNA metabolism or  repair, resulting in a lower or higher reaction rate 
(Bull & Fenech, 2008; Fenech, 2005). 
As mentioned before, the folate-dependent biosynthesis of nucleotide precursors for DNA 
synthesis and genome methylation is dependent on the availability of many vitamins, 
including B12, B6, niacin, riboflavin, and minerals (zinc, cobalt), and is subject to regulation 
by other nutrients, such as  iron and  vitamin A, not  directly  involved  in  DNA  or  SAM  
biosynthesis (Stover, & Caudill 2008). Therefore, impairments in one-carbon metabolism, 
and the SAM cycle in particular, induced by nutritional deficiencies and/or genetic 
polymorphisms that encode folate-dependent enzymes, alter genome methylation patterns 
and gene expression levels (Stover, 2004; Stover, & Caudill 2008).  
Since 1992, supplementation with 0.4 mg/daily of folic acid is recommended for women of 
childbearing age for the prevention of neural tube defects (Centers for Disease Control, 
1992). Barkai et al. (2003) observed that families at risk for neural tube defects present with a 
higher frequency of DS cases and vice-versa, suggesting that both disorders are influenced 
by the same folate-related risk factors. However, two issues ought to be considered in the 
prevention of DS by folic acid: the dose and the timing of folic acid intake (Scala et al., 2006). 
It has been proposed that genomic instability is reduced at plasma folate concentrations 
above 34 nmol/L and Hcy concentrations below 7.5 mol/L; these concentrations can only 
be reached with the ingestion of more than 0.4 mg/day of folic acid (Fenech, 2002). A report 
of a decreased occurrence of DS offspring in mothers supplemented with high doses of folic 
acid (6 mg/day) (Czeizel & Puho, 2005) supports the hypothesis of an involvement of folate 
in the etiology of DS. Concerning the timing of folate intake, it should be remembered that 
maternal MI errors in the primary oocyte may occur in a process that begins during fetal life 
and ends at the time of ovulation, whereas MII errors occur at the time of fertilization (Yoon 
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et al., 1996). Therefore, it is likely that only MII errors would be immediately affected by 
folic acid intake in adult women (Ray et al., 2003).  
9. Conclusion 
Currently available literature suggests that abnormal folate metabolism is associated with 
increased maternal risk for DS, with a complex interaction between genetic polymorphisms, 
environmental factors (i.e., nutritional factors), and epigenetic processes. However, given 
the complexity of the folate pathway, these complex interactions cannot be easily 
understood and none of the polymorphisms studied so far can be used in genetic counseling 
to predict the maternal risk for having a DS child (Coppedè et al., 2009). However, 
nutrigenetics and nutrigenomics are promising areas for evaluating the possibility of DS 
prevention with folic acid supplementation associated with susceptible genotypes. Thus, 
further large-scale studies are necessary to better understand the complex association 
between chromosomal 21 nondisjunction and folate metabolism. 
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Down syndrome is the most common genetic cause of mental retardation in humans, 
occurring in one out of 700 live births. Epidemiological studies suggest that although 
individuals with Down syndrome have an increased risk of infant cardiovascular 
malformation, muscle hypotonia, lymphatic edema, and leukemia, noteworthy they have a 
considerably reduced incidence of most solid tumor, atherosclerosis, and pathological 
angiogenesis-mediated diabetic retinopathy and kidney dysfunction.  
Such data indicate that one or more of the 231 trisomic genes on chromosome 21 are 
responsible for protecting these individuals against cancer and vascular disease. We and 
others recently have identified the candidate genes are Down syndrome critical region 
(DSCR)-1, and A disintegrin and metalloproteinase with thrombospondin motifs 
(ADAMTS)-1. In primary cultured endothelial cells, vascular endothelial cell growth 
factor (VEGF) resulted in rapid and profound upregulation of both genes, which in turn 
negatively feeds back to attenuate VEGF-mediated signaling and following the 
endothelial cell activation. In genome-wide screening, important regulatory transcription 
factor for many pathological features of Down syndrome, NFAT, bound more than 10,000 
independent regions in VEGF-treated activated endothelial cells. Down syndrome trisomy 
model mice or endothelium-specific modest DSCR-1 increases in mice resulted in 
significant suppression of the vascular density in matrigel-plugs, inflammatory leukocyte 
infiltration, and tumor growth. In contrast, DSCR-1 null mice demonstrated markedly 
decreased vascular integrity and increased susceptibility to tumor metastasis. In a mouse 
model of endotoxemia, DSCR-1 null mice showed greater morbidity and mortality 
compared with wild-type littermate. Conversely, adenovirus-mediated overexpression of 
DSCR-1 resulted in marked attenuation of lipopolysaccharide (LPS) or VEGF-mediated 
inflammation. Collectively, these data provide that Down syndrome overexpressed 
protein; DSCR-1 serves to dampen the host response to infection and the tumor growth. 
The molecular research for Down syndrome with patients or model mice unexpectedly 
provide us a great hint for therapeutic targets in solid tumor and vasculopathic disease 
against all individuals. 
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2. Down Syndrome Critical Region (DSCR)-1 expression in activated 
endothelium 
2.1 Foundation of the DSCR-1 from endothelial cell research 
The endothelium is highly malleable cell layer, constantly responding to changes within the 
extracellular environment and responding in ways that are usually beneficial, but at times 
harmful to the organism. Several mediators, including growth factors (e.g. vascular 
endothelial growth factor, VEGF), inflammatory cytokines (e.g. tumor necrosis factor-, 
TNF-), and thrombosis mediator (e.g. thrombin), activate gene transcription in endothelial 
cells, resulting in changes in hemostatic balance, increased leukocyte adhesion, loss of 
barrier function, increased permeability, migration, proliferation and successive 
angiogenesis (Minami and Aird, 2005). The tight control of these processes is essential for 
homeostasis - endothelial cell activation, if excessive, sustained or spatially and temporally 
misplaced, may result in vasculopathic disease. Indeed, different extra-cellular mediators 
engage the endothelium in ways that differ from one signal to the next. A major important 
point is to survey the temporal and spatial dynamics of endothelial cell activation. Using 
DNA microarrays, I carried out a global survey of mRNA in human umbilical vein 
endothelial cells (HUVEC) treated in the VEGF, thrombin, or TNF-. Clustering analyses of 
the data revealed a far closer relationship between VEGF and thrombin, than between other 
pairings (Fig. 1A). Of the various transcripts that were responsive both to VEGF and 
thrombin, DSCR-1 was the most highly induced at the earliest time point (1 h). Compared 
with VEGF and thrombin, TNF- treatment of HUVEC resulted in far less induction of 
DSCR-1 (3.2-fold at 1 h) (not shown).  The rest of the VEGF-mediated induced gene was 
early growth response (Egr)-3, nerve growth factor inducible (NGFI)-B, cyclooxigenase 
(COX)-2, and ADAMTS-1 (Fig. 1B). 
2.2 Molecular information of the DSCR-1 
The DSCR-1 gene consists of 7 exons, of which exons 1-4 can be alternatively spliced, 
resulting in a number of different mRNA isoforms, each of which exhibit different 
expression patterns. In adult, there are two major isoforms, DSCR-1 long variant (DSCR-1L) 
and DSCR-1 short variant (DSCR-1s), expressed in organs (Fuentes et al., 1997). DSCR-1L, 
encoded by exons 1, 5, 6, and 7, is highly expressed in brain. Exon 1 was originally thought 
to encode a 29 amino acid region, but later studies revealed a start site further upstream, 
resulting in a larger 84 amino acid region (Genesca et al., 2003). In contrast, DSCR-1s is 
encoded by exons 4-7 and is under the control of a different promoter located in intron 3 
(intergenic promoter) (Fig. 1C). Each promoter contains different regulatory transcriptional 
subunits. For example, DSCR-1s is mainly regulated by the calcineurin-NFAT pathway, 
which is highly induced by angiogenic and inflammatory stimuli in endothelial cells 
(Minami et al., 2004; Minami et al., 2006).  
While, the DSCR-1L isoform is under the control of a Notch and Hes-1-dependent pathway 
(Mammucari et al., 2005) or TEF-1 dependent pathway (Liu et al., 2008). DSCR-1s inhibits 
calcineurin phosphatase activity, and the C-terminal 57 residues are sufficient for this 
activity. DSCR-1s strongly inhibits the calcineurin mediated NFAT signaling via two ways; 
its ability to disrupt binding of calcineurin to NFAT, and to disrupt calcineurin enzymatic 
activities (Fig. 1D). 
 




Fig. 1. VEGF / thrombin-mediated DSCR-1 induction A, heat map representation of induced 
genes in HUVEC. B, Top 5 genes induced via VEGF, thrombin, or TNF-. C, major two 
variants of DSCR-1. D, structure information of DSCR-1  
2.3 DSCR-1 expression in cultured cells 
VEGF or thrombin induces the DSCR-1s expression in endothelial cells, through the 
coordinate binding of NFATc and GATA to closely positioned NFAT and GATA motifs in 
the intergenic promoter (Minami et al., 2004). VEGF/thrombin induces NFATc nuclear 
localization, and overexpression of the nuclear NFATc1 greatly induces the targeted DSCR-
1s expression (Hesser et al., 2004; Minami et al., 2004; Minami et al., 2006). In addition, 
endothelial cells from the Down syndrome model mice (Ts65Dn) increased DSCR-1 mRNA 
by 1.7-2.0 fold (Baek et al., 2009). NFATc is an important factor for regulating the vertebrate 
development (Graef et al., 2001). In endothelial cells, NFATc1, c2, and c3 are expressed 
(Minami et al., 2009). To survey the NFATc1 binding in genome-widely, we carried out the 
chromatin immunoprecipitation using the antibody against NFATc1 following the 
comprehensive sequencing (ChIP-seq) in endothelial cells. We found totally 10,938 regions 
(P value >20) were identified as NFATc1 enrichment area from the ChIP-seq. DSCR-1 
revealed the profound NFATc1 binding after the VEGF treatment within the proximal 
DSCR-1s promoter (Fig. 2). The area overlapped with positive signals from acetylated 
histone H4 (transcriptional active chromatin) and tri-methylated lysine of histone H3 
(H3K4me3; active promoter marking) (Fig. 2).  
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Fig. 2. Epigenetic information of the DSCR-1 locus Arrow indicates the significant 
enrichment from the ChIP-seq results 
In contrast, erythroid lineage cells isolated from leukemia; K562 indicated the H3K4me3 
positive signals within the proximal DSCR-1L promoter region, but not proximal DSCR-1s 
promoter region (Fig. 2). DSCR-1L reported the proceeding the pathological function in 
neurons (Cook et al., 2005). Moreover, Down syndrome patients have an increased risk of 
leukemia (Lott, 1982). Collectively, DSCR-1s and DSCR-1L obtained separate transcriptional 
machinery. VEGF mediated NFATc activation selectively transactivates the DSCR-1s via the 
profound binding within the promoter. 
2.4 Characterization of the NFAT dependent genes overexpressed in Down syndrome 
Besides DSCR-1, other genes encoded in chromosome 21 also reported as a candidate for 
pathogenesis on the Down syndrome. By using the combination of several NFATc knockout 
mice, dysfunction of NFAT was shown as a key point for the onset of Down syndrome 
(Arron et al., 2006). Around 1.5-fold increasing of both DSCR-1 and DYRK1A caused 
complete NFAT dysfunction. Thus, we test whether many Down syndrome genes obtain the 
NFATc1 binding on the each proximal promoter, by using the whole-genome NFATc1 
ChIP-seq data (Table 1). Interestingly, DYRK1A obtained positive NFATc1 binding. VEGF 
inducible ADAMTS-1 (see Fig. 1B) also showed the NFATc1 positive binding. Ets family, 
Ets2, ERG, and GABP, were highly expressed in endothelial cells, which was shown the 
regulation for the endothelial cell-specific expression or-essential function. All of them have 
a possibility as a NFATc1 direct target downstream gene. 
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From Nature (Reynolds et al.2010) 
 ADAMTS1 A disintegrin and metalloproteinase 
with thrombospondin motifs, type 1 
+ 5’UTR 
 ERG v-ets erythroblastosis virus E26 
oncogene homolog 
+ +5367 & 5th 
intron 
 Ets2 v-ets erythroblastosis virus E26 
oncogene homolog 2
+ +55 
 JAM2 junction adhesion molecule 2 -  




From Lancet (Roizen and Patterson, 2003) 
Energy and reactive oxygen species metabolism
 BTG3 B-cell translocation gene 3 +, weak 1st intron 
 MRPL39 mitochondrial ribosomal protein L39 +, weak 1st exon 
 ATP5J ATP synthase, H+ transporting, 
subunit F6 
+, weak 1st exon 
 GABPA GA binding protein transcription 
factor, alpha 
+, weak +80 
 BACH1 BTB and CNC homology 1, basic 
leucine zipper transcription factor 1 
+, weak 1st intron 
 SOD1 superoxide dismutase 1 + 5’UTR 
 CRYZL1 crystallin, zeta-like 1 +, weak 1st Exon & 
+520 
 ATP5O ATP synthase, H+ transporting, O 
subunit 
+ 5’UTR 
 MRPS6 mitochondrial ribosomal protein S6 +, weak 5'-UTR 
 DSCR-1 Down syndrome critical region gene 
1 
+ Indicated in 
Fig. 2 
 CBR1 carbonyl reductase 1 +, weak 1st exon 
 CBR3 carbonyl reductase 3 + 1st exon 
 SH3BGR SH3 domain binding glutamic acid-
rich protein 
+ 5’UTR 
 NDUFV3 NADH dehydrogenase flavoprotein 
3, 10kDa 
+ +139 
 SNF1LK salt-inducible kinase 1 -  
 C21orf2 chromosome 21 open reading frame 2 +, weak +140 
Brain development, neuronal loss, and Alzheimer's type neuropathology
 SIM2 single-minded homolog 2 -  
 DYRK1A dual-specificity tyrosine-
phosphorylation regulated kinase 1A 
+ +1680 
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 GART phosphoribosylglycinamide 
formyltransferase
+ +513 & 5'-UTR 
 PCP4 Purkinje cell protein 4 -  
 DSCAM Down syndrome cell adhesion 
molecule 
-  
 GRIK1 glutamate receptor, ionotropic, 
kainate 1 
-  
 APP amyloid beta (A4) precursor protein +, weak 1st intron 
 S100B S100 Ca-binding protein B -  
Folate methyl group metabolism 
 N6AMT1 N-6 adenine-specific DNA 
methyltransferase 1 
+, weak 1st exon 
 CBS cystathionine-beta-synthase -  
 DNMT3L DNA methyltransferase 3-like -  
 SLC19A1 Solute carrier family 19 , member 1 -  
 FTCD formiminotransferase cyclodeaminase -  
 HRMT1L1 
(PRMT2) 
Protein arginine methyltransferase 2 + 5’UTR 
Table 1. Candidate genes for Down syndrome, where NFATc1 occupancy on the promoter. 
‘Weak ‘means P value < 20 
2.5 DSCR-1 expression in organ 
Increased DSCR-1 expression was observed in human fetal Down syndrome kidney versus 
age-matched control kidney (Fig. 3A). To determine whether the DSCR-1s promoter region 
directed inducible expression in vivo, the -1664/+83 DSCR-1s promoter was coupled to the 
lacZ reporter gene and targeted the resulting transgenic cassette (DSCR-1-lacZ) to the Hprt 
locus of mice using homologous recombination. The Hprt-locus in vivo promoter analysis 
system has been previously shown to be beneficial in controlling and avoiding the 
undesirable and undetectable effects of copy number and integration site on promoter 
activity (Cvetkovic et al., 2000; Ryan and Sigmund, 2003). We have used this system 
successfully to show the vascular bed specific expression patterns of endothelial cell specific 
promoters, Flt-1, vWF, ROBO4, and Tie-2 (Minami et al., 2002; Minami et al., 2003; Okada et 
al., 2007). At embryonic day 11, whole-mount lacZ staining revealed widespread expression 
of the transgene in the vasculature. In cryosections, strong staining was observed in the 
dorsal aorta, intersomitic vessels, carotid arteries, caudal veins, the primary head vein 
branch, and the endocardium (Fig. 3B). LacZ colocalized with endothelial PECAM-1 (Fig. 
3B). However, after the embryonic day 14, profound DSCR-1s promoter activation in 
vascular endothelium was markedly downregulated correlated with the decline of 
embryonic VEGF levels after the critical steps for angiogenesis and vascular remodeling. In 
adult mice, DSCR-1s-lacZ activity was detected in only a subset of endothelial cells in the 
brain, heart, lung and kidney. Expression was also observed in occasional neurons, vascular 
smooth muscle cells, cardiomyocytes, and renal epithelial cells. In contrast, DSCR-1s-lacZ 
activity was undetectable in the liver, spleen, thigh skeletal muscle, and thymus. These 
findings suggest that the DSCR-1s promoter, though widely expressed in the endothelium 
of embryonic days 11, is downregulated in the later stages of development and in adults.  
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Subsequently, to determine whether the DSCR-1s promoter confers response to 
inflammatory or angiogenic stimuli in vivo, DSCR-1-lacZ mice were systemically 
administrated VEGF or LPS. In whole mount preparations, the X-gal reaction product was 
detectable in the brain and heart of untreated mice and was further upregulated by VEGF 
and LPS. In contrast, lacZ staining was not observed in skeletal muscle, liver, and spleen 
vasculature even after the stimulus (data not shown). 
 
 
Fig. 3. DSCR-1 promoter activation in vivo A, highly DSCR-1 expression in kidney from 
Down syndrome individuals. B, left, whole-mount lacZ staining of embryonic day 11 Hprt-
targeted embryos. C.A., carotid artery; D.A., dorsal aorta; I.V., intersomite vessel. Right, 
serial tissue sections from Hprt-targeted embryo. lacZ (up) and PECAM-1 (down) immuno-
stainings were shown. C, real-time PCR quantification of lacZ epression in various organs. 
*P<0.04, **P<0.01 compared mock treatment in each organ. 
Real-time PCR analysis was used to quantify changes in transgene expression. Under basal 
conditions, lacZ mRNA expression was highest in the heart, followed by the brain, lung, and 
kidney (Fig. 3C). Expression in skeletal muscle, the spleen and liver was below the level of 
detection. VEGF and LPS resulted in significant induction of lacZ transcripts in the heart, 
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 GART phosphoribosylglycinamide 
formyltransferase
+ +513 & 5'-UTR 
 PCP4 Purkinje cell protein 4 -  
 DSCAM Down syndrome cell adhesion 
molecule 
-  
 GRIK1 glutamate receptor, ionotropic, 
kainate 1 
-  
 APP amyloid beta (A4) precursor protein +, weak 1st intron 
 S100B S100 Ca-binding protein B -  
Folate methyl group metabolism 
 N6AMT1 N-6 adenine-specific DNA 
methyltransferase 1 
+, weak 1st exon 
 CBS cystathionine-beta-synthase -  
 DNMT3L DNA methyltransferase 3-like -  
 SLC19A1 Solute carrier family 19 , member 1 -  
 FTCD formiminotransferase cyclodeaminase -  
 HRMT1L1 
(PRMT2) 
Protein arginine methyltransferase 2 + 5’UTR 
Table 1. Candidate genes for Down syndrome, where NFATc1 occupancy on the promoter. 
‘Weak ‘means P value < 20 
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brain, lung, and kidney, but not in spleen, liver or skeletal muscle (Fig. 3C). LPS-mediated 
induction of the endogenous DSCR-1s gene was similarly restricted to the heart (25.3-fold), 
brain (7.0-fold), lung (10.3-fold), and kidney (9.3-fold) (not shown). Agonist treatment failed 
to alter DSCR-1L transcript levels. Thus, VEGF and LPS promote vascular bed-specific 
expression of both the DSCR-1s promoter and the endogenous DSCR-1s gene. 
2.6 DSCR-1 expression in tumor 
Solid tumors produce a variety of pro-angiogenic molecules and inflammatory cytokines, 
which have important paracrine effects on surrounding endothelial cells. To investigated 
whether the DSCR-1s transgene is activated in tumor blood vessels, B16-F1 melanoma and 
Lewis lung carcinoma (LLC) cells were implanted subcutaneously into the flank of DSCR-
1s-lacZ Hprt mice. When tumors reached ≈2.5 cm3 in volume, the xenografts were harvested, 
sectioned and stained for lacZ. As shown in Fig. 4A, there was widespread reporter gene 
activity within both B16-F1 melanoma and LLC tumor neovessels. In double 
immunofluorescence studies, lacZ co-localized with endothelial PECAM-1 (Fig. 4B). 
Consistent with these findings, endogenous DSCR-1 also co-localized with PECAM-1 in 
tumor vessels of both B16-F1 melanoma and LLC xenografts (not shown).  
 
 
Fig. 4. DSCR-1s promoter activation in tumor vasculature. A, lacZ stainings were performed 
of LLC and B16-F1 melanoma xenografts. B, merged image of immunofluorescence staining 
with antibodies against lacZ, PECAM-1 or DAPI. 
3. Biological function of DSCR-1 
3.1 DSCR-1 inhibits nuclear localization of NFATc 
Adenovirus mediated overexpression of DSCR-1, but not control, inhibited VEGF mediated 
nuclear localization of NFATc1 and NFATc2 (Minami et al., 2004). DYRK1A is another 
potential NFAT regulators, which encodes a nuclear serine/threonine kinase that primes 
substrates for phsphorylation by Glycogen synthase kinase (GSK) 3(Gwack et al., 2006). 
GSK3 phosphorylates NFATc proteins in the nucleus, resulting in their inactivation and 
export (Beals et al., 1997). DYRK1A is expressed at elevated levels in some human Down 
syndrome fetal tissues (Arron et al., 2006). In neuronal cells, DYRK1A inhibits FGF8-
mediated induction of NFAT activity. Moreover, it has been shown that a 1.5-fold increase 
in the dosage of DSCR-1 and DYRK1A, both of which lie within the critical region of human 
chromosome 21, cooperatively destabilized the calcineurin-NFAT regulatory circuit (Fig. 5), 
leading to many of the features of Down syndrome (Arron et al., 2006).  
 




Fig. 5. schematic model of NFAT inhibition with DSCR-1 and DYRK1A. 
3.2 DSCR-1s auto-inhibits the VEGF-mediated vascular activation 
VEGF is an endothelial cell specific mitogen, and chemotactic agent, which is involved in 
wound repair, angiogenesis of ischemic tissue, tumor growth, microvascular permeability, 
hemostasis and endothelial cell survival (Isner and Losordo, 1999). DSCR-1 overexpression 
inhibits VEGF-mediated vessel growth, and monocyte cell adhesion (Minami et al., 2006). 
DSCR-1 overexpression did not lead in increased apoptosis (Minami et al., 2009). Taken 
together, these findings suggest that DSCR-1 constitutive expression lead the endothelial 
cells to quiescent status form the VEGF-mediated activated status. 
3.3 DSCR-1s attenuates septic inflammation 
As shown above, DSCR-1s attenuates VEGF-mediated activation of cultured endothelial 
cells. These data led us to hypothesize that VEGF- and LPS-inducible expression of DSCR-1s 
in mice may serve as a negative feedback inhibitor of endothelial activation in vivo. To test 
this hypothesis, I examined the effect of DSCR-1 deficiency or overexpression on 
endotoxemia phenotype. The generation of DSCR-1-/- mice, which carry a targeted deletion 
of both DSCR-1s and DSCR-1L. To overexpress DSCR-1s, I have chosen an adenoviral 
delivery system in which the endothelial-specific Flt-1 promoter is coupled to DSCR-1s 
cassette (Ad-Flt1-DSCR-1s). In vivo delivery of Ad-Flt1-DSCR-1s results in overexpression of 
DSCR-1s in the intact endothelium of mice. Endotoxemia in mice is associated with a 
reduction in heart rate, blood pressure, and body temperature, and an increase in circulating 
interleukin (IL)-6 levels. This effect was accentuated in DSCR-1-/- mice, and attenuated in 
DSCR-1s overexpressing animals. Recently, Yano et.al. reported that endotoxemia in mice is 
associated with increased circulating levels of VEGF (Yano et al., 2006). Further, VEGF plays 
a pathogenic role in sepsis (Yano et al., 2008). Interestingly, resting levels of plasma VEGF 
were 5.0-fold higher in DSCR-1-/- mice compared with wild-type littermates (Fig. 6A), which 
is a parallel correlation with the report that lower VEGF expression in stem cell culture 
derived from amniotic fluid in Down Syndrome (Salvolini et al., 2010). In response to septic 
treatment, DSCR-1-/- mice demonstrated super-induction of circulating VEGF levels (2.2-
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is a parallel correlation with the report that lower VEGF expression in stem cell culture 
derived from amniotic fluid in Down Syndrome (Salvolini et al., 2010). In response to septic 
treatment, DSCR-1-/- mice demonstrated super-induction of circulating VEGF levels (2.2-
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fold higher vs. wild-type mice). Ad-Flt1-DSCR-1s-injected mice had no change in resting 
VEGF levels. However, in response to endotoxemia, DSCR-1s-overexpressing mice 
demonstrated a 61% reduction in circulating VEGF levels compared with septic Ad-Flt1-
control (Fig. 6A).  
To assay for endothelial activation, real-time PCR was performed to measure mRNA 
expression of E-selectin, intercellular adhesion molecule (ICAM)-1 and vascular cell 
adhesion molecule (VCAM)-1 in tissues from mice 6 h following injection of PBS (control) or 
LPS. Compared with wild-type littermate controls, LPS-treated DSCR-1-/- mice 
demonstrated super-induction of E-selectin in the heart and lung, ICAM-1 in heart, and 
VCAM-1 in lung. In contrast, LPS-mediated induction of cell adhesion molecules was 
attenuated by overexpression of DSCR-1s (data not shown).  
I have recently shown that hyper-activation of the VEGF-calcineurin-NFAT pathway 
triggers apoptosis in DSCR-1-deficient tumor endothelial cells (Minami et al., 2009). Given 
that DSCR-1-/- mice have elevated circulating levels of VEGF level (see Fig. 6A), I 
hypothesized that endotoxemia may result in increased endothelial cell apoptosis in DSCR-
1-/- mice. To test this hypothesis, TUNEL assay was carried out in tissue sections from the 
heart and lung of LPS-treated DSCR-1-null mice and their wild-type littermates. 
Endotoxemic wild-type mice demonstrated a small number of TUNEL-positive endothelial 
cells in the heart, and even fewer in the lung. However, in DSCR-1-/- mice, LPS 
administration resulted in a significant increase in the number of TUNEL-positive cells in 
both organs (Minami et al., 2009).  
Finally in survival studies, LPS-treated DSCR-1-/- mice demonstrated markedly increased 
mortality compared with endotoxemic wild-type littermates (Fig.6B, left). In contrast, Ad-
mediated overexpression of DSCR-1s conferred a survival advantage compared with Ad-
Flt1-control (Fig. 6B, right). Taken together, these findings suggest that inflammatory 
induced DSCR-1s obtains a critical role in the host response. 
 
 
Fig. 6. DSCR-1 modulates inflammatory VEGF expression and sepsis mortality. A, Blood 
was harvested for plasma, and VEGF levels were measured using ELISA. *P<0.001, **P<0.01 
compared with wild type or Ad-Flt1-control (cont), n=10. B, Survival studies in mice 
administrated LPS. Percentages of mice (surviving/total) are indicated. 
 
Down Syndrome Expressed Protein; DSCR-1 Deters Cancer and Septic Inflammation   
 
131 
3.4 DSCR-1s attenuates tumor progression 
Having established an inhibitory role for DSCR-1 on inflammation in vivo, I next study the 
functional relevance of angiogenesis, tumor growth, and tumor metastasis in vivo. 
Adenovirus mediated locally DSCR-1 expression in vascular demonstrated significant 
reduction of the blood vessel formation in a matrigel-plug, compared to the Ad-control 
treated-plug vascularity. In a xenograft model with B16 melanoma and Lewis lung 
carcinoma revealed that DSCR-1 overexpression statistically significant (more than 70%) 
reduction of the tumor growth, in the parallel for the reduction of the vessel density from 
DSCR-1 treated tumor. Subsequently, to test whether DSCR-1 stable expression in the 
vascular endothelium inhibit the tumor growth, the transgenic mice was generated 
containing the endothelial cell specific Tie 2 promoter-linked DSCR-1s cDNA constract. Two 
independent transgenic lines indicate the vascular-specific DSCR-1s expression, both of 
which delayed the tumor growth at the early step, up to the tumor mass ≈1,500 cm3. 
Cryosection of the xenografted tumor and immunostained with anti-PECAM1 antibody 
revealed the reduction of the vascular density in vascular specific DSCR-1s transgenic mice 
compared with wild type control mice. Taken together, DSCR-1s expressed in endothelial 
cells in vivo would function as an anti-angiogenic molecule. Stable expression of the DSCR-
1s would lead the endogenous anti-tumor activities. 
3.5 DSCR-1s attenuates tumor metastasis 
During the study for the DSCR-1s promoter activity in vivo, by using the tumor metastasis 
model, we found the DSCR-1s promoter was already active in the lung microvascular 
endothelium, before the tumor metastasis colony had not yet observed. This DSCR-1s-lacZ 
activity in endothelial lining of lung was clearly abolished by systemic treatment with 
cyclosporine A. In addition, we have previously shown that stimuli induced DSCR-1 auto-
inhibited inflammation in HUVEC (Minami et al., 2004; Minami et al., 2006). Thus, I 
hypothesized two things; DSCR-1s promoter would be useful for the marker for the pre-
metastatic condition, and the DSCR-1s stable expression would overcome the tumor 
metastasis. At first, to test the latter thing, mice were injected intravenously with 2x105 B16 
melanoma cells. Three days later, mice were administrated with adenovirus containing Flt-1 
promoter-DSCR-1s, or the control into the lung via the airway with vapor infection. Twenty 
days after the B16-F10 injection, lungs were harvested and photographed. There was no 
difference in body weight between the experimental and control groups (data not shown). 
The Ad-Flt1-Control group exhibited significant endothelial cell surface invaded-melanoma 
metastasis and the lungs showed significant swelling (Fig. 7A). In contrast, the Ad-Flt1-
DSCR-1s group exhibited little B16 melanoma metastasis and showed no significant lung 
swelling. To semi-quantify the metastasis rate, the melanoma-growing area per whole 
surface was calculated. Compared with control, Ad-Flt1-DSCR-1s treatment resulted in 
statistically significant reduction (54%) of the B16 melanoma metastasis (Fig. 7B). In 
addition to DSCR-1s’s ability to inhibit B16 melanoma metastasis to lung, DSCR-1s treated 
lung showed a significant reduction in the expression of the inflammatory adhesion 
molecules, VCAM-1 and E-selectin. It has been reported that endothelial cells expressed 
VCAM-1 and E-selectin positively influence cancer cell adhesion and migration to lung 
(Biancone et al., 1996; Fukuda et al., 2000; Futakuchi et al., 2004). Our performed metastasis 
assays, however, could not distinguish whether reduction in these adhesion molecules 
attenuated tumor metastasis, or reduced tumor cell migration to lung inhibited 
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Fig. 6. DSCR-1 modulates inflammatory VEGF expression and sepsis mortality. A, Blood 
was harvested for plasma, and VEGF levels were measured using ELISA. *P<0.001, **P<0.01 
compared with wild type or Ad-Flt1-control (cont), n=10. B, Survival studies in mice 
administrated LPS. Percentages of mice (surviving/total) are indicated. 
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inflammation and adhesion molecule induction. We have reported DSCR-1s strongly 
attenuates adhesion molecule expression in cultured endothelial cells (Minami et al., 2006). 
Moreover, DSCR-1 stably expressed in cultured endothelial cells significantly blocked B16 
melanoma attachment to the endothelial cell surface (data not shown), suggesting that the 
blunting of adhesion molecule expression by DSCR-1s might be a critical factor in the 
inhibition of tumor metastasis. Collectively, These data suggest that DSCR-1s stable 
expression inhibits the inflammatory coordinated pre-metastatic niche formation, resulting 
the strong interfering of the onset of tumor metastasis to lung. 
 
 
Fig. 7. Endothelial specific DSCR-1s overexpression downregulates the tumor metastasis to 
lung. A, after 20 days for B16-F10 injection administrated either Ad-Flt1-control or Ad-Flt1-
DSCR-1s, lungs were harvested, washed and photographed. B, to quantify the metastasis 
rate, metastasis area from the whole surface lung was calculated by using Image J software. 
Data are expressed as means and standard deviations; n=10. 
3.6 Lacking DSCR-1 results with controversy 
While our findings reported here lend further evidence toward DSCR-1s as a negative 
regulator of NFAT-calcineurin signaling in vivo, the exact function of DSCR-1 is not without 
controversy. It has been reported that in CHO cells cultured in vitro, a portion of the 
phosphorylated form of DSCR-1 associated with the 14-3-3 protein, which competitively 
activated calcineurin activity (Abbasi et al., 2006). However, in a separate report it was 
shown that phosphorylation of DSCR-1 markedly decreased its stability (Genesca et al., 
2003), likely leading to degradation, and thus an increase in calcineurin activity. In 
endothelial cells, we observed that the non-phosphorylated form of DSCR-1, which we 
consider to be the pre-active form, was the dominant form during the early phase response 
to VEGF or thrombin. The phenotype exhibited by the DSCR-1 whole gene knockout mice 
shows exacerbated constitutively active calcineurin-dependent cardiac hypertrophy, 
whereas cardiac hypertrophy in response to pressure overload and chronic adrenergic 
stimulation was blunted in these mice (Vega et al., 2003). In addition, double knockout mice 
of DSCR-1 and modulator of calcineurin interacting protein (MCIP) 2 also resulted in 
calcineurin facilitation, although it is difficult to distinguish the relative contribution 
between DSCR-1 and MCIP2 in these events (Sanna et al., 2006). It light of previous results 
and the results presented here suggesting differing expression patterns and functions of the 
DSCR-1s and 1L isoforms, it is plausible that the phenotype of the DSCR-1 null mice results 
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from the complex deletion of both DSCR-1L and DSCR-1s isoforms. Qin et.al., recently 
reported DSCR-1s inhibited vascular growth and capillary tube formation, consistent with 
our findings, whereas DSCR-1L induced NFATc transcriptional activity and endothelial cell 
growth (Qin et al., 2006). Using siRNA or adenoviral miRNA in endothelial cells or in mice 
in vivo, respectively, I recently showed that the DSCR-1s promoter is specifically activated 
through NFATc1, c2, c3 and GATA-2 (Minami et al., 2009), whereas DSCR-1L, which lacks 
the NFAT consensus region, is regulated by Notch and glucocorticoid signaling 
(Mammucari et al., 2005). The lack of such elements in the DSCR-1L promoter, suggest that 
once DSCR-1L is expressed, the tightly regulated calcineurin-NFATc-DSCR-1s feedback 
loop may be broken, owing to a lack of NFATc regulation of the DSCR-1L promoter. I also 
cannot rule out the possibility that the DSCR-1 exon 1 has an as yet ‘undetermined’ function. 
Interestingly, in an attempt to understand this regulatory system, an attractive 
computationally simulated threshold model was shown by Shin, et. al (Shin et al., 2006), in 
which low-level stimulus causes weak NFAT activation, resulting in only minor DSCR-1s 
upregulation, and at a level not sufficient to block the target calcineurin (under the 
threshold). Continuing stimulus facilitates the dissociation of the calcineurin-DSCR-1 
complex, so that DSCR-1 appears as an activator of calcineurin. 
  
 
Fig. 8. Schmatic model of the balance of the endothelial cell growth 
Interestingly in the endothelial cells, Sandra.et.al., indicated that DSCR-1-/- mice 
demonstrated reduced blood vessel formation in Matrigel, cornel micropocket, and tumor 
xenograft assays (Ryeom et al., 2008). DSCR-1-/- endothelial cells displayed hyper-activation 
of the calcineurin/NFAT pathway and increased sensitivity to VEGF signaling. However, 
rather than inducing cell proliferation, VEGF-mediated activation of calcineurin/NFAT in 
DSCR-1-/- endothelial cells ‘re-routed’ downstream signaling, resulting in increased 
apoptosis, which thus explains the paradoxical reduction in neovascularization. 
Collectively, considered with the data from DSCR-1 stable expression and null mutation, 
calcineurin/NFAT activity and DSCR-1s expression level was tightly regulated, resulting 
the balance would define the endothelial cell growth, viability and tumor angiogenesis (Fig. 
8). Future animal studies of DSCR-1 function should be performed by endothelial cell-
specific knockout mice targeting either DSCR-1s or DSCR-1L separately. 
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inflammation and adhesion molecule induction. We have reported DSCR-1s strongly 
attenuates adhesion molecule expression in cultured endothelial cells (Minami et al., 2006). 
Moreover, DSCR-1 stably expressed in cultured endothelial cells significantly blocked B16 
melanoma attachment to the endothelial cell surface (data not shown), suggesting that the 
blunting of adhesion molecule expression by DSCR-1s might be a critical factor in the 
inhibition of tumor metastasis. Collectively, These data suggest that DSCR-1s stable 
expression inhibits the inflammatory coordinated pre-metastatic niche formation, resulting 
the strong interfering of the onset of tumor metastasis to lung. 
 
 
Fig. 7. Endothelial specific DSCR-1s overexpression downregulates the tumor metastasis to 
lung. A, after 20 days for B16-F10 injection administrated either Ad-Flt1-control or Ad-Flt1-
DSCR-1s, lungs were harvested, washed and photographed. B, to quantify the metastasis 
rate, metastasis area from the whole surface lung was calculated by using Image J software. 
Data are expressed as means and standard deviations; n=10. 
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DSCR-1 was identified by the study with vascular activation. DSCR-1 was highest induced 
by VEGF treatment in primary cultured endothelial cells. Previously, DSCR-1 was simply 
termed by the localization of the human chromosome 21. However, DSCR-1 indeed highly 
expressed in Down syndrome individuals, and clearly upregulated with NFAT activation in 
cells. Moreover, combined with same 21st chromosome encoded protein; ‘DYRK1A’, DSCR-1 
strongly feedback attenuated the NFAT activation, resulting the pathogenesis of Down 
syndrome. I show here that DSCR-1s is highly expressed during embryonic vascular 
development, and then largely downregulated in adult, yet was highly activated 
predominantly in endothelium in response to the administration of VEGF or LPS. 
Stimulated DSCR-1s worked in the auto-inhibition of endothelial cell activation and 
inflammation. It has still unanswered problems with understanding the phenotypes from 
DSCR-1 lacking condition, and pathogenesis from DSCR-1L overexpression in neuron. 
However, based on this knowledge, I believe that DSCR-1s stable expression or the way of 
DSCR-1s stabilization may lend itself to therapeutic manipulation in vasculopathic disease 
states, including tumor angiogenesis, metastasis, and inflammation. 
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1. Introduction 
Down Syndrome (DS) is one of the most common genetic disorders to date, occurring in 1 
out of every 800-1000 live births (Egan et al. 2004; Roizen & Patterson, 2003; Stoll et al. 1990). 
DS patients often display several developmental and cognitive deficiencies. Common 
phenotypes of DS patients include congenital heart disease, dysmorphic physical features, 
and early-onset Alzheimer’s disease (AD). Since the discovery in 1959 that DS occurs from 
an extra copy of human chromosome 21 (hChr21) (Lejeune J, Gautier & Turpin, 1959), 
questions arose whether a 1.5-fold increase in a gene or set of genes were responsible for the 
phenotypes associated with DS. Sequence analysis of hChr21 indentified over 225 genes 
and/or predicted genes (Hattori et al. 2000). With the recent advances in sequencing, the 
gene content of hChr21 is now estimated to exceed 300 genes (Roizen & Patterson, 2003). 
While typically characterized by complete trisomy of hChr21, several DS cases, however, 
demonstrate that partial trisomy of hChr21 is enough to elicit the phenotypes associated 
with DS (Stoll et al. 1990), hence arising the concept of a Down Syndrome Critical Region 
(DSCR). The DSCR theory suggests that enhanced expression of a few genes located in this 
critical chromosomal region (between markers D21S17 and D21S55 (Delabar et al. 1993; 
Korenberg et al. 1994)) are responsible for some, if not all, of the features of DS. Olson LE et 
al show, however, that triplication of this region alone is not enough to fully manifest the 
phenotypes associated with DS (Olson et al. 2004; Olson et al. 2007). These findings 
contradict the longstanding DSCR theory, indicating that the genetic instability seen with 
hChr21 triplication is not merely from excess gene expression. Rather, the functional 
interactions occurring within a set of overexpressed genes may explain the various 
phenotypes observed in DS.  
Many of the triplicate genes on hChr21 are implicated in several diseases. Cohorts of genes, 
interestingly, have been associated with pathologies that appear to be more common for DS 
individuals. A group of at least 16 genes on hChr21 have been correlated with a role in 
energy and reactive oxygen species (ROS) metabolism (Roizen & Patterson, 2003). Several 
studies have linked mitochondrial dysfunction and metabolic disorders with DS (Arbuzova, 
Hutchin & Cuckle, 2002). In vitro, DS neurons were observed to have 3- to 4-fold increases in 
reactive oxygen species compared to control cells, with elevated rates of consequent cell 
apoptosis (Busciglio & Yankner, 1995). Degeneration of DS neurons was rescued by 
administration of free-radical scavengers, suggesting DS neurons are unable to efficiently 
metabolize ROS. DS patients are also evidenced to have increased mitochondrial superoxide 
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production compared to control groups (Capone et al. 2002). In addition, Busciglio J et al. 
show altered processing of the amyloid precursor protein (APP) in DS astrocytes and 
neurons (Busciglio et al. 2002). Elevated levels of APP, a gene also located on hChr21, have 
been associated with AD progression. Given that DS patients invariably display the 
characteristic plaques and tangles suggestive of AD (Hardy & Selkoe, 2002), this 1.5-fold 
increase in particular hChr21-located genes may explain the metabolic-related diseases 
associated with DS patients.  
Another cohort of at least 10 genes located on hChr21 have been demonstrated to influence 
the central nervous system (CNS), and may hence play a role in the neuropathogenesis of 
DS (Capone, 2001). Considering the major phenotypes of DS patients include altered brain 
development, neuronal loss, and Alzheimer’s-like neuropathology, the identification of 
CNS-related genes is not surprising. As demonstrated by these two gene clusters, 
phenotypic outcome is dependent not only on genotype but also on successive protein 
interactions. It is therefore possible that additional sets of genes, when in excess as a result 
of trisomy hChr21, lead to the manifestation of other DS-related pathologies, such as 
vascular-related pathologies. 
2. Clinical observations and chapter overview 
While developmental and behavioral disorders have been extensively studied in adults with 
DS, relatively little is known regarding their propensity to vascular-related diseases. Several 
intriguing clinical observations relating to the vasculature have been reported amongst DS 
patients over the last several decades. Unlike the aforementioned developmental deficits of 
DS individuals, DS patients appear to have a unique advantage in the context of several 
vascular pathologies.  
2.1 Cancer incidence in DS patients 
While adults with DS have been shown to have a higher incidence of leukemia compared to 
the  general public, the risk of solid tumors appear to be strikingly low in individuals with 
DS (Hasle, Clemmensen & Mikkelsen, 2000). A population-based study on causes of 
mortality in over 17,000 DS patients showed a significant lack of malignant neoplasms as a 
cause of death (Yang, Rasmussen & Friedman, 2002). These findings suggest that 
individuals with DS express possible tumor-suppressor genes on hChr21, such that trisomy 
of a set of genes results in an antineoplastic effect on solid tumors. It is possible that these set 
of genes modulate a common biological mechanism that is critical for tumorigenesis and/or 
cancer progression. 
2.2 Atherosclerosis in DS patients 
A post-mortem, observational study published in 1977 found that 40-66 year old patients 
with DS displayed an almost complete absence of atherosclerotic plaque formation in 
arteries, compared to those without DS (Murdoch et al. 1977). Additional population studies 
in DS patients have found consistent results (Draheim, Geijer & Dengel, 2010; Yla-Herttuala 
et al. 1989), leading one to speculate that an unidentified factor(s) specific to DS patients 
explains the near absence of atherosclerotic plaque formation. Considering the vascular 
similarities between tumorigenesis and atherosclerosis, it is possible these events are driven 
by a shared molecular mechanism. 
 
Down Syndrome and Vascular Disease: DSCR1 and NFAT Signaling 
 
139 
2.3 Other vascular pathologies in DS patients 
Studies focusing on vascular tone show that DS patients have extremely low percentages of 
hypertension (Kerins et al. 2008). Significant decreases in both systolic and diastolic pressures 
were observed in DS patients when compared to reference populations (Morrison et al. 1996; 
Richards & Enver, 1979). Low blood pressures have also been observed in Alzheimer’s disease 
(AD) (Burke et al. 1994; Landin et al. 1993), suggesting the mechanisms driving AD contribute 
to the observed hypotensive tendencies of DS patients. The already mentioned propensity for 
DS patients to develop AD, in addition to blood pressure levels similar to that of AD patients, 
strongly suggests a shared genetic contribution(s) of hChr21-located genes.  
The observed decrease in solid tumor growth, lack of atherosclerotic plaque formation, and 
hypotensive nature of DS adults indicates onset of these vascular disorders may share an 
underlying molecular mechanism. This chapter will aim to discuss the observed differences 
in the vasculature of DS patients based on current literature to date. As of now, there is no 
concrete evidence distinguishing DS patients from non-DS patients on a genetic level 
concerning vascular anomalies. Correlative studies, however, suggest DS individuals 
harness a genetic advantage in regard to vascular health and disease. 
3. Tumorigenesis in Down Syndrome 
The molecular mechanisms underlying oncogenesis are undoubtedly one of the most 
intricate processes to date. Accumulation of multiple genomic mutations leads to the 
dysregulation of cell signaling pathways that are critical for controlling basic cellular 
functions including cell growth, survival, and cell fate. The extensive cross-talk between 
various signaling cascades highlights the sophisticated communication that transpires 
during cancer development and progression.  
3.1 Calcium/calcineurin/NFAT signaling 
Calcium (Ca2+) fluxes are involved in multiple cell processes such as cell metabolism, 
membrane transport, cell permeability, and apoptosis. Changes in intracellular Ca2+ levels 
affect downstream gene expression and cell function through various mechanisms. In 
particular, intracellular Ca2+ concentrations often regulate kinase and phosphatase activity 
through the Ca2+-binding protein, calmodulin (CaM). Increases in intracellular Ca2+ have 
been demonstrated in various cell types to activate the Ca2+/CaM-dependent serine-
threonine protein phosphatase, calcineurin (Cn). The Cn pathway is critical for the 
transduction of many extracellular, adaptive stimuli. Activated Cn subsequently 
dephosphorylates target proteins, including the nuclear factor of activated T-cells (NFATc1-
c4) family of transcription factors (Figure 1). The NFAT family was originally identified in 
lymphocytes for its role in cytokine gene expression. While first identified in immune cells, 
recent findings show NFAT proteins are ubiquitously expressed. NFAT at the basal state are 
localized to the cytoplasm in an inactive form, with more than 20 identified phosphorylation 
sites (Okamura et al. 2000). CaM/Cn-mediated dephosphorylation of NFAT promotes 
nuclear translocation and target gene transcription (Figure 1). As downstream effectors of 
the Cn signaling pathway, NFAT-dependent gene transcription influences a range of 
cellular functions, including endothelial cell migration (Minami et al. 2004), skeletal muscle 
differentiation (Rothermel et al. 2000), cardiac valve development (Lange, Molkentin & 
Yutzey, 2004), and vascular smooth muscle cell adaptation (Crabtree & Olson, 2002; 
Horsley& Pavlath, 2002; Lee et al. 2010).  
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Fig. 1. The Cn/NFAT signaling pathway. calmodulin (CaM), calcineurin (Cn), cyclosporin A 
(CsA) (adapted from Viola, J.B.P., 2005) 
Given the versatility of NFAT activation, it is not surprising that solid tumors and 
haematological malignances are correlated with overexpression of NFATc isoforms. For 
example, pancreatic carcinomas display elevated levels of NFATc1 for transcriptional 
activation of the c-myc oncogene (Buchholz et al. 2006). Studies using human breast 
carcinoma cell lines also show NFATc2 expression promotes carcinoma migration and 
invasion (Jauliac et al. 2002). The increased NFATc activity in malignant cells suggests 
activation of downstream NFATc targets is critical for tumor progression. Cyclooxygenase-2 
(COX2/PTGS2) has been reported by several groups as an NFAT-dependent gene in non-
lymphoid tissues, including endothelial cells (Hernandez et al. 2001), mesangial cells 
(Sugimoto et al. 2001), and vascular smooth muscle cells (Pritchard, Jr. et al. 1994). As an 
enzyme involved in prostaglandin formation, COX2 expression plays an important role in 
cell survival and angiogenesis. A gain-of-function approach shows that forced 
overexpression of COX2 alone is enough to induce mammary gland tumorigenesis (Liu et al. 
2001). On the converse, inhibition of COX2 significantly reduces colon tumor incidence and 
multiplicity in a dose-dependent manner (Reddy et al. 2000). These findings strongly 
support the notion that tumor growth/invasion necessitates an abundance of COX2 levels. 
The increased expression of COX2 in a multitude of cancer lines (i.e. gastric, esophageal, 
breast, bladder, cervical, colorectal, endometrial (Brown & DuBois, 2005; Duque, Fresno & 
Iniguez, 2005b)) have thus launched the production of several COX2 inhibitors with 
therapeutic potential. It is, however, important to note the importance of COX2 in other cell 
types. Unlike the constitutively expressed COX1 isoform, COX2 expression occurs in a 
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limited number of cell types, primarily in response to cytokines, inflammatory mediators, 
and tissue damage (Lipsky et al. 2000). The inducible nature of COX2 activation results in 
prostaglandin formation, including prostacyclin, a vasodilator and a potent inhibitor of 
platelet aggregation. Prostacylin formation in vascular endothelial cells thus provides a 
mechanism by which the thrombotic response in platelet activation can be regulated (Rudic 
et al. 2005). Hence, COX2 expression is necessary to maintain vascular health. While COX2-
selective inhibitors may attenuate tumor angiogenesis, COX2 antagonists will undoubtedly 
shift eicosanoid balance toward a prothrombotic state, promoting the risk for cardiovascular 
events (Mukherjee, Nissen & Topol, 2001). Targeting other proteins involved in Cn/NFAT 
signaling aside from COX2 may yield similar anti-neoplastic results. 
Tumor survival and growth is highly-dependent on a vascular system for delivery of 
essential nutrients and oxygen. A tumor’s vasculature also provides a mechanism by which 
aberrant cells can disseminate and metastasize to other organs. Without a constant blood 
supply, tumor volumes tend to remain 1-2mm3 in size (Brown & DuBois, 2005). 
Angiogenesis is a multi-step process that involves migration, proliferation, and 
differentiation of both endothelial and vascular smooth muscle cells for generation of 
mature vessels. Tumor cells can facilitate an ‘angiogeneic switch’ by altering gene 
transcription and the surrounding microenvironment. Somatic mutations of various proto-
oncogenes and/or tumor suppressor genes offset the balance between activators and 
inhibitors of angiogenesis, ultimately favoring angiogenic activity (Hanahan & Weinberg, 
2000). Pro-angiogeneic gene expression is induced by a number of physiological stimuli, 
such as hypoxia. Cells in hypoxic conditions produce the hypoxia-inducible factor (HIF) 
transcription factor, where expression of HIF-1 results in Vascular Endothelial Growth 
Factor (VEGF) transcription (Forsythe et al. 1996). VEGF, a major stimulator of angiogenesis, 
is a potent endothelial mitogen involved in both physiological and pathological blood vessel 
formation. VEGF is critical for proper embryonic vasculogenesis, as even heterozygous 
VEGF-deficient mice display abnormal blood vessel formation and consequent embryonic 
lethality (Carmeliet et al. 1996). While necessary for proper blood vessel development, excess 
VEGF can result in pathological angiogenesis. HIF-1-mediated VEGF expression and 
activation of other angiogenesis-related genes exemplifies the adaptive responses seen in 
tumor survival and growth. VEGF has also been demonstrated to induce COX2 expression 
in a Cn/NFAT-dependent manner (Duque, Fresno & Iniguez, 2005c). As previously 
mentioned, COX2 expression is critical for tumor cell migration and tube formation. The 
emerging role of NFAT signaling in oncogenesis is further highlighted, as pharmacological 
inhibition of NFAT blocks VEGF-stimulated COX2 expression and subsequent cell 
proliferation and/or angiogenesis both in vitro and in vivo (Hernandez et al. 2001). These 
results imply activation of Cn/NFAT signaling is required for the formation of new blood 
vessels, where regulation of angiogenesis is dependent on a local balance between 
angiogenic factors and inhibitors. The identification of Cn/NFAT activators and 
downstream NFAT target genes in the last few decades has therefore helped elucidate the 
biological mechanisms underlying oncogenesis. 
3.2 DSCR1 in cancer progression 
Cancer incidence for all solid tumors and malignancies have been shown in multiple DS 
population studies to be significantly lower in DS patients compared to control groups 
(Hasle et al. 2000; Yang et al. 2002). Interestingly, a large focus has been placed on the role of 
the Down Syndrome Candidate Region 1 (DSCR1/RCAN1/MCIP1) gene in cancer 
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limited number of cell types, primarily in response to cytokines, inflammatory mediators, 
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progression. Located on hChr21, DSCR1 has been demonstrated as a negative feedback 
regulator of Cn/NFAT signaling through physical binding to the catalytic subunit of Cn 
(Fuentes et al. 2000) (Figure 1). In endothelial cells, VEGF and thrombin stimulation 
dramatically upregulate DSCR1 expression in a Cn/NFAT dependent manner (Iizuka et al. 
2004; Minami et al. 2004). Several studies in endothelial cells have shown that DSCR1 
overexpression inhibits NFAT transcriptional activity, suppresses NFAT nuclear 
accumulation, and attenuates NFAT-dependent inflammatory marker gene expression, such 
as COX2 (Hesser et al. 2004; Yao & Duh, 2004). Studies also show DSCR1 overexpression in 
endothelial cells reduces vascular density in matrigel plugs in vitro and in tumor growth in 
mice (Minami et al. 2004). Lastly, functional data indicate constitutive expression of DSCR1 
impairs endothelial cell proliferation and tube formation (Minami et al. 2004). Taken 
together, VEGF and thrombin-mediated endothelial cell proliferation/vascularization 
induces expression of DSCR1 as a mechanism to negatively regulate the angiogenic 
processes.  
Researchers have attempted to explain the lack of tumorigenesis in the DS population 
through use of genetically modified mice. Comparative mapping between mice and humans 
identify that hChr21 is genetically homologous to mouse chromosome 16 (mChr16) (Reeves 
& Citron, 1994). Thus, mice exhibiting trisomy of mChr16 (Ts16) were originally developed 
to study DS. Ts16 mice, however, die in utero and therefore pose as a limitation. In addition, 
several genes located on mChr16 are found on human chromosomes other than hChr21. The 
observed embryonic lethality as well as gene dosage imbalances resulted in generation of 
the Ts65Dn mouse (Reeves et al. 1995). The Ts65Dn mouse model reflects partial trisomy of 
hChr21, where mice have been reported to display a variety of phenotypes, including 
behavioral abnormalities consistent with DS (Reeves et al. 1995). Ts65Dn mice are now 
widely used to study DS at all stages of development.  
A recent publication highlights the suppression of tumor growth seen in DS individuals 
using two different models: 1) the Ts65Dn mouse and 2) a DSCR1-transgenic mouse. 
Ts65Dn mice possess extra genetic information including the DSCR1 gene – Ts65Dn mice 
exhibit a 1.7-fold increase in DSCR1 protein expression compared to diploid controls (Baek 
et al. 2009). Baek KH et al demonstrate that both lung carcinoma and melanoma cell growth 
was significantly suppressed in Ts65Dn mice, when compared to control groups (Baek et al. 
2009). Under the transplantable tumor model, Ts65Dn mice also display significant 
decreases in tumor growth and microvessel density (Baek et al. 2009). Similar results were 
seen when using DSCR1-transgenic mice, suggesting that one extra copy of DSCR1 is 
sufficient for tumor growth suppression. Given that hChr21 contains over 200 genes, 
however, it is likely that other genes act in concert with DSCR1 to facilitate tumor 
suppressive effects. Another gene of interest includes Dual-specificity tyrosine-(Y)-
phosphorylation regulated kinase (DYRK1A), a nuclear serine/threonine kinase located on 
hChr21. DYRK1A phosphorylates several transcription factors including NFAT. DYRK1A 
can therefore reduce Cn/NFAT-dependent transcription through its ability to export 
nuclear NFAT. Baek KH et al also show that endothelial cells overexpressing DSCR1 
together with DYRK1A demonstrate an even greater suppression of VEGF-mediated cell 
proliferation (Baek et al. 2009). Future work by Baek KH et al will focus on additional 
hChr21-located genes known to suppress tumor angiogenesis through alternate mechanisms 
(Ryeom, Baek & Zaslavsky, 2009), such as COLLAGEN XVIII (COL18A1), a precursor to the 
angiogenesis inhibitor endostatin, and ADAMTS1, a metalloproteinase known to regulate 
the anti-angiogeneic function of thrombospondin-1 (Iruela-Arispe, Carpizo & Luque, 2003; 
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Zaslavsky et al. 2010). In summary, the tumorigenic protective effects seen in DS adults may 
be due to increased expression of select hChr21-located genes, including DSCR1. 
4. Atherosclerosis in Down Syndrome 
Atherosclerosis progression is a complex process involving several cell types, multiple 
biological mechanisms, and environmental factors. The pathogenesis of atherosclerotic 
plaque formation is highly dependent on hemodynamic flow patterns (DeBakey, Lawrie & 
Glaeser, 1985; Vanderlaan, Reardon & Getz, 2004), thrombotic processes, and inflammatory 
signaling cascades (Lusis, 2000). Atherosclerosis is one of the leading causes of mortality in 
Westernized societies, and thus several cardiovascular risk factors have been identified over 
the last few decades in an effort to predict cardiovascular events. Given that atherosclerosis 
is characterized by accumulation of lipids in the large arteries, it is not surprising that 
elevated plasma triglyceride levels have been demonstrated as a direct propagator of 
cardiovascular disease (Austin, Hokanson & Edwards, 1998; Hokanson & Austin, 1996). 
Other plasma measurements indicative of cardiovascular risk include reduced levels of 
high-density lipoprotein (HDL) (Assmann et al. 1996; Gordon et al. 1977), and elevated 
serum levels of C-reactive protein (CRP), an indicator of inflammation (Mendall et al. 1996). 
High values for body mass index have also been demonstrated as a measure of 
cardiovascular risk (Berenson et al. 1998).  
Atherosclerotic cardiovascular disease has been associated with metabolic syndrome, which 
includes several clinical disorders such as obesity, insulin resistance, glucose intolerance, 
hypertension, and dyslipidemia (Moller & Kaufman, 2005). Consistent with the 
aforementioned metabolic deficiencies associated with DS patients, individuals with DS also 
exhibit impaired lipid metabolism (Ishihara et al. 2009). In addition, DS patients have lower 
levels of low-density lipoprotein receptor (LDLR) expression compared to adults without 
DS (Corsi et al. 2005). Interestingly, lack of or dysfunctional LDLR expression results in 
familial hypercholesterolemia, a genetic disease characterized by elevated cholesterol levels 
and premature coronary artery disease (Brown & Goldstein, 1976). LDLR-null mice have 
since been generated and is now a widely used atherosclerotic mouse model (Ishibashi et al. 
1993; Wouters et al. 2005). Lastly, DS patients exhibit significantly elevated levels of plasma 
triglycerides, low levels of HDL, high levels of CRP, and high levels of total body fat (Corsi 
et al. 2005; Draheim et al. 2010; Nishida et al. 1977). Taken together, these findings imply DS 
adults are surely at risk for cardiovascular events. DS patients, however, are significantly 
less susceptible to cardiovascular disease. A comparison of intimal-to-medial thickness 
(IMT) of the common carotid artery in DS adults show significantly lower IMT ratios when 
compared to control groups (Draheim et al. 2010). These findings corroborate the 
observational findings in 1977 where DS patients were proposed to be an “an atheroma-free 
model” (Murdoch et al. 1977). One can speculate that DS patients thus express an altered 
gene expression profile where an additional copy of hChr21-located genes results in 
protection against atheroma formation, despite the many validated plasma indicators of 
cardiovascular risk. Similar to the identified gene clusters responsible for the metabolic and 
developmental deficiencies in DS patients, it is highly likely that a cohort of genes located on 
hChr21 is responsible for the protective effects against cardiovascular disease. Identification 
of these genes will therefore provide a therapeutic direction as we continue to understand 
the etiology behind atherosclerotic plaque formation.  
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4.1 Vascular smooth muscle and atherogenesis 
At the cellular level, atherosclerosis progression is characterized by lipid accumulation and 
fibrous lesion formation in large arteries, resulting in chronic arterial wall inflammation. The 
release of cytokines and growth factors induce vascular smooth muscle cells (SMC) to 
undergo a process known as phenotypic modulation, whereby an adult, contractile SMC 
alters its expression profile to facilitate cell proliferation, migration, and/or inflammatory 
cell recruitment (Shin et al. 2008) (Figure 2). Phenotypic modulation is a key event 
underlying atherogenesis and in-stent restenosis that involves several signaling cascades, 
including the Cn/NFAT pathway. Activation of Cn/NFAT signaling has been shown to 
induce vascular SMC proliferation and migration in response to receptor tyrosine kinase 
and G-protein-coupled receptor agonists, respectively (Liu, Dronadula & Rao, 2004; 
Yellaturu et al. 2002). Cn/NFAT activity is also critical for vessel wall assembly (Graef et al. 
2001). Cyclosporin A (CsA) and the VIVIT peptide are commonly used Cn and NFAT 
inhibitors, respectively (Figure 1). A third pharmacological compound, A-285222, also 
inhibits Cn/NFAT signaling (Lee et al. 2010; Nilsson et al. 2007). Inhibition of Cn/NFAT 
signaling through use of either CsA or A-285222 attenuates Cn/NFAT-mediated SMC 
migration and proliferation in vitro (unpublished, Figure 1). Previous literature also shows 
that blocking Cn/NFAT signaling in vivo significantly inhibits vascular-injury-induced 
neointima formation (Liu et al. 2005), supporting the notion that Cn/NFAT signaling is 
intimately involved in the smooth muscle response to vascular injury. While NFAT-
dependent gene regulation has been widely studied in lymphocytes, cardiac and skeletal 
muscle, the lack of known NFAT target genes in SMCs limits our understanding of 
Cn/NFAT signaling in vascular remodeling. 
 
  
Fig. 2. The interplay between SMC phenotypic modulation and Cn/NFAT signaling in 
vascular disease. 
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4.2 Identification of DSCR1 using integrative genomics 
We recently developed an unbiased, top-down, integrative genomics approach to determine 
downstream targets of Cn/NFAT activation in vascular SMCs (Lee et al. 2010). In brief, 
whole-genome expression data sets were analyzed to identify differentially upregulated 
genes in human, mouse, and rat SMCs. Comparison between control and phenotypic 
modulatory stimuli identified 63 species-conserved, upregulated genes. Differentially 
upregulated genes were then compared against an in silico NFAT-ome (a list of gene 
promoters containing at least one species-conserved physical NFAT binding site), yielding 
18 potential Cn/NFAT-dependent genes. Use of pharmacological Cn/NFAT inhibitors 
substantiated the NFAT-dependent role for COX2, a previously identified Cn/NFAT 
dependent gene, and revealed the Cn/NFAT-dependent property of DSCR1 in vascular 
SMCs (Lee et al. 2010). DSCR1 has been reported in other cell types to function as a negative 
feedback regulator of Cn/NFAT signaling (Figure 1). Both gain- and loss-of-function studies 
were conducted to determine the role of DSCR1 in vascular SMCs. Overexpression of 
DSCR1 resulted in decreased NFAT transcriptional activity and reduced expression of other 
Cn/NFAT-dependent genes, such as COX2. Conversely, knockdown of endogenous DSCR1 
enhanced NFAT transcriptional activity suggesting DSCR1 also functions as a negative 
regulator in vascular SMCs (Lee et al. 2010). Lastly, analysis of in vivo whole-genome 
expression arrays found significant DSCR1 upregulation with acute vascular injury in 
mouse carotid arteries, regardless of strain type (Lee et al. 2010). The significant induction of 
DSCR1 exemplifies its functional importance and may be critical for modulating the 
vascular injury response. Similarly, an extra copy of the DSCR1 gene in DS patients may 
function in an atheroprotective manner through its ability to negatively regulate Cn/NFAT 
signaling. The recent study highlighting significantly less tumor growth in DSCR1-
transgenic mice (Baek et al. 2009) fosters the regulatory role of DSCR1 in Cn/NFAT-
mediated cell growth. It is possible DSCR1 functions in both endothelial cells and vascular 
SMCs as a modulator of cell proliferation, thereby providing a shared mechanism 
underlying tumorigenesis and atheroma formation. 
4.3 Ongoing research 
Several studies are currently underway in an effort to understand the functional role of 
DSCR1 in SMC phenotypic modulation and atherosclerotic plaque formation. DSCR1-
deficient mice have since been obtained and are proving to be instrumental as we continue 
to elucidate the role of DSCR1 in atherogenesis. DSCR1-related family members, however, 
have been identified in most eukaryotic organisms. In humans, DSCR1 family members 
include DSCR1-like 1 (DSCR1L1/ZAKI-4/RCAN2) and DSCR1-like 2 (DSCR1L2/RCAN3) 
(Strippoli et al. 2000). Interestingly, DSCR1L1 mimics the inhibitory effects of DSCR1 on Cn 
signaling in endothelial cells and inhibits angiogenesis (Gollogly, Ryeom & Yoon, 2007). In 
lymphocytes, DSCR1L2 blocks nuclear NFAT translocation and inhibits NFAT-dependent 
cytokine gene expression (Mulero et al. 2007). Given the functional overlap between the 
DSCR1 family members, global DSCR1-/- mouse models may possibly exhibit 
compensation by DSCR1L1 and/or DSCR1L2. In addition, DSCR1 plays a critical role in 
each of the major cell types seen with atherogenesis and will therefore be difficult to 
attribute our findings as a vascular SMC-specific response. Until a SMC-specific conditional 
knock-out mouse study is carried out, a conservative approach must be taken when 
interpreting results gathered from DSCR1-null mice given the complexities surrounding 
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DSCR1 expression and regulation in other cell types. Nonetheless, the data gathered will 
provide a better understanding of DSCR1 function. 
Apolipoprotein E (ApoE) is critical for lipoprotein metabolism. Defects in ApoE expression 
can consequently increase plasma cholesterol and triglyceride levels. Hence, targeted 
mutagenesis of the ApoE gene in mice promotes elevated serum cholesterol levels, where 
combination with a high fat/cholesterol diet results in massive accumulation of cholesterol 
and causative atherosclerotic lesion formation. DSCR1-/-; ApoE-/--double knockout mice 
have been generated in an effort to study how the absence of DSCR1 affects atherosclerotic 
plaque formation. These double-null mice have been placed on a 20-week, high 
fat/cholesterol diet to ensure plaque formation, where atherosclerotic plaque size will be 
quantified and compared against proper control groups. Given the literature to date, we 
predict atherosclerotic lesion formation and size to significantly increase in DSCR1-/-; ApoE-
/- double-null mice. The absence of DSCR1, a negative regulator of Cn/NFAT activity, 
should in theory promote SMC proliferation and infiltration into the neointima. A recent 
publication, however, emphasizes the dual role of DSCR1, suggesting DSCR1 is necessary 
for both Cn/NFAT activation and self-regulation (Liu, Busby & Molkentin, 2009). This effect 
has been demonstrated in cardiomyocytes and hypertrophy, an adaptive response driven by 
Cn and NFATc4 signaling (De Windt et al. 2001; Molkentin et al. 1998). Several groups have 
shown an attenuation of cardiac hypertrophy with overexpression of DSCR1 (Rothermel et 
al. 2001). DSCR1-/-; DSCR1L1-/- double-null mice were thus hypothesized to demonstrate 
significantly greater cardiac hypertrophy. DSCR1-/-; DSCR1L1-/- double-null mice, however, 
exhibit the reverse response – cardiac hypertrophy is impaired in response to adrenergic 
stimulation or exercise, similar to responses seen in calcineurin Aβ-/- mice (Sanna et al. 
2006). These results suggest a basal level of DSCR1 is necessary to properly activate 
Cn/NFAT signaling. The DSCR1 yeast homolog, RCN1/CBP1, has also been functionally 
characterized as a facilitator of Cn/NFAT signaling (Kingsbury & Cunningham, 2000). The 
notion that DSCR1 may also activate Cn/NFAT signaling highlights the elaborate nature of 
this protein, suggesting that the paradoxical function of DSCR1 depends on initial protein 
concentrations (Shin et al. 2006). It is thus possible we may instead observe a decrease in 
atherosclerotic lesion formation in the DSCR1-/-; ApoE-/- double-null mice. With this in 
mind, we have also placed DSCR1+/-; ApoE-/- mice to observe how DSCR1 
haploinsufficiency affects plaque formation. The presence of one DSCR1 allele will allow for 
minimal DSCR1 expression, yet also test the effects of reduced DSCR1 expression on lesion 
formation.  
We are also performing several in vitro assays on primary aortic SMC cultures from DSCR1-
/- mice to determine the consequences of DSCR1 absence on cell functionality. With our 
recent findings demonstrating DSCR1 as a negative regulator of Cn/NFAT signaling in 
vascular SMCs (Lee et al. 2010), one would hypothesize that DSCR1-null vascular SMCs to 
exhibit increased cell proliferation in response to phenotypic modulatory stimuli. 
Preliminary data, however, show a reduced proliferative response in DSCR1-null vascular 
SMCs when stimulated with either platelet-derived growth factor (PDGF-BB) or serum 
(unpublished). These initial results support the emerging dual role of DSCR1, suggesting 
basal levels of DSCR1 is necessary for Cn/NFAT activation. While our model cannot fully 
explain the almost complete absence of atheroma formation in DS patients, our results will 
not only help elucidate the functional role of DSCR1 in atherogenesis, but also provide 
insight on the effects of trisomy 21 through a single gene approach. 
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5. Vascular tone and Down Syndrome 
Enzyme activity of endothelial nitric oxide synthase (eNOS) plays a critical role in 
determining vascular tone through its ability to generate nitric oxide (NO) and consequently 
affect vascular smooth muscle contraction. Regulation of eNOS enzymatic activity is a 
highly dynamic system involving several kinases and phosphatases with significant 
downstream effects on NO-signaling (Duran, Breslin & Sanchez, 2010). While 
phosphorylation of eNOS is typically associated with enzyme activation, several groups 
demonstrate that dephosphorylation of eNOS can also trigger eNOS activation and 
subsequent NO production (Harris et al. 2001; Kou, Greif & Michel, 2002; Thomas, Chen & 
Keaney, Jr., 2002). The Cn phosphatase has been shown to target several proteins aside from 
NFAT, including eNOS (Kou et al. 2002). While the absolute role of DSCR1 is unknown in 
the vasculature, recent literature suggests DSCR1 plays a vital role in vessel contraction. 
DSCR1-/- mice have been reported to exhibit an attenuated vasocontriction response with 
phenylephrine treatment compared to appropriate controls (Riper et al. 2008). Riper DV et al 
speculate that the altered vascular constriction in DSCR1-/- mice may be due to Cn 
dysregulation, thereby facilitating excess endothelial NO production. Based on the proposed 
mechanism, overexpression of DSCR1 should then limit NO formation and promote 
vasoconstriction. As stated earlier, however, adults with DS are significantly hypotensive 
when compared to control groups (Morrison et al. 1996; Richards & Enver, 1979). Although 
the attenuated vasoconstriction response in DSCR1-/- mice may contradict the hypertensive 
nature of DS patients, the account by Riper DV et al is the first publication to date revealing 
a potential role of DSCR1 in vascular tone.  
It is also important to note that these observations of a weakened vasoconstriction response 
in DSCR1-/- mice reflect those of mesenteric rather than carotid arteries. While the 
underlying effects of NO on smooth muscle and vascular tone may be synonymous between 
the differing vascular beds, vasoconstriction could be regulated through different 
mechanisms. The effect of vascular bed type is further exemplified by the fact that while DS 
patients may be significantly hypotensive, they are also at an increased risk of developing 
pulmonary arterial hypertension (PAH) (Cua et al. 2007). The observed increase in PAH 
incidence amongst DS individuals may be due to several factors such as chronic upper 
airway obstruction (Jacobs, Gray & Todd, 1996) and abnormal pulmonary vasculature 
growth (Chi, 1975). Vascular tone therefore appears to depend not only on the vascular bed 
of interest but also on peripheral influences. In addition, basal levels of DSCR1 may be 
required for proper Cn/NFAT function, as previously described. Future contractility studies 
in haploinsufficient DSCR1+/- mice may thus provide clarity on the true role of DSCR1 in 
vascular tone. This study clearly demonstrates the widespread effect of DSCR1 loss, where 
dysregulation of Cn/NFAT activity in the endothelium alters paracrine signaling molecule 
production, creating invariable effects on neighboring cell types. The prevalent nature of 
DSCR1 prompts consideration for cell-cell interaction effects as we continue to decipher 
DSCR1 function in vascular disease. 
6. NFAT regulation and other considerations 
The importance of calcium signaling, NFATc transcriptional regulation, and ensuing 
downstream gene expression is increasingly evident. Adequate and controlled Cn/NFAT 
signaling is necessary, as dysregulation results in several vascular pathologies. Both the 
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versatility in DNA binding and the presence of multiple NFAT family members suggest 
NFAT proteins have a more extensive role than originally anticipated. A few notable 
features of NFAT are brought to attention below. 
NFAT transcription factors bind to DNA in a rather versatile manner. The promiscuous 
nature of NFAT-DNA binding suggests the presence of other binding partners. The most 
common and well-documented binding partner of NFAT is AP-1, a transcription factor 
comprised of Fos- and Jun- family proteins (Rao, Luo & Hogan, 1997). Several groups have 
demonstrated the need for cooperative NFAT-AP1 binding for optimal target gene 
transcription (Hogan et al. 2003). In addition to AP-1, NFAT has been shown to interact with 
other transcription factors involved in cell growth and differentiation, including GATA4, 
MEF2, and FOXP3 (Crabtree & Olson, 2002; Wu et al. 2006). Several groups have also noted 
the presence of multiple NFAT binding sites in validated NFAT-target gene promoters, such 
as interleukin-2 (Randak et al. 1990), interleukin-4 (Chuvpilo et al. 1993), and DSCR1 (Harris, 
Ermak & Davies, 2005). These multiple NFAT binding domains most likely confer a 
synergistic effect between NFAT-containing complexes and thereby promote efficient gene 
transcription (Rao et al. 1997). Thus, NFAT proteins may serve as ‘coincidence detectors’ 
(Crabtree & Olson, 2002) that can integrate information from multiple signaling pathways to 
coordinate gene expression.  
The ubiquitous nature of NFAT amongst various cell types and processes demonstrates the 
broad-range effects of NFAT activity. While functional redundancy has been noted between 
the different NFAT isoforms, differences in tissue distribution (Rao et al. 1997), evidence of 
multiple splice variants, and distinguishing phenotypes of NFAT-deficient mice suggest 
NFAT proteins may in fact possess unique isoform-specific functions. For example, while 
NFATc1 and NFATc2 share 72% sequence agreement and demonstrate functional similarities, 
genetic deletion for either NFATc isoform results in divergent mouse phenotypes. Whereas 
NFATc2-/- mice are viable and demonstrate an enhanced immune response (Duque, Fresno & 
Iniguez, 2005a), NFATc1-/- mice display abnormal cardiac valve development and consequent 
embryonic lethality (de la Pompa et al. 1998). Variations between NFAT proteins is further 
seen where targeted disruption of NFATc3, but not NFATc4, significantly reduces Cn 
transgene-induced cardiac hypertrophy (Wilkins et al. 2002). The disparate outcomes from 
NFATc genetic deletions as well as the ability for NFATc isoforms to compensate one another 
limits the use of NFATc-specific knock-out mice.  
Recent data have also challenged the longstanding premise viewing NFAT as a 
transcriptional activator. Several groups have in fact demonstrated the dual role of NFAT as 
both a gene activator and silencer (Robbs et al. 2008). NFATc1 and NFATc2 have been 
shown to repress cyclin-dependent kinase 4 (Horsley et al. 2008) and cyclinA2 (Carvalho et 
al. 2007) expression, respectively. NFATc2 has also been demonstrated as a negative 
regulator of cyclin B1 and cyclin E in lymphocytes (Caetano et al. 2002). The nonoverlapping 
functions and apparent gene silencing effects of individual NFATc proteins further 
complicates our understanding of Cn/NFAT signaling. NFAT is clearly involved in 
maintaining a balance between cell quiescence and cell proliferation – the two fundamental 
biological mechanisms underlying tumorigenesis and atherosclerosis.  
7. Conclusions 
The Cn/NFAT signaling cascade is undoubtedly a major determinant of cell growth and 
differentiation. Regulation of Cn/NFAT signaling is a critical determinant of neoplastic and 
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cardiovascular risk. With DSCR1 now known as an endogenous regulator of Cn/NFAT 
signaling, several groups have successfully manipulated downstream gene expression and 
cell function by altering DSCR1 levels. The observation that DS patients exhibit significantly 
less tumor growth and arterial plaque formation cannot be mere coincidence, but rather 
evidence supporting the notion that these large-scale, vascular-related pathologies share an 
underlying mechanism. This is further reinforced by the fact that DSCR1 and other 
candidate antiangiogenic genes found on hChr21 are of growing attention. A more 
comprehensive analysis of hChr21-located genes may therefore provide direction as we 
continue to elucidate the mechanisms underlying tumorigenesis and atherosclerotic plaque 
formation.  
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1. Introduction  
Alzheimer’s disease (AD), the most common type of dementia in old age, is a complex, 
multifactorial neurodegenerative disorder currently affecting 35,6 million people in either 
familial (genetic) or sporadic form, whose prevalence is expected to quadruple worldwide 
by the year 2050 (Alzheimer’s Disease International, 2010; Ferri et al., 2005). While genetic or 
early-onset AD accounts for only 5% of all cases (Cummings, 2004), 95% of sporadic or late-
onset AD is attributed to the interaction between advancing age, environmental factors 
(Grant, et al., 2002; Tanzi & Bertram, 2001), and to the few risk-enhancing genetic 
polymorphisms discovered so far (Bertram & Tanzi, 2004). Autosomal dominant mutations 
in the amyloid precursor protein (APP), presenilin 1 (PS1), and presenilin 2 (PS2) are linked 
to early-onset (familial) AD (FAD, Hardy, 2009). A combination of bio-psycho-social factors, 
especially if experienced at midlife, such as abnormal glucose and cholesterol metabolism, 
cerebral hypoperfusion, hypertension, physical and mental inactivity, diet, head injury, 
depression and small social networks are thought to contribute to sporadic AD initiation 
and development (reviewed in Flicker, 2010; Bendlin et al., 2010; Hughes & Ganguli, 2009). 
There is a temporal gap between clinical and pathological manifestation of Alzheimer’s 
dementia; AD has a long prodromal phase and many clinically silent older adults are 
experiencing substantial pathological burden (Elias et al., 2000; Small et al., 2000). Common 
clinical manifestation of AD include memory impairment and dysfunctions in several 
cognitive domains such as language, problem solving, executive function, visuospatial 
skills, and others along with changes in personality and behavior (Maurer & Hoyer, 2006).  
1.1 Neuropathology of Alzheimer’s disease  
The brain pathology of AD is characterized by extracellular deposits of the amyloid-beta 
peptide (Aβ), a main constituent of senile plaques, and intracellular accumulation of the 
hyperphosphorylated protein tau (p-tau) (Selkoe, 1999; 2001).  The central hypothesis of AD, 
the amyloid cascade hypothesis, posits that an imbalance between Aβ production, 
aggregation and clearance from the brain is the initiating event in the disease process 
leading to synaptic loss, neuronal degeneration, inflammation, senile plaque formation and 
dementia (Blennow, de Leon, & Zetterberg, 2006; Hardy, 2006; Hardy & Selkoe, 2002; Lee et 
al., 2004; Potter et al., 2001). 
The main constituent of the extracellular senile plaques is a highly neurotoxic Aβ42 isoform 
of Aβ protein, produced by consecutive action of two cleaving proteases, β- (BACE-1) and γ-
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secretase, from a larger transmembrane protein, the Amyloid Precursor Protein (APP) 
(Hardy, 2009; Haass & Selkoe, 1993; Wolfe, 2003) within cholesterol rich membrane domains 
(Wahrle et al., 2002). A number of biochemical and genetic studies have indicated that 
oligomerization or polymerization of Aβ peptide driven by inflammation-induced proteins 
is a crucial step in AD pathogenesis (Potter et al., 2001; Hardy, 2006). Aβ42 self-aggregates 
and forms insoluble plaque deposits that include dystrophic neurites, activated microglia 
and reactive astrocytes (Itagati et al., 1989) which express a number of proinflammatory 
proteins (Akiyama et al., 2000; Potter et al., 2001). Furthermore, Aβ induces increased 
phosphorylation of the intracellular protein tau, resulting in destabilization of microtubules 
(MT) (Small & Duff, 2008). The evidence from transgenic mice and human studies indicates 
that not only extracellular, but also intracellular Aβ accumulates in diseased neurons and 
contributes to dementia progression by affecting the function of mitochondria, calcium ion 
channels and synapses (La Ferla, Green, and Oddo, 2007; Li et al., 2007). It is still unclear 
which toxic species of the Aβ peptide are most damaging to the neurons or whether the 
process of aggregation itself is detrimental to neuronal membranes.   
Neurofibrillary tangles (NFTs) are the second major pathological hallmark in AD, which 
result from abnormally aggregated tau protein filling the intracellular space of the neurons. 
In AD brain, tau gets hyperphosphorylated, detaches from microtubules and forms paired 
helical filaments, which cause disruption in neuronal signaling, synaptic failure, impaired 
nutrient trafficking and neuronal death (Alonso et al., 2006; Grundke-Iqbal et al., 1986).  
Furthermore, oxidative damage as a consequence of free radical and reactive oxygen species 
(ROS) attacks has been observed in post-mortem AD brains in the form of oxidized lipids 
and proteins, mutated DNA, and mitochondrial damage (Floyd & Hensley, 2002). 
Formation of amyloid plaques and neurofibrillary tangles is not only associated with 
neuronal and synaptic loss, and depletion of neurotransmitters (Scheff, et al., 2006; Selkoe, 
1999; 2004), but with abnormal axonal transport of key molecules and organelles important 
for neural cells survival and communication early in the disease process (Stokin et al., 2005; 
Stokin & Goldstein, 2006).  Neurons, with their long axons, branched dendrites and large 
cell surface are especially vulnerable to energy and/or oxygen deprivation, impaired 
movement of molecules, and neurotoxins observed in AD pathology (Mattson & Magnus, 
2006). The development of early diagnosis and successful treatments of AD will be greatly 
aided by a complete understanding of the pathological pathway that leads to formation of 
misfolded proteins, inflammation and neurodegeneration.  
1.2 The Down syndrome model of Alzheimer’s disease  
The discovery that Down syndrome (DS) patients who live beyond the age of 30 or 40 
develop neuropathology indistinguishable from the one observed in classic AD (Glenner & 
Wang, 1984; Olson & Shaw, 1969; Wisniewski et al., 1988) provided an important insight 
into AD pathogenesis, shifting the focus on nondisjunction of human chromosome 21 
(HSA21) where the APP gene resides (Goldgaber et al. 1987; Neve et al., 1988; Petterson et 
al., 1988; Tanzi et al., 1987 ), and on the consequence of the gene overexpression in DS 
(Epstein, 1990). The fact that an extra copy of APP and subsequent 50% increase in gene 
dosage due to trisomy 21 in every cell of the body in DS individuals is sufficient to cause AD 
later in life instigated research on common biological links between AD and DS (Potter, 
1991, 2008; Geller & Potter, 1999). Trisomy 21 results in altered APP processing and in an 
increased ratio of more amyloidogenic Aβ42 over Aβ40 (Teller et al., 1996), similar to the 
process observed in animal models of AD and in patients harboring mutations in FAD 
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genes, PS1, PS2 and APP (Haas & De Stooper, 1999; Hardy & Selkoe, 2002; Suzuki et al., 
1994; Wolfe, 2003). 
Several biochemical and genetic studies have shown that both sporadic and familial AD 
patients, including those carrying FAD mutations, are abnormal in one or more aspects of 
the cell cycle (Arendt et al., 1996; Geller & Potter, 1999; Potter, 1991; Varvel et al., 2008; Yang 
et al., 2001; 2006; Yang & Herrup, 2007; reviewed in Nagy, 2005; Obrenovic et al., 2003; 
Potter, 2004, 2008). The universal presence of AD pathology in DS individuals and the 
occurrence of an aberrant cell cycle in the brains of FAD mouse models and AD patients, led 
us to hypothesize that a slow accumulation of aneuploid, including  trisomy 21 cells through 
defective mitosis and chromosome mis-segregation in central and peripheral tissues over 
the course of life of an individual could cause or at least help promote late-onset 
Alzheimer’s (Potter, 1991; 2008). The extra copy of chromsome 21 that in full human trisomy 
of DS leads to neurodegeneration and dementia, could account for both genetic and 
sporadic AD, depending upon whether the chromosomal instability and mosaic aneuploidy 
was induced by a genetic (familial) mutation or by environmental insults. We further 
postulated that the microtubule disfunction likely responsible for the mitotic defects and 
genomic instability in AD could be linked to altered APP production and increased Aβ 
levels, probably affecting other aspects of neuronal physiology and function (Borysov et al., 
2011; Granic et al., 2010; Potter, 2008).   
The Down syndrome model and chromosome mis-segregation/microtubule disfunction 
hypothesis of AD made several predictions (Geller & Potter, 1999; Potter, 2008): 
1. Alzheimer’s patients should harbor a small number of aneuploid, including trisomy 21 
cells in their somatic tissues. Altered genomic stability and development of trisomy 21 
mosaicism would contribute to dementia onset and neurodegeneration but at slower 
pace than in DS due to the modulating effect of mostly disomic cells in the body.  
2. Mutations that cause familial AD should occur in genes that encode proteins directly or 
indirectly involved in the cell cycle and chromosome segregation. 
3. There should be alternations in microtubules, mitotic spindle apparatus and mitosis-
related proteins in AD cells that could lead to aneuploidy, including trisomy 21 
mosaicism. 
In the past twenty years, compelling epidemiological and molecular evidence from our and 
other laboratories has been accumulated to test all three predictions. Together, the evidence 
suggests a link between pathological changes observed in the brains of DS and AD 
individuals and  chromosomal instability and mosaic aneuploidy, including nondisjunction 
of HSA21 which likely contributes to dementia initiation and/or progression, with 
important implications for AD diagnosis and therapy.  
2. The epidemiology of trisomy 21 mosaicism in Alzheimer’s disease 
Early epidemiological evidence indicating that chromosome mis-segregation and trisomy 21 
mosaicism might be implicated in AD pathogenesis came for the studies showing a 
significantly higher number of Down syndrome offspring born in some families with FAD 
mutations (Heston et al., 1981; Heyman et al., 1983). The studies that failed to confirm this 
association reported to have too small sample sizes to observe statistically significant results 
(Amaducci et al., 1986; Chandra et al., 1987) suggesting that larger scale studies are needed 
to establish a connection between a higher frequency of DS children in families with genetic 
forms of AD. An important result that provided support for the trisomy 21 model of AD 
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came from a retrospective study of young mothers (aged <35) showing a five-fold greater 
risk of developing AD later in life compared to either older DS mothers or the general 
population (Schupf et al., 1994; 2001). Schupf and her colleagues interpreted this 
phenomenon as a novel form of ‘accelerated aging’. In the light of our trisomy 21 model of 
AD, we postulated that the young DS mothers were most likely mosaic for chromosome 21 
and had a predisposition for genomic instability, which resulted in DS progeny and their 
own increased risk of AD later in life. Indeed, a recent study by Migliore et al. (2006; 2009) 
confirmed the susceptibility to aneuploidy and trisomy 21 nondisjunction in young mothers 
of DS children. Case studies of patients with trisomy 21 mosaicism and no intellectual 
impairments of the DS type who developed AD by the age of 40 demonstrated that a small 
percentage of chromosomal instability is sufficient to result in early-onset AD (Hardy, et al., 
1989; Ringman et al. 2008; Schapiro et al., 1989). Similarly, a slow accumulation of a low 
number of trisomy 21 cells over the life span may lead and/or contribute to the 
pathogenesis of both genetic and sporadic form of AD.  
In order to directly test if Alzheimer’s patients harboured mis-segregated including trisomy 
21 cells, we and others have used fluorescence in situ hybridization (FISH), a cytogenetic 
technique that allows one to detect the number of copies of a particular chromosome in both 
metaphase and interphase cells (Ried, 1998) with great sensitivity and specificity. This 
method is especially suitable for poorly and non-dividing cells, or for the cells with a very 
low level of aneuploidy (e.g., lymphocytes). In our early study of chromosome mis-
segregation in AD, we found more than twice the frequency of trisomy 21 in skin fibroblasts 
of AD patients (p=0.007) compared to age-matched controls, which was not related to the 
age of affected individuals (Figure 1, Geller & Potter, 1999). A small parallel study of 
chromosome 18 nondisjunction showed a similar increase in aneuploidy, indicating that the 
mitotic defect likely affected all chromosomes. The AD fibroblasts in our study included 
those with sporadic (late-onset) AD and those carrying a familial AD mutation in PS1, PS2, 
or APP which are now known to cause early AD onset and altered APP processing (e.g., Li 
et al., 1995; Schellenberg et al., 1993; Rogaev et al. 1995). 
 
 
Fig. 1. AD fibroblasts, including those with PS1 or PS2 mutation (FAD) and those of 
sporadic origin (SAD) showed increased trisomy 21, *p < 0.01; **p < 0.001. (Used with 
permission from Geller & Potter, 1999, Neurobiology of Disease).  
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Trisomy 21 mosaicism and chromosome mis-segregation have also been observed among 
peripheral blood lymphocytes (Migliore 1997; 1999; Trippi et al., 2001), buccal cells (Thomas 
& Fenech, 2008), and neurons from sporadic AD patients (Arendt et al., 2010; Iourov et al., 
2009; Mosch et al., 2007; Yang et al., 2001). Specifically, AD brains harbor up to 35% of 
hyperploid, including trisomy 21 and other tetrasomic neurons which are detectable at mild 
stages of the disease before any evident neuronal loss (Arendt et al., 2010; Iourov et al. 2009). 
The presence of tetrasomic neurons as explained by some reseachers, may indicate re-entry 
into an incomplete cell cycle and selective vulnerability to cell death of post-mitotic, mosaic 
neurons as an important pathogenic event in AD (Arendt et al., 2010; Obrenovich et al., 
2003; Varvel et al., 2008; Vincent et al., 1996; Yang & Herrup, 2007). In our studies of AD 
mosaicism (Boeras et al., 2008; Geller & Potter, 1999; Granic et al., 2010), we failed to observe 
statistically significant  induction of tetrasomic cells in sporadic and familial models of AD, 
but rather pronounced accumulation of trisomy cells in both peripheral and brain tissues. A 
larger scale cytogenetic autopsy and biopsy study, preferably at the single cell level is 
needed to further elucitate the type and extent of pathologic genetic instability in AD and 
other neurodegenerative diseases.  
In summary, several laboratories confirmed that trisomy 21 mosaicism is commonly 
associated with AD. Moreover, there is an indication of a dose response effect in which full 
trisomy 21 in DS individuals elicits AD-like pathology by age 20 and by middle age in 
familial AD and even later in sporadic Alzheimer’s patients, who also belonged to the 
trisomy 21 mosaic group found to have an increased frequency of DS children before the age 
of 35. The recent discovery of families that develop early-onset inherited AD only because 
the APP gene on one chromosome 21 is duplicated (McNaughton et al., 2010; Rovelet-
Lecrux et al., 2006; Sleegers et al., 2006) indicates that the extra copy of the APP gene and 
consequent overproduction of Aβ peptide is the likely cause of AD in both Down syndrome 
and trisomy 21 mosaic individuals.  
2.1 Mitotic defects in Alzheimer’s disease  
Along with the studies described above, separate lines of investigations provided 
independent evidence that other mitotic defects and mitosis-specific proteins may be 
present in the cells of AD patients (reviewed in Potter, 2004). For instance, the mitotic 
spindles in dividing AD cells exhibit abnormalities and susceptibility to premature 
centromere division (PCD) and micronucleation upon chemically induced (e.g., colchicines) 
microtubule damage (e.g., Fitzgerald et al., 1986; Potter et al., 1995; Trippi et al., 2001). The 
event of PCD, in which individual sister chromatids are separated by a clear gap and not 
connected at the centromeres, has been observed in patients prone to genomic instability 
and chromosome mis-segregation, and recently confirmed in neurons of individuals with 
sporadic AD (Spremo-Potparević et al., 2008).  
Further evidence linking cell cycle defects with AD pathogenesis came for the finding that 
both APP and the microtubule-stabilizing tau protein get increasingly phosphorylated 
during mitosis (Suzuki et al., 1994; Pope et al., 1994; Padmanabhan et al., 2011). Also, 
phospho-tau and other mitosis-specific phospho-proteins are overexpressed in AD but not 
in normal brains (e.g., Arendt et al., 1996; Vincent et al., 1996; Nagy et al., 1997), indicating a 
cycling stage of AD neurons. The idea of unscheduled cycle in fully differentiated neurons 
challenged the dogma of their post-mitotic nature and the inability to replicate (Rakic, 1985). 
To date, the evidence drawn from animal models of AD and autopsy studies of human 
brains indicates that reactivation of the cell cycle and DNA duplication (e.g., Yang et al., 
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and trisomy 21 mosaic individuals.  
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present in the cells of AD patients (reviewed in Potter, 2004). For instance, the mitotic 
spindles in dividing AD cells exhibit abnormalities and susceptibility to premature 
centromere division (PCD) and micronucleation upon chemically induced (e.g., colchicines) 
microtubule damage (e.g., Fitzgerald et al., 1986; Potter et al., 1995; Trippi et al., 2001). The 
event of PCD, in which individual sister chromatids are separated by a clear gap and not 
connected at the centromeres, has been observed in patients prone to genomic instability 
and chromosome mis-segregation, and recently confirmed in neurons of individuals with 
sporadic AD (Spremo-Potparević et al., 2008).  
Further evidence linking cell cycle defects with AD pathogenesis came for the finding that 
both APP and the microtubule-stabilizing tau protein get increasingly phosphorylated 
during mitosis (Suzuki et al., 1994; Pope et al., 1994; Padmanabhan et al., 2011). Also, 
phospho-tau and other mitosis-specific phospho-proteins are overexpressed in AD but not 
in normal brains (e.g., Arendt et al., 1996; Vincent et al., 1996; Nagy et al., 1997), indicating a 
cycling stage of AD neurons. The idea of unscheduled cycle in fully differentiated neurons 
challenged the dogma of their post-mitotic nature and the inability to replicate (Rakic, 1985). 
To date, the evidence drawn from animal models of AD and autopsy studies of human 
brains indicates that reactivation of the cell cycle and DNA duplication (e.g., Yang et al., 
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2001) in the vulnerable population of AD neurons may present a fundamental initiator of 
AD pathogenesis (Nagy, 2005; Vincent et al., 1996; Varvel et al., 2008; Yang & Herrup, 2007; 
Yang et al., 2006) present before deposition of fibrilar Aβ and neuronal death, and could also 
lead to chromosome mis-segregation and aneuploidy.  
3. Presenilin and APP mutations induced aneuploidy  
The finding that fibroblast cultures from patients carrying autosomal dominant mutations in 
the PS1, PS2 or APP gene harbour chromosomal instability and trisomy 21 mosaicism 
provided the first indication that FAD genes are likely to be involved in mitosis and 
chromosome mis-segregation, or to be associated with structures and proteins of the cell 
cycle (Geller & Potter, 1999).  
Indeed, we and others have confirmed a major location of PS1 and PS2 proteins in dividing 
cells in the centromeres, the nuclear envelope, and the kinetochores during interphase (Li et 
al., 1997; Honda et al., 2000). Further support for a mitotic function of presenilins comes 
from studies showing inhibition of the cell cycle (Janicki & Montero, 1999) and increased 
sensitivity to apoptosis (Vito et al., 1996; Wolozin et al., 1996) in the cells carrying a mutated 
PS gene. Furthermore, polymorphisms in the PS1 gene have been associated with an 
increased risk of AD (Wragg et al., 1996; Higuchi et al., 1996; Scott et al., 1996) and with an 
increase of DS offspring via a meiosis II defect (Petersen et al., 2000; Lucarelli et al., 2004) as 
a more direct confirmation of PS1 involvement in the cell cycle.  
Further research should be directed at discovering the mechanism by which the mutant 
presenilins influence chromosome segregation. One possibility supported by the data 
collected so far points to inability of altered presenilin proteins to properly link the 
chromosomes to the nuclear envelope and to release them at the appropriate time during 
mitosis, which may lead to chromosome mis-segregation and other cell cycle abnormalities. 
Another possibility discussed further below links PS mutations to altered processing of APP 
and increased production of neurotoxic Aβ42 as a likely effector molecule responsible for 
cell cycle defects, including mitotic spindle abnormalities and chromosome mis-segregation 
(Boeras et al., 2008; Borysov et al., 2011, Granic et al., 2010). Similarly, APP is also found to 
localize to the centrosomes and nuclear membrane in dividing cells (Nizzari et al., 2007; 
Zitnik et al., 2006), and to get increasingly phosphorylated during the cell cycle 
(Padmanabhan et al., 2011).  
In a series of in vivo and in vitro experiments we investigated the role of mutated PS1 and 
APP genes and their proteolytic product, the Aβ peptide in chromosome mis-segregation 
and trisomy 21 mosaicism. All assays, tissues and cells from transgenic mice carrying AD 
mutations and the cells transfected with FAD genes or treated with Aβ peptide yielded 
comparable results: overexpression of FAD genes in vivo and in vitro and exposure to Aβ 
peptide induced chromosome instability and trisomy 21 mosaicism through several defects 
in mitotic spindle apparatii and dysfunction of microtubule assembly (Boeras et al., 2008; 
Borysov et al., 2011; Granic et al., 2010; Potter et al., 2008).   
3.1 Presenilin and APP mutations induced aneuploidy in transgenic mice  
We asked whether chromosome mis-segregation and trisomy 21 mosaicism observed in 
human fibroblasts with PS1 or APP mutations could be mimicked in peripheral and brain 
tissues of FAD-transgenic mice. For example, whole brains from PS1 (M146l and M146V) 
and APP (V717) mutant mice and non-transgenic littermates were processed to yield 
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primary cultures.  The isolated neurons were hybridized with a mouse chromosome 16 BAC 
probe (Kulnane et al., 2002), followed by immunocytochemistry to stain for neurons. Most 
cells were disomic with two copies of chromosome 16; while the neurons from PS1 mutant 
and PS1 knock in mice exhibited up to 4% of trisomy 16 (data not shown, Boeras et al, 2008), 
the APP-transgenic mice had about 6.5% of trisomies (Figure 2, Granic et al., 2010). 
  
 
Fig. 2. Quantitative FISH analysis revealed significantly higher levels of trisomy 16 in APP 
mice (A & B) compared to controls but no tetrasomy (D) and no induction of aneuploidy in 
non-neuronal cells (C). (Used with permission from Granic et al., 2010, Molecular Biology of 
the Cell). 
3.2 Presenilin and APP mutations induced aneuploidy in transfected cells   
To determine whether the aneuploidy observed in FAD-transgenic and knock-in mice was 
caused directly by mutated genes and not by some other factors, parallel cultures of the 
hTERT-HME1, an immortalized primary mammary epithelial cell line with a stable 
karyotype (Clontech) were transiently transfected with WT-PS1, mutant PS1 (M146L), 
mutant APP (K595N/M596L and V642I or V717) and control empty vector (pcDNA3 and 
paG3). FISH was used to assess the levels of aneuploidy for chromosome 21 and 12. 
Overexpression of FAD-genes induced between 2-3% of trisomy 21 and/or trisomy 12 
(Boeras et al., 2008; Granic et al., 2010), and about 30% of total aneuploidy in metaphase cells 
within 48 hours (Boeras et al., 2008). These results indicated that an aneugenic effect of FAD-
mutations likely affected all chromosomes with random gains and losses of whole 
chromosomes, and that chromosome mis-segregation was not restricted only to the cells 
expressing mutated genes, but extended to nearby, non-transfected cells. We hypothesized 
that Aβ peptide itself found at increased levels in both familial and sporadic AD might be 
the probable effector molecule interfering with mitosis and chromosome segregation (Boeras 
et al., 2008; Potter, 2008). Lastly, immunocytochemistry of PS1-transfected cells revealed 
several abnormalities in the mitotic spindles, with disarrayed microtubules, multiple 
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expressing mutated genes, but extended to nearby, non-transfected cells. We hypothesized 
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several abnormalities in the mitotic spindles, with disarrayed microtubules, multiple 
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centosomes and lagging chromosomes as the most prominent spindle malformations 
(Boeras et al., 2008).  
3.3 Aβ induced aneuploidy and the role of tau  
Sequential cleavage of the APP protein with β- and presenilin/γ-secretase enzymes yields 
more amyloidogenic Aβ42 peptide as a central event in AD pathogenesis. We proposed to 
test the role of Aβ in genomic instability and trisomy 21 induction. Led by our initial 
observation that more cells became aneuploid than are transfected and express FAD genes, 
we examined the aneugenic effect of Aβ peptide in culture. hTERT-HME cells treated with 
1μM Aβ40 and Aβ42 develop more than 20% aneuploid metaphases and about 2% trisomy 
21  and 12 cells within the 48 hours of exposure compared to 6% and less than 1% of the cells 
treated with various control peptides (Figure 3, Granic et al., 2010). These results indicated 
that AD might be a self-propagating disorder in which the product of FAD mutations and 
trisomy 21, the Aβ peptide, further induces chromosome segregation and generation of 
trisomy 21 cells.  
 
 
Fig. 3. Quantitative FISH analysis with a dual color probe revealed an increased induction of 
trisomy 21 (SpectrumOrange, Vysis) and trisomy 12 (SpectrumGreen) in Aβ treated hTERT-
HME cells (A-C). (Used with permission from Granic et al., 2010, Molecular Biology of the 
Cell).  
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To investigate the mechanism by which Aβ exerts its aneugenic effect on dividing cells, we 
analyzed the peptide’s other toxic activities especially those related to microtubule function. 
Several lines of investigation have indicated that Aβ induces and requires downstream 
changes/defects in microtubules (MT) to exert its neurodegenerative activity. Numerous in 
vitro and in vivo studies have shown that Aβ induces phosphorylation of tau (e.g., Small & 
Duff, 2008), and that Aβ toxicity depends on the presence of tau (Rappaport et al., 2002). 
Therefore, we investigated the role of tau in Aβ induced aneuploidy. Splenocytes prepared 
from normal, Tau+/-, Tau -/- mice were treated with Aβ peptide and analyzed for 
aneuploidy 48 hours later. Knocking out one or even more effectively both copies of Tau 
induced up to 5% aneuploidy (trisomy 16). However, the Aβ aneugenic effect was greatly 
attenuated in the cells lacking Tau but not in normal cells, indicating that Aβ induced 
chromosome mis-segregation requires tau protein and disrupts normal tau-stabilizing 
microtubule function. In a series of studies, Borysov et al. (2011) have shown that Aβ42 
peptide  added to Xenopus egg extracts impairs the structure and stability of mitotic 
spindles, and inhibits three motor kinesins, Eg5, KIF4A, and MCAK, required for normal 
mitotic spindle function and proper chromosome segregation.  
Recently, we have shown that overexperssion of APP prevents the localization of low 
density lipoprotein receptor (LDLR) from the Golgi to the cell membrane (Abisambra et al., 
2010).  This latest finding led us to hypothetize that neurons exposed to Aβ in AD brains 
may also fail to localize other key receptors to the cell membrane, including those for 
neurotrophins and neurotransmitters, causing neuronal disfunction and dementia. Future 
studies are under way to confirm if the interference with microtubule function by Aβ will 
cause defects in neuroplasticity through mis-localization of the receptors away from the 
plasma membrane, as well as contributing to defective neurogenesis leading to 
dysfunctional, aneuploid, including trisomy 21 neurons prone to Aβ overproduction and 
neurodegeneration.  
4. How trisomy 21 mosaicism may lead to Alzheimer’s disease  
Several potential mechanisms could explain how trisomy 21 mosaicism could lead to AD 
(Potter, 1991; 2004; 2008). For instance, aneuploidy cells might be prone to cell death and 
neurodegeneration (Arendt et al., 2010), similar to cortical neurons in DS brains that 
undergo spontaneous apoptosis (Busciglio & Yankner, 1997). Apoptosis could also 
indirectly affect APP processing and Aβ levels in mosaic AD brain. The support for the 
latter hypothesis comes from the finding that embryonic DS brains and adult sera contain a 
higher ratio of neurotoxic Aβ42 over Aβ40 peptide (Teller et al., 1996). Also, trisomy 21 
microglia overexpress inflammatory proteins and begin an inflammatory cascade that 
promotes Aβ fibrilization (Potter et al., 2001). Finally, aneuploidy in AD may arise from a 
defect in microtubule function which may lead to poor protein, neurotransmitters and 
nutrient trafficking (Cash et al., 2003). Trisomy 21 may be both a cause and an effect of 
microtubule dysfunction generating a feed-forward loop further promoting AD progression. 
5. Implications of the trisomy 21 model of Alzheimer’s disease for diagnosis 
and therapy  
The mechanistic implication of the results discussed in this review is that an early step in 
Alzheimer’s disease pathogenesis may be the development of genomic instability and 
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trisomy 21, contributing to progression of dementia. The search for more effective diagnoses 
should take into account the events of mitotic defects in peripheral and central tissues of 
individuals at risk. Chromosome analysis and detection of low levels of trisomy 21 in skin 
fibroblasts or buccal cells in patients during the pre-clinical phase of dementia could be a 
potential diagnostic test.  Another implication of the data presented above that trisomy 21 in 
AD may be the initiating event in disease pathogenesis also suggests new approaches to 
treatments (Potter, 2004). For example, drugs that would repair the mitotic defects and 
strengthen the fidelity of the chromosome segregation could be searched for and used 
prophylactically. Further, aneugenic environmental agents that cause chromosome 
instability could be identified and counteracted with drugs that restore genomic 
homeostasis. Another more difficult but equally effective approach to therapy would be to 
detect and remove mis-segregated cells from the body by exploiting their unique cell 
biology and/or gene expression.  
To summarize, the results from several laboratories over the past twenty years have shown 
that Alzheimer’s patients are prone to genomic instability accumulating about  2-3 fold more 
trisomy 21 cells throughout the body compared to age matched healthy controls. The precise 
mechanism by which these abnormal cells arise during the life span of an individual and 
how or whether they contribute to disease initiation and progression are subjects of active 
investigation. The better understanding of these novel findings has the potential to 
contribute to the development of future diagnoses and therapies for Alzheimer’s disease.    
6. Summary  
Convincing epidemiological and molecular evidence has been accumulating that link 
pathological changes observed in the brains of both Down syndrome individuals and 
neurodegeneration in Alzheimer’s disease to chromosomal instability and trisomy 21 
mosaicism. The results from several laboratories indicate that errors in mitosis, specifically 
mis-segregation of somatic chromosomes in peripheral and brain tissues of AD patients may 
play an important role in both early (familial) and late (sporadic) onset of disease. Here, we 
proposed a unifying hypothesis for Alzheimer’s and Down syndrome neurodegeneration—
development of a mosaic population of aneuploid, including trisomy 21 cells and alternation 
in genomic stability may lead to classic AD neuropathology observed in both diseases. The 
evidence for this hypothesis include: a) cells from familial and sporadic AD patients exhibit 
mis-segregated, including trisomy 21 cells in brain, blood, mucosa and skin, and harbour 
abnormalities in several aspects of the cell cycle that may contribute to aneuploidy and 
neurodegeneration; b) overexpression of mutated Alzheimer’s genes, presenilin 1 and APP, 
in cellular and transgenic mouse models induce aneuploidy, including trisomy 21; and c) Aβ 
peptide is the likely effector molecule responsible for disruption of proper functioning of 
microtubules and mitotic spindle integrity leading to mitotic defects and apoptosis.  The 
possibility that many cases of Alzheimer’s disease are mosaic for trisomy 21 opens new 
approaches for diagnosis and therapy.    
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trisomy 21, contributing to progression of dementia. The search for more effective diagnoses 
should take into account the events of mitotic defects in peripheral and central tissues of 
individuals at risk. Chromosome analysis and detection of low levels of trisomy 21 in skin 
fibroblasts or buccal cells in patients during the pre-clinical phase of dementia could be a 
potential diagnostic test.  Another implication of the data presented above that trisomy 21 in 
AD may be the initiating event in disease pathogenesis also suggests new approaches to 
treatments (Potter, 2004). For example, drugs that would repair the mitotic defects and 
strengthen the fidelity of the chromosome segregation could be searched for and used 
prophylactically. Further, aneugenic environmental agents that cause chromosome 
instability could be identified and counteracted with drugs that restore genomic 
homeostasis. Another more difficult but equally effective approach to therapy would be to 
detect and remove mis-segregated cells from the body by exploiting their unique cell 
biology and/or gene expression.  
To summarize, the results from several laboratories over the past twenty years have shown 
that Alzheimer’s patients are prone to genomic instability accumulating about  2-3 fold more 
trisomy 21 cells throughout the body compared to age matched healthy controls. The precise 
mechanism by which these abnormal cells arise during the life span of an individual and 
how or whether they contribute to disease initiation and progression are subjects of active 
investigation. The better understanding of these novel findings has the potential to 
contribute to the development of future diagnoses and therapies for Alzheimer’s disease.    
6. Summary  
Convincing epidemiological and molecular evidence has been accumulating that link 
pathological changes observed in the brains of both Down syndrome individuals and 
neurodegeneration in Alzheimer’s disease to chromosomal instability and trisomy 21 
mosaicism. The results from several laboratories indicate that errors in mitosis, specifically 
mis-segregation of somatic chromosomes in peripheral and brain tissues of AD patients may 
play an important role in both early (familial) and late (sporadic) onset of disease. Here, we 
proposed a unifying hypothesis for Alzheimer’s and Down syndrome neurodegeneration—
development of a mosaic population of aneuploid, including trisomy 21 cells and alternation 
in genomic stability may lead to classic AD neuropathology observed in both diseases. The 
evidence for this hypothesis include: a) cells from familial and sporadic AD patients exhibit 
mis-segregated, including trisomy 21 cells in brain, blood, mucosa and skin, and harbour 
abnormalities in several aspects of the cell cycle that may contribute to aneuploidy and 
neurodegeneration; b) overexpression of mutated Alzheimer’s genes, presenilin 1 and APP, 
in cellular and transgenic mouse models induce aneuploidy, including trisomy 21; and c) Aβ 
peptide is the likely effector molecule responsible for disruption of proper functioning of 
microtubules and mitotic spindle integrity leading to mitotic defects and apoptosis.  The 
possibility that many cases of Alzheimer’s disease are mosaic for trisomy 21 opens new 
approaches for diagnosis and therapy.    
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Deficiency of Adult Neurogenesis in the Ts65Dn 
Mouse Model of Down Syndrome 
Pavel V. Belichenko and Alexander M. Kleschevnikov  
 University of California, San Diego, School of Medicine, La Jolla, California 
USA 
1. Introduction 
Neurogenesis in the mammalian adult brain is a well established phenomenon (for the 
recent reviews see Carpentier & Palmer, 2009; Kaneko & Sawamoto, 2009; Rodriguez & 
Verkhratsky, 2011) that is important in both young and aging brain (Galvan & Jin, 2007; Rao 
et al., 2006). The subventricular zone, subgranular layer of the dentate gyrus (DG), and 
cortex are the main sites of adult neurogenesis (Gould et al., 1999; Luskin & Boone, 1994; 
Palmer et al., 2000; Seki et al., 2007; Yoneyama et al., 2011). Newly-born neurons during 
adult neurogenesis have the ability to integrate into previously established neuronal 
networks (Kee et al., 2007; Markakis & Gage, 1999; Sandoval et al., 2011). Alteration of 
neurogenesis under different experimental and pathological conditions has been described 
to a great extent (Rodriguez & Verkhratsky, 2011; Sandoval et al., 2011; Winner et al., 2011; 
Yoneyama et al., 2011; Yu et al., 2009). Significant decreases of neurogenesis have been 
found in neurodevelopmental (Contestabile et al., 2007; Guidi et al., 2008, 2010) and in 
neurodegenerative diseases (Rodriguez & Verkhratsky, 2011).  Numerous studies provide 
evidence that a lack of neurogenesis significantly diminishes plasticity in the adult brain and 
interferes with learning and memory (reviewed in Koehl & Abrous, 2011; Mongiat & 
Schinder, 2011). Different mechanisms have been proposed to regulate neurogenesis in the 
adult brain, including brain injury (Kernie & Parent, 2010; Moriyama et al., 2011), ischemia 
(Kernie & Parent, 2010; Kreuzberg et al., 2010), and inflammation (Voloboueva et al., 2010). 
One of the least studied factors that affects neurogenesis are chromosomal aberrations. 
Down syndrome (DS) results from the extra copy of chromosome 21 occurring with a 
prevalence of 1 in 733 live births (Canfield et al., 2006).  Subjects with DS show 
developmental regression, diminished cognitive ability, and autonomic dysfunction 
(Antonarakis & Epstein, 2006; Chapman & Hesketh, 2000). The DS brain is severely affected 
showing a reduction in both overall size and of particular areas (frontal cortex, 
hippocampus, cerebellum, and brainstem) due to a reduced number of neurons (Aylward et 
al., 1997, 1999; Kesslak et al., 1994; Pinter et al., 2001; Raz et al., 1995; Wisniewski et al., 1984).   
1.1 Neurogenesis in subjects with DS  
Very little data is available describing neurognesis in subjects with DS. In hippocampal DG 
and neocortex of fetuses with DS the number of proliferating cells was found to be 
significantly reduced (Contestabile et al., 2007). These reductions were mainly due to a 
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1. Introduction 
Neurogenesis in the mammalian adult brain is a well established phenomenon (for the 
recent reviews see Carpentier & Palmer, 2009; Kaneko & Sawamoto, 2009; Rodriguez & 
Verkhratsky, 2011) that is important in both young and aging brain (Galvan & Jin, 2007; Rao 
et al., 2006). The subventricular zone, subgranular layer of the dentate gyrus (DG), and 
cortex are the main sites of adult neurogenesis (Gould et al., 1999; Luskin & Boone, 1994; 
Palmer et al., 2000; Seki et al., 2007; Yoneyama et al., 2011). Newly-born neurons during 
adult neurogenesis have the ability to integrate into previously established neuronal 
networks (Kee et al., 2007; Markakis & Gage, 1999; Sandoval et al., 2011). Alteration of 
neurogenesis under different experimental and pathological conditions has been described 
to a great extent (Rodriguez & Verkhratsky, 2011; Sandoval et al., 2011; Winner et al., 2011; 
Yoneyama et al., 2011; Yu et al., 2009). Significant decreases of neurogenesis have been 
found in neurodevelopmental (Contestabile et al., 2007; Guidi et al., 2008, 2010) and in 
neurodegenerative diseases (Rodriguez & Verkhratsky, 2011).  Numerous studies provide 
evidence that a lack of neurogenesis significantly diminishes plasticity in the adult brain and 
interferes with learning and memory (reviewed in Koehl & Abrous, 2011; Mongiat & 
Schinder, 2011). Different mechanisms have been proposed to regulate neurogenesis in the 
adult brain, including brain injury (Kernie & Parent, 2010; Moriyama et al., 2011), ischemia 
(Kernie & Parent, 2010; Kreuzberg et al., 2010), and inflammation (Voloboueva et al., 2010). 
One of the least studied factors that affects neurogenesis are chromosomal aberrations. 
Down syndrome (DS) results from the extra copy of chromosome 21 occurring with a 
prevalence of 1 in 733 live births (Canfield et al., 2006).  Subjects with DS show 
developmental regression, diminished cognitive ability, and autonomic dysfunction 
(Antonarakis & Epstein, 2006; Chapman & Hesketh, 2000). The DS brain is severely affected 
showing a reduction in both overall size and of particular areas (frontal cortex, 
hippocampus, cerebellum, and brainstem) due to a reduced number of neurons (Aylward et 
al., 1997, 1999; Kesslak et al., 1994; Pinter et al., 2001; Raz et al., 1995; Wisniewski et al., 1984).   
1.1 Neurogenesis in subjects with DS  
Very little data is available describing neurognesis in subjects with DS. In hippocampal DG 
and neocortex of fetuses with DS the number of proliferating cells was found to be 
significantly reduced (Contestabile et al., 2007). These reductions were mainly due to a 
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reduced number of cycling cells in S phase (Contestabile et al., 2007).  Both a reduction in 
neurogenesis and significantly higher incidence of apoptotic cell death in the hippocampal 
region of fetuses with DS has been noted (Guidi et al., 2008). Also, trisomy 21 significantly 
modify cell phenotypes producing higher numbers of cycling cells going to a glial 
phenotype and less cells expressing neuronal markers (Guidi et al., 2008). Detailed analysis 
of the consequences of both reduced neurogenesis and increased apoptosis in fetuses with 
DS, revealed a severe reduction in the volume and cell number of investigated brain areas 
(Guidi et al., 2008).  More recently, significant neurogenesis impairments were also revealed 
in the cerebellum of fetuses with DS (Guidi et al., 2010). However, apoptotic cell death was 
similar in the cerebellum in fetuses with DS vs. controls (Guidi et al., 2010). The differences 
between the levels of apoptosis in hippocampus vs. cerebellum in fetuses with DS points to 
different mechanisms for the reduced cell number in hippocampus and cerebellum in DS. 
For the hippocampus, a reduction of neurogenesis, increased apoptosis and changing cell 
phenotypes in favor of glia may underlie reduced cell number in fetuses with DS. As for the 
cerebellum, only a reduction in neurogenesis may be the main factor in decreased cerebellar 
volume in fetuses with DS.  
1.2 Neurogenesis in mouse models of DS 
Taking to account that this subject is very important for the neurobiology of DS, only a few 
papers addressed neurogenesis in mouse models of DS (Bianchi et al., 2010; Chakrabarti et 
al., 2007; Clark et al., 2006; Contestabile et al., 2007; Lorenzi & Reeves, 2006; Rueda et al., 
2005). It was noted that in prenatal and newborn Ts65Dn mice neurogenesis was 
significantly reduced (Chakrabarti et al., 2007; Contestabile et al., 2007; Lorenzi & Reeves, 
2006). At postnatal day 2 cell proliferation in Ts65Dn mice, assessed 2 hours after single 
injection of bromodeoxyuridine (BrdU) was significantly reduced (Contestabile et al., 2007);  
similar results were revealed at postnatal day 15 (Bianchi et al., 2010). However in young 
adult Ts65Dn mice the results are conflicting (Clark et al., 2006; Rueda et al., 2005). Similar 
procedures in young (3-5 months) Ts65Dn mice shows no difference in hippocampal cell 
proliferation and survival (Rueda et al., 2005). However, in aged (13-15 months) Ts65Dn 
mice, cell proliferation in the hippocampus (Rueda et al., 2005) and in the subventricular 
zone (Bianchi et al., 2010) were significantly reduced.  Finally, Clark et al. (2006) found a 
difference in DG neurogenesis in young (2-5 months) Ts65Dn mice.  
It seems that genetic dissections of mouse partial trisomy 16 (Ts65Dn model) did not restore 
reduced neurogenesis. Indeed, Ts1Cje and Ts2Cje mouse models of DS showed a similar 
degree of impairment in adult neurogenesis (Hewitt et al., 2010; Ishihara et al., 2010).  
To solve these conflicting results in DS mouse models a recent study was initiated to 
examine young adult neurogenesis, and we also expanded this study to include DG, cortex 
and corpus callosum (CC) at three different levels.  We chose to investigate whether or not 
trisomy has any affect on neurogenesis in Ts65Dn mice. To carry out this work we injected 
BrdU in 2N and Ts65Dn mice. Combining BrdU immunoreactivity and high resolution 
confocal microscopy, we examined the number of BrdU-positive (BrdU+) neurons in DG, 
cortex and CC at three different levels: rostral, middle and caudal. Comparing 2N and 
Ts65Dn mice, we discovered significant decreases in the density of BrdU+ cells in trisomic 
mice in the cortex and DG. We found that the number of cells per cluster was significantly 
reduced in both the rostral and the caudal parts of DG in the Ts65Dn vs. 2N. This change 
resulted in reduced cell density in the caudal DG, while the density of clusters was not 
 
Deficiency of Adult Neurogenesis in the Ts65Dn Mouse Model of Down Syndrome 
 
179 
altered. Our findings are evidence for decreased neurogenesis in young adult cortex and DG 
of Ts65Dn mice and indicate neurogenesis as a potential target for pharmacological 
intervention to avert neuronal plasticity in individuals with DS. 
2. Materials and methods 
All experiments were conducted in accordance with the National Institutes of Health 
guidelines for the care and use of animals and with an approved animal protocol from the 
Stanford University Institutional Animal Care and Use Committee. All efforts were made to 
minimize animal stress and discomfort. 
2.1 Mice husbandry 
Details of maintenance and using Ts65Dn mouse colony were described previously 
(Belichenko et al., 2004). The Ts65Dn mouse colony was maintained for more than 10 
generations by crossing B6EiC3Sn-Ts(1716)65Dn females (Jackson Laboratory, Bar Harbor, 
ME) with B6EiC3Sn F1/J A/a males (Jackson Laboratory). This breeding scheme was used 
because trisomic mice breed very poorly or not at all when inbred; the B6C3 background has 
been the most successful. To distinguish 2N from Ts65Dn mice, genomic DNA was 
extracted from tail samples.  A quantitative PCR protocol (provided by The Jackson 
laboratory) was used to measure Mx1 gene expression, which is present in three copies in 
Ts65Dn. Each mouse was genotyped twice. Male littermates mice were used in all studies at 
ages 2-3 months. 
2.2 BrdU injections and immunofluorescent staining 
In the beginning of experiment we weighed mice. Each animal was injected once a day for 6 
consecutive days with 5-bromo-2′-deoxyuridine (BrdU, 10 mg/ml in saline, i.p.) (Cat. # 
B9285, Sigma-Aldrich Corp., St. Louis, MO, USA) to a final dose of 50 mg/kg body weight. 
Twenty four hours after the last injection, animals were deeply anesthetized with sodium 
pentobarbital (200 mg/kg i.p.) (Abbott Laboratories, North Chicago, IL, USA), again 
weighed, and transcardially perfused for 1 minute with 0.9% sodium chloride (10 ml) and 
then for 20 minutes with 4% paraformaldehyde in 0.1 M phosphate-buffered saline (PBS), 
pH 7.4 (200 ml). After perfusion, the brain was immediately removed and postfixed for 
another 24 hours. The weight of the entire brain (including the olfactory bulbs, cerebellum, 
and brainstem along with the cervical spinal cord through C1–C2) was recorded. The brain 
was then sectioned coronally at 100-m with a Vibratome (series 1000, TPI Inc., St. Louis, 
MO, USA), and sections were placed in 0.9% NaCl solution. Immunofluorescence method 
with anti-BrdU antibody was used to reveal BrdU+ cells as follows. Free-floating sections 
were rinsed twice in saline (0.9 % NaCl) for 10 min at RT, and then pretreated with 1M HCl 
for 30 minutes at 37oC. Sections were neutralized by rinsing 3 times in PBS and then pre-
incubated in a solution of 0.1 M PBS containing 5% non-fat milk and 0.3% Triton-X 100 
(PBS+), for 1 hour at room temperature. Then sections were incubated overnight at 4oC with 
primary rat anti-BrdU antibody (Cat. #MCA2060, Serotec, Raleigh, NC, USA) at a dilution 
1:100 in PBS+. Sections were rinsed in PBS (20 minutes, three changes) and incubated for 1 
hour at room temperature with biotinylated donkey anti-rat IgG (1:200; Jackson 
ImmunoResearch Labs, West Grove, PA). After being rinsed with PBS (20 minutes, three 
changes), sections were incubated with FITC-conjugated streptavidin (1:500; Jackson 
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reduced number of cycling cells in S phase (Contestabile et al., 2007).  Both a reduction in 
neurogenesis and significantly higher incidence of apoptotic cell death in the hippocampal 
region of fetuses with DS has been noted (Guidi et al., 2008). Also, trisomy 21 significantly 
modify cell phenotypes producing higher numbers of cycling cells going to a glial 
phenotype and less cells expressing neuronal markers (Guidi et al., 2008). Detailed analysis 
of the consequences of both reduced neurogenesis and increased apoptosis in fetuses with 
DS, revealed a severe reduction in the volume and cell number of investigated brain areas 
(Guidi et al., 2008).  More recently, significant neurogenesis impairments were also revealed 
in the cerebellum of fetuses with DS (Guidi et al., 2010). However, apoptotic cell death was 
similar in the cerebellum in fetuses with DS vs. controls (Guidi et al., 2010). The differences 
between the levels of apoptosis in hippocampus vs. cerebellum in fetuses with DS points to 
different mechanisms for the reduced cell number in hippocampus and cerebellum in DS. 
For the hippocampus, a reduction of neurogenesis, increased apoptosis and changing cell 
phenotypes in favor of glia may underlie reduced cell number in fetuses with DS. As for the 
cerebellum, only a reduction in neurogenesis may be the main factor in decreased cerebellar 
volume in fetuses with DS.  
1.2 Neurogenesis in mouse models of DS 
Taking to account that this subject is very important for the neurobiology of DS, only a few 
papers addressed neurogenesis in mouse models of DS (Bianchi et al., 2010; Chakrabarti et 
al., 2007; Clark et al., 2006; Contestabile et al., 2007; Lorenzi & Reeves, 2006; Rueda et al., 
2005). It was noted that in prenatal and newborn Ts65Dn mice neurogenesis was 
significantly reduced (Chakrabarti et al., 2007; Contestabile et al., 2007; Lorenzi & Reeves, 
2006). At postnatal day 2 cell proliferation in Ts65Dn mice, assessed 2 hours after single 
injection of bromodeoxyuridine (BrdU) was significantly reduced (Contestabile et al., 2007);  
similar results were revealed at postnatal day 15 (Bianchi et al., 2010). However in young 
adult Ts65Dn mice the results are conflicting (Clark et al., 2006; Rueda et al., 2005). Similar 
procedures in young (3-5 months) Ts65Dn mice shows no difference in hippocampal cell 
proliferation and survival (Rueda et al., 2005). However, in aged (13-15 months) Ts65Dn 
mice, cell proliferation in the hippocampus (Rueda et al., 2005) and in the subventricular 
zone (Bianchi et al., 2010) were significantly reduced.  Finally, Clark et al. (2006) found a 
difference in DG neurogenesis in young (2-5 months) Ts65Dn mice.  
It seems that genetic dissections of mouse partial trisomy 16 (Ts65Dn model) did not restore 
reduced neurogenesis. Indeed, Ts1Cje and Ts2Cje mouse models of DS showed a similar 
degree of impairment in adult neurogenesis (Hewitt et al., 2010; Ishihara et al., 2010).  
To solve these conflicting results in DS mouse models a recent study was initiated to 
examine young adult neurogenesis, and we also expanded this study to include DG, cortex 
and corpus callosum (CC) at three different levels.  We chose to investigate whether or not 
trisomy has any affect on neurogenesis in Ts65Dn mice. To carry out this work we injected 
BrdU in 2N and Ts65Dn mice. Combining BrdU immunoreactivity and high resolution 
confocal microscopy, we examined the number of BrdU-positive (BrdU+) neurons in DG, 
cortex and CC at three different levels: rostral, middle and caudal. Comparing 2N and 
Ts65Dn mice, we discovered significant decreases in the density of BrdU+ cells in trisomic 
mice in the cortex and DG. We found that the number of cells per cluster was significantly 
reduced in both the rostral and the caudal parts of DG in the Ts65Dn vs. 2N. This change 
resulted in reduced cell density in the caudal DG, while the density of clusters was not 
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altered. Our findings are evidence for decreased neurogenesis in young adult cortex and DG 
of Ts65Dn mice and indicate neurogenesis as a potential target for pharmacological 
intervention to avert neuronal plasticity in individuals with DS. 
2. Materials and methods 
All experiments were conducted in accordance with the National Institutes of Health 
guidelines for the care and use of animals and with an approved animal protocol from the 
Stanford University Institutional Animal Care and Use Committee. All efforts were made to 
minimize animal stress and discomfort. 
2.1 Mice husbandry 
Details of maintenance and using Ts65Dn mouse colony were described previously 
(Belichenko et al., 2004). The Ts65Dn mouse colony was maintained for more than 10 
generations by crossing B6EiC3Sn-Ts(1716)65Dn females (Jackson Laboratory, Bar Harbor, 
ME) with B6EiC3Sn F1/J A/a males (Jackson Laboratory). This breeding scheme was used 
because trisomic mice breed very poorly or not at all when inbred; the B6C3 background has 
been the most successful. To distinguish 2N from Ts65Dn mice, genomic DNA was 
extracted from tail samples.  A quantitative PCR protocol (provided by The Jackson 
laboratory) was used to measure Mx1 gene expression, which is present in three copies in 
Ts65Dn. Each mouse was genotyped twice. Male littermates mice were used in all studies at 
ages 2-3 months. 
2.2 BrdU injections and immunofluorescent staining 
In the beginning of experiment we weighed mice. Each animal was injected once a day for 6 
consecutive days with 5-bromo-2′-deoxyuridine (BrdU, 10 mg/ml in saline, i.p.) (Cat. # 
B9285, Sigma-Aldrich Corp., St. Louis, MO, USA) to a final dose of 50 mg/kg body weight. 
Twenty four hours after the last injection, animals were deeply anesthetized with sodium 
pentobarbital (200 mg/kg i.p.) (Abbott Laboratories, North Chicago, IL, USA), again 
weighed, and transcardially perfused for 1 minute with 0.9% sodium chloride (10 ml) and 
then for 20 minutes with 4% paraformaldehyde in 0.1 M phosphate-buffered saline (PBS), 
pH 7.4 (200 ml). After perfusion, the brain was immediately removed and postfixed for 
another 24 hours. The weight of the entire brain (including the olfactory bulbs, cerebellum, 
and brainstem along with the cervical spinal cord through C1–C2) was recorded. The brain 
was then sectioned coronally at 100-m with a Vibratome (series 1000, TPI Inc., St. Louis, 
MO, USA), and sections were placed in 0.9% NaCl solution. Immunofluorescence method 
with anti-BrdU antibody was used to reveal BrdU+ cells as follows. Free-floating sections 
were rinsed twice in saline (0.9 % NaCl) for 10 min at RT, and then pretreated with 1M HCl 
for 30 minutes at 37oC. Sections were neutralized by rinsing 3 times in PBS and then pre-
incubated in a solution of 0.1 M PBS containing 5% non-fat milk and 0.3% Triton-X 100 
(PBS+), for 1 hour at room temperature. Then sections were incubated overnight at 4oC with 
primary rat anti-BrdU antibody (Cat. #MCA2060, Serotec, Raleigh, NC, USA) at a dilution 
1:100 in PBS+. Sections were rinsed in PBS (20 minutes, three changes) and incubated for 1 
hour at room temperature with biotinylated donkey anti-rat IgG (1:200; Jackson 
ImmunoResearch Labs, West Grove, PA). After being rinsed with PBS (20 minutes, three 
changes), sections were incubated with FITC-conjugated streptavidin (1:500; Jackson 
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ImmunoResearch Labs, West Grove, PA) for 1 hour at room temperature. Following further 
careful rinsing, the sections were mounted on microscope glass slides and coverslipped with 
90% glycerol in PB.  
2.3 Confocal microscopy imaging, cell quantification, cluster and statistical analyses 
To study cell proliferation and clustering in 2N and Ts65Dn mice we used confocal 
microscopy imaging of BrdU+ cells in the cortex, hippocampus and CC. Confocal imaging 
of brain slices labeled with one fluorophores was performed as previously described 
(Belichenko et al., 2004). In brief, slices with BrdU+ cells were examined and scanned in a 
Radiance 2000 confocal microscope (BioRad, Hertfordshire, United Kingdom) attached to a 
Nikon Eclipse E800 fluorescence microscope. LaserSharp software (Bio Rad) was used to 
establish optimal conditions for collecting images. The laser was an argon/krypton mixed 
gas laser with exciting wavelengths for FITC (488 ). The emission was registered with 
HQ515/30 “green” filter. Sections with FITC staining of BrdU immunoreactivity were 
studied under the following optimal conditions: the lens was a x10 objective (Nikon; Plan 
Fluor x10/0.30); laser power was 10%; the zoom factor was 1; scan speed was 500 lines per 
second; each optical section was the result of 3 scans followed by Kalman filtering; the size 
of the image was 512 x 512 pixels (i.e., 1208 x 1208 µm). 
LazerPix software (Bio Rad) analysis of confocal images was used to measure the area or 
length of investigated brain structures, and for quantitative analysis of BrdU+ cells. Three 
slices per mouse (500 m apart) were used. The location of each coronal section was 
designated based on its relative position to bregma in mm (Hof et al., 2000). Rostral section 
was corresponded to bregma -1.60 mm level, middle section – to bregma -2.10 mm level, 
and caudal section to bregma -2.60 mm level. Entire DG at these three different locations 
was imaged. CC was imaged from midline and then for 1200 m to the left or right 
extension at the same three different locations. Based on mouse brain atlas (Hof et al., 2000), 
cortex were correspondent to motor cortex at rostral and middle sections and to visual 
cortex at caudal section). Images from the both the left and right side for each mouse brain 
were analyzed. To count number of BrdU+ cells, we first outlined the area of interest and 
measure area or length (in a case of DG). Next, for each image, the intensity thresholds were 
estimated by analyzing the distribution of pixel intensities in the image areas that did not 
contain immunoreactivity. This value, the background threshold, was then subtracted and 
number of BrdU+ cells was counted. In addition each BrdU+ cells were traced manually and 
their XY coordinates were exported to Excel. The number of BrdU+ cell in each hemisphere 
was expressed for DG as per 100-m length of neurogenic subgranule zone, and for cortex 
and CC as per 1 mm2. We also counted the occurrence of BrdU+ cell clusters. To quantify 
the number of clusters we used previously established criteria (Palmer et al., 2000), where 
cluster was defined as a contiguous group of cells separated by less than 25 m. Special 
macro was design in Excel program for cluster counting.  For every section, X and Y 
coordinates of individual BrdU+ cell were recorded using LaserPix software (BioRad). 
Distance between all pairs of the BrdU+ cells within one section were calculated using an 
Excel Microsoft macro, and the cells with distances < 25 m were regarded as belonging to a 
cluster. All analyses were performed by the same investigator blinded to mice genotype. 
Digital images were imported, enhanced for brightness and contrast, assembled and labeled 
in Adobe Photoshop CS2 9.0.2, and archived. Figures were printed with a Phaser 7300 color 
printer (Tektronix by Xerox, Norwalk, CT). 
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The data for body and brain weights, total number of BrdU+ cells, their coordinates and 
cluster evaluations were exported to Excel (Microsoft, Redmond, WA) and statistical 
comparisons were performed using two-way analysis of variance (ANOVA) and for two 
samples using two-tailed Student’s t-tests. All results are expressed as mean ± SEM, and P 
values < 0.05 were considered to be significant.  
3. Results 
3.1 Body and brain weights 
The body weight of 2N and Ts65Dn mice at 2-3 months was similar (2N: 31.1  1.6 g, n = 6; 
Ts65Dn = 26.7  2.3 g, n = 5; P = 0.14). The brain weight was also unchanged (2N: 0.43  0.01 
g, n = 6; Ts65Dn = 0.43  0.01 g, n = 5; P =0.60). Of note, there was no effect of the BrdU 
injection on changes in  body weight during 6 day injections since no significant differences 
were found between 2N and Ts65Dn mice (2N: -0.60  0.29 g, n = 6; Ts65Dn = -0.20   0.51 g, 
n = 5; P =0.49). These mice also showed no aversive or any other neurological symptoms 
during injection. 
3.2 Changes in BrdU+ cells number and in cell cluster density in Ts65Dn mice 
We examined the density of BrdU+ cells in DG of hippocampus, cortex and CC in 2N and 
Ts65Dn male mice (Table 1, Figs. 1, 2). The BrdU+ cells were bright fluorescent, allowing for 
a detailed quantitative analysis by confocal microscopy (Figs. 1a, 2a). For this analysis, the 
number of BrdU+ cells per 100 m length of subgranule zone for DG or per 1 mm2 area of 
cortex or CC was counted to define cell density (Table 1).  In addition we measured the 
number of cell cluster, the number of BrdU+ cells per cluster and the frequency distribution 
of BrdU+ cells per cluster (Table 1; Figs. 1 d,e; 2 d,e).  
Comparing BrdU+ cell densities in 2N and Ts65Dn mice, there was a statistically significant 
decrease in the caudal part of DG (by 27%) and in the rostral part of motor cortex (by 36%; P 
< 0. 01; Table 1).  Interestingly, BrdU+ neurons in the inferior blade were on average 30% 
fewer than in the superior blade for 2N, and 23% fewer for Ts65Dn mice (P < 0.01; Table 1). 
BrdU+ cell density were similar for CC in 2N and Ts65Dn mice, and 33% more in caudal 
then rostral CC for 2N mice (P < 0.01; Table 1).  
Comparing BrdU+ cell cluster densities in 2N and Ts65Dn mice, there was a statistically 
significant decrease in the rostral part of motor cortex (by 29%; P < 0. 01; Table 1). In the 
inferior blade there were on average 9% fewer than in superior blade for 2N, and 25% fewer 
for Ts65Dn mice (P < 0.05; Table 1). Interestingly, in the DG the BrdU+ cell cluster density 
was not different in 2N and Ts65Dn mice (Table 1). 
We next quantified the number of cells per cluster (Table 1). As compared to 2N mice, 
significantly lower numbers of BrdU+ cells per cluster were present in rostral (mainly due to 
superior blade, P < 0.003; Table 1) and in the caudal part of DG in Ts65Dn mice (P = 0.03; 
Table 1), and in the rostral part of motor cortex in Ts65Dn mice (P < 0.01; Table 1). 
Comparing the superior and inferior blades in 2N mice, numbers of cells per cluster were 
~1.5 times higher in the rostral and middle parts of the superior blade of the DG in 2N mice 
(P < 0.02; Table 1).  
In conclusion, significant differences in the number of BrdU+ cells, cell cluster densities, and 
in number of BrdU+ cells per cluster were evident for Ts65Dn mice as compared to their 2N 
cohorts. These findings are evidence for reduced neurogenesis in both DG and cortex due to 
mouse chromosome 16 trisomy.  
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ImmunoResearch Labs, West Grove, PA) for 1 hour at room temperature. Following further 
careful rinsing, the sections were mounted on microscope glass slides and coverslipped with 
90% glycerol in PB.  
2.3 Confocal microscopy imaging, cell quantification, cluster and statistical analyses 
To study cell proliferation and clustering in 2N and Ts65Dn mice we used confocal 
microscopy imaging of BrdU+ cells in the cortex, hippocampus and CC. Confocal imaging 
of brain slices labeled with one fluorophores was performed as previously described 
(Belichenko et al., 2004). In brief, slices with BrdU+ cells were examined and scanned in a 
Radiance 2000 confocal microscope (BioRad, Hertfordshire, United Kingdom) attached to a 
Nikon Eclipse E800 fluorescence microscope. LaserSharp software (Bio Rad) was used to 
establish optimal conditions for collecting images. The laser was an argon/krypton mixed 
gas laser with exciting wavelengths for FITC (488 ). The emission was registered with 
HQ515/30 “green” filter. Sections with FITC staining of BrdU immunoreactivity were 
studied under the following optimal conditions: the lens was a x10 objective (Nikon; Plan 
Fluor x10/0.30); laser power was 10%; the zoom factor was 1; scan speed was 500 lines per 
second; each optical section was the result of 3 scans followed by Kalman filtering; the size 
of the image was 512 x 512 pixels (i.e., 1208 x 1208 µm). 
LazerPix software (Bio Rad) analysis of confocal images was used to measure the area or 
length of investigated brain structures, and for quantitative analysis of BrdU+ cells. Three 
slices per mouse (500 m apart) were used. The location of each coronal section was 
designated based on its relative position to bregma in mm (Hof et al., 2000). Rostral section 
was corresponded to bregma -1.60 mm level, middle section – to bregma -2.10 mm level, 
and caudal section to bregma -2.60 mm level. Entire DG at these three different locations 
was imaged. CC was imaged from midline and then for 1200 m to the left or right 
extension at the same three different locations. Based on mouse brain atlas (Hof et al., 2000), 
cortex were correspondent to motor cortex at rostral and middle sections and to visual 
cortex at caudal section). Images from the both the left and right side for each mouse brain 
were analyzed. To count number of BrdU+ cells, we first outlined the area of interest and 
measure area or length (in a case of DG). Next, for each image, the intensity thresholds were 
estimated by analyzing the distribution of pixel intensities in the image areas that did not 
contain immunoreactivity. This value, the background threshold, was then subtracted and 
number of BrdU+ cells was counted. In addition each BrdU+ cells were traced manually and 
their XY coordinates were exported to Excel. The number of BrdU+ cell in each hemisphere 
was expressed for DG as per 100-m length of neurogenic subgranule zone, and for cortex 
and CC as per 1 mm2. We also counted the occurrence of BrdU+ cell clusters. To quantify 
the number of clusters we used previously established criteria (Palmer et al., 2000), where 
cluster was defined as a contiguous group of cells separated by less than 25 m. Special 
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printer (Tektronix by Xerox, Norwalk, CT). 
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The data for body and brain weights, total number of BrdU+ cells, their coordinates and 
cluster evaluations were exported to Excel (Microsoft, Redmond, WA) and statistical 
comparisons were performed using two-way analysis of variance (ANOVA) and for two 
samples using two-tailed Student’s t-tests. All results are expressed as mean ± SEM, and P 
values < 0.05 were considered to be significant.  
3. Results 
3.1 Body and brain weights 
The body weight of 2N and Ts65Dn mice at 2-3 months was similar (2N: 31.1  1.6 g, n = 6; 
Ts65Dn = 26.7  2.3 g, n = 5; P = 0.14). The brain weight was also unchanged (2N: 0.43  0.01 
g, n = 6; Ts65Dn = 0.43  0.01 g, n = 5; P =0.60). Of note, there was no effect of the BrdU 
injection on changes in  body weight during 6 day injections since no significant differences 
were found between 2N and Ts65Dn mice (2N: -0.60  0.29 g, n = 6; Ts65Dn = -0.20   0.51 g, 
n = 5; P =0.49). These mice also showed no aversive or any other neurological symptoms 
during injection. 
3.2 Changes in BrdU+ cells number and in cell cluster density in Ts65Dn mice 
We examined the density of BrdU+ cells in DG of hippocampus, cortex and CC in 2N and 
Ts65Dn male mice (Table 1, Figs. 1, 2). The BrdU+ cells were bright fluorescent, allowing for 
a detailed quantitative analysis by confocal microscopy (Figs. 1a, 2a). For this analysis, the 
number of BrdU+ cells per 100 m length of subgranule zone for DG or per 1 mm2 area of 
cortex or CC was counted to define cell density (Table 1).  In addition we measured the 
number of cell cluster, the number of BrdU+ cells per cluster and the frequency distribution 
of BrdU+ cells per cluster (Table 1; Figs. 1 d,e; 2 d,e).  
Comparing BrdU+ cell densities in 2N and Ts65Dn mice, there was a statistically significant 
decrease in the caudal part of DG (by 27%) and in the rostral part of motor cortex (by 36%; P 
< 0. 01; Table 1).  Interestingly, BrdU+ neurons in the inferior blade were on average 30% 
fewer than in the superior blade for 2N, and 23% fewer for Ts65Dn mice (P < 0.01; Table 1). 
BrdU+ cell density were similar for CC in 2N and Ts65Dn mice, and 33% more in caudal 
then rostral CC for 2N mice (P < 0.01; Table 1).  
Comparing BrdU+ cell cluster densities in 2N and Ts65Dn mice, there was a statistically 
significant decrease in the rostral part of motor cortex (by 29%; P < 0. 01; Table 1). In the 
inferior blade there were on average 9% fewer than in superior blade for 2N, and 25% fewer 
for Ts65Dn mice (P < 0.05; Table 1). Interestingly, in the DG the BrdU+ cell cluster density 
was not different in 2N and Ts65Dn mice (Table 1). 
We next quantified the number of cells per cluster (Table 1). As compared to 2N mice, 
significantly lower numbers of BrdU+ cells per cluster were present in rostral (mainly due to 
superior blade, P < 0.003; Table 1) and in the caudal part of DG in Ts65Dn mice (P = 0.03; 
Table 1), and in the rostral part of motor cortex in Ts65Dn mice (P < 0.01; Table 1). 
Comparing the superior and inferior blades in 2N mice, numbers of cells per cluster were 
~1.5 times higher in the rostral and middle parts of the superior blade of the DG in 2N mice 
(P < 0.02; Table 1).  
In conclusion, significant differences in the number of BrdU+ cells, cell cluster densities, and 
in number of BrdU+ cells per cluster were evident for Ts65Dn mice as compared to their 2N 
cohorts. These findings are evidence for reduced neurogenesis in both DG and cortex due to 
mouse chromosome 16 trisomy.  
 












Fig. 1. Morphometry of BrdU+ cells in dentate gyrus in 2N and Ts65Dn mice. (a) Confocal 
image of BrdU+ cells in caudal part of dentate gyrus of  2N and Ts65Dn mice. BrdU+ cell 
density in superior (b) and inferior blades (c) of dentate gyrus. Note a significant reduction 
of BrdU+ cell in caudal DG in Ts65Dn mice. The number of cells per cluster in rostral (d) 
and caudal (e) part of DG. Scale bar = 50 m. 
 



















































Fig. 2. Neurogenesis in cortex in 2N and Ts65Dn mice. (a) Confocal image of BrdU+ cells in 
the rostral part of cortex of  2N and Ts65Dn mice. (b) BrdU+ cell density in cortex. Note 
significant reduction of BrdU+ cell in rostral cortex in Ts65Dn mice. (c) The number of cells 
per cluster in rostral part of cortex. Scale bar = 100 m. 
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Fig. 2. Neurogenesis in cortex in 2N and Ts65Dn mice. (a) Confocal image of BrdU+ cells in 
the rostral part of cortex of  2N and Ts65Dn mice. (b) BrdU+ cell density in cortex. Note 
significant reduction of BrdU+ cell in rostral cortex in Ts65Dn mice. (c) The number of cells 
per cluster in rostral part of cortex. Scale bar = 100 m. 
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      cell density cluster density         # cells per cluster 
   2N Ts65Dn 2N Ts65Dn 2N Ts65Dn 
Dentate gyrus         
 Rostral       
  Total 3.06 ± 0.27 2.87 ± 0.25 1.01 ± 0.08 1.22 ± 0.09 3.05 ± 0.22 2.39 ± 0.16a 
  
Superior 
blade 3.61 ± 0.29 3.13 ± 0.36 1.02 ± 0.11 1.25 ± 0.09 3.69 ± 0.29 2.47 ± 0.21a 
  
Inferior 
blade 2.55 ± 0.25b 2.55 ± 0.25 0.99 ± 0.08 1.19 ± 0.13 2.65 ± 0.29b 2.42 ± 0.37 
 Middle       
  Total 2.88 ± 0.17 2.77 ± 0.15 1.21 ± 0.05 1.17 ± 0.08 2.56 ± 0.20 2.52 ± 0.12 
  
Superior 
blade 3.33 ± 0.21 3.01 ± 0.17 1.23 ± 0.05 1.24 ± 0.09 3.01 ± 0.26 2.66 ± 0.12 
  
Inferior 
blade 2.28 ± 0.18b 2.46 ± 0.20c 1.19 ± 0.08 1.08 ± 0.14 1.96 ± 0.17b 2.51 ± 0.34 
 Caudal       
  Total 2.73 ± 0.19 2.00 ± 0.08a 1.13 ± 0.04 1.10 ± 0.08 2.59 ± 0.31 2.01 ± 0.12a 
  
Superior 
blade 3.09 ± 0.27 2.31 ± 0.12a 1.21 ± 0.07 1.22 ± 0.10 2.84 ± 0.27 1.69 ± 0.16a 
  
Inferior 
blade 2.20 ± 0.19b 1.55 ± 0.15a,c 1.10 ± 0.06b 0.92 ± 0.07c 2.21 ± 0.22 1.69 ± 0.16a 
Cortex       
 Rostral 21.1 ± 2.2 14.6 ± 1.4a 14.4 ± 1.4  10.2 ± 1.2a 1.46 ± 0.04 1.24 ± 0.05a 
 Middle 22.3 ± 2.9 19.5 ± 1.8 15.9 ± 1.5 14.9 ± 1.7 1.25 ± 0.03 1.22 ± 0.02 
 Caudal 25.0 ± 2.5 19.7 ± 2.7 14.9 ± 1.7 13.9 ± 1.7 1.30 ± 0.03 1.26 ± 0.04 
Corpus callosum       
 Rostral 74.7 ± 11.3 87.2 ± 12.6 56.7 ± 3.1 53.0 ± 5.6 1.15 ± 0.05 1.16 ± 0.03 
 Middle 96.1 ± 15.8 77.3 ± 13.4 64.1 ± 7.2 62.6 ± 7.6 1.28 ± 0.07 1.22 ± 0.03 
  Caudal 111.2 ± 11.8b 105.1 ± 16.1 73.8 ± 7.3 73.2 ± 9.4 1.36 ± 0.06 1.32 ± 0.04 
The number of mice used was as follows: 2N/Ts65Dn = 6/5.     
Each value represents the mean ± SEM.     
BrdU+ cells and clusters densities are expressed as: for FD per 100 m length of subgranule  zone, for 
cortex and CC per 1 mm2. 
a, P < 0.05, significantly different from 2N mice.     
b, P < 0.05, significantly different between 2N mice.    
c, P < 0.05, significantly different between Ts65Dn mice.    
Table 1. Morphometry of BrdU+ cells in 2N and Ts65Dn mice 
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4. Discussion  
Numerous studies have shown that adult neurogenesis is affected by various 
neurodegenerative diseases such as Alzheimer’s, Parkinson’s, and Huntington’s diseases 
(reviewed in Curtis et al., 2011; Kaneko & Sawamoto, 2009; Rodriguez & Verkhratsky, 2011; 
Winner et al., 2011). Alteration of neurogenesis in neurodevelopmental disorders were studied 
to a lesser extent in DS (Contestabile et al., 2007; Guidi et al., 2008, 2010), autism spectrum 
disorders (Greco et al., 2011; Wegiel et al., 2010), including Rett syndrome (Ronnett et al., 2003).   
Studies to understand the neurobiology of DS have benefited from the ability to examine 
mouse models of the disorder (Belichenko et al., 2004; 2007; 2009; Kleschevnikov et al., 2004; 
Popov et al., 2011). Previous studies demonstrated that trisomy in Ts65Dn mouse model of 
DS resulted in alteration of hippocampal long-term potentiation (LTP) (Kleschevnikov et al., 
2004; Siarey et al., 1997). Significant alteration of neurogenesis could be one of the 
contributing factors to diminished plasticity in DS. Interestingly, studies involving mice to 
different enrichments or pharmacotherapies enhanced both neurogenesis and learning 
(Deng et al., 2010; Mongiat & Schinder, 2011; Saxe et al., 2006; Shors et al., 2002; Singer at al., 
2011), including Ts65Dn mice (Bianchi et al., 2010). Moreover, manipulations that stimulate 
adult neurogenesis in mice also increase LTP (van Praag et al., 1999). 
Our study in the Ts65Dn mouse model of DS presents novel evidence of altered 
neurogenesis in adult young mice (2-3 months of age). Significant increases in the number of 
clusters containing single BrdU+ cells in Ts65Dn mice point to severely affected cell 
proliferation.  Our present data are in agreement with previous data (Clark et al., 2006) and 
conflicting with Rueda et al. (2005) data on young adult Ts65Dn mice. The discrepancy with 
the Rueda et al. (2005) results likely result from several factors including the different 
gender of mice (we used only male mice and no gender of studied mice were mentioned in 
Rueda et al., 2005), the different brain areas investigated (we studied rostral, middle, and 
caudal parts of hippocampus, cortex and CC separately, while in Rueda et al. (2005) the 
entire hippocampus was studied). The BrdU injection protocol was also different. We used 
standard a procedure with BrdU injection during 6 days, while Rueda et al., (2005) used a 12 
days injection approach. 
The majority of BrdU+ cells in adult brain during the proliferation phase formed clusters 
(Palmer et al., 2000; Seki et al., 2007). Data on neurogenesis in adult rat hippocampus 
suggests that newly-born cells appeared to stay in clusters for a few days and then migrate 
from clusters (Seki et al., 2007). Currently, little is known about the molecular mechanisms 
of cluster formation. Previous reports suggested that cell clustering supports intercellular 
contacts and/or signals that encourage neurogenesis (Seki et al., 2007). It is possible that the 
initial formation of a cluster is triggered by a certain factor, which is not affected in Ts65Dn 
mice. Thus, we have similar cluster density in Ts65Dn vs. 2N mice. The ‘just-divided’ cells 
could be divided further, thus resulting in a cluster (Seki et al., 2007). However, this could 
be only accomplished when the cell is going through all cycles. Indeed, as was shown 
previously (Contestabile et al., 2008) that the dividing in Ts65Dn cells are ‘stuck’ in S phase, 
thus decreasing the probability of cell cycle re-entry. This delay could suspend the second 
and the following divisions, thus resulting in a reduced number of the newly-born cells per 
cluster. Interestingly, we observed that the number of cells per cluster was reduced only in 
the rostral and caudal, but not in the middle part of the Ts65Dn hippocampus. The exact 
nature of this phenomenon is not clear yet, but may result from differences in the structure 
and function of hippocampus along the rostro-caudal axis. Indeed, neuronal network 
architecture is different in hippocampus (Witter et al., 2000). 
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initial formation of a cluster is triggered by a certain factor, which is not affected in Ts65Dn 
mice. Thus, we have similar cluster density in Ts65Dn vs. 2N mice. The ‘just-divided’ cells 
could be divided further, thus resulting in a cluster (Seki et al., 2007). However, this could 
be only accomplished when the cell is going through all cycles. Indeed, as was shown 
previously (Contestabile et al., 2008) that the dividing in Ts65Dn cells are ‘stuck’ in S phase, 
thus decreasing the probability of cell cycle re-entry. This delay could suspend the second 
and the following divisions, thus resulting in a reduced number of the newly-born cells per 
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the rostral and caudal, but not in the middle part of the Ts65Dn hippocampus. The exact 
nature of this phenomenon is not clear yet, but may result from differences in the structure 
and function of hippocampus along the rostro-caudal axis. Indeed, neuronal network 
architecture is different in hippocampus (Witter et al., 2000). 
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Reduction in the number of cells per cluster leads to a reduction of total number of newly-born 
neurons in the Ts65Dn hippocampus. It was shown previously that LTP in the DG depends 
strongly on neurogenesis, and that a blockade of neurogenesis results in reduced synaptic 
plasticity (Snyder et al., 2001). Because we observed that LTP in the DG of Ts65Dn mice is 
significantly diminished (Kleschevnikov et al., 2004), it is tempting to assume that reduced 
neurogenesis is one of the factors contributing to this abnormality. It is clear that alteration in 
prenatal growth of the cortex and hippocampus in trisomic mice is due to a longer cell cycle 
and reduced neurogenesis (Chakrabarti et al., 2007; Contestabile et al., 2007).  
We further propose that alteration of neurogenesis may also affect the balance between 
excitation and inhibition. Indeed, the putative young neurons are completely unaffected by 
GABA(A) inhibition (Wang et al., 2000). Reduced number of such disinhibited neurons in 
DG of Ts65Dn mice could thus result in elevation of the overall efficiency of the inhibitory 
system (Belichenko et al., 2009; Kleschevnikov et al., 2004). The excitatory/inhibitory neuron 
ratio could be affected also in other bran regions. The new granule cells of the DG, olfactory 
bulb, and cerebellum and the new cells in cortex are constantly produced during adult 
neurogenesis. However, there are many differences between these cells. For example, in the 
olfactory bulb and neocortex the newly-born cells are mainly inhibitory (GABAergic) 
(reviewed in Cameron & Dayer, 2008). Reduced neurogenesis in these regions could result 
in relative disinhibition and, thus, could be regarded as a factor contributing to epilepsy in 
DS (Goldberg-Stern et al., 2001; Menendez, 2005; Pueschel et al., 1991).  In contrast, DG and 
cerebellar granule cells are excitatory (glutamatergic). However, this question needs to be 
studied in greater detail. The influence of chromosomal aberration on the transition from 
proliferating stage to differentiated stage into either glutamatergic or GABA-ergic neurons 
should be also studied.  
Numerous factors can be implicated in the control of adult neurogenesis, including 
chromosomal aberrations. Although the exact mechanism(s) of influence of partial or 
complete trisomy on neurogenesis is not known, we can extract some data from the 
scattered information. Impaired neurogenesis has been described not only in Ts65Dn 
(Rueda et al., 2005; Clark et al., 2006; Lorenzi and Reeves, 2006; Constestabile et al., 2007; 
Chakrabarti et al., 2007; Bianchi et al., 2010) and Ts2Cje (Ishihara et al., 2010) mouse models 
of DS, but also in TsCje1 mice (Hewitt et al., 2010; Ishihara et al., 2010) with smaller 
triplicated chromosomal region. Genetic dissection approaches (Ts65Dn vs. Ts1Cje) point 
out to the same genes in smaller triplicated region, i.e. Itsn1, Dyrk1A, Olig2 may involve in 
neurogenesis (Hewitt et al., 2010; Ishihara et al., 2010). It has been proposed that 
overexpressions of Dyrk1A in trisomic segment may be responsible for impaired 
neurogenesis in Ts65Dn, Ts2Cje, and Ts1Cje mouse models of DS (Canzonetta et al., 2008; 
Ishihara et al., 2010). These authors also suggest that altered neurogenesis in the Ts1Cje 
mouse is due to a reduction in neuronal progenitors and neuroblasts rather than neural stem 
cells (Hewitt et al., 2010). The further identification and characterization of triplicated genes 
in altered neurogenesis may significantly contribute to understanding the neurobiology of 
DS and may lead to the development of pharmacotherapy for DS.   
5. Conclusion 
Down syndrome (DS) is a neurodevelopmental disorder caused by the triplication of 
chromosome 21.  Few studies have explored neurogenesis in mouse models of DS and these 
have produced conflicting results on the alteration of neurogenesis. Using confocal 
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microscopy analysis we have examined adult neurogenesis in the hippocampus (dentate 
gyrus, DG), motor cortex and corpus callosum (CC) of male wild-type (2N) and Ts65Dn 
mice at age 2-3 months. In Ts65D we found significant decreases in the BrdU+ cells density 
in DG and motor cortex. BrdU+ cell cluster density were higher in rostral motor cortex in 
Ts65Dn. Number of BrdU+ cells per cluster were significantly lower in DG and motor cortex 
of Ts65Dn mice, mainly due to the presence of single cell clusters. Density of BrdU+ cells 
was significantly lower in the inferior than in the superior blade of DG. Thus, we show for 
the first time a lower density of BrdU+ cells in Ts65Dn mice. Our findings are evidence on a 
deficiency of adult neurogenesis in Ts65Dn mouse model of DS. Moreover, we propose a 
correlation of the present data with our previously published data on alteration of LTP due 
to excessive inhibition in Ts65Dn mouse model of DS. The new findings can shed light on 
possible mechanisms underlying the changes in the Ts65Dn neurogenesis, synaptic 
structure and function that were described previously.  Based on our data and recent studies 
we reasonable suggested that new complex therapies should improve neurogenesis, and as 
consequence also learning and memory.  
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strongly on neurogenesis, and that a blockade of neurogenesis results in reduced synaptic 
plasticity (Snyder et al., 2001). Because we observed that LTP in the DG of Ts65Dn mice is 
significantly diminished (Kleschevnikov et al., 2004), it is tempting to assume that reduced 
neurogenesis is one of the factors contributing to this abnormality. It is clear that alteration in 
prenatal growth of the cortex and hippocampus in trisomic mice is due to a longer cell cycle 
and reduced neurogenesis (Chakrabarti et al., 2007; Contestabile et al., 2007).  
We further propose that alteration of neurogenesis may also affect the balance between 
excitation and inhibition. Indeed, the putative young neurons are completely unaffected by 
GABA(A) inhibition (Wang et al., 2000). Reduced number of such disinhibited neurons in 
DG of Ts65Dn mice could thus result in elevation of the overall efficiency of the inhibitory 
system (Belichenko et al., 2009; Kleschevnikov et al., 2004). The excitatory/inhibitory neuron 
ratio could be affected also in other bran regions. The new granule cells of the DG, olfactory 
bulb, and cerebellum and the new cells in cortex are constantly produced during adult 
neurogenesis. However, there are many differences between these cells. For example, in the 
olfactory bulb and neocortex the newly-born cells are mainly inhibitory (GABAergic) 
(reviewed in Cameron & Dayer, 2008). Reduced neurogenesis in these regions could result 
in relative disinhibition and, thus, could be regarded as a factor contributing to epilepsy in 
DS (Goldberg-Stern et al., 2001; Menendez, 2005; Pueschel et al., 1991).  In contrast, DG and 
cerebellar granule cells are excitatory (glutamatergic). However, this question needs to be 
studied in greater detail. The influence of chromosomal aberration on the transition from 
proliferating stage to differentiated stage into either glutamatergic or GABA-ergic neurons 
should be also studied.  
Numerous factors can be implicated in the control of adult neurogenesis, including 
chromosomal aberrations. Although the exact mechanism(s) of influence of partial or 
complete trisomy on neurogenesis is not known, we can extract some data from the 
scattered information. Impaired neurogenesis has been described not only in Ts65Dn 
(Rueda et al., 2005; Clark et al., 2006; Lorenzi and Reeves, 2006; Constestabile et al., 2007; 
Chakrabarti et al., 2007; Bianchi et al., 2010) and Ts2Cje (Ishihara et al., 2010) mouse models 
of DS, but also in TsCje1 mice (Hewitt et al., 2010; Ishihara et al., 2010) with smaller 
triplicated chromosomal region. Genetic dissection approaches (Ts65Dn vs. Ts1Cje) point 
out to the same genes in smaller triplicated region, i.e. Itsn1, Dyrk1A, Olig2 may involve in 
neurogenesis (Hewitt et al., 2010; Ishihara et al., 2010). It has been proposed that 
overexpressions of Dyrk1A in trisomic segment may be responsible for impaired 
neurogenesis in Ts65Dn, Ts2Cje, and Ts1Cje mouse models of DS (Canzonetta et al., 2008; 
Ishihara et al., 2010). These authors also suggest that altered neurogenesis in the Ts1Cje 
mouse is due to a reduction in neuronal progenitors and neuroblasts rather than neural stem 
cells (Hewitt et al., 2010). The further identification and characterization of triplicated genes 
in altered neurogenesis may significantly contribute to understanding the neurobiology of 
DS and may lead to the development of pharmacotherapy for DS.   
5. Conclusion 
Down syndrome (DS) is a neurodevelopmental disorder caused by the triplication of 
chromosome 21.  Few studies have explored neurogenesis in mouse models of DS and these 
have produced conflicting results on the alteration of neurogenesis. Using confocal 
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microscopy analysis we have examined adult neurogenesis in the hippocampus (dentate 
gyrus, DG), motor cortex and corpus callosum (CC) of male wild-type (2N) and Ts65Dn 
mice at age 2-3 months. In Ts65D we found significant decreases in the BrdU+ cells density 
in DG and motor cortex. BrdU+ cell cluster density were higher in rostral motor cortex in 
Ts65Dn. Number of BrdU+ cells per cluster were significantly lower in DG and motor cortex 
of Ts65Dn mice, mainly due to the presence of single cell clusters. Density of BrdU+ cells 
was significantly lower in the inferior than in the superior blade of DG. Thus, we show for 
the first time a lower density of BrdU+ cells in Ts65Dn mice. Our findings are evidence on a 
deficiency of adult neurogenesis in Ts65Dn mouse model of DS. Moreover, we propose a 
correlation of the present data with our previously published data on alteration of LTP due 
to excessive inhibition in Ts65Dn mouse model of DS. The new findings can shed light on 
possible mechanisms underlying the changes in the Ts65Dn neurogenesis, synaptic 
structure and function that were described previously.  Based on our data and recent studies 
we reasonable suggested that new complex therapies should improve neurogenesis, and as 
consequence also learning and memory.  
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Dermatological Manifestations  
of Down Syndrome 
Dominguez-Cruz JJ and Bueno Delgado MA 
Virgen del Rocío Universitary Hospital, Sevilla 
Spain 
1. Introduction 
Down syndrome (DS) is increased frequency of some common dermatoses and associated 
with rare dermatological disorders. With the increasing life span and number of DS patients 
in the population, dermatologists are more likely to encounter skin manifestations 
associated with DS. Subjects with DS have high rates of infections and autoimmune 
phenomena. The immunological disturbances in DS (High IgG and low IgM levels, reduced 
total T-lymphocyte numbers, high CD8+ and low CD4+ count, decreased chemotaxis,…) 
could be implicated in some higher cutaneous manifestations.   
In this chapter, it has been exposed the dermatological disorders associated with DS. Very 
few studies in the literature have studied dermatological manifestations of DS. Newer 
reports are mostly in the form of case reports highlighting the rare dermatological findings. 
Dermatologic manifestation in DS has been studied in 6 major surveys but the results are 
not concordant. These studies differ in some aspects (age range, living conditions of the 
study group,...). Daneshpazhooh et al studied 100 children with DS with a mean age of 11.2 
years; Carter and Jegasothy examined 213 institutionalized patients with ages between 12 
and 48 years old; Ercis et al studied 71 children who live with their families; Polenghi et al 
observed adults with ages between 14 and 53 years old; Schepis et al examined 203 patients 
from infancy till adulthood with a mean age of 11.7 years; and  Sureshbabu et al  studied 95 
patients with a mean age of 11.9 years, ranging from 6 months to 40 years. 
These dermatologic disorders can be separated in manifestations that could be, or not, 
associated to immunological alterations (Table 1). 
 









Milia-like calcinosis cutis 
Acanthosis nigricans 
Syringomas elastosis perforans serpiginosa 
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2. Dermatological manifestations that could be associated to immunological 
alterations 
2.1 Atopic dermatitis 
Atopic dermatitis (AD) is a chronic inflammatory skin condition that appears to involve a 
genetic defect in the proteins supporting the epidermal barrier. AD affects approximately 5-
20% of children worldwide. The incidence of AD appears to be increasing. Onset tends to 
occur during childhood and gradually diminishes with age, although it can persist or even 
appear in adults. The term AD was coined by Wise and Sulzberger in 1933 to define an 
entity characterized by dry skin, pruritus, erythematous lesions, and a chronic recurrent 
course. Currently, the terms AD and atopic eczema are used and both are acceptable. 
Its prevalence has increased 3-fold or 4- fold in recent decades in some countries. According 
to the International Study of Asthma and Allergies in Childhood, during a minimum period 
of 1 year, the prevalence of symptoms of AD in 6- or 7-year-old children presented great 
variability between different geographic areas. Thus, prevalence was almost 20% in England 
or Australia but less than 2% in China or Iran. There is a higher prevalence in urban areas 
than in rural ones in developed countries, and higher social classes are more affected.  
Regarding the disease by sex, a study of 12- to 16-year-olds found a higher prevalence 
among girls (25.7%) than among boys (17%). The onset of AD occurred during the first 6 
months of life in 45% of children, in the first year in 60%, and in the first 5 years in more 
than 85%. 
One study diagnosed AD in 56.5% of DS, and another a prevalence of more than 50%. The 
high reported prevalence of AD, in some studies, could be an overestimate and isolated 
signs such as facial dermatitis and generalized xerosis could easily be misinterpreted as AD.  
Pathogenesis of AD is complex; several factors are involved, many of which are still not well 
understood. Likewise, it has yet to be determined how these factors might interact with one 
another origin of atopic eczema seems to involve a feedback cycle: pruritus and mechanical 
damage caused by scratching leads to the production of proinflammatory cytokines 
(interleukin [IL]-1, IL-18, tumor necrosis factor, granulocyte-macrophage colony stimulating 
factor) that recruit leukocytes to the skin. 
Different leukocyte populations are activated through different processes; on induction by 
dendritic cells, the lymphocytes differentiate via the Th2 pathway; these dendritic cells also 
show increased antigen-presenting capacity and bind to the IgE-antigen complex. The IgE 
antigen complex in turn induces mast cell accumulation and activation. The activated Th2 
cells release IL-4 and IL-13, which suppress the production of antimicrobial peptides. 
Viruses, bacteria, and fungi take advantage of these reduced peptide levels, colonizing the 
skin and releasing proinflammatory products (superantigens, proteoglycans, and 
lipoteichoic acid) that amplify leukocyte activation. This activation increases the release of 
inflammatory mediators, such as proteases and IL-31, which perpetuate pruritus.  
Increased prevalence of childhood AD in developed countries has led to the appearance of 
many theories on the possible involvement of environmental factors. Increases in the 
prevalence of allergic disease probably depend more on environmental factors than on other 
individual characteristics. 
The diagnosis of AD is based on a constellation of signs and symptoms. There is no 
laboratory "gold standard" for the diagnosis of AD. In a majority of the cases, the diagnosis 
is quite easy. Establishing firm diagnostic criteria for all forms of AD is difficult due to the 
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clinical and pathophysiological heterogeneity. Atopic individuals can also suffer from other 
dermatitis or dermatoses, and because every dermatitis in an atopic individual need not be 
AD. Hanifin and Rajka for the first time proposed a systematic approach toward the 
standardization of the diagnosis of AD by incorporating three major/basic and 23 minor 
features. They suggested that a diagnosis of AD can be established if 3 of the major and 3 of 







2. Typcial morphology and distribution: 
- Flexural lichenification or linearity in 
adults 
- Facial and extensor involvement in 
infants and children 
3. Chronic or chronically relapsing 
dermatitis 
4. Personal or family history of atopy 




2. Ichthyosis/palmar hyperlinearity/keratosis 
pilaris 
3. Immediate (type 1) skin test reactivity 
4. Elevated serum IgE 
5. Early age at onset 
6. Tendency toward cutaneous infections (esp. 
Staph. aureus and Herpes 
simplex)/impaired cell-mediated immunity 
7. Tendency toward nonspecific hand or foot 
dermatitis 
8. Nipple eczema 
9. Cheilitis 
10. Recurrent conjuntivitis 
11. Dennie-Morgan infraorbital folds 
12. Keratoconus 
13. Anterior subcapsular cataracts 
14. Orbital darkening 
15. Facial pallor/facial erythema 
16. Pityriasis alba 
17. Anterior neck folds 
18. Itch when sweating 
19. Intolerance to wool or lipid solvents 
20. Perifollicular accentuation 
21. Food intolerance 
22. Course influenced by 
environmental/emotional factors 
23. White dermographism/delayed blanch 
Table 2. Diagnostic criteria of Hanifin and Rajka Diagnosis of AD can be established if 3 of 
the major and 3 of the minor criteria are present 
In DS, the skin in infancy is usually soft, but soon becomes dry, thick, and rough, with 
patchy lichenification. The reported frequency of xerosis differs from 9.8 percent to 85 
percent in various studies. Sureshbabu et al observed disorders lichenification as the most 
common disorder, seen in 52.6% of DS patients, with a peak incidence in the 5-10 year age 
group. High incidence of AD reported by Carter et al (56.5%) and cited in some major review 
articles contrast with Sureshbabu et al study which none of subjects fulfilled the criteria of 
Hanifin and Rajka for AD.  Two studies observed 3% and 4.9% for the prevalence of AD in 
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DS using the criteria of Rajka and Hanifin, These results are in favour of the opinion that AD 
is not as common as previously thought when using the acknowledged diagnostic criteria of 
Rajka and Hanifin.  
In the treatment of AD, topical corticosteroids are considered the gold standard for 
assessment of other treatments. The potency and formulation employed depends on the area 
to be treated and the chronicity of the lesions. Areas with have undergone lichenification 
requiring stronger formulations. One application per day is sufficient, as treatment twice a 
day confers no advantage while increasing the likelihood of adverse reactions. Adverse 
reactions are well known and frequently overestimated by patients and their family 
members, even though the new formulations have a demonstrated lower risk of causing 
cutaneous atrophy than the older ones and that several studies have found a far lower 
incidence of local and systemic complications.  
Application of topical antibiotics in combination with corticosteroid therapy has advantages 
compared to topical corticosteroids. Fusidic acid appears to be the topical antibacterial 
treatment of choice, due to its low minimum inhibitory concentration and its good 
penetration. 
Topical calcineurin inhibitors have proven to be effective in the treatment of AD. Topical 
tacrolimus seems to have an efficacy similar to high-potency corticosteroids, whereas 
pimecrolimus is substantially weaker. Controlled pediatric studies have confirmed the 
superior efficacy of topical tacrolimus compared to pimecrolimus and hydrocortisone. There 
appear to be no significant differences between the response of children to concentrations of 
0.03% and 0.1%. Neither tacrolimus nor pimecrolimus cause cutaneous atrophy, but they 
can cause other adverse reactions such as local itching-burning sensation when being 
applied, which is an added discomfort for the skin of children with AD.  
Use of emollients is widely recognized as a basic measure in the treatment and prevention of 
flares of AD. It has been shown that their use in combination with topical corticosteroids 
accelerates healing and decreases the total dose of corticosteroids required to resolve the 
flare.  
Dietary restrictions have proven effective in the case of children with egg-specific IgE, but 
not for other foods which have the same effect. It seems reasonable to establish diets that 
avoid food proven to cause an allergic response using the radioallergosorbent test, although 
the most relevant test would be the challenge test, which in many cases cannot be 
performed. Psychological care is recommended to help deal with the emotional needs of 
patients with atopic dermatitis, and should be based on providing education and 
information on the clinical and preventable aspects of the disease. One study found that this 
type of intervention reduced anxiety scores. 
Short-course systemic corticosteroids are recommended to control acute flares of AD, taking 
into account that new flares are frequent after stopping treatment. Their long term use in 
children is not recommended. Little evidence exists to support using oral antihistamines in 
AD. Other systemic treatments to AD are: Cyclosporine A, azathioprine, interferon, light 
therapy or intravenous immunoglobulins. Biologic treatment has recently appeared in the 
field of dermatology and has shown some potential. 
2.2 Seborrhoeic dermatitis 
Seborrhoeic dermatitis (SD) is a common, chronic dermatoses of unknown aetiology, 
characterized by scaling and redness occurring primarily in the areas with the highest 
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concentration of sebaceous glands such as the scalp, face (mid-facial region), and certain 
areas of the trunk, such as the mid-thoracic and interscapular areas and the area around the 
buttocks. On the scalp, it generally appears first as small patches of scales, progressing to 
involve the entire scalp with exfoliation of excessive amounts of dry scales.  
It affects around 1% to 3% of the immunocompetent adult population, with a higher 
prevalence in men than women. Although it can appear at any age, the highest prevalence is 
observed in individuals aged 30 to 60 years and in the first 3 months of life in the infantile 
form of the disease. 
Clinically, the disease is characterized by erythema and flaking of the skin in the affected 
area. Lesions are well delimited, reddish, and covered with oily yellowish-white scales. 
On the scalp, in the milder form of the disease, the scales are small, dry, and whitish, and 
they detach easily and spontaneously in steady amounts. In the more severe form of the 
disease, plaques are observed that range in size from a few centimeters to areas covering a 
large part of the scalp; they are made up of thick dry scales. On the face they are found in 
the eyebrows, around the nose, at the edge of the scalp, and on the inner surface of the 
auricle. In the thorax, the lesions are rounded, well delimited, and reddish brown; they 
are located on the medial part of the chest and on the back, between the shoulder blades. 
All of these forms are associated with varying degrees of itching. In adults, the course of 
SD involves periods of remission and exacerbation, irrespective of the treatments 
administered. Outbreaks are common under conditions of emotional stress, fatigue, and 
depression. 
While the disease rarely causes serious complications, it always leads to a marked esthetic 
deterioration that leads to emotional and social difficulties for the affected individual. 
The etiology of seborrheic dermatitis is not fully understood but is known to involve various 
factors. Increased secretion by the sebaceous glands favours the development of 
microorganisms of the genus Malassezia, which are responsible for the symptoms.  
It appears more frequently in patients with neurological disorders such as Parkinson 
disease, in those suffering from depression, and in patients with AIDS. One study, by Carter 
and Jegasothy, found a 36% prevalence of SD in DS patients and another was found a 
similar prevalence (Ercis et 31%; mostly during the first year of life). SD was seen in 4.2% of 
DS by Sureshbabu et al. al. SD is commonly seen in patients with immunodeficiency. High 
prevalence of pityrosporum folliculitis in DS patients could have a pathogenic role. 
A diet rich in animal fats and lacking in vegetables, as well as alcohol consumption can also 
potentiate the appearance of lesions. Topical corticosteroids are the first choice treatment for 
SD.  Others drugs can currently be used to minimize the effects of this dermatologic disease: 
antifungals, keratolytics, tar or pyrithione derivatives, and selenium sulfate. Many of these 
treatments have been tested as both monotherapy and in combination. 
2.3 Alopecia areata 
Alopecia areata (AA) is a recurrent nonscarring type of hair loss that can affect any hair-
bearing area. Clinically, AA can manifest many different patterns. Although medically 
benign, AA can cause tremendous emotional and psychosocial distress in affected patients 
and their families.  
AA is a genetically determined, immune-mediated disorder of the hair follicle with an 
estimated lifetime risk of approximately 2%, making it one of the most common 
autoimmune diseases  
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AA is characterized by patchy hair loss on the scalp, which can eventually involve the entire 
scalp (alopecia totalis) or the entire body (alopecia universalis). The onset of the disease can be 
sudden, its progression is unpredictable, and it can be recurrent throughout life. It is 
thought that AA represents a breakdown in immune privelege with the subsequent unable 
to function of the hair follicle by T lymphocytes. AA has a deeply disturbing psychologic 
impact on affected individuals. It shows a spectrum of severity that ranges from patchy 
localized hair loss on the scalp to the complete absence of hair everywhere on the body. 
Treatment of AA may induce hair growth, but usually does not change the course of the 
disease. When treatment is stopped, hair loss recurs. Many patients with one or two small 
patches can be managed without treatment and with reassurance of the benign nature of the 
condition.  Treatment with topical and oral steroids, topical minoxidil, topical cyclosporine, 
and photo-dynamic therapy has been found no long-term benefit of these interventions. In 
patients with persistent hair loss and less than 50% scalp involvement, intralesional 
corticosteroid therapy is the first-line treatment. Patients with more than 50% hair loss can 
be treated with topical immunotherapy using diphenyl-cyclopropenone or squaric acid. 
Alopecia totalis and alopecia universalis have the worst prognosis, with fewer than 10% of 
patients recovering.  
AA occurs in approximately 0.1% of the general but a recognized association of AA with DS 
exists and it was reported between 20% to 1.4% prevalence.  Sureshbabu et al saw in 9.4% of 
DS with AA. Female predilection was observed by Carter and Jegasothy but not in other 
studies. AA was observed in 3% of DS patients in the study of Schepis et al, with the usual 
age of onset in middle childhood (5-10 years). AA, in DS patients, is usually severe and 
refractory to the standard treatments.  
2.4 Vitiligo 
Vitiligo is a hypopigmentation disorder where the loss of functioning melanocytes causes 
the appearance of white patches on the skin. It occurs when melanocytes, the cells 
responsible for skin pigmentation, die or are unable to function. The cause of vitiligo is 
unknown, but research suggests that it may arise from autoimmune, genetic, oxidative 
stress, neural, or viral causes. Vitiligo is an autoimmune disease characterized by 
melanocyte loss, which results in patchy depigmentation of skin and hair, and is associated 
with an elevated risk of other autoimmune diseases. It is a genetically complex disorder 
involving multiple susceptibility genes and unknown environmental triggers. Recent data 
provide strong evidence supporting an autoimmune pathogenesis of vitiligo. Genetic factors 
also appear to play a role in the etiopathogenesis of vitiligo as 20% to 30% of patients have a 
family history of the disorder. Vitiligo is associated with other autoimmune diseases 
(Addison´s disease, hyperthyroidism and pernicious anemia). 
Vitiligo affects 1% of the world population, but the prevalence has been reported as high as 
4% in some South Asian, Mexican and American populations. Vitiligo can develop at any 
age, but several studies report that 50% of cases appear before the age of 20 years old. Only 
one study investigated the association between vitiligo and DS found a prevalence of 1.9%.  
75% of this also had AA. However, Sureshbabu et al did not observed an incidence 
significantly higher in DS people. 
Flat areas of normal-feeling skin without any pigment appear suddenly or gradually. These 
areas have a darker border. The edges are well defined but irregular. Vitiligo most often 
affects the face, elbows and knees, hands and feet, and genits. It affects both sides of the 
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body equally. Vitiligo is more noticeable in darker-skinned people because of the contrast of 
white patches against dark skin. No other skin changes occur. Sometimes, the use of Wood's 
light can improve to see lesions. In some cases, a skin biopsy may be needed to rule out 
other causes of pigment loss. 
Vitiligo is difficult to treat. As vitiligo can have a major effect on quality of life, treatment 
can be considered and should preferably begin early when the disease is active. Current 
treatment modalities are directed towards stopping progression of the disease and 
achieving repigmentation. Therapies include corticosteroids, topical immunomodulators, 
phototherapy, surgery, combination therapies and depigmentation of normall pigmented 
skin. Topical corticosteroids can be used for localized vitiligo. The use of topical 
immunomodulators seems to be equally effective as topical steroids, especially when used 
in the face and neck region. Narrowband ultraviolet-B therapy seems to be superior to 
psoralen ultraviolet-A. Depigmentation therapy can be considered if vitiligo affects more 
than 60% to 80% of the body. 
2.5 Onychomycosis 
Onychomycosis is one of the most prevalent fungal infections in the population with a 
higher rate of treatment failures. Onychomycosis is a frequent nail disease caused by 
dermatophytes, yeasts, and nondermatophyte molds. Trichophyton rubrum, T mentagrophytes, 
and Epidermophyton floccosum are the most common etiologic agents worldwide.  
Onychomycosis may be classified into several types: distal subungual, white superficial, 
proximal subungual, endonyx, and total dystrophic. Distal subungual onychomycosis, the 
most common type, involves the nail bed and, subsequently, the nail plate. White superficial 
onychomycosis usually manifests as superficial white patches with distinct edges on the 
surface of the nail plate. Proximal subungual onychomycosis results when the fungal 
organism enters via the cuticle and the ventral aspect of the proximal nail fold. In endonyx 
onychomycosis, fungal organisms invade the nail plate without resulting nail bed 
hyperkeratosis, onycholysis, or nail bed inflammatory changes. In total dystrophic 
onychomycosis, complete dystrophy of the nail plate occurs; these changes may be primary 
or secondary. 
Diagnosis is corroborated by direct microscopic examination, culture, and histomycology. 
Treatment is based on oral antifungals. Systemic treatment for onychomycosis includes 
terbinafine, an allylamine that is primarily fungicidal, and itraconazole, a triazole that is 
primarily fungistatic. Both represent a major therapeutic advancement over griseofulvin in 
the treatment of this condition. 
For toenail infection, terbinafine is usually taken continuously for 12 weeks, whereas 
itraconazole is taken either continuously or intermittently that is 1 week in 4 weeks for the 
same period. Because therapeutic concentration of itraconazole is believed to persist in the 
nail for a considerable time after systemic treatment is stopped, intermittent therapy with 
higher daily doses to achieve and maintain therapeutic concentration might be an effective 
alternative to continuous treatment. 
Such intermittent treatment is widely used currently to treat onychomycosis and is claimed 
to be as effective for this condition as both continuous itraconazole and continuous 
terbinafine 
Although both itraconazole and terbinafine are well tolerated and highly effective drugs, 
continuous terbinafine is more effective than intermittent itraconazole at achieving 
mycological cure of toenail onychomycosis. 
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There is a higher frequency of onychomycosis in DS patients. It has been reported 
prevalence of 67,8% to 4,4%. A low incidence of infection was seen in Sureshbabu et al study 
in contrast to Carter et al who reported a high prevalence of fungal infections. Schepis et al 
also reported a relatively low figure for onychomycosis and tinea corporis. Fungal infections 
may have been over diagnosed in the past or may be caused by poor hygienic conditions.  
2.6 Scabies 
Scabies (caused by Sarcoptes scabiei) is probably one of the most common parasitic infections, 
usually spread by bodily contact, though other contaminated objects can also infect. There is 
severe itching, usually worse at night, with lesions (mostly excoriated burrows) on the 
fingerwebs, volar wrists, buttocks, Scabies is an infestation caused by human itch mite, 
Sarcoptes scabiei, which infests some 300 million persons each year and is one of the most 
common causes of itching dermatoses throughout the world. Gravid female mite measuring 
0.3 to 0.4 mm in length burrows superficially beneath the stratum corneum for a month, 
depositing two or three eggs a day. Nymphs that hatch from these eggs mature in about 2 
weeks through a series of molts and then emerge as adults to the surface of the skin, where 
they mate and subsequently reinvade the skin of the same or another host. Transfer of 
newly fertilized female mites from person to person occurs by intimate personal contact and 
is facilitated by crowding, uncleanliness and sexual promiscuity. 
The most commonly used to treatment scabies is permethrin 5% cream which applied all 
over the body. The whole family or sexual partners of infected people should be treated, 
even if they do not have symptoms. Creams are applied as a one-time treatment or they may 
be repeated in 1 week. Wash underwear, towels, and sleepwear in hot water. Vacuum the 
carpets and upholstered furniture. For difficult cases, oral Ivermectin 200-400 μgr/Kg may 
be used. 
Other creams include benzyl benzoate, sulfur in petrolatum, and crotamiton. Lindane is 
rarely used because of its side effects.  
Itching may continue for 2 weeks or more after treatment begins, but it will disappear if the 
infection is over. 
Patients with DS seem predisposed to crusted scabies.  Immunological dysfunction has been 
proposed as one factor for this propensity. However, Norwegian scabies can appear as 
isolated or epidemic conditions but no cases were recorded in some studies 
3. Other dermatological manifestations that would not be associated to 
immunological alterations 
3.1 Anetoderma 
Anetoderma is a rare benign dermatosis caused by a loss of mid-dermal elastic tissue 
resulting in well-circumscribed areas of pouchlike herniations of flaccid skin. It has been 
hypothesized that a congenital malformation of elastic fibres in this population may be 
responsible for anetoderma. 
Sureshbabu et al observed anetoderma in 3.2% of DS. Schepis et al reported 3.9% of patients 
having anetoderma in their study. It has been hypothesized that a congenital malformation 
of elastic fibers in this population may be responsible for anetoderma secondary to chronic 
folliculitis. Anetoderma is due to elastolysis probably induced by leukocytes or bacteria 
during the recurrent inflammatory events 
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3.2 Milia-like calcinosis cutis 
Milia-like idiopathic calcinosis cutis (MICC) is a rare entity. Only few cases have been 
reported so far. Two-thirds of these have been associated with Down syndrome.  
MICC is a micronodular, whitish, acral, calcified lesion. Laboratory tests are usually within 
normal range (including serum calcium and phosphate, urinary calcium and parathyroid 
hormone). The term MICC was introduced in the literature by Smith et al who described a 6-
year-old child affected by DS. Some additional cases of MICC have been reported in 
children or adolescents affected by DS. 
Milia-like idiopathic calcinosis cutis has long been regarded as a peculiar subtype of 
idiopathic calcinosis cutis. The pathogenesis of the disorder remains unclear. The 
pathogenesis of MICC in association with DS is unclear. Higher concentrations of calcium in 
sweat have been found in DS, which may lead to sweat-duct calcification 
3.3 Acanthosis nigricans 
Acanthosis nigricans (AN) is a skin disorder in which there is darker, thick, velvety skin in 
body folds and creases. Obesity can lead to AN, as can some endocrine disorders. It is often 
found in people with obesity-related diabetes Some drugs, particularly hormones such as 
human growth hormone or oral contraceptives, can also cause AN. Because AN usually 
only changes the skin's appearance, no treatment is needed. It is important, however, to 
treat any underlying medical problem that may be causing these skin changes. When AN is 
related to obesity, losing weight often improves the condition. 
AN was seen by Sureshbabu et al in 8,4% of DS. The increased incidence of AN in adults is 
more than in children, but this fact may be attributed to the fact that all these patients were 
obese with a high BMI (> 30). 
3.4 Elastosis perforans serpiginosa 
Elastosis perforans serpiginosa (EPS) is characterized clinically by papules and keratotic 
plaques and histologically by focal elastosis of the dermis and transepidermal elimination of 
abnormal elastic fibers. It is a rare skin disease classified as a primary perforating 
dermatosis similar to reactive perforating collagenosis. It was given the current 
denomination of EPS  by Dammert and Putkonen. 
The incidence of EPS has yet to be established, although looks like higher in DS people. 
Around 90% of patients develop symptoms of the disease prior to 30 years of age, the 
majority between 6 and 20 years of age; however, age at onset may range from 5 to 89 years, 
as reported in the literature. Approximately 75% of those affected are male.  
Etiopathogenesis is as yet unclear. It is believed that the focal inflammation in the dermis, 
which has a biochemical or mechanical origin, may induce the formation of epidermal and 
follicular channels to expulse abnormal elastic fibers considered irritants.  
The disorder can present with papules and erythematous or normochromic, keratotic, 
asymptomatic or pruriginous plaques grouped in an annular, arciform or serpiginous 
pattern, surrounded by satellite lesions. They have umbilicated centers from which dermal 
material is eliminated. The lesions are characteristically symmetrical except in cases 
associated with DS. 
Various forms of treatment have been indicated; however, management of the disease is 
difficult and there is no standard treatment. There have been reports of therapeutic success 
using cryotherapy with liquid nitrogen and oral isotretinoin. 
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There is a higher frequency of onychomycosis in DS patients. It has been reported 
prevalence of 67,8% to 4,4%. A low incidence of infection was seen in Sureshbabu et al study 
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may have been over diagnosed in the past or may be caused by poor hygienic conditions.  
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having anetoderma in their study. It has been hypothesized that a congenital malformation 
of elastic fibers in this population may be responsible for anetoderma secondary to chronic 
folliculitis. Anetoderma is due to elastolysis probably induced by leukocytes or bacteria 
during the recurrent inflammatory events 
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It also has been reported higher prevalence of other skin alterations I DS patients: 
syringomas, leukaemia cutis, acrocyanosis and cutis marmorata, keratodermatoses… 
However, none all studies have observed them; for example Sureshbabu et al did not see 
syringoma, milia-like calcinosis cutis, leukemia cutis, elastosis perforans serpiginosa, 
carotenemia, or vascular instability; they referred that may relate to the fact that their study 
was not hospital based, unlike other previous studies. Other miscellaneous cutaneous 
lesions were probably coincidentally seen in the studies, concordant with that seen in the 
general population.  
4. Conclusions 
DS is increased frequency of some common dermatoses. Some dermatologic manifestation 
in DS can been in relation with their immunological alterations. Skin alterations of DS have 
been observed by few studies. Their management is equal to rest patient, but they can 
occasionally be more resistant to conventional treatment, for example AA.   
AD is one of the most frequent skin diseases associated a DS. However, perhaps this high 
association observed in first studies could be overestimated. Newer studies, which have 
used criteria of Hanifin and Rajka to diagnostic AD, does not show so higher incidence of 
AD in DS. SD can be more extensive than in other patients. 
Some immunologic skin diseases, as vitiligo and AA, have been reported with high 
incidence in DS. Also, fungal infection and scabies has been observed with higher 
prevalence in DS than rest population. However, scabies in DS could be overestimated in 
some studies with patients under epidemic conditions. 
MICC y EPS are rare skin alterations observed more frequently in DS. AN, frequently 
associated to overweight, can usually been observed in patients with IMC>30. Other 
miscellaneous cutaneous lesions were probably coincidentally seen in every study. 
5. References 
[1] Madan V, Williams J, Lear JT. Dermatological manifestations of Down’s syndrome. Clin 
Exp Dermatol. 2006 ;31:623-9. 
[2] Barankin B, Guenther L. Dermatological manifestations of Down’s syndrome. J Cutan 
Med Surg. 2001;5:289-93. 
[3] Ercis M, Balci S, Atakan N. Dermatologic manifestations of 71 Down syndrome children 
admitted to a clinical genetics unit. Clin Genet. 1996;50:317-20  
[4] Carter DM, Jegasothy BV. Alopecia areata and Down syndrome. Arch Dermatol. 
1976;112:1397-9. 
[5] Polenghi MM, Plattoni F, Orsini GB, et al. Dermatologic disorders in Down syndrome. 
Am J Med Genet 1990; 7:324. 
[6] Schepis C, Barone C, Siragusa M et al. An updated survey on skin conditions in Down 
syndrome. Dermatology 2002;205: 234-8. 
[7]  Daneshpazhooh M, Nazemi TM, Bigdeloo L, Yoosefi M. Mucocutaneous findings in 100 
children with Down syndrome. Pediatr Dermatol. 2007;24:317-20. 
[8] Liyanage S, Barnes J. The eye and Down's syndrome. British Br J Hosp Med. 2008;11:632-
4. 
 
Dermatological Manifestations of Down Syndrome 
 
205 
[9] Aase JM: The physical examination: Hands and feet - Minor variants; in Aase JM  
(ed): Diagnostic Dysmorphology. New York, Plenum Medical Book Co, 1990, p. 
236-237. 
[10] Valia RG, Valia AR., IADVL Textbook of dermatology, 2rd ed. Mumbai: Bhalani 
Publishing House, 2001. p. 121-122 
[11] Sureshbabu R, Kumari R, Ranugha S, Sathyamoorthy S, Udayashankar C, 
Oudeacoumar P.Phenotypic and dermatological manifestations in Down 
Syndrome. Dermatology Online Journal 2011;17:3  
[12] Zeligman I, Scalia SP. Dermatologic manifestations of mongolism. A M A Arch 
Dermatol Syphil 1954: 69: 342-344. 
[13] Pueschel SM. Clinical aspects of Down syndrome from infancy to adulthood. Am J 
Med Genet 1990; 7 (suppl):52-56. 
[14] Howells G. Down’s syndrome and the general practitioner. JR Coll Gen Pract 1989; 39: 
470-475. 
[15] Van Schrojensterin Lantman-de Valk HMJ, Haveman MJ, Crebolder HFJM. 
Comorbidity in people with Down’s syndrome: a criteria-based analysis. J Intellect 
Disabil Res 1996; 40:385-399. 
[16] Hanifin JM, Rajka G. Diagnostic features of atopic dermatitis. Acta Dermatol Venerol 
1980;92(Suppl.):44-47. 
[17] Scherbenske JM, Benson PM, Rotchford JP. Cutaneous and ocular manifestations of 
Down syndrome. J Am Acad Dermatol 1990; 22: 933-8. 
[18] Schepis C, Barone C, Siragusa M. Prevalence of atopic dermatitis in patients with 
Down syndrome: a clinical survey. J Am Acad Dermatol 1997; 36: 1019-21. 
[19] Hart RW, Setlow RB. Correlation between deoxyribonucleic acid excision-repair and 
life-span in a number of mammalian species. Proc Natl Acad Sci USA 1974; 71:2169-
73. 
[20] Butterworth T, Leoni EP, Beerman H, et al. Cheilitis of mongolism. J Invest Dermatol 
1960; 35:347-352. 
[21] Hatamochi A, Ueki H. Successful treatment of alopecia areata with 
dinitrochlorobenzene in a patient with Down’s syndrome. J Dermatol 1984; 11: 191-
3. 
[22] Freedberg IM, Eisen AZ, Wolff K, Austen KF, Goldsmith LA, Katz SI, editors. 
Fitzpatrick's dermatology in general medicine. 6th ed. New York: McGraw-Hill; 
2003. p. 1199 
[23] Bieber T. 1. Atopic dermatitis. N Engl J Med 2008; 358:1483–1494. 
[24] Levy RM, Gelfand JM, Yan AC. The epidemiology of atopic dermatitis. Clin Dermatol 
2003; 21: 109–115. 
[25] Cookson W. The immunogenetics of asthma and eczema: a new focus on the 
epithelium. Nat Rev Immunol 2004;4: 978–988. 
[26] Taïeb A. Hypothesis: from epidermal barrier dysfunction to atopic disorders. Contact 
Dermatitis 1999; 41: 177–180. 
[27] Halkjaer LB, Loland L, Buchvald FF, Agner T, Skov L,Strand M, et al. Development of 
atopic dermatitis during the first 3 years of life: the Copenhagen Prospective Study 
 




It also has been reported higher prevalence of other skin alterations I DS patients: 
syringomas, leukaemia cutis, acrocyanosis and cutis marmorata, keratodermatoses… 
However, none all studies have observed them; for example Sureshbabu et al did not see 
syringoma, milia-like calcinosis cutis, leukemia cutis, elastosis perforans serpiginosa, 
carotenemia, or vascular instability; they referred that may relate to the fact that their study 
was not hospital based, unlike other previous studies. Other miscellaneous cutaneous 
lesions were probably coincidentally seen in the studies, concordant with that seen in the 
general population.  
4. Conclusions 
DS is increased frequency of some common dermatoses. Some dermatologic manifestation 
in DS can been in relation with their immunological alterations. Skin alterations of DS have 
been observed by few studies. Their management is equal to rest patient, but they can 
occasionally be more resistant to conventional treatment, for example AA.   
AD is one of the most frequent skin diseases associated a DS. However, perhaps this high 
association observed in first studies could be overestimated. Newer studies, which have 
used criteria of Hanifin and Rajka to diagnostic AD, does not show so higher incidence of 
AD in DS. SD can be more extensive than in other patients. 
Some immunologic skin diseases, as vitiligo and AA, have been reported with high 
incidence in DS. Also, fungal infection and scabies has been observed with higher 
prevalence in DS than rest population. However, scabies in DS could be overestimated in 
some studies with patients under epidemic conditions. 
MICC y EPS are rare skin alterations observed more frequently in DS. AN, frequently 
associated to overweight, can usually been observed in patients with IMC>30. Other 
miscellaneous cutaneous lesions were probably coincidentally seen in every study. 
5. References 
[1] Madan V, Williams J, Lear JT. Dermatological manifestations of Down’s syndrome. Clin 
Exp Dermatol. 2006 ;31:623-9. 
[2] Barankin B, Guenther L. Dermatological manifestations of Down’s syndrome. J Cutan 
Med Surg. 2001;5:289-93. 
[3] Ercis M, Balci S, Atakan N. Dermatologic manifestations of 71 Down syndrome children 
admitted to a clinical genetics unit. Clin Genet. 1996;50:317-20  
[4] Carter DM, Jegasothy BV. Alopecia areata and Down syndrome. Arch Dermatol. 
1976;112:1397-9. 
[5] Polenghi MM, Plattoni F, Orsini GB, et al. Dermatologic disorders in Down syndrome. 
Am J Med Genet 1990; 7:324. 
[6] Schepis C, Barone C, Siragusa M et al. An updated survey on skin conditions in Down 
syndrome. Dermatology 2002;205: 234-8. 
[7]  Daneshpazhooh M, Nazemi TM, Bigdeloo L, Yoosefi M. Mucocutaneous findings in 100 
children with Down syndrome. Pediatr Dermatol. 2007;24:317-20. 
[8] Liyanage S, Barnes J. The eye and Down's syndrome. British Br J Hosp Med. 2008;11:632-
4. 
 
Dermatological Manifestations of Down Syndrome 
 
205 
[9] Aase JM: The physical examination: Hands and feet - Minor variants; in Aase JM  
(ed): Diagnostic Dysmorphology. New York, Plenum Medical Book Co, 1990, p. 
236-237. 
[10] Valia RG, Valia AR., IADVL Textbook of dermatology, 2rd ed. Mumbai: Bhalani 
Publishing House, 2001. p. 121-122 
[11] Sureshbabu R, Kumari R, Ranugha S, Sathyamoorthy S, Udayashankar C, 
Oudeacoumar P.Phenotypic and dermatological manifestations in Down 
Syndrome. Dermatology Online Journal 2011;17:3  
[12] Zeligman I, Scalia SP. Dermatologic manifestations of mongolism. A M A Arch 
Dermatol Syphil 1954: 69: 342-344. 
[13] Pueschel SM. Clinical aspects of Down syndrome from infancy to adulthood. Am J 
Med Genet 1990; 7 (suppl):52-56. 
[14] Howells G. Down’s syndrome and the general practitioner. JR Coll Gen Pract 1989; 39: 
470-475. 
[15] Van Schrojensterin Lantman-de Valk HMJ, Haveman MJ, Crebolder HFJM. 
Comorbidity in people with Down’s syndrome: a criteria-based analysis. J Intellect 
Disabil Res 1996; 40:385-399. 
[16] Hanifin JM, Rajka G. Diagnostic features of atopic dermatitis. Acta Dermatol Venerol 
1980;92(Suppl.):44-47. 
[17] Scherbenske JM, Benson PM, Rotchford JP. Cutaneous and ocular manifestations of 
Down syndrome. J Am Acad Dermatol 1990; 22: 933-8. 
[18] Schepis C, Barone C, Siragusa M. Prevalence of atopic dermatitis in patients with 
Down syndrome: a clinical survey. J Am Acad Dermatol 1997; 36: 1019-21. 
[19] Hart RW, Setlow RB. Correlation between deoxyribonucleic acid excision-repair and 
life-span in a number of mammalian species. Proc Natl Acad Sci USA 1974; 71:2169-
73. 
[20] Butterworth T, Leoni EP, Beerman H, et al. Cheilitis of mongolism. J Invest Dermatol 
1960; 35:347-352. 
[21] Hatamochi A, Ueki H. Successful treatment of alopecia areata with 
dinitrochlorobenzene in a patient with Down’s syndrome. J Dermatol 1984; 11: 191-
3. 
[22] Freedberg IM, Eisen AZ, Wolff K, Austen KF, Goldsmith LA, Katz SI, editors. 
Fitzpatrick's dermatology in general medicine. 6th ed. New York: McGraw-Hill; 
2003. p. 1199 
[23] Bieber T. 1. Atopic dermatitis. N Engl J Med 2008; 358:1483–1494. 
[24] Levy RM, Gelfand JM, Yan AC. The epidemiology of atopic dermatitis. Clin Dermatol 
2003; 21: 109–115. 
[25] Cookson W. The immunogenetics of asthma and eczema: a new focus on the 
epithelium. Nat Rev Immunol 2004;4: 978–988. 
[26] Taïeb A. Hypothesis: from epidermal barrier dysfunction to atopic disorders. Contact 
Dermatitis 1999; 41: 177–180. 
[27] Halkjaer LB, Loland L, Buchvald FF, Agner T, Skov L,Strand M, et al. Development of 
atopic dermatitis during the first 3 years of life: the Copenhagen Prospective Study 
 
Genetics and Etiology of Down Syndrome 
 
206 
on asthma in childhood cohort study in high-risk children. Arch Dermatol 2006; 
142: 561–566. 
[28] Wang CY, Lai CS, Chen GY, Cheng YW, Chen WC. Comparative analysis of the 
prevalence of atopic dermatitis in elementary schoolchildren in Kaohsiung and 
Penghu County. Dermatol Sinica 2006; 24: 94–101. 
[29] Lee YL, Li CW, Sung FC, Guo YL. Increasing prevalence of atopic eczema in Taiwanese 
adolescents from 1995 to 2001. Clin Exp Allergy 2007; 37: 543–551. 
[30] Lee YL, Li CW, Sung FC, Yu HS, Sheu HM, Guo YL. Environmental factors, parental 
atopy and atopic eczema in primary-school children: a cross-sectional study in 
Taiwan. Br J Dermatol 2007; 157: 1217–1224. 
[31] Kao CC, Huang JL, Ou LS, See LC. The prevalence, severity and seasonal variations of 
asthma, rhinitis and eczema in Taiwanese schoolchildren. Pediatr Allergy Immunol 
2005; 16: 408–415. 
[32] Vichyanond P, Sunthornchart S, Singhirannusorn V, Ruangrat S, Kaewsomboon S, 
Visitsunthorn N. Prevalence of asthma, allergic rhinitis and eczema among 
university students in Bangkok. Respir Med 2002; 96: 34–38. 
[33] Illi S, von Mutius E, Lau S, Nickel R, Gruber C, Niggemann B, et al. The natural course 
of atopic dermatitis from birth to age 7 years and the association with asthma. J 
Allergy Clin Immunol 2004; 113: 925–931. 
[34] Bousquet J, Van Cauwenberge P, Khaltaev N. Allergic rhinitis and its impact on 
asthma. J Allergy Clin Immunol 2001; 108: S147–334. 
[35] Arruda LK, Sole D, Baena-Cagnani CE, Naspitz CK. Risk factors for asthma and atopy. 
Curr Opin Allergy Clin Immunol 2005; 5: 153–159. 
[36] Gupta AK, Bluhm R, Cooper EA, Summerbell RC, Batra R. Seborrheic dermatitis. 
Dermatol Clin. 2003;21:401-12. 
[37]  Schwartz RA, Janusz CA, Janniger CK. Seborrheic dermatitis: an overview. Am Fam 
Physician. 2006;74:125-30. 
[38] Picardi A, Abeni D. Stressful life events and skin diseases: disentangling evidence from 
myth. Psychother Psychosom.2001;70:118-36. 
[39] Gupta AK, Nicol KA. Seborrheic dermatitis of the scalp: etiology and treatment. J 
Drugs Dermatol. 2004;3:155-8.  
[40] Mastrolonardo M, Diaferio A, Logroscino G. Seborrheic dermatitis, increased sebum 
excretion, and Parkinson’s disease: a survey of (im)possible links. Med Hypotheses. 
2003;60: 907-11. 
[41] Jones-Caballero M, Penas PF, García-Díez A, Badía X, Chren MM. The Spanish version 
of Skindex-29. Int J Dermatol. 2000;39:907-12. 
[42] Gupta AK, Bluhm R. Seborrheic dermatitis. JEADV. 2004;18:13-26. 
[43] Alkhalifah A, Alsantali A, Wang E, McElwee KJ, Shapiro J.Alopecia areata update: part 
II. Treatment. J Am Acad Dermatol. 2010:62:191-202. 
[44] Harries MJ, Sun J, Paus R, King LE Jr. Management of alopecia areata. BMJ. 2010; 23-41. 
[45] Friedli A, Harms M. Alopecia areata. Ther Umsch. 2002;59:233-7. 
[46] Alkhateeb A, Fain PR, Thody A, Bennett DC, et al. Epidemiology of vitiligo and 
associated autoimmune diseases in Caucasian probands and their families. Pigment 
cell res. 2003;16(3):208–214. 
 
Dermatological Manifestations of Down Syndrome 
 
207 
[47] Delamere FM, Sladden MM, Dobbins HM, Leonardi-Bee J. Interventions for alopecia 
areata. Cochrane Database Syst Rev. 2008 Apr 16;(2):CD004413. 
[48] Garg S, Messenger AG. Alopecia areata: evidence-based treatments. Semin Cutan Med 
Surg. 2009;28:15-8. 
[49] Gauthier Y, Cario Andre M, Taïeb A. A critical appraisal of vitiligo etiologic theories. Is 
melanocyte loss a melanocytorrhagy? Pigment Cell Res. 2003;16(4):322–332. 
[50] Esfandiarpour I, Ekhlasi A, Farajzadeh S, Shamsadini S. The efficacy of pimecrolimus 
1% cream plus narrow-band ultraviolet B in the treatment of vitiligo: A double-
blind, placebo-controlled clinical trial. J Dermatolog Treat. In press 2008. 
[51] 35. El Mofty M, Mostafa W, Esmat S. Narrow band Ultraviolet B 311 nm in the 
treatment of vitiligo: two right-left comparison studies. Photodermatol 
Photoimmunol Photomed. 2006;22(1):6–11. 
[52] Yones SS, Palmer RA, Garibaldinos TM, Hawk JL. Randomized double-blind trial of 
treatment of vitiligo: effi cacy of psoralen-UV-A therapy vs Narrowband-UV-B 
therapy. Arch Dermatol. 2007;143(5): 578–584. 
[53] Arca E, Tastan HB, Erbil AH, Sezer E, Koc E, Kurumlu Z. Narrow-band ultraviolet B as 
monotherapy and in combination with topical calcipotriol in the treatment of 
vitiligo. J Dermatol. 2006;33(5):338–343. 
[54] Passeron T, Ortonne JP. Use of the 308-nm excimer laser for psoriasis and vitiligo. Clin 
Dermatol. 2006;24(1):33–42 
[55] Hadi S, Tinio P, Al-Ghaithi K, et al. Treatment of vitiligo using the 308-nm excimer 
laser. Photomed Laser Surg. 2006;24(3):354–357. 
[56] Passeron T, Ostovari N, Zakaria W. Topical tacrolimus and the 308-nm excimer laser: a 
synergistic combination for the treatment of vitiligo. Arch Dermatol. 
2004;140(9):1065–1069. 
[57] Goldinger SM, Dummer R, Schmid P, et al. Combination of 308-nm xenon chloride 
excimer laser and topical calcipotriol in vitiligo. J Eur Acad Dermatol Venereol. 
2007;21(4):504–508. 
[58] Schepis C, Siragusa M. Secondary anetoderma in people with Down’s syndrome. Acta 
Derm Venereol 1999;79:245. 
[59] Gupta AK. Types of onychomycosis. Cutis. 2001 Aug;68:4-7. 
[60] Derby R, Rohal P, Jackson C, Beutler A, Olsen C. Novel treatment of onychomycosis 
using over-the-counter mentholated ointment: a clinical case series. J Am Board 
Fam Med. 2011;24:69-74. 
[61] Krob AH, Fleischer AB Jr, D'Agostino R Jr, Feldman SR.Terbinafine is more effective 
than itraconazole in treating toenail onychomycosis: results from a meta-analysis of 
randomized controlled trials. J Cutan Med Surg. 2003;7:306-11. 
[62] Trivedi NA, Shah PC. A meta-analysis comparing efficacy of continous terbinafine 
with intermittent itraconazole for yoenal onychomycosis. Indian J Dermatol. 2010; 
55: 198–199. 
[63] Gilmore SJ. Control strategies for endemic childhood scabies. PLoS One. 2011;6:e15990. 
[64] Schepis C, Siragusa M, Alberti A. Guess what! Milia-like idiopathic calcinosis cutis. 
Eur J Dermatol. 2000;10:637-8. 
 
Genetics and Etiology of Down Syndrome 
 
206 
on asthma in childhood cohort study in high-risk children. Arch Dermatol 2006; 
142: 561–566. 
[28] Wang CY, Lai CS, Chen GY, Cheng YW, Chen WC. Comparative analysis of the 
prevalence of atopic dermatitis in elementary schoolchildren in Kaohsiung and 
Penghu County. Dermatol Sinica 2006; 24: 94–101. 
[29] Lee YL, Li CW, Sung FC, Guo YL. Increasing prevalence of atopic eczema in Taiwanese 
adolescents from 1995 to 2001. Clin Exp Allergy 2007; 37: 543–551. 
[30] Lee YL, Li CW, Sung FC, Yu HS, Sheu HM, Guo YL. Environmental factors, parental 
atopy and atopic eczema in primary-school children: a cross-sectional study in 
Taiwan. Br J Dermatol 2007; 157: 1217–1224. 
[31] Kao CC, Huang JL, Ou LS, See LC. The prevalence, severity and seasonal variations of 
asthma, rhinitis and eczema in Taiwanese schoolchildren. Pediatr Allergy Immunol 
2005; 16: 408–415. 
[32] Vichyanond P, Sunthornchart S, Singhirannusorn V, Ruangrat S, Kaewsomboon S, 
Visitsunthorn N. Prevalence of asthma, allergic rhinitis and eczema among 
university students in Bangkok. Respir Med 2002; 96: 34–38. 
[33] Illi S, von Mutius E, Lau S, Nickel R, Gruber C, Niggemann B, et al. The natural course 
of atopic dermatitis from birth to age 7 years and the association with asthma. J 
Allergy Clin Immunol 2004; 113: 925–931. 
[34] Bousquet J, Van Cauwenberge P, Khaltaev N. Allergic rhinitis and its impact on 
asthma. J Allergy Clin Immunol 2001; 108: S147–334. 
[35] Arruda LK, Sole D, Baena-Cagnani CE, Naspitz CK. Risk factors for asthma and atopy. 
Curr Opin Allergy Clin Immunol 2005; 5: 153–159. 
[36] Gupta AK, Bluhm R, Cooper EA, Summerbell RC, Batra R. Seborrheic dermatitis. 
Dermatol Clin. 2003;21:401-12. 
[37]  Schwartz RA, Janusz CA, Janniger CK. Seborrheic dermatitis: an overview. Am Fam 
Physician. 2006;74:125-30. 
[38] Picardi A, Abeni D. Stressful life events and skin diseases: disentangling evidence from 
myth. Psychother Psychosom.2001;70:118-36. 
[39] Gupta AK, Nicol KA. Seborrheic dermatitis of the scalp: etiology and treatment. J 
Drugs Dermatol. 2004;3:155-8.  
[40] Mastrolonardo M, Diaferio A, Logroscino G. Seborrheic dermatitis, increased sebum 
excretion, and Parkinson’s disease: a survey of (im)possible links. Med Hypotheses. 
2003;60: 907-11. 
[41] Jones-Caballero M, Penas PF, García-Díez A, Badía X, Chren MM. The Spanish version 
of Skindex-29. Int J Dermatol. 2000;39:907-12. 
[42] Gupta AK, Bluhm R. Seborrheic dermatitis. JEADV. 2004;18:13-26. 
[43] Alkhalifah A, Alsantali A, Wang E, McElwee KJ, Shapiro J.Alopecia areata update: part 
II. Treatment. J Am Acad Dermatol. 2010:62:191-202. 
[44] Harries MJ, Sun J, Paus R, King LE Jr. Management of alopecia areata. BMJ. 2010; 23-41. 
[45] Friedli A, Harms M. Alopecia areata. Ther Umsch. 2002;59:233-7. 
[46] Alkhateeb A, Fain PR, Thody A, Bennett DC, et al. Epidemiology of vitiligo and 
associated autoimmune diseases in Caucasian probands and their families. Pigment 
cell res. 2003;16(3):208–214. 
 
Dermatological Manifestations of Down Syndrome 
 
207 
[47] Delamere FM, Sladden MM, Dobbins HM, Leonardi-Bee J. Interventions for alopecia 
areata. Cochrane Database Syst Rev. 2008 Apr 16;(2):CD004413. 
[48] Garg S, Messenger AG. Alopecia areata: evidence-based treatments. Semin Cutan Med 
Surg. 2009;28:15-8. 
[49] Gauthier Y, Cario Andre M, Taïeb A. A critical appraisal of vitiligo etiologic theories. Is 
melanocyte loss a melanocytorrhagy? Pigment Cell Res. 2003;16(4):322–332. 
[50] Esfandiarpour I, Ekhlasi A, Farajzadeh S, Shamsadini S. The efficacy of pimecrolimus 
1% cream plus narrow-band ultraviolet B in the treatment of vitiligo: A double-
blind, placebo-controlled clinical trial. J Dermatolog Treat. In press 2008. 
[51] 35. El Mofty M, Mostafa W, Esmat S. Narrow band Ultraviolet B 311 nm in the 
treatment of vitiligo: two right-left comparison studies. Photodermatol 
Photoimmunol Photomed. 2006;22(1):6–11. 
[52] Yones SS, Palmer RA, Garibaldinos TM, Hawk JL. Randomized double-blind trial of 
treatment of vitiligo: effi cacy of psoralen-UV-A therapy vs Narrowband-UV-B 
therapy. Arch Dermatol. 2007;143(5): 578–584. 
[53] Arca E, Tastan HB, Erbil AH, Sezer E, Koc E, Kurumlu Z. Narrow-band ultraviolet B as 
monotherapy and in combination with topical calcipotriol in the treatment of 
vitiligo. J Dermatol. 2006;33(5):338–343. 
[54] Passeron T, Ortonne JP. Use of the 308-nm excimer laser for psoriasis and vitiligo. Clin 
Dermatol. 2006;24(1):33–42 
[55] Hadi S, Tinio P, Al-Ghaithi K, et al. Treatment of vitiligo using the 308-nm excimer 
laser. Photomed Laser Surg. 2006;24(3):354–357. 
[56] Passeron T, Ostovari N, Zakaria W. Topical tacrolimus and the 308-nm excimer laser: a 
synergistic combination for the treatment of vitiligo. Arch Dermatol. 
2004;140(9):1065–1069. 
[57] Goldinger SM, Dummer R, Schmid P, et al. Combination of 308-nm xenon chloride 
excimer laser and topical calcipotriol in vitiligo. J Eur Acad Dermatol Venereol. 
2007;21(4):504–508. 
[58] Schepis C, Siragusa M. Secondary anetoderma in people with Down’s syndrome. Acta 
Derm Venereol 1999;79:245. 
[59] Gupta AK. Types of onychomycosis. Cutis. 2001 Aug;68:4-7. 
[60] Derby R, Rohal P, Jackson C, Beutler A, Olsen C. Novel treatment of onychomycosis 
using over-the-counter mentholated ointment: a clinical case series. J Am Board 
Fam Med. 2011;24:69-74. 
[61] Krob AH, Fleischer AB Jr, D'Agostino R Jr, Feldman SR.Terbinafine is more effective 
than itraconazole in treating toenail onychomycosis: results from a meta-analysis of 
randomized controlled trials. J Cutan Med Surg. 2003;7:306-11. 
[62] Trivedi NA, Shah PC. A meta-analysis comparing efficacy of continous terbinafine 
with intermittent itraconazole for yoenal onychomycosis. Indian J Dermatol. 2010; 
55: 198–199. 
[63] Gilmore SJ. Control strategies for endemic childhood scabies. PLoS One. 2011;6:e15990. 
[64] Schepis C, Siragusa M, Alberti A. Guess what! Milia-like idiopathic calcinosis cutis. 
Eur J Dermatol. 2000;10:637-8. 
 
Genetics and Etiology of Down Syndrome 
 
208 
[65] Pereira AC, Baeta IG, Costa Júnior SR, Gontijo Júnior OM, Vale EC. Elastosis perforans 
serpiginosa in a patient with Down's syndrome. An Bras Dermatol. 2010;85:691-4. 11 
Down Syndrome and Periodontal Disease 
Ahmed Khocht 
Temple University, School of Dentistry 
United States 
1. Introduction 
Periodontal diseases are inflammatory diseases of the supporting structures of the teeth 
(Cochran, 2008; Kornman, 2008). They are initiated by periodontopathic bacteria and result 
in progressive destruction and loss of the periodontium (Cochran, 2008; Kornman, 2008). 
Progression of periodontal disease eventually leads to tooth loss (Chambrone, et al., 2010). 
Periodontal diseases are multifactorial with complex pathogenesis (Cochran, 2008; 
Kornman, 2008).  
Plaque bacteria trigger a host inflammatory response in the gingival tissues (Kornman, 
2008). Neutrophils migrate from within the gingival tissues towards the gingival crevice and 
build a barrier wall against the bacteria (Kornman, 2008). Within the gingival connective 
tissue, the gingival macrophages and fibroblasts produce inflammatory cytokines (e.g. 
interleukin-1 and tumor necrosis factor- alpha) that activate collagenases and other 
degrading enzymes (Kornman, 2008). These enzymes when released and activated destroy 
the gingival collagen. Lymphocytes are recruited to the gingival lesion to initiate an 
adaptive immune response and help with containing the infection (Kornman, 2008). With 
persistence of the microbial infection, the inflammatory changes in the gingival tissues 
expand apically and reach the alveolar bone (Cochran, 2008). Inflammatory mediators such 
as interleukin-1, interleukin-6, tumor necrosis factor alpha and prostaglandins induce 
osteoclasogenesis (Cochran, 2008). Increased inflammatory activity disrupts the normal 
balance of bone formation/resorption and results in alveolar bone loss (Cochran, 2008).  
Periodontal disease is a serious and morbid oral condition among Down-syndrome (DS) 
affected individuals (Morgan, 2007). Gingivitis and periodontitis start early in life and their 
severity increases with age (Reuland-Bosma, et al., 1988). Periodontal disease advances rapidly 
in DS individuals and is characterized by severe gingival inflammation, loss of periodontal 
attachment and radiographic alveolar bone loss (Agholme, et al., 1999; Saxen, et al., 1977). 
Heavy amounts of plaque and calculus are often present (Morgan, 2007). Periodontal disease is 
an important cause of tooth loss among DS individuals (Reuland-Bosma, et al., 2001). 
The exact reason (or reasons) for this increased susceptibility to periodontitis is (are) not 
known. Understanding the pathogenesis of periodontitis in DS individuals would greatly 
help with the management and control of the destructive process associated with the disease 
and help DS affected individuals retain their teeth hopefully throughout their lifetime. 
Previously researchers have investigated factors usually associated with periodontitis such as 
subgingival plaque microbial composition, immune and inflammatory responses individually 
in DS affected individuals. The individual factors investigated were never collectively 
evaluated together to provide an overall understanding of the pathogenesis of periodontitis in 
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individuals with DS. The objective of this chapter is to review in a systematic fashion all the 
involved factors previously reported together to generate a hypothetical collective model of the 
pathogenesis of periodontal disease in individuals with DS. Such a model would enhance our 
understanding of periodontal disease development/progression in this vulnerable group, 
would help with disease management, would identify gaps in knowledge, and would provide 
enlightenment for future research endeavors.  
In this review I have searched the available dental/medical literature for studies 
investigating the main factors suspected in the increased susceptibility to periodontitis in DS 
individuals. I have summarized the main findings from these studies and used this 
information to generate a hypothetical model of the pathogenesis of periodontitis in DS 
individuals. 
2. Methods 
The methodology applied in this review covers the literature search strategy, inclusion and 
exclusion criteria for choosing articles, screening of articles and quality assessment of the 
selected articles. 
2.1 Search strategy 
Electronic searching was performed using the following databases: MEDLINE (1948-2011) 
and PubMed. The search terms that were used related to the subject groups of interest: 
Down syndrome and mental retardation; the oral condition: gingivitis, periodontitis, 
periodontal disease, gingiva, periodontium, tooth loss; etiological factors: microbiological 
(dental plaque, subgingival plaque, periodontopathic bacteria), immune factors 
(neutrophils, lymphocytes, antibody production) and inflammatory factors (cytokines, 
prostaglandins, metalloproteinases) and the type of study: comparative study, randomized 
controlled trial, or review. The search was limited to English language literature. The 
electronic search was supplemented by checking bibliographies of review papers. One 
hundred forty five articles were initially identified.  
2.2 Inclusion criteria 
Studies were included if they met the following minimum criteria: 
1. Human subjects with Down syndrome. 
2. Clinical measures of periodontal status. 
3. Microbiological, immune or inflammatory measures. 
4. Comparison of DS subjects to a control/comparison group(s). 
5. Written in English. 
2.3 Exclusion criteria 
Editorial letters, historical reviews and descriptive studies such as case reports were 
excluded. In addition, studies that did not specifically address the main focus of the search 
or duplicated other studies were also excluded. 
2.4 Screening and selection of papers 
At first the articles were screened by title and abstract. A review of abstracts based on the 
criteria above led to initial consideration of 32 articles. Then full text was retrieved either 
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electronically or in printed format. Further review of full texts resulted in inclusion of 20 
articles.  
2.5 Quality assessment 
Systematic reviews need to assess the methodological quality of the included studies (Pai, et 
al., 2004). Quality within the context of this chapter refers to the minimization of bias. An 
objective of this assessment was to judge the strength of the scientific evidence with higher 
score given to studies free of bias. To minimize bias, the comparison group needs to be 
matched as close as possible to the DS group. In addition, the evaluated parameters should 
be assessed in the same manner between the groups. Studies with an adequately matched 
control group were scored higher than studies that used population data or previously 
collected data for comparison. 
The instrument used for judging articles for this chapter was based freely on the use of 
STROBE methodology (von Elm, et al., 2007) evaluating the following parameters: 
 Down syndrome diagnosis: clearly stated and explained. 
 Inclusion of a comparison group: well matched (age, gender, race) or not. 
 Periodontal parameters: how periodontitis was defined and measured. Adequate if 
clinical attachment level was reported. Inadequate when only periodontal probing 
depth or radiographic measurements are reported. 
 Laboratory methodology to assess microbial, immune or inflammatory factors: was the 
methodology clearly explained. Was the methodology appropriate or not. 
 Examiner calibration: adequate if reported, inadequate if not reported. 
 Descriptive information: characteristics of study participants (number of subjects, 
gender, mean and range of age) were clearly presented. 
 Confounders identified: confounders that may affect periodontal status such as age, 
gender, and plaque levels were clearly defined. 
 Data analysis: adequate when multivariate analysis adjusting for confounders was 
presented. Inadequate if only bivariate analysis was presented. 
The studies included in the review were scored as follows: 
 Score 1: when all the parameters presented above were reported in the study. 
 Score 2: when only DS diagnosis, inclusion of a comparison group, clinical periodontal 
measures and laboratory measures were reported. 
 Score 3: other than score 1 and 2. 
3. Results 
A total of 20 articles were selected, 5 articles related to microbiological evaluations, 3 articles 
related to neutrophil function, 3 articles related to gingival cellular immunity, 4 articles 
related to antibody production and 5 articles related to degrading enzymes and 
inflammatory mediators. All selected articles met the minimum inclusion criteria previously 
described. Two articles were scored as 1, fifteen articles were scored as 2 and three articles 
were scored as 3. 
Nineteen out of the twenty selected studies were designed as cross-sectional case-controlled 
studies. Thus in addition to the DS group, they included a matched comparison group of 
either medically healthy and periodontally healthy individuals or a comparison group with 
mental disability other than DS. One study was longitudinal (Zaldivar-Chiapa, et al., 2005).  
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Fig. 1. Summary of search strategy. 
Down subjects in most of the studies were either children or young adults. Few of the 
selected studies included DS adults (Amano, et al., 2001; Chaushu, et al., 2007; Komatsu, et 
al., 2001; Sakellari, et al., 2005; Sohoel, et al., 1995).  
3.1 Summary of study methodologies 
Microbiology studies employed a variety of techniques including culturing, polymerase 
chain reaction and checkerboard DND-DNA hybridization techniques to investigate the 
composition of subgingival plaque. All the studies attempted to compare the subgingival 
plaque composition of DS individuals to a matched comparison group. In addition some 
studies attempted to determine at what age important periodontopathic bacteria become 
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detectable in DS individuals. A few studies attempted to investigate the association between 
presence of periodontopathic bacteria and clinical periodontal parameters in DS individuals. 
Neutrophil function studies mainly focused on neutrophil chemotaxis. Neutrophil 
chemotaxis was measured by the Boyden chamber method. All selected studies compared 
neutrophil chemotaxis of DS individuals to a matched comparison group. One of the studies 
investigated the relation between neutrophil chemotaxis measures with clinical and 
radiographic periodontal measures. 
Gingival cellular immunity studies examined the immune cellular composition, expression 
of HLA Class II antigens on the surfaces of immune cells and gamma/delta T-cell receptor-
bearing lymphocytes in discarded gingival tissues from DS individuals. Indirect 
immunofluorescent techniques were used to examine the gingival tissues. All the selected 
studies compared the gingival tissue cellular findings in DS individuals to medically and 
periodontally healthy individuals. 
The selected antibody production studies focused on specific antibodies against some 
important periodontopathic bacteria. The studies examined either serum antibody titers or 
salivary antibody levels. All selected studies used an enzyme-linked immunosorbent assay 
(ELISA). Four of the selected studies compared the antibody serum titer or saliva levels in 
DS individuals to matched controls. One study made the comparison to a normal adult 
reference serum pool. 
The selected studies investigating degrading enzymes and inflammatory mediators mainly 
focused on matrix metalloproteinases (MMP) activity in gingival fluid. One study examined 
cultured fibroblast MMP activity. Two studies examined prostaglandin E2 (PGE2) and one 
study examined interleukin-1 (IL-1) in gingival fluid. All selected studies compared their 
findings in DS individuals with non-DS controls. MMP activity was assessed with a variety 
of techniques including gel electrophoresis, Western blot analysis and ELISA. PGE2 was 
assessed with a radio-immuno-assay and IL-1 with ELISA. 
3.2 Summary of study findings 
A summary of all selected articles and their main findings is presented in the following 
tables: 
3.2.1 Subgingival plaque composition studies 
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All of the pathogens were 
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in the DS children. Tannerella 
forsythia (Bacteroides forsythus), 
Treponema denticola, Prevotella 
nigrescens, and Campylobacter 
rectus were significantly 
prevalent throughout all age 
brackets of the DS children. The 
occurrence of Porphyromonas 
gingivalis was also significant in 
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Fusobacterium nucleatum and 
Campylobacter rectus in the 
subgingival plaque were 
determined using anaerobic 
culture techniques. 
No differences in the prevalence 
of distinct suspected 
periodontopathic bacteria and 
bacterial subgingival 
composition between the DS 
group and the comparison group 
could be established. 
Scr = score, DS = number of DS group, CG = number of comparison group, Yng = young, Adt = adult, 
NC = normal controls, MR = mental retardation not Down. 
Table 1. Summarizes the findings of the subgingival plaque composition studies.  
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3.2.2 Neutrophil function studies 
 
Author Scr. DS  CG Measures Findings 
Izumi 
1989 




DS patients showed significantly 
lower chemotaxis than healthy 
volunteers. Bone loss in DS subjects 
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parameters, chemotaxis 
and random migration 
of neutrophils. 
The random migration and 
chemotaxis of neutrophils from DS 
subjects were significantly 








9 Clinical parameters and 
neutrophil function. 
Neutrophil chemotaxis, phagocytic 
activity, and production of super-
oxide anion were significantly 
decreased in the DS patients. 
Scr = score, DS = number of DS group, CG = number of comparison group. 
Table 2. Summarizes the neutrophil function studies.  
3.2.3 Gingival immune response studies 
 
Author Scr. DS CG Measures Findings 
Sohoel 
1992 
3 16 12 Indirect immune-
fluorescence used 






Denser inflammatory infiltrate in DS 
individuals. Counting showed 
different cell distribution and cell 




3 16 14 Expression of 
HLA Class II 
antigens on the 
surfaces of 
immune cells. 
Increased frequency of HLA Class II 
(HLA-expression on inflammatory 
cells and on keratinocytes of the oral 
gingival epithelium) in chronic 
periodontitis of DS patients compared 
to sections from non-DS subjects. 
Sohoel 
1995 






Gamma/delta T-cell receptor-bearing 
lymphocytes are decreased in inflamed 
gingival tissues of DS individuals. 
Scr = score, DS = number of DS group, CG = number of comparison group, NR = not reported. 
Table 3. Summarizes the gingival immune cellular response studies. 
  
Genetics and Etiology of Down Syndrome 
 
214 







60 Ten periodontal pathogens 
were surveyed in 
subgingival plaque samples 
using a polymerase chain 
reaction. 
All of the pathogens were 
detected with greater frequency 
in the DS children. Tannerella 
forsythia (Bacteroides forsythus), 
Treponema denticola, Prevotella 
nigrescens, and Campylobacter 
rectus were significantly 
prevalent throughout all age 
brackets of the DS children. The 
occurrence of Porphyromonas 
gingivalis was also significant in 





41 Ten periodontal pathogens 
were surveyed in 
subgingival plaque samples 
using a polymerase chain 
reaction. 
No significant differences were 
observed in the bacterial profiles 










Clinical parameters and 
microbiological analysis by 
“checkerboard” DNA-DNA 
hybridization. 
Important periodontal pathogens 
including Porphyromonas 
gingivalis, Tannerella forsythia 
(Bacteroides forsythus) and A. 
actinomycetemcomitans colonize 





2 17 17 Prevalence and proportions 








Fusobacterium nucleatum and 
Campylobacter rectus in the 
subgingival plaque were 
determined using anaerobic 
culture techniques. 
No differences in the prevalence 
of distinct suspected 
periodontopathic bacteria and 
bacterial subgingival 
composition between the DS 
group and the comparison group 
could be established. 
Scr = score, DS = number of DS group, CG = number of comparison group, Yng = young, Adt = adult, 
NC = normal controls, MR = mental retardation not Down. 
Table 1. Summarizes the findings of the subgingival plaque composition studies.  
 
Down Syndrome and Periodontal Disease   
 
215 
3.2.2 Neutrophil function studies 
 
Author Scr. DS  CG Measures Findings 
Izumi 
1989 




DS patients showed significantly 
lower chemotaxis than healthy 
volunteers. Bone loss in DS subjects 





2 15 15 Clinical periodontal 
parameters, chemotaxis 
and random migration 
of neutrophils. 
The random migration and 
chemotaxis of neutrophils from DS 
subjects were significantly 








9 Clinical parameters and 
neutrophil function. 
Neutrophil chemotaxis, phagocytic 
activity, and production of super-
oxide anion were significantly 
decreased in the DS patients. 
Scr = score, DS = number of DS group, CG = number of comparison group. 
Table 2. Summarizes the neutrophil function studies.  
3.2.3 Gingival immune response studies 
 
Author Scr. DS CG Measures Findings 
Sohoel 
1992 
3 16 12 Indirect immune-
fluorescence used 






Denser inflammatory infiltrate in DS 
individuals. Counting showed 
different cell distribution and cell 




3 16 14 Expression of 
HLA Class II 
antigens on the 
surfaces of 
immune cells. 
Increased frequency of HLA Class II 
(HLA-expression on inflammatory 
cells and on keratinocytes of the oral 
gingival epithelium) in chronic 
periodontitis of DS patients compared 
to sections from non-DS subjects. 
Sohoel 
1995 






Gamma/delta T-cell receptor-bearing 
lymphocytes are decreased in inflamed 
gingival tissues of DS individuals. 
Scr = score, DS = number of DS group, CG = number of comparison group, NR = not reported. 
Table 3. Summarizes the gingival immune cellular response studies. 
  
Genetics and Etiology of Down Syndrome 
 
216 
3.2.4 Antibody production studies 
 
Author Scr. DS  CG Measures Findings 
Santos 
1996 
2 16  
 
10 Circulating antibody 
titers to A. 
actinomycetemcomitans
. 
Significant differences were noted 
between the control group and the DS 
subjects (p = 0.05), with the DS 
periodontitis group having the highest 
response, followed by the DS gingivitis 
group and normal controls, respectively. 




















IgG antibody titers to Pg, Aa, Sel, and Mi 
increased significantly with increasing 
gingival inflammtion score. Furthermore, 
the IgG antibody titers to Pg were higher 
(P < 0.05) in the most extensive disease 
group compared to the DS no-disease 
group. The IgG antibody titers to Pg at 
early puberty were significantly higher 




2 20 19 Salivary levels of 
immunoglobulins 







The immunoglobulin levels of sIgA, IgM, 
the sum of IgG subclasses, and the 
concentration of albumin did not differ 
significantly between the 2 groups. 
However, the proportion of IgG1 
expressed as percentage of the sum of total 
IgG was significantly higher (P < 0.01) in 
the Down syndrome group compared to 
controls. On the contrary, the proportion 
of IgG2, IgG3, and IgG4 subclasses in 







The levels of total 
IgA, and specific 











The median secretion rates of the specific 
antibodies in whole and parotid saliva 
were 70-77% and 34-60% (respectively) 
lower in young DS individuals as 
compared to young controls and farther 
77-100% and 75-88% (respectively) lower 
in old DS compared to young DS. 
Scr = score, DS = number of DS group, CG = number of comparison group, RSP = reference serum pool. 
Table 4. Summarizes the antibody production studies.  
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3.2.5 Inflammatory mediator studies 
 
Author Scr. DS CG Measures Findings 
Halinen 
1996 




(MMP-8 and -9) 
activities in saliva 
and in gingival 
crevicular fluid. 
The endogenously active collagenase and total 
collagenase activities were slightly higher in 
GCF of DS children compared to healthy 
controls. GCF collagenase of DS patients was 
human neutrophil collagenase (MMP-8 or 
collagenase-2), in DS patients, but not in 
controls. Salivary collagenase in DS was high 
when compared to controls but of the same 
MMP-8 type as in control saliva.  
Barr-Agholme 
1997 








The mean level of PGE2 in GCF was 
significantly higher (P < 0.05) in the Down 
syndrome group than in the control group. In 
GCF samples collected from sites 
characterized as non-inflamed, the mean level 
of PGE2 was significantly higher (P < 0.001) in 
the Down syndrome group than in the 
controls. The mean level of PGE2 in samples 
from inflamed sites, on the other hand, did 
not differ between the two groups. The mean 
level of IL-1 beta was not significantly higher 




2 9 9 Enzyme activity 




(MMPs) of cultured 
gingival fibroblasts 
(GF) and fresh 
gingival tissues.
The production of the active type of MMP-2 in 
GF from Down's syndrome patients (D-GF) 
was found to be significantly higher (P < 0.05) 




2 18 14 Levels of 
prostaglandin E2 
(PGE2), leukotriene 






The mean levels of PGE2, LTB4, and MMP-9 
were significantly (P<0.05) higher in GCF 





1 14 14 Matrix 
metalloproteinase 
(MMP-8 and MMP-
2) activity in 
gingival crevicular 
fluid.
Levels of MMP-2 and MMP-8 in Down's 
syndrome patients were higher than those in 
healthy control subjects. 
Scr = score, DS = number of DS group, CG = number of comparison group. 
Table 5. Summarizes the inflammatory mediator studies. 
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Periodontal disease is a common problem among DS individuals with an estimated 
prevalence between 58% and 96% for those under 35 years of age (Morgan, 2007). The 
disease starts early in life and progresses with age eventually leading to tooth loss (Reuland-
Bosma, et al., 2001; Saxen, et al., 1977; Saxen & Aula, 1982). Periodontal disease in DS 
individuals adversely impacts on the quality of their life (Amaral Loureiro, et al., 2007). The 
increased prevalence and severity of periodontal disease in DS individuals inspired many 
researchers to investigate the various factors that might be involved. 
Periodontal diseases are initiated by bacterial plaque build-up in the dentogingival region 
(Kornman, 2008). It is well documented that DS individuals have difficulty with maintaining 
adequate oral hygiene levels and thus tend to harbor high levels of bacterial plaque on their 
teeth (Cohen, et al., 1961; Khocht, et al., 2010; Sakellari, et al., 2005). In addition, DS 
individuals following oral hygiene instructions have reduced ability to master adequate 
plaque control (Sakellari, et al., 2001). It was often surmised that mental disability associated 
with DS is an important factor in their reduced ability to maintain adequate oral hygiene 
and consequently increases their susceptibility to periodontitis (Desai, 1997; Morgan, 2007). 
Our group (Khocht, et al., 2010) recently showed in a multivariate model including 
traditional risk factors for periodontitis combined with mental disability that loss of 
periodontal attachment in DS individuals was not associated with mental disability. Thus 
other factors associated with DS might be involved.  
It is well documented that DS is associated with immune deficiencies and host response 
impairment (Kusters, et al., 2009; Reuland-Bosma, et al., 1988). Infections, in particular 
respiratory infections are an important cause of death in DS individuals (Thase, 1982). The 
most likely reason for this increased susceptibility to infection and reduced immunity in DS 
individuals is an increased dosage of a protein product or products encoded by 
chromosome 21. Several proteins important in immune function are encoded on 
chromosome 21. Examples include superoxide dismutase (SOD), carbonyl reductase 
(NADPH) (Lemieux, et al., 1993) and integrin beta-2 (CD18). Increased SOD and NADPH 
production is associated with increased oxidative stress and tissue injury in DS individuals 
(Akinci, et al., 2010; Strydom, et al., 2009). Aberrant expression of CD18 integrin on immune 
cell surfaces in DS individuals may be associated with altered lymphocyte function (Kusters, 
et al., 2009; Taylor, 1987). The IL10RB component of the IL-10 receptor (involved with 
resolution of inflammation) is encoded by chromosome 21 and its function may be altered in 
DS individuals (Glocker, et al., 2009). In addition, it seems that interleukin-1 (IL-1) is 
upregulated indirectly by some chromosome 21 based genes (Mrak & Griffin, 2004). IL-1 is 
an important immune/inflammatory mediator. Its increased production in DS individuals 
was associated with brain tissue damage (Mrak & Griffin, 2004). 
Since periodontitis is initiated by bacterial infections, indeed it is conceivable that altered 
immunity in DS individuals may be the primary reason for their increased susceptibility to 
periodontal infections. Perhaps reduced immunity in DS individuals would make it easier 
for virulent periodontopathic microbial species to colonize their subgingival plaque. If true, 
such elevated microbial presence, unchallenged and unchecked, would induce an intense 
inflammatory reaction within the gingival tissues. Increased gingival inflammation within 
the gingival tissues would lead to elevated production of degrading enzymes and alter bone 
remodeling. The end result of these inflammatory induced changes would be the loss and 
destruction of the periodontium and eventually tooth loss. Several studies (microbiological, 
immune and inflammatory) attempted to investigate these hypotheses.  
 




Fig. 2. The above schematic illustrates the main findings of the selected articles. Decreased 
salivary flow and associated decreased salivary antibody production. Neutrophils with 
defective chemotaxis incapable of reaching the target pathogens. Early colonization of the 
dentogingival region with periodntopathic bacteria. Gingival marginal tissues heavily 
infiltrated with immune cells such as macrophages and lymphocytes. Antigen presenting 
cells active in processing and presenting microbial antigens. Robust humoral antibody 
production. Macrophages and other gingival cells engaged in producing degrading 
enzymes (MMPs). Collagen degradation. Tissue injury and release of prostaglandins 
(PGE2). Increased osteoclastic activity and alveolar bone loss. 
4.1 Microbiological studies 
Barr-Agholme et al. (1992) reported increased presence of Aggregatibacter (Actinobacillus) 
actinomycetemcomitans, Capnocytophaga and Porphyromonas gingivalis in subgingival plaque of 
adolescents with DS. A. Actinomycetemcomitans was detected in 35% of patients with DS 
compared to 5% in the healthy, age and sex matched controls. The authors suggested that 
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4.1 Microbiological studies 
Barr-Agholme et al. (1992) reported increased presence of Aggregatibacter (Actinobacillus) 
actinomycetemcomitans, Capnocytophaga and Porphyromonas gingivalis in subgingival plaque of 
adolescents with DS. A. Actinomycetemcomitans was detected in 35% of patients with DS 
compared to 5% in the healthy, age and sex matched controls. The authors suggested that 
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this increased frequency of A. actinomycetemcomitans indicated an altered microbial 
composition in the subgingival plaque of DS patients as compared to healthy controls. 
Amano et al. (2000) found various periodontal disease-causing bacteria present in very young 
DS patients. The authors reported that various periodontopathic bacteria could colonize the 
teeth in the very early childhood of DS patients. Pathogens in DS patient’s subgingival 
plaque were detected with far greater frequency than in the age-matched controls. This may 
be the reason why these DS patients have such intense gingival inflammation. The authors 
concluded that periodontopathic pathogens establish a presence at a very early age, and that 
certain bacteria, like P. gingivalis, play a key role in the initiation of gingival inflammation. 
Sakellari et al. (2005) evaluated seventy DS patients, 121 age-matched healthy individuals 
and 76 patients with cerebral palsy. Full-mouth recordings of clinical periodontal 
parameters were assessed and subgingival plaque samples were taken from the Ramfjord 
teeth and analysed for 14 species using "checkerboard" DNA-DNA hybridization. They 
reported that important periodontal pathogens colonize these subjects earlier and at higher 
levels compared with age-matched healthy individuals and patients with cerebral palsy. 
Reuland-Bosma et al. (2001) compared subgingival microflora in DS adult patients to other 
mentally retarded individuals. Despite advanced periodontitis in DS patients, no differences 
in the prevalence of distinct suspected periodontopathic bacteria were established between 
the DS patients and the control group. The authors concluded that host factors are the most 
likely explanation for the advanced periodontal disease associated with DS patients. 
Amano et al. (2001) took subgingival plaque specimens from 67 DS young adults and 41 
age-matched systemically healthy individuals with mental disabilities (MD). The prevalence 
of Actinobacillus actinomycetemcomitans, Porphyromonas gingivalis, Bacteroides forsythus, 
Treponema denticola, Prevotella intermedia, Prevotella nigrescens, Capnocytophaga ochracea, 
Capnocytophaga sputigena, Campylobacter rectus, and Eikenella corrodens, were investigated in 
subgingival plaque samples using a polymerase chain reaction method. The authors found 
no significant differences in the bacterial profiles between the groups.  
The cited microbiological studies indicate early colonization of important periodontal 
pathogens in children and adolescents with DS. However, the microbial subgingival profile 
of adult DS individuals is not different from matched non-DS individuals. Perhaps reduced 
immunity in young DS individuals facilitates early colonization in comparison to young 
non-DS individuals with normal immunity. With age, and a combination of long-term 
exposure to pathogens and changes in immune response, non-DS individuals may also be 
susceptible to colonization by periodontal pathogens. However, despite lack of differences 
in microbial profiles between adult DS and non-DS individuals, adult DS individuals still 
show greater loss of periodontal attachment (Amano, et al., 2001; Reuland-Bosma, et al., 
2001). This suggests that the host response to the same bacteria is different between DS and 
non-DS individuals. It seems that the immune-inflammatory response in DS is more intense 
resulting in greater tissue damage. The following studies will investigate this claim. 
4.2 Immune dysfunction studies 
As we said earlier, DS is associated with immune dysfunction (Kusters, et al., 2009). Various 
studies investigated different components of the immune system in relation to periodontitis 
in DS patients. These studies mainly focused on neutrophil function, the gingival immune 
cellular response and antibody production against periodontopathic bacteria. 
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4.2.1 Neutrophil function studies 
Izumi et al. (1989) found a faulty neutrophil chemotaxis in DS patients. The authors reported 
that DS patients had significantly lower chemotaxis compared to healthy controls.  Since the 
neutrophils are the main cells involved in the first line of host defense in a bacterial 
invasion, having a defective neutrophil chemotaxis can lead to the progression of 
periodontitis. Significant correlations were identified between the amount of bone loss and 
the age and chemotactic index of the DS patients.  The authors found that the rate of 
periodontal destruction was dependent on the degree of defective chemotaxis.  
Yavuzyilmaz et al. (1993) evaluated clinical parameters, chemotaxis and random migration 
of neutrophils in 15 patients with DS and 15 healthy subjects. Signs of more severe gingival 
inflammation were present in the DS group. The random migration and chemotaxis of 
neutrophils were significantly decreased in comparison with the control group. 
Zaldivar-Chiapa (2005) examined patients with DS to evaluate the effectiveness of surgical 
and non-surgical periodontal therapies and to assess their neutrophil immunological status. 
The population consisted of 14 DS patients, 14 to 30 years old. Surgical and non-surgical 
periodontal therapies were compared in a split-mouth design. Clinical periodontal 
parameters were recorded at baseline, post-treatment, 6 months, and 1 year. Neutrophil 
chemotaxis, phagocytic activity, and production of super-oxide anion were compared 
between DS patients and healthy controls. Both surgical and non-surgical therapies showed 
a significant improvement in all the clinical parameters compared to baseline. Neutrophil 
chemotaxis, phagocytic activity, and production of super-oxide anion were significantly 
decreased in the DS patients. The authors concluded that the neutrophil impairment does 
not seem to affect the clinical response to therapy. 
All the presented studies showed deficient neutrophil chemotaxis in DS subjects. The reason 
for impaired neutrophil chemotaxis in DS individuals may be secondary to increased 
oxidative stress associated with trisomy of chromosome 21 (Akinci, et al., 2010). Oxidative 
stress may impair internal cell function and disrupt chemotaxis. One study positively 
correlated such reduced chemotaxis with measures of periodontitis (Izumi, et al., 1989). 
Another study gave hope that despite reduced neutrophil chemotaxis, periodontal therapy 
aiming at reducing plaque and correcting periodontal architecture is still helpful (Zaldivar-
Chiapa, et al., 2005).  
4.2.2 Gingival Immune cellular response 
Sohoel et al. (1992) examined the composition of mononuclear cells in the gingival 
inflammatory infiltrate in DS patients with marginal periodontitis. The authors reported 
that DS patients had a higher number of cells in the cellular infiltrate of chronic marginal 
periodontitis (CMP) compared to normal patients.  There were also an increased number of 
CD22+ cells (B lymphocytes), CD3+ cells, CD4+ cells, CD8+ cells, and CD11+ cells 
(macrophages).  There was also a significantly higher CD4+/CD8+ ratio in DS patients 
when compared to the normal controls, which could indicate active tissue destruction.  This 
study concluded that DS patients have a more pronounced and altered gingival cellular 
immune response when compare to controls. 
Sohoel et al. (1995) investigated the expression of HLA class II antigens in chronic marginal 
periodontitis (CMP) in patients with DS. Variations in the expression of HLA class II 
antigens on antigen-presenting cells play an important role in immune regulation. The 
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this increased frequency of A. actinomycetemcomitans indicated an altered microbial 
composition in the subgingival plaque of DS patients as compared to healthy controls. 
Amano et al. (2000) found various periodontal disease-causing bacteria present in very young 
DS patients. The authors reported that various periodontopathic bacteria could colonize the 
teeth in the very early childhood of DS patients. Pathogens in DS patient’s subgingival 
plaque were detected with far greater frequency than in the age-matched controls. This may 
be the reason why these DS patients have such intense gingival inflammation. The authors 
concluded that periodontopathic pathogens establish a presence at a very early age, and that 
certain bacteria, like P. gingivalis, play a key role in the initiation of gingival inflammation. 
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and 76 patients with cerebral palsy. Full-mouth recordings of clinical periodontal 
parameters were assessed and subgingival plaque samples were taken from the Ramfjord 
teeth and analysed for 14 species using "checkerboard" DNA-DNA hybridization. They 
reported that important periodontal pathogens colonize these subjects earlier and at higher 
levels compared with age-matched healthy individuals and patients with cerebral palsy. 
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mentally retarded individuals. Despite advanced periodontitis in DS patients, no differences 
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Treponema denticola, Prevotella intermedia, Prevotella nigrescens, Capnocytophaga ochracea, 
Capnocytophaga sputigena, Campylobacter rectus, and Eikenella corrodens, were investigated in 
subgingival plaque samples using a polymerase chain reaction method. The authors found 
no significant differences in the bacterial profiles between the groups.  
The cited microbiological studies indicate early colonization of important periodontal 
pathogens in children and adolescents with DS. However, the microbial subgingival profile 
of adult DS individuals is not different from matched non-DS individuals. Perhaps reduced 
immunity in young DS individuals facilitates early colonization in comparison to young 
non-DS individuals with normal immunity. With age, and a combination of long-term 
exposure to pathogens and changes in immune response, non-DS individuals may also be 
susceptible to colonization by periodontal pathogens. However, despite lack of differences 
in microbial profiles between adult DS and non-DS individuals, adult DS individuals still 
show greater loss of periodontal attachment (Amano, et al., 2001; Reuland-Bosma, et al., 
2001). This suggests that the host response to the same bacteria is different between DS and 
non-DS individuals. It seems that the immune-inflammatory response in DS is more intense 
resulting in greater tissue damage. The following studies will investigate this claim. 
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As we said earlier, DS is associated with immune dysfunction (Kusters, et al., 2009). Various 
studies investigated different components of the immune system in relation to periodontitis 
in DS patients. These studies mainly focused on neutrophil function, the gingival immune 
cellular response and antibody production against periodontopathic bacteria. 
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4.2.1 Neutrophil function studies 
Izumi et al. (1989) found a faulty neutrophil chemotaxis in DS patients. The authors reported 
that DS patients had significantly lower chemotaxis compared to healthy controls.  Since the 
neutrophils are the main cells involved in the first line of host defense in a bacterial 
invasion, having a defective neutrophil chemotaxis can lead to the progression of 
periodontitis. Significant correlations were identified between the amount of bone loss and 
the age and chemotactic index of the DS patients.  The authors found that the rate of 
periodontal destruction was dependent on the degree of defective chemotaxis.  
Yavuzyilmaz et al. (1993) evaluated clinical parameters, chemotaxis and random migration 
of neutrophils in 15 patients with DS and 15 healthy subjects. Signs of more severe gingival 
inflammation were present in the DS group. The random migration and chemotaxis of 
neutrophils were significantly decreased in comparison with the control group. 
Zaldivar-Chiapa (2005) examined patients with DS to evaluate the effectiveness of surgical 
and non-surgical periodontal therapies and to assess their neutrophil immunological status. 
The population consisted of 14 DS patients, 14 to 30 years old. Surgical and non-surgical 
periodontal therapies were compared in a split-mouth design. Clinical periodontal 
parameters were recorded at baseline, post-treatment, 6 months, and 1 year. Neutrophil 
chemotaxis, phagocytic activity, and production of super-oxide anion were compared 
between DS patients and healthy controls. Both surgical and non-surgical therapies showed 
a significant improvement in all the clinical parameters compared to baseline. Neutrophil 
chemotaxis, phagocytic activity, and production of super-oxide anion were significantly 
decreased in the DS patients. The authors concluded that the neutrophil impairment does 
not seem to affect the clinical response to therapy. 
All the presented studies showed deficient neutrophil chemotaxis in DS subjects. The reason 
for impaired neutrophil chemotaxis in DS individuals may be secondary to increased 
oxidative stress associated with trisomy of chromosome 21 (Akinci, et al., 2010). Oxidative 
stress may impair internal cell function and disrupt chemotaxis. One study positively 
correlated such reduced chemotaxis with measures of periodontitis (Izumi, et al., 1989). 
Another study gave hope that despite reduced neutrophil chemotaxis, periodontal therapy 
aiming at reducing plaque and correcting periodontal architecture is still helpful (Zaldivar-
Chiapa, et al., 2005).  
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that DS patients had a higher number of cells in the cellular infiltrate of chronic marginal 
periodontitis (CMP) compared to normal patients.  There were also an increased number of 
CD22+ cells (B lymphocytes), CD3+ cells, CD4+ cells, CD8+ cells, and CD11+ cells 
(macrophages).  There was also a significantly higher CD4+/CD8+ ratio in DS patients 
when compared to the normal controls, which could indicate active tissue destruction.  This 
study concluded that DS patients have a more pronounced and altered gingival cellular 
immune response when compare to controls. 
Sohoel et al. (1995) investigated the expression of HLA class II antigens in chronic marginal 
periodontitis (CMP) in patients with DS. Variations in the expression of HLA class II 
antigens on antigen-presenting cells play an important role in immune regulation. The 
results of this study indicated an increased frequency of HLA class II antigens in the 
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gingival tissues of CMP DS patients when compared to controls. There were significantly 
higher numbers of CD1a+ cells and ratios of HLA-DR+/CD1a+ cells and HLA-DP+/CD1a+ 
cells in the DS group compared to the control group. The authors concluded that there is a 
highly activated immune response in DS patients.  
The same investigators (Sohoel, et al., 1995) also investigated gamma/delta T lymphocytes 
in gingival tissues of DS individuals. The T-cell receptor (TCR) of gamma/delta T 
lymphocytes is different from the alpha/beta TCR. The gamma/delta TCR binds to antigens 
that are intact proteins and antigens that are not presented within class I or class II 
histocompatibility molecules. The gamma/delta T lymphocytes usually reside within 
epithelial tissues and encounter antigens on the surface of epithelial cells. The researchers 
reported that the percentage of gamma/delta T lymphocytes in the gingival tissues of DS 
subjects was less than 1%. 
The presented studies showed an intense presence of a variety of immune cells within the 
gingival tissues of DS patients with periodontitis. Increased production of HLA class II 
antigens on the surfaces of antigen producing cells suggests that the cells are locally 
engaged in specific immune responses. The low presence of gamma/delta T lymphocytes 
may increase the vulnerability to microbial noxious agents.  
4.2.3 Antibody/immunoglobulin production 
These studies investigated specific antibodies against periodontopathic bacteria in serum 
and saliva. 
Santos et al. (1996) determined the circulating antibody titers to Aggregatibacter 
(Actinobacillus) actinomycetemcomitans (Aa) in sera of DS and normal patients. Eleven DS 
patients with periodontitis (pocket depth > 4 mm), five DS patients with gingivitis 
(inflammation and pocket depth < or = 3 mm), and 10 non-DS healthy subjects had blood 
drawn and analyzed for antibody response to Aa. The authors noted significant differences 
between the control group and the DS groups (p = 0.05), with the DS periodontal group 
having the highest response, followed by the DS gingivitis and normal controls, 
respectively. 
Morinushi et al. (1997) obtained sera from 75 DS subjects (aged 2 to 18 years) and their 
gingival health assessed using a modified gingival inflammation index (PMA Index). 
Antibody titers to Porphyromonas gingivalis, Prevotella intermedia, Treponema denticola, 
Fusobacterium nucleatum, Selenomonas sputigena, Actinobacillus actinomycetemcomitans, and 
Streptococcus mitis were determined using a micro-ELISA. The average antibody titers to A. 
actinomycetemcomitans, S. mitis, and F. nucleatum exceeded those of the normal adult 
reference serum pool. In addition, IgG antibody titers to P. gingivalis , A 
actinomycetemcomitans, F. nucleatum, S. sputigena, and S. mitis correlated significantly with the 
modified PMA scores.  
Barr-Agholme et al. (1998) investigated the clinical periodontal conditions and salivary 
immunoglobulins in patients with DS.  The results showed an altered distribution of IgG 
subclasses in saliva, with an increased amount of IgG1 in DS patients compared to 
controls. This is in agreement with other studies that show increased IgG1 in DS patients 
(Kusters, et al., 2009). On the contrary, the proportion of IgG2, IgG3, and IgG4 subclasses 
in saliva did not differ between the 2 groups. Also, in DS patients with bone loss, it was 
noted that they have an increased level of sIgA, compared to those DS patients without 
bone loss. 
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Chaushu et al. (2007) assessed age-related changes in the salivary-specific humoral 
immunity of DS subjects. Parotid and whole saliva were collected from a young group of 
DS, an older group of DS individuals and compared to two age-matched groups of healthy 
volunteers. The levels of total IgA, and specific antibodies to three common oral pathogens 
(Porphyromonas gingivalis, Aggregatibacter (Actinobacillus) actinomycetemcomitans and 
Streptococcus mutans) were analyzed. The median secretion rates of the specific antibodies in 
whole and parotid saliva were 70-77% and 34-60% (respectively) lower in young DS 
individuals as compared to young controls and farther 77-100% and 75-88% (respectively) 
lower in old DS compared to young DS.  
The presented studies were somewhat controversial and indicated different antibody 
responses between saliva and serum in DS individuals. While in saliva the antibody 
response was low in DS individuals, in serum the antibody responses to several 
periodontopathic bacteria were elevated. The low antibody responses in saliva were 
associated with decreased salivary flow in DS individuals. The low salivary antibody 
activity may facilitate the colonization of periodontal pathogens in DS individuals. The 
elevated antibody titers in DS serum corroborate the gingival immune cellular activity 
described previously. It demonstrates that DS individuals despite known immune 
deficiencies are capable of mounting a humoral specific immune response. Such antibodies 
would find their way into the gingival tissues and fluid and help with containing the 
microbial damage. Increased antibody levels in gingival tissues may also accentuate the 
gingival inflammatory response through complement activation. 
4.3 Inflammatory response studies 
Inflammatory response studies focused on inflammatory mediators and degrading enzymes 
in gingival crevicular fluid. 
4.3.1 Studies investigating inflammatory mediators 
Barr-Agholme et al. (1997) investigated the levels of prostaglandin E2 (PGE2) and 
interleukin-1 (IL-1) in gingival crevicular fluid (GCF). GCF was collected from both DS 
patients and healthy controls. They found the mean level of PGE2 in GCF was significantly 
higher in the DS patients as compared to the controls. This finding suggests an alteration in 
arachidonic acid metabolism in DS patients. The mean level of IL-1 in the GCF was not 
significantly higher in the DS patients as compared to the healthy controls. Perhaps the 
reason the IL-1 levels did not differ between the groups, despite the fact that the gingival 
inflammation was more severe in the DS group, may be because PGE2 has been reported to 
down-regulate the production of IL-1 (Kunkel, et al., 1987). This issue has not been 
revisited since and indeed is worthy of further investigation. 
Tsilingaridis et al. (2003) determined the levels of PGE2, LTB4, and MMP-9 in GCF from 18 
Down syndrome patients and from 14 controls matched with respect to age and degree of 
gingival inflammation. Clinical periodontal parameters were recorded including probing 
depth (PD) and bleeding on probing (BOP). The mean levels of PGE2, LTB4, and MMP-9 
were significantly (P<0.05) higher in GCF from Down syndrome patients compared to 
controls. When comparing the two groups, the correlation coefficients for LTB4 to BOP and 
PD, respectively, as well as for MMP-9 to BOP significantly differed between Down 
syndrome and controls (P<0.05).  
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would find their way into the gingival tissues and fluid and help with containing the 
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PD, respectively, as well as for MMP-9 to BOP significantly differed between Down 
syndrome and controls (P<0.05).  
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4.3.2 Studies investigating degrading enzymes 
Halinen et al. (1996) characterized the periodontal status of 9 non-institutionalized DS 
children 9 to 17 years old relative to their age-matched systemically and periodontally 
healthy controls. Clinical periodontal parameters were recorded. They also assessed the 
collagenase and gelatinase activities in the gingival crevicular fluid (GCF) and saliva 
samples collected from DS patients and from the controls. The endogenously active 
collagenase and total collagenase activities were slightly higher in GCF of DS children 
compared to healthy controls. Western blot demonstrated that GCF collagenase of DS 
patients was human neutrophil collagenase (MMP-8 or collagenase-2). Salivary collagenase 
in DS was high when compared to controls but of the same MMP-8 type as in control saliva. 
Komatsu et al. (2001) examined both the amount present and the enzyme activity of matrix 
metalloproteinases (MMP-2) in the gingival tissues of Down syndrome patients and 
controls. The authors reported that there was a significantly higher production of MMP-2 in 
the cultured gingival fibroblasts of the Down syndrome patients when compared with the 
controls.  In addition, the mRNA expressions of membrane-type I metalloproteinases (MTI-
MMP) and MMP-2 were markedly different when the cultured fibroblasts of the DS patients 
were compared to the controls.  This would indicate that the increased amount of active 
MMP-2 produced in DS could be linked to the simultaneous expression of MTI-MMP, which 
could also be connected to the cause of periodontal disease that is seen in a majority of DS 
patients. 
Yamazaki-Kubota et al. (2010) investigated levels of matrix metalloproteinase-2 (MMP-2) 
and matrix metalloproteinase-8 (MMP-8) in gingival crevicular fluid (GCF) and detection of 
periodontopathic bacteria from subgingival plaque. Samples of GCF and plaque were 
isolated from central incisors. Levels of MMPs were evaluated by enzyme-linked 
immunosorbent assay, and periodontopathic bacteria were detected by polymerase chain 
reaction. Levels of MMP-2 and MMP-8 in DS patients were higher than those in healthy 
control subjects. In the DS group, increases in these MMPs were observed in GCF from 
patients with good oral hygiene and absence of bleeding on probing. The detection rate of 
periodontopathic bacteria in DS patients was higher than that in the control subjects. 
Surprisingly, MMP-2 levels in sites harbouring Porphyromonas gingivalis or Aggregatibacter 
(Actinobacillus) actinomycetemcomitans were lower than in those without these 
microorganisms. 
The cited studies indicate increased matrix metalloproteinase activity in the gingival tissues 
of DS individuals. The presence of MMP-8 suggests that neutrophils in their frustration to 
reach their target pathogens release their enzymes extracellularly. Matrix metalloproteinases 
are involved in the breakdown of the extracellular matrix. Their increased activity in the 
gingival tissues of DS individuals explains the gingival tissue loss and associated clinical 
signs (increased probing depth and loss of attachment) described. In addition the increased 
levels of prostaglandin E2 in combination with increased activity of MMP-9 suggests 
increased osteoclastic activity and explains the increased alveolar bone loss described in DS 
individuals. 
5. A hypothesized model of the pathogenesis of periodontitis in Down 
syndrome 
The presented articles viewed collectively suggest the following sequence of events in the 
pathogenesis of periodontitis in DS. Decreased salivary flow accompanied by reduced 
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salivary antibody production and defective neutrophil chemotaxis facilitates early microbial 
colonization in the dentogingival region and makes it easier for periodontal pathogens to 
gain a foothold. The heavy microbial presence initiates a strong gingival 
immune/inflammatory response characterized by the presence of high numbers of 
macrophages and lymphocytes in the gingival tissues. Antigen presenting cells are active in 
initiating adaptive immunity (as evidenced by the increased expression of HLA Class II 
antigens on inflammatory cells) and eventually the production of a strong humoral antibody 
response. The specific antibodies may help with containing the microbial infection. In 
addition, macrophages and other gingival resident cells (fibroblasts) seem to be engaged in 
high production of degrading enzymes. Frustrated neutrophils may release their degrading 
enzymes extracellularly into the gingival tissues. Tissue injury releases arachidonic acid 
metabolites (prostaglandins). The degrading enzymes and prostaglandins are involved with 








Fig. 3. Hypothesized model of periodontitis pathogenesis in Down syndrome. 
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salivary antibody production and defective neutrophil chemotaxis facilitates early microbial 
colonization in the dentogingival region and makes it easier for periodontal pathogens to 
gain a foothold. The heavy microbial presence initiates a strong gingival 
immune/inflammatory response characterized by the presence of high numbers of 
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Fig. 3. Hypothesized model of periodontitis pathogenesis in Down syndrome. 
  




In summary I have attempted to use the available periodontal literature on periodontitis in 
DS to construct a hypothesized model of the pathogenesis of the disease. Periodontitis in DS 
individuals is characterized by an intense and persistent immune/inflammatory response. 
Viewing this body of literature as a temporal sequence of events suggests that therapies 
aiming at reduction of microbial colonization could greatly benefit DS individuals by 
reducing the immune/inflammatory response and associated inflammatory mediators and 
degrading enzymes. The model also may suggest future therapies such as host response 
modulation. Strikingly absent from the model is information related to core 
immune/inflammatory abnormalities associated with DS such as increased oxidative stress, 
altered integrin expression (and associated altered lymphocyte function), altered IL-10 
receptor expression (and possible impact on resolution of inflammation), and increased IL-1 
production and their relation to periodontal disease. Further studies are needed to resolve 
these gaps in knowledge, and to access the implications for everyday periodontal care of 
this periodontally vulnerable population. 
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In summary I have attempted to use the available periodontal literature on periodontitis in 
DS to construct a hypothesized model of the pathogenesis of the disease. Periodontitis in DS 
individuals is characterized by an intense and persistent immune/inflammatory response. 
Viewing this body of literature as a temporal sequence of events suggests that therapies 
aiming at reduction of microbial colonization could greatly benefit DS individuals by 
reducing the immune/inflammatory response and associated inflammatory mediators and 
degrading enzymes. The model also may suggest future therapies such as host response 
modulation. Strikingly absent from the model is information related to core 
immune/inflammatory abnormalities associated with DS such as increased oxidative stress, 
altered integrin expression (and associated altered lymphocyte function), altered IL-10 
receptor expression (and possible impact on resolution of inflammation), and increased IL-1 
production and their relation to periodontal disease. Further studies are needed to resolve 
these gaps in knowledge, and to access the implications for everyday periodontal care of 
this periodontally vulnerable population. 
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1. Introduction 
Down syndrome (DS), the most common chromosomal abnormality with a prevalence of 1 
case per 600 live births (Dennis & Marder,2001), has many manifestations that can affect 
multiple organ systems (American Academy of Pediatrics Comittee on Genetics, 2001; 
Kallen et al., 1996) including urological abnormalities which have been recognized 
throughout urinary tract (Ariel et al., 1991; Berg et al.,1960; Ahmed, 1990; Kravtzova et al., 
1975; Handel et al., 2003; Kupferman et al., 1996; Bielek et al., 1996; Narashiman & Gupta, 
2004; Koksal et al., 2003; Lang et al., 1987; Paulozzi et al., 1997). The extra copy of 
chromosome 21 has been suggested as an actor underlying the accompanied phenotypic 
abnormalities in the syndrome (Lejeune, 1959). 
Berg et al. described the first cases of urological anomalies associated with DS in their study 
of 141 DS autopsy cases and found 1 patient (0.7%) with renal agenesis and 5 patients (3.6%) 
with horseshoe kidney (Berg et al., 1960). Glomerular microcysts, renal hypoplasia and 
obstructive uropathy have also been recognized as the most common upper urinary tract 
anomalies in DS and their incidences were reported by Ariel et al. who examined 124 
autopsy cases of DS for abnormalities in urinary tract system to be as high as 23.7% (23 of 97 
patients), 21.4% (18 of 84 patients), and 6.45% (8 of the 124 cases), respectively (Ariel et al., 
1991). In addition, simple renal cysts were also found in 7 of 124 cases (5.6%). 
Anomalies in ureteral structure has also been identified in DS (Ariel et al., 1991; Kravtzova 
et al., 1975; Handel et al., 2003). The incidence of obstructed megaureter or 
hydroureteronephrosis was reported in 2 of 124 cases (1.6%), while ureteral atresia was seen 
in 1 of 124 cases (0.8%) (Ariel et al., 1991). In addition, vesicoureteral reflux (Kravtzova et al., 
1975), ureterovesical junction and ureteropelvic junction obstructions have also been 
described in patients with trisomy 21 (Handel et al., 2003). 
Trisomy 21 is one of genetic disorders that can also be accompanied by some urological 
abnormalities in lower urinary tract. Non-neurogenic neurogenic bladder (NNB) has been 
reported as a functional lower urinary tract abnormality seen in DS.  Handel et al. 
retrospectively reviewed 26 patients with trisomy 21 and found 4 patients (15.4%) with NNB 
(Handel et al., 2003).  Posterior urethral valve has also been identified in patients with 
trisomy 21 (Bielek et al., 1996; Narashiman & Gupta, 2004; Koksal et al., 2003; Lang DJ et al., 
1987). Bielek et al who reviewed 48 cases of posterior urethral valves found 4 patients with 
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DS (Bielek et al., 1996). Hypospadia has also a higher incidence in patients with the 
syndrome (Paulozzi et al., 1997). 
There is a lack of awareness regarding DS related urological manifestations in daily clinical 
practice. The associated urological anomalies have received little attention from physicians 
especially for NNB which often cause the delay in referring the patients for further 
management. In this chapter we will focus on the NNB which represents voiding 
dysfunction due to functional bladder outlet obstruction recognized in DS. The discussion 
will include the evaluation and management of this particular disorder. Urodynamic 
assessment as the most important part in the diagnosis of NNB will also be described. 
2. Dysfunctional voiding of non-neurogenic neurogenic bladder in Down 
Syndrome 
2.1 Historical note 
Non-neurogenic neurogenic bladder, the most severe form of dysfunctional voiding, is a 
pure functional bladder outlet obstruction without any neurological abnormalities which 
was described by Hinman (Hinman, 1986). However, it was first described by Beer who 
reported four patients with chronic urinary retention and upper urinary tract changes 
without any evidence of neurological pathology (Beer, 1915). He observed the disharmony 
between the detrusor and sphincter muscles in the patients.  
Incoordination syndrome of voiding contraction reflex was also found by Laidley (Ladley, 
1942). The syndrome was then called “achalasia of the urinary tract”. Paquin et al. reported 
symptoms of dysfunctional voiding with large bladder in 27 children and the term 
“megacystis syndrome” was used to represent the syndrome (Paquin et al., 1960). Ambrose 
and Swanson reported the 13 children with hypertonic detrusor contraction without any 
neurologic lesion and labeled the syndrome as “hypertonic-type neurogenic bladder” 
(Ambrose & Swanson, 1960). 
Hinman & Baumann  reported voiding difficulties in children associated with upper urinary 
tract deterioration without any anatomical obstruction or neurologic lesion with the 
identified psychological disorder (Hinman & Baumann, 1972). The term “non-neurogenic 
neurogenic bladder” was introduced in order to emphasize the absence of neurologic 
lesions. The cases were followed for 15 years and then reported with new term “Hinman 
syndrome” according to the important of psychological factors which contribute to the 
syndrome and change the previous term which was not appropriate and cause confusion. 
However, the underlying psychological disturbances were not recognized in the syndrome 
as reported by Allan (Allan ,1977).  
Non neurogenic-neurogenic syndrome in association with trisomy 21 was first identified by 
Handel et al. who reviewed 26 children with DS (all boys) and found higher incidence of 
NNB compare to other urological abnormalities in DS (Handel et al., 2003). Hicks et al 
reported the first women with NNB associated with DS and also found higher incidence of 
NNB cases in trisomy 21 (Hicks et al., 2007).  
2.2 Epidemiology 
The true prevalence of NNB has not been reported. The available prevalence is only based 
on data obtained from some centers. Groutz et al. reported that NNB was found in 2% of 
patients who underwent video-urodynamic studies but the real prevalence would be even 
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higher (Groutz et al., 2001). Jorgensen et al. reported lower prevalence of NNB (0.5%) among 
patients referred for urodynamic evaluation (Jorgensen et al., 1982).  
Handel et al. reported a higher incidence of NNB in patients with trisomy 21. Among 26 
patients with DS who were reviewed, 4 (15.4%) was reported to have NNB (Handel et al., 
2003). Hicks et al also found higher incidence of NNB cases in DS (Hicks et al., 2007).23 Non-
neurogenic neurogenic bladder has been reported not only in infant and children but also in 
adult patients (Handel et al., 2003; Hicks et al., 2007; Jayanthi et al., 1997; Kai et al., 2007). 
2.3 Etiology 
The etiology of the disease is not clearly defined. Some evidences suggest overtraining of the 
pelvic floor to avoid urine loss due to not only various emotional conditions such as 
depression, phobias, stress, trauma associated with toilet training but also psychiatric 
diseases, the presence of detrusor overactivity and other associated voiding dysfunctions as 
an underlying factors which may contribute to cause NNB (Hoebeke et al., 1996; Koff et al., 
1979; Goldston & Perlmutter, 1973; Schimtt, 1982; Ellsworth, 1995). The well known mental 
retardation and psychological problems in patients with DS may also explain the higher 
incidence of NNB in this trisomy 21.  
In normal voiding function, bladder filling is accommodated at low bladder pressures with 
a bladder outlet that remains closed while bladder emptying requires a coordinated and 
sustained contraction of the bladder muscle with concomitant relaxation of the external 
urethral sphincter. The reflex of micturition is controlled by parasympathetic and somatic 
components of the sacral spinal cord and sympathetic innervation. 
In NNB, functional bladder outlet obstruction is caused by active contractions of the 
voluntary external sphincters during voiding. The inability to inhibit the detrusor 
contraction reflex as well as overactivity of the external sphincter as compensation has 
become fundamental characteristics of patients with NNB (Hinman, 1986). The 
dyssynergistic voiding pattern created by the incoordination between the bladder and 
sphincter contraction reflex may result in impairment of renal function caused by functional 
obstruction (obstructive uropathy) due to unacceptable high voiding pressure with potential 
upper and lower urinary tract deterioration . 
2.4 Diagnosis 
General history-taking should include relevant questions for the screening of NNB. A 
thorough patient history will indicate incontinence associated with chronic urinary 
retention. History-taking in patients with DS is difficult especially in children due to the 
impairment of cognitive function and should be supplemented by information obtained 
from the parents. Because of the intelligence level, some of the existence as well as other 
underlying factors in patients with DS may be masked or neglected resulting in the delay of 
the diagnosis which often seen in clinical practice (Handel et al., 2003; Kai et al., 2007; 
Fernandez & Moore., 1986). 
Although unerderlying factors could not be found in some cases, It is important to make 
sure that history taking have already included all the underlying factors of NNB which may 
guide to the diagnosis (Goldston & Perlmutter, 1973; Schmitt, 1982; Ellsworth et al., 1995). 
Neurological symptoms and abnormalities will not be present in NNB but should be 
confirmed by carefully clinical examination. Laboratory results may show elevated serum 
creatinine and reduce clearance or decreased renal function with or without signs of urinary 
tract infection in most of the cases. 
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Ultrasound is useful to evaluate bladder after voiding which can show residual urine 
volume as well as determine the bladder thickness. In addition, ultrasound is also important 
to detect the upper urinary tract dilatation with or without dilatation of the ureters as a 
complication of functional obstruction in NNB. In trisomy 21, this tool is also useful to 
identify other associated organ anomalies including abnormalities in the kidney.  
To diagnose NNB in trisomy 21 patients, other associated anomalies such as Hirschsprung’s 
disease, spinal cord defects, and posterior urethral valves must be excluded first before 
concluding that they have a functional rather than anatomical obstruction especially those 
who present with constipation, recurrent urinary tract infections, incontinence and voiding 
dysfunction (Handel et al., 2003). In order to rule out the neurological lesions, imaging 
studies of computed tomography (CT) scans and magnetic resonance imaging (MRI) should 
be performed (Johnson et al., 1992). 
Non-neurogenic neurogenic bladder should be suspected if negative results have been 
confirmed by standard rectal biopsies and urological evaluation demonstrates the absence 
of anatomical obstruction and neurological evaluation including imaging studies confirms 
the absence of any neurologic lesions (Handel et al., 2003).  
2.4.1 Voiding-cystourethrography 
Voiding-cystourethrography is an important radiologic tool to show varying grade of 
vesico-ureter reflux in some cases of NNB.  In addition, it also shows bladder appearance as 
a result of functional obstruction such as a trabeculated and enlarged bladder with a lot of 
residual urine still remains in the bladder after voiding without any evidence of mechanical 
obstruction (Fig. 1). 
 
 
Fig. 1. Voiding cystourethrography shows a deformity of the bladder wall with 
trabeculation (left) and narrowing of the posterior urethra as pointed by white arrows with 
significant residual urine (right) without vesico-urethral reflux 
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In contrast, anatomical obstruction by posterior urethral valve can be identified by posterior 
urethral dilatation with poor visualization of the anterior urethra. However, it is important 
to note that the appearance of posterior urethra may entirely normal during early voiding 
but distended after contraction of the external sphincter as voiding progress which was 
found in 4 patients who previously diagnosed with NNB as reported by Johnson et al who 
reviewed the genitourinary images of six boys in whom NNB was diagnosed in the past 5 
years (Johnson et al., 1992). 
2.4.2 Uroflowmetry 
Uroflowmetry is useful for the screening of NNB since it is able to measure the urinary 
stream during the voiding phase, providing information of bladder and outlet function 
(Allan & Bright, 1978; Stanton et al., 1983). In uroflowmetry measurement, it is important to 
pay attention on the the flow pattern beside other important parameters (Vijverberg et al., 
1997). Normal urine flow is continuous bell-shaped curve. Continuous plateau shape curve 
(lower urinary flow rate with prolonged voiding time) is typical for anatomical obstruction.  
In contrast, functional obstruction is typically reflected by a staccato pattern  as interrupted 
flow of urine occurs due to uninhibited external sphincter contraction and usually 
demonstrates intermittency with reduced flow rates and prolonged voiding time (Fig. 2). 
The results also depend on the stage of the disease since the above pattern is hardly ever 
seen in advance cases with atonia of the bladder and poor detrusor contractility due to 
decompensated bladder. Uroflowmetry can also be used as a tool for follow-up of bladder 
training, and biofeedback training (Vijverberg et al., 1997; Hellstrom et al., 1987; Hjalmas, 






Fig. 2. The illustration of normal and abnormal uroflowmetry patterns. 
2.4.3 Urodynamics 
Urodynamics study is the gold standard for the diagnosis of patients with voiding 
dysfunction. (Nitti, 2005) Hypertonicity, instability with impaired external sphincter 
relaxation during micturation are typical characteristics in patients with NNB (Allan & 
Bright, 1978). Electromyography (EMG) shows a spastic activity with a high amplitude 
during voiding phase (Fig. 3).  
Normal Plateau Staccato 
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True detrusor-external sphincter dyssynergia and NNB can be differentiated 
urodynamically (Rudy & Woodside, 1991). Detrusor-external sphincter dyssynergia is 
characterized urodynamically by increasing EMG activity during upslope and decreasing 
activity during down slope of the intravesical pressure tracing during a detrusor 
contraction. However, NNB is characterized urodynamically by quieting of the EMG during 













Fig. 3. Urodynamic results indcate a decrease in the bladder sensation without detrusor 
overactivity. A low urinary flow rate with a high detrusor pressure is shown in the voiding 
phase. Electromyography shows a spastic activity with a high amplitude during voiding. 
(Filling rate = 50 ml/min). 
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Management of patients with NNB must be focused on the relaxation of external urethral 
sphincter muscle in order to obtain a more physiological micturation with relaxed sphincter 
muscle during voiding and to restore the balance of voiding and voluntary sphincter 
contraction reflex to prevent upper and lower urinary tract deterioration. The additional 
goals of treatment include prevention of urinary tract infections with proper antibiotics. The 
management should be addressed to all patients regardless of their intellectual capacity 
including those with trisomy 21. The intellectual Impairment of patients with DS may cause 
some difficulties in conducting the treatment.  
Anti-cholinergics and alpha blocker therapy either alone or in combination may be useful in 
the treatment of NNB (Krane & Olsson, 1973; Paul et al., 1999; Bogaert et al., 2004) since 
significant improvement in emptying was shown in neurogenic cases treated with non 
selective alpha blocker (Krane & Olsson, 1973). If there is no response to conservative 
treatment, intermittent catheterization may be required. Trisomy 21 associated NNB 
patients with abnormal voiding mechanism against a closed sphincter may deal with the 
difficulty in conducting urethral clean intermittent catheterization due to their intellectual 
limitation (Handel et al, 2003).   
Surgical treatment for renal preservation is also required for social continence. Self-
catheterization protocols via the catheterizable stoma may allow trisomy 21 patients with a 
sufficient intellectual level master such techniques. Patients with NNB who are refractory to 
conservative treatment or present with an advanced pathological condition may require 
surgical intervention. Augmentation of the bladder in order to increase the bladder capacity 
may still be required in those in whom the upper tracts are threatened (Handel et al, 2003). 
The use of Botulinum-A toxin injection into detrusor or the external sphincter may help 
cause striated muscle paralysis and may also restore voiding function especially in those 
who failed with drug therapy (Schurch et al., 1996). Patients with NNB in DS could also be 
performed such procedure. This particular treatment is dose dependent and also reversible. 
Injection may be necessary in every two months.  
3. Summary  
Children with trisomy 21 have many associated multi organ anomalies including urological 
abnormalities. Non-neurogenic neurogenic bladder is the most frequent DS associated lower 
urinary tract disorder. Early diagnosis and prompt management should be conducted in 
order to prevent upper urinary tract deterioration. According to the high incidence of NND 
in DS, early and regular sonographic and urodynamic evaluation of the bladder function is 
mandatory in patients with Down syndrome. 
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1. Introduction  
Down syndrome (DS) is associated with many neurological complications including 
cognitive deficits, early-onset dementia -which resembles Alzheimer’s disease- and seizures. 
Although seizures and epilepsy were not mentioned in the original description of DS 
(Down, 1866)  the prevalence of seizures in individuals with DS is now known to be higher 
than in the general population, but lower than in patients with some other types of mental 
retardation (Corvett et al., 1975). Reported rates of epilepsy in DS range from 1 to 13% (see 
table 1) (Tatsumo et al., 1984). Individual series are difficult to compare because of 
differences in inclusion criteria and study populations. The increased seizure susceptibility 
in DS has been attributed to inherent structural and molecular anomalies of the brain or to 
associated medical complications, such as cardiovascular abnormalities and recurrent 
infections. 
Medical interventions in DS have resulted in increased longevity, with estimated life 
expectancy of people with DS in developed countries increasing from an average of 12 years 
in the 1940s to an average of 57,8  years for women and 61,1  years for men (Bittles et al., 
2007). Epilepsy onset in people with DS is age-specific; therefore, because certain 
complications will arise in childhood and others in adulthood, their occurrence is relevant to 
paediatric and adult neurologists. This chapter will provide a critical overview of epilepsy 
in DS.  
                   
Authors  No. of patients Percentage (%) 
Romano et al.    113 13.00
Pueschel et al.   405 8.10
Stafstrom et al.    737 6.40
Table 1. Reported incidence of seizures in patients with Down syndrome in the 1990s 
2. Epidemiology 
Patients with DS show a higher incidence of febrile and non febrile seizures than non-DS 
individuals. Seizures occur in a bimodal distribution in DS, with 40% of individuals first 
developing seizures before 1 year of age and another 40% having an onset in their thirties or 
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2. Epidemiology 
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individuals. Seizures occur in a bimodal distribution in DS, with 40% of individuals first 
developing seizures before 1 year of age and another 40% having an onset in their thirties or 
  
Genetics and Etiology of Down Syndrome 
 
242 
later (Pueschel et al., 1991). Boys tend to have an earlier age onset, regardless of seizure type, 
although this may reflect the general male predominance in the infantile spasm group aged 
less than 1 year at onset. The prevalence of epilepsy increases with age and reaches 46% in 
those over 50. In general, about 8% of patients with DS have seizure disorders: 47% of  
them develop partial seizures, 32% infantile spasms and 21% generalized tonic-clonic 
seizures.  
3. Pathophysiology  
The mechanisms underlying the increased seizure susceptibility in DS have not yet been 
completely elucidated. Seizures in infancy have been linked to inherent structural brain 
abnormalities, such as fewer inhibitory neurons, abnormal cortical lamination, persistent 
fetal dendritic morphology, and underdeveloped synaptic profiles (Kemper et al., 1988). 
Concentrations of carbonic anhydrase II, which potentially increases seizure susceptibility, 
are upregulated in the brains of young children with DS and in a mouse model of the 
disorder. (Palminello et al., 2008)  (Tatsuno et al., 1984). 
Altered membrane potassium permeability, which may lead to a decreased voltage 
threshold for spike generation, smaller hyperpolarization following spikes, or increased 
action potential duration, has also been documented in patients with DS. Indeed, in the 
mouse model of trisomy 16, the experimental model of DS, a rapid spike rise and fall was 
recorded from the dorsal root ganglia neurons (Scott et al., 1981) 
In DS there is an overexpression of the 21st chromosome. Many enzymes that are encoded on 
the extra 21st chromosome are known to be actively transcribed, which results in 
overexpression of the enzymes, overconsumption of enzymatic substrates and overproduction 
of metabolic end-products. For example, the superoxide dismutase-1 gene on the 21st 
chromosome is approximately 50% overexpressed, which decreases levels of superoxide (the 
enzyme’s substrate) and increases  levels of hydrogen peroxide (the enzyme’s metabolite, end 
product or output). These primary consequences of genetic overexpression may then produce 
secondary metabolic adaptations as homeostatic systems attempt to compensate. Thus, 
decreased levels of superoxide might alter levels of nitric oxide, peroxynitrate, and nitric oxide 
synthetase, or they may impair aromatic hydroxylation  enzymes and thereby impair 
neurotransmitter synthesis. For another example, increased levels of hydrogen peroxide might 
induce glutathione peroxidase production and thereby increase selenium requirements. Such 
genetically driven enzymatic and metabolic disturbances may help explain why individuals 
with DS appear to be more likely to develop various forms of epilepsy and intractable epilepsy 
(Smigielska-Kuzia et al. 2009). 
Seizures can also be regarded as complications of congenital cardiovascular anomalies in 
children with DS (Marsh et al., 2009). Moyamoya’s disease is a rare vascular complication 
which seems to occur with a higher frequency in children with DS than in those without it. 
Moyamoya’s disease is characterised by a chronic occlusive cerebrovascular alteration of 
unknown pathogenesis in which there is progressive stenosis of the supraclinoid portions of 
the internal carotid arteries. Associated with this stenosis is the formation of convoluted 
arterial collaterals at the base of the brain. Although the presentation of Moyamoya’s disease 
in adults is haemorrhagic, the presenting symptoms in children are typically ischaemic, with 
a fixed unilateral neurological deficit or alternating hemiplegia. Some children with Down’s 
syndrome who have Moyamoya’s disease also develop seizures or involuntary movements. 
(Nascimento et al. 2006). 
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Adult-onset seizures in the absence of dementia are rare in people with DS but might 
become more frequent in the future because of the extension of the lifespan of people with 
the disorder. Late-onset seizures in people with DS seem to be associated with a propensity 
to dementia resembling Alzheimer’s disease. The cause of seizures in adults with DS who 
do not have dementia is not yet clear (Puri, 2001) 
Once seizures occur in the course of dementia in patients with DS, functional decline is often 
rapid, to the point where floor effects preclude further cognitive testing. Seizures are 
common in people with early-onset Alzheimer’s disease associated with genetic defects, 
including mutations that result in overexpression of amyloid-β, such as those involving 
presenilin 1 genes. Animals with overexpression of the APP gene have a lower threshold to 
induced seizures. High concentrations of amyloid-β caused by APP overexpression result in 
epileptiform activity in vivo, even in the absence of neurodegeneration, suggesting that 
these high concentrations are a direct cause of epilepsy. (T Llot 2010).  
4. Clinical and electrophysiological features  
Epilepsy in DS showed a bimodal distribution; in the younger age group, infantile spasms 
and tonic-clonic seizures with myoclonus are the main finding, whereas older patients often 
have partial simplex or partial complex seizures as well as tonic-clonic seizures (Pueschel et 
al., 1991).  
4.1 Seizures in infancy and childhood 
It is currently known that there is a higher incidence of seizures, particularly infantile 
spasms, in DS compared to the general population. Few children with DS have their first 
epileptic attacks after the age of 3. These patients often have partial simplex or partial 
complex seizures as well as tonic-clonic seizures.  
Infantile spasms are an age-dependent epilepsy that most frequently appears in the first 
year of life, with ictal episodes consisting of spasms that usually occur in clusters  
(Dulac et al., 1994). There is a characteristic chaotic and high-voltage interictal 
electroencephalography (EEG) pattern, which, when typical, is called hypsarrhythmia. 
West’s syndrome is the term employed when such spasms are concomitant with delayed 
psychomotor development and EEG hypsarrhythmia. It has been reported that 6.4% of 737 
patients with DS had epilepsy, and 12.8% of epileptic patients with DS had West syndrome. 
In addition, it has been reported that 8.1% of 405 patients with DS had epilepsy in 
childhood, and 18% of the epileptic patients were diagnosed as having infantile spasms. 
Infantile spasms, which often indicate poor prognosis in the general population, do not 
seem to be associated with difficulties in long-term seizure control in children with DS. 
However, in children with DS who have infantile spasms, there seems to be a substantial 
association between treatment and developmental quotient as well as progression to 
autistic features. There are no long-term studies of the intellectual outcome of children 
with DS in whom infantile spasms were successfully controlled. In our experience, 
patients with Down syndrome with infantile spasms and abnormal but non-
hypsarrhythmic EEG may have poor disease progression (figure 1 a and b & Figure 2 a 
and b), with persistence of seizures and severely impaired psychomotor development  
(Nascimento & Ortez 2009).  
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later (Pueschel et al., 1991). Boys tend to have an earlier age onset, regardless of seizure type, 
although this may reflect the general male predominance in the infantile spasm group aged 
less than 1 year at onset. The prevalence of epilepsy increases with age and reaches 46% in 
those over 50. In general, about 8% of patients with DS have seizure disorders: 47% of  
them develop partial seizures, 32% infantile spasms and 21% generalized tonic-clonic 
seizures.  
3. Pathophysiology  
The mechanisms underlying the increased seizure susceptibility in DS have not yet been 
completely elucidated. Seizures in infancy have been linked to inherent structural brain 
abnormalities, such as fewer inhibitory neurons, abnormal cortical lamination, persistent 
fetal dendritic morphology, and underdeveloped synaptic profiles (Kemper et al., 1988). 
Concentrations of carbonic anhydrase II, which potentially increases seizure susceptibility, 
are upregulated in the brains of young children with DS and in a mouse model of the 
disorder. (Palminello et al., 2008)  (Tatsuno et al., 1984). 
Altered membrane potassium permeability, which may lead to a decreased voltage 
threshold for spike generation, smaller hyperpolarization following spikes, or increased 
action potential duration, has also been documented in patients with DS. Indeed, in the 
mouse model of trisomy 16, the experimental model of DS, a rapid spike rise and fall was 
recorded from the dorsal root ganglia neurons (Scott et al., 1981) 
In DS there is an overexpression of the 21st chromosome. Many enzymes that are encoded on 
the extra 21st chromosome are known to be actively transcribed, which results in 
overexpression of the enzymes, overconsumption of enzymatic substrates and overproduction 
of metabolic end-products. For example, the superoxide dismutase-1 gene on the 21st 
chromosome is approximately 50% overexpressed, which decreases levels of superoxide (the 
enzyme’s substrate) and increases  levels of hydrogen peroxide (the enzyme’s metabolite, end 
product or output). These primary consequences of genetic overexpression may then produce 
secondary metabolic adaptations as homeostatic systems attempt to compensate. Thus, 
decreased levels of superoxide might alter levels of nitric oxide, peroxynitrate, and nitric oxide 
synthetase, or they may impair aromatic hydroxylation  enzymes and thereby impair 
neurotransmitter synthesis. For another example, increased levels of hydrogen peroxide might 
induce glutathione peroxidase production and thereby increase selenium requirements. Such 
genetically driven enzymatic and metabolic disturbances may help explain why individuals 
with DS appear to be more likely to develop various forms of epilepsy and intractable epilepsy 
(Smigielska-Kuzia et al. 2009). 
Seizures can also be regarded as complications of congenital cardiovascular anomalies in 
children with DS (Marsh et al., 2009). Moyamoya’s disease is a rare vascular complication 
which seems to occur with a higher frequency in children with DS than in those without it. 
Moyamoya’s disease is characterised by a chronic occlusive cerebrovascular alteration of 
unknown pathogenesis in which there is progressive stenosis of the supraclinoid portions of 
the internal carotid arteries. Associated with this stenosis is the formation of convoluted 
arterial collaterals at the base of the brain. Although the presentation of Moyamoya’s disease 
in adults is haemorrhagic, the presenting symptoms in children are typically ischaemic, with 
a fixed unilateral neurological deficit or alternating hemiplegia. Some children with Down’s 
syndrome who have Moyamoya’s disease also develop seizures or involuntary movements. 
(Nascimento et al. 2006). 
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Fig. 1. EEG of an 8m21d boy with DS.  a)  In a sleep stage, no physiological graphoelements 
were observed and there were very frequent multifocal paroxysms in the form of high-
voltage spike-wave complexes; paroxistic alterations persisted during the waking stage. b) 
There was an electroclinical episode consisting of the emergence of a high-voltage spike-
wave complex clinically accompanied by extension and abduction of the upper limbs and a 
slight extension of the lower limbs. Note the contraction recorded over both deltoid muscles. 
 












Fig. 2. EEG of a 3-year-old girl with DS initially affected by West’s syndrome who then 
evolved to Lennox-Gastaut syndrome. a) Tonic seizure: Ictal electroencephalography (EEG) 
shows a diphasic, mid-voltage slow wave, followed by recruiting low-voltage fast activity, 
replaced by spike and polyspike and wave discharges; tonic contraction was recorded over 
both deltoid muscles. b) Waking stage: brain activity constituted by an association of delta 
and theta waves and low-voltage beta rhythms, with a diffuse distribution. Frequent focal 
paroxysms were observed in the form of spikes and complex spike-waves of irregular 
medium and high amplitude, located independently in the frontal and parieto-occipital 
regions of both hemispheres. 
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There is a chance that DS in association with West’s syndrome may evolve to Lennox-Gastaut 
syndrome (LGS). LGS has classically been defined by the triad of drug-resistant epilepsy with 
multiple seizure types, typically diurnal atonic as well as atypical absences, and mainly 
nocturnal tonic seizures; electroencephalography abnormalities, principally diffuse slow spike-
wave or polyspike-wave discharges during wakefulness and bursts of diffuse fast rhythms at 
10–20 Hz during sleep; mental deterioration of variable severity as well as behavioural 
disturbances may also occur (Gastaut et al., 1966; Dulac & N’Guyen, 1993). A series of DS 
patients with late onset LGS has been described, having a higher frequency of reflex seizures 
and more cognitive impairment ( Figure 3). (Ferlazzo et al., 2009) 
 
 
Fig. 3. 7-year-old boy. Tonic seizure triggered by a sudden noise (black arrow). Note the 
marked tonic contraction recorded over both deltoid muscles. Ictal electroencephalography 
(EEG) shows a diphasic, mid-voltage slow wave, followed by recruiting low-voltage fast 
activity, replaced by spike and polyspike and wave discharges, predominant over anterior 
leads, lasting for about 10 s. Electrocardiography shows an increased heart rate during 
seizure. Zoom: detail of the ictal discharge recorded over the vertex derivation, where 
muscular artifacts are less evident. (Ferlazzo et al. 2009) 
Why do some infants with DS develop infantile spasms, whereas others with the same 
disorder do not? The cause has never been fully understood. Naming DS as the ‘‘cause’’ of 
the infantile spasms may, therefore, be at best inaccurate and at worst totally misleading, 
suggesting that we understand why the disorder has arisen in that particular child when DS 
has merely predisposed the child to infantile spasms. Only a few infants with Down 
syndrome develop infantile spasms, yet Down syndrome is accepted (Eisermann et al., 2003) 
as a ‘‘cause,’’ and frequently such infants are not given a brain scan. As a result, other 
authors have proposed adopting a terminology that distinguishes the underlying etiology 
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from the cause. According to this scheme, we use the term proven etiology to refer to any 
identified underlying neurological disorder, and employ cause as a more specific term that 
may be a complex and less well-understood sequence or combination of events. Perhaps 
because of the many different diagnoses that can be made in these infants and the 
developmental outcomes associated with them, classification into diagnostic groups has 
been commonly attempted. (Osborne et al., 2010) 
The most frequent nomenclature has classified cases as either symptomatic, cryptogenic, or 
idiopathic, but unfortunately there is no clear definition of these terms (Lux & Osborne, 
2005). “Symptomatic” is often used to indicate that a prior disorder exists. “Cryptogenic” is 
often used to mean that there must be an etiology, but that one has not been found. A recent 
report of the International League Against Epilepsy (ILAE) Commission on Classification 
and Terminology also suggests that the terms idiopathic, symptomatic, and cryptogenic 
should be replaced (Berg et al., 2010). It has suggested broad etiologic categories: genetic, 
structural–metabolic, and unknown. 
4.2 Seizure in adulthood 
The prevalence of epilepsy in DS has increased with longevity, reaching 46% in those older 
than 50. Descriptions of late-onset epilepsy in the absence of dementia in DS patients 
(LOMEDS) are rare, but since life expectancy of DS patients has markedly increased, 
LOMEDS may be more frequent than currently acknowledged and should be considered in 
the differential diagnosis of adult-onset myoclonic epilepsies. The electroclinical features are 
myoclonic jerks on awakening and generalised tonic-clonic seizures, with generalised spike 
and wave on EEG, and progressive dementia (Moller et al., 2002). 
Familial Alzheimer’s dementia (FAD) and progressive myoclonic epilepsy (Unverricht–
Lundborg type) are both linked to chromosome 21. In an interesting study of 68 DS adults, it 
was found that among those with a history of seizures, individuals aged over 45 years were 
significantly more likely to develop AD than those under 45, and up to 84% of demented 
individuals with DS developed seizures. It suggests that late-onset epilepsy in DS is 
associated with AD, while early-onset epilepsy is associated with an absence of dementia 
(Menéndez, 2005). 
Seizures in adults with DS differ from those in adults with Alzheimer’s disease who do not 
have DS: myoclonic seizures usually occur late in the course of Alzheimer’s disease whereas 
partial or tonic–clonic seizures occur in adults with Down’s syndrome and are often 
precursors to cognitive decline. Adults with DS aged over 45 years who have seizures are 
substantially more likely to develop signs of Alzheimer’s disease (Puri et al; 2001). Once 
seizures occur in the course of dementia in patients with DS, functional decline is often 
rapid, to the point where floor effects preclude further cognitive testing. Seizures are 
common in people with early-onset Alzheimer’s disease associated with genetic defects, 
including mutations that result in overexpression of amyloid-β, such as those involving 
presenilin 1 genes.  
Animals with overexpression of the APP gene have a lower threshold to induced seizures. 
High concentrations of amyloid-β caused by APP overexpression result in epileptiform 
activity in vivo, even in the absence of neurodegeneration, suggesting these high 
concentrations directly as a cause of aberrant neuronal network synchronisation. Slowing 
of the dominant occipital rhythm seems to be associated with dementia in individuals 
with DS, and the frequency of dominant occipital activity decreases as cognition 
deteriorates. 
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4.3 Seizure in Alzheimer´s and DS  
Despite the apparent clinical heterogeneity in aged individuals with DS, age-associated AD-
like neuropathology is a consistent feature. This is due to the fact that trisomy 21 leads to a 
dose-dependent increase in the production of the APP and subsequently the production of 
the amyloidogenic fragments leading to early and predominant senile plaque formation. 
Ten percent of patients with AD have seizures, and another 10% have myoclonus. The 
incidence of seizures is about 10 times higher than expected in a reference population. Both 
seizures and myoclonus, individually or together, are manifestations of AD and may be seen 
at any time in the course of the illness, but myoclonus is often a late manifestation. (Volicer 
et al., 1995) 
4.4 Electroencephalography (EEG) features  
Individuals with DS have increased absolute power in all the EEG bands, independent of 
cognition functions. In the power spectrum of the resting EEG, there is a cognition-related 
increase in power at theta- and alpha-slowing. Furthermore, in the stimulated EEG, there 
are several cognition-related abnormalities, such as decreased responses to 12-Hz 
stimulation and decreased integral of beta- and gamma-band responses, indicative of 
decreased responsiveness to photic stimulation. Other reports note an increase in power at 
theta and delta in children with DS during sleep. (S’migielska-Kuzia et al., 2009). There is a 
significant increase in theta, delta, and beta power and a decrease in alpha compared with 
non-DS with epilepsy. (Figure 3) 
 
 
Fig. 3. Spectral power of alpha, theta, delta, and beta bands of DS, n = 12, DS Non-Epilepsy 
(Non-Epi) n=10 versus Non-DS (epileptic children) n = 28. Alpha Non-DS versus alpha DS P 
< .001; alpha Non-DS versus alpha DS Non-Epi P = .001; alpha DS versus alpha DS Non-Epi 
P < .001; theta Non-DS versus theta DS P = .767; theta Non-DS versus theta DS Non-Epi P < 
.001; theta DS versus theta DS Non-Epi P < .001; delta Non-DS versus delta DS P < .001; 
delta Non-DS versus delta DS Non-Epi P < .001; delta DS versus delta DS Non-Epi P < 
.001;beta Non-DS versus beta DS P < .001; beta Non-DS versus beta DS Non-Epi P < .001; 
beta DS versus beta DS Non-Epi P < .001. (S’migielska-Kuzia et al., 2009) 
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5. Treatment of epilepsy in DS 
The pharmacological treatment of epilepsy in DS is no different from that of other patients 
diagnosed with epilepsy; the key is proper clinical and electrical classification to guide 
epilepsy treatment and thereby obtain good therapeutic results. 
Although the cognitive profiles of newer antiepileptic drugs (AEDs) are in general better 
than those of older antiepileptic drugs, neurological adverse events do occur, including 
somnolence, distractibility, dizziness, and an altered pattern of sleep architecture. 
Individuals with DS have an unusually high number of side-effects from phenytoin 
(Tsiouris et al., 2002).  
Over time, with the advent of advances in molecular biology, many AEDs have been 
uncovered, so they have come to be classified as first-, second- and third-generation drugs. 















Table 2. Antipileptica drugs by generation 
Figures 4 a & b and table 3 describe the different mechanisms of action demonstrated for  
antiepileptic drugs (AEDs).  
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Fig. 4. a& b Proposed mechanisms of action of currently available AEDs at excitatory and 
inhibitory synapses. 
a | Currently available antiepileptic drugs (AEDs) are thought to target several molecules at 
the excitatory synapse. These include voltage-gated Na+ channels, synaptic vesicle 
glycoprotein 2A (SV2A), the α2δ subunit of the voltage-gated Ca2+ channel, AMPA (α-
amino-3-hydroxy-5-methyl-4-isoxazole propionic acid) receptors, and NMDA (N-methyl-D-
aspartate) receptors. Many of the AEDs can modulate voltage-gated Na+ channels. This 
would be expected to decrease depolarization-induced Ca+ influx and vesicular release of 
neurotransmitters. In addition, lacosamide is thought to enhance slow inactivation of 
voltage-gated Na+ channels. This effect is different from that of other listed AEDs, which are 
thought to enhance fast inactivation. Levetiracetam is the only available drug that binds to 
SV2A, which might have a role in neurotransmitter release. Gabapentin and pregabalin  
bind to the a2δ subunit of voltage-gated Ca2+ channels, which is thought to be associated 
with a decrease in neurotransmitter release. Excitatory neurotransmission at the 
postsynaptic membrane can be limited by topiramate (acting on AMPA and kainate 
receptors) and felbamate (acting on NMDA receptors). 
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 b | AED targets at inhibitory synapses have also been proposed. These include the g-
aminobutyric acid (GABA) transporter GAT1 (also known as SLC6A1), which is inhibited by 
tiagabine, leading to a decrease in GABA uptake into presynaptic terminals and 
surrounding glia; and GABA transaminase (GABA-T), which is irreversibly inhibited by 
vigabatrin. This decreases the metabolism of GABA in presynaptic terminals and glial cells. 
The benzodiazepines, barbiturates, topiramate and felbamate have been found to enhance 
inhibitory neurotransmission by allosterically modulating GABAA receptor-mediated Cl− 
currents. However, the action of each of these drugs is different and is dependent on the 
subunit conformation of the GABAA receptor complex. GAD, glutamic acid decarboxylase. 
(Bailer & White 2010). 
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Table 4 describes the different AEDs and the main indication for the type of epilepsy 
diagnosed. Table 5 describes the AEDs, dose in children and adults and side effects. 
 
FIRST GENERATION 
AEDs MAIN INDICATION 
Benzodiazepines Status epilpeticus. Partial an generalizated seizures 
Carbamazepine Partial seizures (with and whithout secondary 
generalization) and primarily generalized tonic-clonic 
seizures. 
Ethosuximide Absence seizures, continuous spike – waves during slow 
sleep. 
Phenytoin Partial seizures (with and whithout secondary 
generalization) and primarily generalized tonic-clonic 
seizures. Status epilepticus.  




Felbamate Severe epilepsies, particulary Lennox-Gastaut syndrome, 
refractory to all other AEDs. 
Gabapentin Partial seizures (with and whithout secondary 
generalization) 
Lamotrigine Partial and generalized seizures (may aggravate severe 
myoclonic epilepsy of infancy) 
Levetiracetam Partial and probably generalized seizures. 
Oxcarbamacepine Partial seizures (with and whithout secondary 
generalization) and primarily generalized tonic-clonic 
seizures. 
Pregabalin Partial seizures (with and whithout secondary 
generalization). 
Tiagabaline Partial seizures (with and whithout secondary 
generalization). 
Topiramate Partial and generalized seizures (efficacy against absence 
seizures not proven) 
Vigabatrin Infantile spasms and West Sindrome. Partial seizure (with 
and whithout secondary generalization) refractory to all 
other AEDs. 
Zonisamide Partial and, probably, generalized seizures. 
 
Table 4. AEDs and the main indication for the type of epilepsy diagnosed 
 











Dose mg/day. Side Effects. 
Carbamacepine 15-30  600 – 2000 mg divided into 
up to 4 doses a day. 
Skin rash, if allergic to 
carbamazepine. Diplopia 
(double vision), ataxia 
(unsteadiness) and nausea 
may occur initially or if 
the dose is too high. 
Clobazam 0,1-0,2  20 - 50 mg divided into 1 or 
2 doses a day. 
Drowsiness may occur but 
this drug is less sedating 
than clonazepam or 
diazepam. Tolerance may 
develop. 
Clonazepam 0,5-0,8 1 – 4 mg divided into 2 
doses a day. 
Drowsiness and sedation 
are quite common but 
these may wear off.  
Ethosuximide 20-35 750 – 1500 mg divided  into 
2 or 3 doses a day. 
Nausea and drowsiness 
may occur initially or if 
the dose is too high. 
Anorexia (weight loss). 
Gabapentine 30 1800 – 3600 mg  divided 
into 3 doses a day. 
Drowsiness, dizziness, 
and headache 
Levetiracetam 20-60 1000 – 3000 mg divided into 





tremor, headache, nausea 
may occur in high dosages 
or when doses are 
increased, but will usually 
disappear after a few 
days. 
Lamotrigine 5-15  
1-5 + VPA 
 
100  - 200mg if taken alone 
or if also taking sodium 
valproate. 200 – 400 mg if 
also taking phenytoin , 
Skin rash if allergic to 
lamotrigine. Drowsiness, 
diplopia (double vision), 
dizziness, headache, 
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Dose mg/day. Side Effects. 
phenobarbitone or 
carbamazepine. 
insomnia, tremor and flu-
like  symptoms. 
Oxcarbamazepine 15-30 1200 - 2400mg divided into 
2 or 3 doses a day. 
Skin rash, if allergic to 
oxcarbazepine. Diplopia 
(double vision), ataxia 
(unsteadiness), headache, 
nausea, confusion and 
vomiting. 
Phenobarbital 3-5 30 – 180 mg divided into 2 
doses a day. 
Drowsiness may occur 
initially. Lethargy, 
sedation and slowing of 
mental performance may 
be long-lasting. 
Phenytoin 5-10 150 – 600 mg divided into 1 
or 2 doses a day. 
Skin rash if allergic to 
phenytoin. Drowsiness, 
ataxia (unsteadiness) and 
slurred speech may occur 
if the dose is too high. 
Coarsening of facial 
features, overgrowth of 
gums, excess hair growth 
and acne may occur with 
prolonged therapy (over 
many years), as can some 
anaemias. 
Topiramate 5-9 Up to 400 mg daily if taken 
alone. Usually 200 – 400 mg 
daily if taken with other 




(pins and needles in hands 
and feet), loss of weight, 
and kidney stones. Speech 
disorder, impaired 
memory and 
concentration may occur 
when dose is increased 
 











Dose mg/day. Side Effects. 
but will usually disappear 
after a few days.  
Sodium 
valproate 
20-50 400 – 2000 mg divided into 
1 or 2 doses a day. 
Drowsiness and tremor 
are infrequent side effects. 
Hair loss occurs in some 
people but is not usually 
severe and is usually 
reversible if the dose is 
reduced. Weight gain may 
occur. Liver. damage is 
rare. Sodium valproate 
has been associated with 
increased incidence of 
Polycystic  Ovary 
Syndrome and menstrual 
irregularitiesthan other 
AEDs, if taken in 
pregnancy. 
Vigabatrine 50-200 1000 – 4000 mg divided into 
1 or 2 doses a day. 
Drowsiness, behaviour 
and mood changes. 
Psychotic reactions have 
been reported. Visual field 
defects have been 
reported in one in three 
people taking vigabatrin 
in the long term.  
Zonizamide 4-8 300  - 500mg divided into 1 
or 2 doses a day. 
Skin rash if allergic to 
zonisamide. Drowsiness, 
dizziness, weight  
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The findings of the last decade regarding the significant percentage of children with DS and 
epilepsy (approximately 1 in 10) highlight the importance of the awareness that physicians 
should start developing about this association so that they can intervene as early as possible 
when seizures are suspected, to maximize the patient’s development and improve quality of 
life as much as possible. 
The diagnosis, classification and treatment of epilepsy in DS must follow the guidelines 
applied to the general population. 
Children with DS have a greater predisposition to epilepsy (specifically to West Syndrome 
and infantile spasms) attributed to structural and molecular abnormalities. In contrast, in 
adults with DS, epilepsy is associated with the accumulation of amyloid-β, due to the 
expression of APP that is observed in DS patients with early-onset Alzheimer-like dementia. 
The prognosis of patients with DS and epilepsy will depend on several factors:  type of 
epilepsy, age of initiation, etiology, early diagnosis and treatment’s response. Epilepsy in 
patients with DS, as well as in the general population, in most cases represents an alteration 
of brain function that can be detrimental to neurological development; this produces a great 
amount of anxiety and concern in their parents and relatives. For this reason, all of the 
prognostic factors must be carefully taken into account when considering each individual 
case. The disease, its control and its management should be discussed in a clear and simple 
way with the family.  
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1. Introduction  
One of the goals of Healthy People 2011 is to increase the quality of life and the years of 
healthy life of all citizens. As the life expectancy of people with Down Syndrome [DS] 
increases, changes in body function and structure due to ageing may lead to lead to activity 
limitations and participation restrictions for this population. The physical conditions seen in 
people with DS include endocrine dysfunction, cardiovascular disorders, obesity, and 
musculoskeletal disorders (Finesilver, 2002; Thompson, 1999). These physical problems can 
have a negative impact on the quality of life, regarding both professional and leisure 
activities.  
Compared with their peers who are not mentally retarded, individuals with DS, regardless 
of their age, have lower cardiovascular fitness levels (Horvat & Croce, 1995; Tsimaras et al., 
2003). This lower level of cardiovascular fitness may be the result of poor eating habits, a 
sedentary lifestyle, a lack of opportunity for recreational activities, a poor coordination, and 
a poor motivation for physical activity. In addition, the lack of cardiovascular fitness may be 
due to or caused by the high obesity rates observed among adults with mental retardation 
(Draheim et al., 2002). Poor cardiovascular fitness levels also may contribute to an increased 
risk of heart disease and stroke in adults with mental retardation (Sutherland et al., 2002). 
Therefore, involvement in cardiovascular conditioning programs would seem to be 
essential, however, can the cardiovascular fitness levels of these individuals, be improved 
with exercise, without major health risks?  
If exercise programs seem to be likely to improve the health of adults with DS, thereby 
increasing their quality of life and life expectancy, yet further research is needed to 
investigate the effects of exercise on adults, because some autonomic nervous regulations 
and endocrine adaptations are known to be inadequate in individuals with DS (Baynard et 
al., 2004; Figueroa et al., 2005; Iellamo et al., 2005; Gouloupoulou et al., 2006; Bricout et al. 
2008). 
2. Situation of the subject in international literature 
One hypothesis explaining the improvements in life expectancy of DS individuals is based 
on the physical stimulation and psychological standing of these subjects (Eberhard et al., 
1989; Draheim et al., 2002). Now, adults with trisomy 21 are living longer than previously 
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and individuals surviving into their sixth or seventh decade of life are encountered (Prasher 
& Krishnan, 1993). So, there is a need for an overall assessment of the health of adults with 
trisomy 21, and specifically as the sport activities helps improve the quality of life, and 
reduce risk factors, it seems important to know the possible effects of physical exercise on 
the health of these young people with Down syndrome. 
In this order, few studies have investigated cardiac and hormonal responses in patients with 
Down syndrome subjected to acute physical exercise (Murdoch, 1977; Murdoch et al. 1978; 
Fernhall & Otterstetter, 2003; Baynard et al., 2004; Iellamo et al., 2005; Figueroa et al., 2005; 
Gouloupoulou et al., 2006). The conclusions of these few studies show that there are 
inappropriate responses that lead to the appearance of early fatigue, a premature stop of the 
effort, and/or a limitation to the activity. It was previously suggested that fatigue during 
exercise, or at least premature stop or the incapacity to do prolonged physical exercise in DS 
subjects, may partly be explained by a dysfunction of the autonomic nervous system [ANS] 
(Baynard et al., 2004; Iellamo et al., 2005; Figueroa et al., 2005; Gouloupoulou et al., 2006).  
Secondly, others studies have investigated the hormonal adaptation’s in specific physical 
tests and the results of all these works agree to show that heart rate [HR] is lower (-7 to 15 
beats per minute) in DS individuals. Specifically, numerous studies hypothesized that the 
lower catecholamine responses (epinephrine and norepinephrine) in DS population to 
maximal exercise could explain the weaker heart rate (Fernhall et al., 2009).   
These observations are reinforced by the results of a work achieved by Eberhard et al., (1989, 
1991) and Bricout et al., (2008) evaluating catecholamine’s kinetics during and after exercise. 
These authors showed that the plasma concentrations of epinephrine and norepinephrine 
after an exercise on bicycle or on treadmill were lower in subjects with DS than in control 
subjects, and could partly explain the relatively low elevation of HR during exercise, named 
"chronotropic incompetence”. 
However, some others factors may explain the reduced aerobic capacity and the possible 
incapacity to long physical exercise in DS. If endocrine dysfunction, cardiovascular 
pathologies, obesity, and musculoskeletal disorders are now well established as limiting to 
do prolonged physical exercise, DS individuals were also not highly motivating to repeat 
exercise, which contributes to more easily adopt a sedentary lifestyle, because the effort can 
be quickly perceived as painful, difficult and without sense for them.  
The mechanisms of exercise intolerance in trisomy 21 require further consideration and in 
particular the relationship between the sympathetic nervous system, hormonal system 
which its importance in the adaptation effort is crucial. 
Thus, many studies confirm that DS subjects present some endocrine diseases, such as 
diabetes, hypothyroidism, and insulin resistance ... (Murdoch, 1977; Murdoch et al. 1978; 
Sharav et al., 1991; Sasagawa et al., 1993; Konings et al., 2001). In a study conducted at the 
University Hospital of Grenoble between 2003 and 2005, on 14 young adults with trisomy 
21, some of these endocrine disorders at rest (hypothyroidism and hypogonadism) were 
confirmed. 
During muscular effort, it was shown that the responses of the adrenal axis (cortisol and 
catecholamine) and gonadal axis (testosterone) especially are the most affected when 
exercise is prolonged. Indeed, with exercise, the elevated catecholamine response, classically 
described in healthy subjects (Galbo, 1985) is lower in DS patients, and it can be suggested 
that the decreased response of catecholamine during effort in DS subjects explains the lesser 
capacity of these subjects to perform a muscular exercise which intensity and duration rise 
(Nagaoka et al., 1996; Fernhall & Otterstetter, 2003,). 
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In addition, some studies show that in patients with Down syndrome without adrenal 
insufficiency, basal cortisol is always lower (Murdoch, 1977; Murdoch et al. 1978). The 
pathogenesis of this observation remains difficult to explain, although it may have metabolic 
and physiological implications. During muscular exercise, the elevation of plasma cortisol, 
classically described in healthy subjects does not occur in DS subjects (Eberhard et al., 1993; 
1996). Several hypotheses may be advanced to explain this fact: 
 insufficient effort in intensity and / or duration, for subjects with trisomy are very 
reluctant to make long efforts, 
 a possible adrenal dysfunction, which yet, remains unlikely (Konings et al., 2001). A 
more general dysfunction of the hypothalamic-pituitary-adrenal could exist, but the 
lack of studies on the regulation of secretion of CRF and ACTH in Down syndrome 
does not allow us to reverse or confirm this hypothesis. If dys-regulation of the HPA 
axis to stress in DS individuals partly explains the difficulty to use free fatty acids as 
energy substrates, there may be other endocrine factors directly related to adipose 
tissue, such as leptin, or in connection with the gonadotropic through testosterone, and 
its lipolytic action (Galbo, 1985). 
Moreover, Bricout et al., (2008) show that DS subjects are characterised by an absence of 
elevated glycaemia during prolonged exercise, contrary to what is observed in healthy 
controls (Galbo, 1985). In addition, the concentration of lactatemia rises less than in controls 
suggesting that the peripheral utilisation of glucose is impaired. Therefore, it seems highly 
relevant to examine whether the gluco-regulation during exercise is impaired by a 
dysfunction of the autonomic nervous system response and / or impaired secretion of 
catecholamines and / or balance insulin / glucagon imbalance; and to know its impact on 
exercise capacity.  
Furthermore, results of maximal exercise test show that 4 in 14 subjects presented 
chronotropic incompetence, and that these patients have an altered metabolic profile 
(increased fat mass, alterations in leptin, insulin, cortisol and plasma catecholamine at rest 
and during exercise) suggesting the close link between chronotropic incompetence, 
abnormal metabolic profile and endocrine regulation. These points deserve to be confirmed 
by future studies. 
Recently, Fernhall et al., (2009) have conducted a study on catecholamine response to 
maximal exercise in persons with Down syndrome. This work reported an adrenergic drive 
largely absent in DS group, even though a sharp increase in catecholamine at high exercise 
intensities is largely responsible for increase in HR above the anaerobic threshold. In 
conclusion, the authors showed significant differences in baroreceptor sensitivity between 
individuals with and without DS, but not between DS compared with controls, suggesting 
that altered baroreceptor sensitivity does not fully explain the blunted HR response in DS 
population. 
3. Exercise limitations and chronotropic incompetence 
Meanwhile, investigation methods of the sympathetic nervous system are now well known 
and described in literature to be applied in this context (Nagaoka et al., 1996; Grote et al., 
2004; Gouloupoulou et al., 2006). The measurement of heart rate variability is a non invasive 
method to assess both parasympathetic and sympathetic nervous activities (Task Force, 
1996). The application of this method has revealed abnormalities associated with abnormal 
fatigue in athletes (Furlan et al., 1993). It has recently been used in trisomy 21 at rest, 
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exercise and orthostatic tests (Baynard et al., 2004; Fernhall et al., 2005; Iellamo et al., 2005; 
Figueroa et al., 2005).  
The common hypothesis found in literature is that the individual with Down syndrome, has 
a reduced exercise capacity associated with chronotropic incompetence, expressed by 
maximum heart rate values (HRmax) decreased in response to a standardised exercise 
(Fernhall et al., 2001). Because peak exercise HR is correlated with age, the traditional 
approach has been to consider a patient as chronotropically incompetent when 85% of the 
age-predicted HR is achieved (Lauer, 2004). This measure is still confounded (Lauer et al., 
1996) by resting HR and functional capacity, and Wilkoff & Miller, (1992) proposed the 
concept of HR reserve which is the difference between maximal predicted HR (or 220 beats 
/min minus the patient’s age) and resting HR. Failure to use 80% of HR reserve constitutes 
chronotropic incompetence (Lauer et al., 1996).  
In DS population, reduced HR response to prolonged exercise has been identified as the 
primary contributor to the low physical work capacity and cardiorespiratory fitness 
(Fernhall et al., 1996; 2001), but chronotropic incompetence is also an independent predictive 
factor of sudden death even in adult DS population without underlying coronary heart 
disease. Although it is debated (Guerra et al., 2003); understand the chronotropic 
incompetence in DS may be clinically relevant because it could partially explain the higher 
incidence of premature cardiac death in this population (Day et al., 2005).  
Nevertheless, the mechanism of this alteration of cardiac response remains unknown, 
although dysregulation of the ANS appears to be the most probable explanation, by a 
decrease in sympathetic stimulation during exercise, and vagal tone incompletely removed 
(Fernhall et al., 2000; 2001). The rise in heart rate, normally induced by the removal of vagal 
inhibition and a gradual increase in sympathetic activation, is lower in DS population 
during a muscular effort (Fernhall & Otterstetter, 2003). This autonomic dysfunction has 
been studied by Figueroa et al. (2005) who used the HR variability [HRV] to explore the 
autonomic modulation of the sinoatrial node at rest and during exercise. Spectral 
components of HRV analysis in the low frequency [LF] and high frequency [HF] bands 
reflect sympathetic activity [LF/HF ratio] and parasympathetic tone [HF spectrum] (Task 
Force, 1996). These authors report an attenuated HR in individuals with DS due to blunted 
vagal withdrawal.  
The results of these studies show significant abnormalities of ANS, with an observed 
increase in parasympathetic tone at rest (Baynard et al., 2004) a decrease of sympathetic 
stimulation during stress and during the tilt test, evoke a possible recall impaired baroreflex 
(Fernhall et al., 2005).  
So, the mechanism responsible for the impairment of the autonomic cardiac regulation in DS 
population remains unclear. Even if the dysfunction of the ANS and /or the hormonal 
system is the main areas of research, we can also suggest that neurological damage are 
involved in the impairment of this cardiac regulation. The consistent findings of 
abnormalities in brain stem auditory evoked potentials, failure of growth and maturation in 
the brain from an early age, with loss of neurons and dentrites, and damage to the 
neurotransmitter system would provide the anatomic substrate for the autonomic 
dysfunction occurring at a central, brain stem site as a result of the genetic disorder (Yates et 
al., 1980; Mann et al., 1985; Wisniewski, 1990). 
In the future, this dysfunction of the ANS must be supplemented by further investigations 
to better understand the possible mechanisms, especially through the involvement of 
hormonal factors. 
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4. Exercise limitations and obesity 
One of the characteristics of the person with trisomy 21 is the propensity for becoming obese 
(Murray & Ryan-Krause, 2010). It affects between 15 and 20% of children and develops in 
most cases early in age; some studies have shown that nearly 10% of the children with 
Down syndrome were already located beyond the 95° percentile at 4 years old (Beange et al., 
1995). The development of physical activity in the management of the obesity of young 
Down syndrome could play a major role. Indeed, the benefits of physical activity (combined 
with dietary measures) on cardiovascular risk have been clearly demonstrated in these 
populations, whether they live in special centers or in a family environment (Draheim et al., 
2002; Montgomery et al., 1988). 
Thus, in the general population, as in that of Down's syndrome, cardiovascular risk factors 
are associated with metabolic abnormalities, which are grouped under the generic common 
name 'metabolic syndrome' (Grundy et al., 2000). Among these metabolic abnormalities we 
can note a decrease in insulin resistance and excess body fat. Being overweight or obese can 
increase insulin resistance, which is characterised by a lack of insulin to stimulate glucose 
uptake by peripheral tissues and muscles, even though the plasma insulin concentration is 
abnormally high. The numerous endocrine studies showed that hyper-insulinemia 
stimulates the sympathetic nervous system, as is found in obese subjects (Monroe et al., 
2000). This activation of the sympathetic nervous system is paradoxical, because it is part of 
a vicious circle in which there is a desensitisation of adrenergic signalling pathways (Lohse, 
1996) hence a decrease in energy expenditure easing body fat storage. Simultaneously, this 
activation of the sympathetic nervous system adrenergic effects on the heart, blood vessels 
and kidneys promotes the development of hypertension. All these factors contribute highly 
to rise cardiovascular risk factors. 
However, the factors restricting the effort in obesity are still insufficiently explored, 
especially for subjects with a mental disability. It seems that the place of regular physical 
activity in this population is highly relevant, especially since many studies have shown 
smaller performance in trisomy 21 (Pitetti & Tan, 1991a; Pitetti & Campbell, 1991b; Guerra et 
al., 2003; Fernhall & Otterstetter, 2003). The reasons for this disability to exercise are not 
clear and may reflect an insufficient stimulation (motivation problem) and / or the onset of 
fatigue induced by a limitation of use of energy substrates during prolonged exercise 
(Bricout et al., 2008) or to increased oxidative stress (Flore et al., 2008). 
In adults, excess body fat may induce inflammation called 'low grade' and excessive 
oxidative stress (Wellen & Miller, 2005). Adipose tissue, then produce pro-inflammatory 
cytokines that alter insulin sensitivity. On the other hand, an inverse relationship between 
fitness level and markers of inflammation (high-sensitivity CRP) suggest a protective role of 
physical activity. Thus, the decrease in circulating CRP in regular physical activity suggests 
that it may limit this low-grade systemic inflammation (Oberbach et al., 2006). The effects of 
acute exercise have also been clearly demonstrated on the action of TNF- (suppressive 
effect). Thus in young Down syndrome often over-weight and with a high percentage of 
body fat, the study of low-grade inflammation, its relationship with insulin sensitivity, 
biological markers of metabolic risk and cardiovascular inactivity and fitness need to be 
clarified. Several authors have demonstrated the positive impact of endurance exercise 
training on these markers. This reduced level of sensitivity CRP could reach 40% and was 
distinct from body composition and the level of initial CRP (Colbert et al., 2004). The 
checking of such a systemic effect in favour of a specific population "at risk" is therefore 
  
Genetics and Etiology of Down Syndrome 
 
262 
exercise and orthostatic tests (Baynard et al., 2004; Fernhall et al., 2005; Iellamo et al., 2005; 
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al., 2003; Fernhall & Otterstetter, 2003). The reasons for this disability to exercise are not 
clear and may reflect an insufficient stimulation (motivation problem) and / or the onset of 
fatigue induced by a limitation of use of energy substrates during prolonged exercise 
(Bricout et al., 2008) or to increased oxidative stress (Flore et al., 2008). 
In adults, excess body fat may induce inflammation called 'low grade' and excessive 
oxidative stress (Wellen & Miller, 2005). Adipose tissue, then produce pro-inflammatory 
cytokines that alter insulin sensitivity. On the other hand, an inverse relationship between 
fitness level and markers of inflammation (high-sensitivity CRP) suggest a protective role of 
physical activity. Thus, the decrease in circulating CRP in regular physical activity suggests 
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highly pertinent. This reduction in plasma levels of inflammatory markers may represent a 
relevant therapeutic target. 
5. Hormonal results during physical exercise in people with Down syndrome 
and possible link with an exercise limitation?  
Historically, people with intellectual disabilities have long been away from sports 
associations. Then gradually, with the development of adapted physical activities, 
awareness of the benefits of such control on health has raised, and attitudes to integrate 
these people have evolved (Eberhard, 2006). The first work that reports on the involvement 
of subjects with mental disabilities in sport is those of Bell and colleagues in 1977, 
demonstrating the feasibility of integrating these people into sport. In the following decade, 
many studies will have demonstrated that training and regular codified sports practices are 
not only possible but present real health benefits (Pitetti et al., 1989; 1991a; 1991b; 1993; 
Draheim et al., 2002). In this analysis, we must differentiate the effects of practice on health 
indicators (e.g. on body fat, the risk of obesity ...) from indicators of performance, not 
specifically looked for in this context. 
Thus, for subjects with trisomy 21, regular physical activity can for example: 
 promote fat loss, and positively influence lipid parameters (cholesterol, lipoproteins; 
(Eberhard et al., 1993)) 
 reduce the risk of developing diabetes (Marliss & Vranic, 2002; McGavock et al., 2004) 
 reduce the risk of developing hypertension (Fernhall et al., 2001) 
 help perform long-term efforts. 
For twenty years, the department of Sports Medicine, at the hospital of Grenoble, has been 
focusing on hormonal adaptations during exercise in young trisomy 21. Early works 
attached in 1989 (Eberhard et al., 1989) tested the effects of a short physical exercise on a 
cycle ergometer to evaluate the physical abilities of young DS teenagers. These preliminary 
results showed that DS subjects had a less important physical ability to make efforts not 
only because of a lack of motivation or behavioural problems, but also a possible 
cardiovascular dysfunction. Two years later the major result led, to propose further 
investigations on the relationship between "the biochemical adaptations and catecholamine 
responses after a maximum incremental exercise in these young DS teenagers (Eberhard, et 
al., 1991). This study has highlighted that exercise performed by young DS individuals is 
reflected by elevated plasma catecholamine lower than that traditionally seen in control 
subjects, also correlated with a maximum heart rate always lower than control subjects at 
the end of exercise. The hypothesis of a blunted adrenergic response in this population 
therefore emerged. In 1993, a new study was proposed in the department with the aim to 
assess metabolic parameters at rest then an effort, but also and after 12 weeks of training, the 
idea was to make the possible link with adaptive responses to exercise (Eberhard, et al., 
1993, 1996, 1997). The results obtained in these studies confirmed the previous ones results, 
but also demonstrated that endurance training over a period of three months led to a better 
balance of lipid profile frequently observed to be abnormal in a sedentary population with 
Down syndrome. 
This promotion of physical activity has becomes a real concern for this specific population. 
Relayed by local associations, it has given rise to a major support of young Down syndrome, 
involving them more in physical activities. Over the last years, adaptive sports clubs which 
include a large population of mentally handicapped people, have regularly organized 
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weekly training sessions that allow these young people to compete at a national level, and 
some of them achieve excellent results. These benefits had an immediate impact, improving 
measurable physiological parameters during exercise testing. 
For example, in a last study proposed in 2002 in France (Grenoble), VO2max values (gold 
index of aerobic fitness) obtained by a  group of young DS adults, are excellent (44.2 ± 3.0 
ml.min-1.kg-1 - Min = 39 Max = 60). For higher values, some young DS subjects get even 
better results than some control subjects of similar age. However, in this work, hormonal 
and metabolic investigations have shown that DS subjects present some alterations in 
adaptive response to maximal and sub-maximal exercise. Specific factors appear to be 
associated with result, such as obesity, a high percentage of body fat, hyper-insulinemia, 
and hyper-leptin levels (Bjorntrop & Rosmond, 2000). During the sub-maximal exercise, 
hormonal responses of young DS adults (cortisol, catecholamine) do not follow the observed 
rise in controls, whereas these adaptations allow glycolysis, gluconeogenesis and lipolysis 
when muscular exercise continues.  
This result is expressed in a moderate elevation of blood glucose and HR, which could 
explain why people with Down syndrome can not continue muscular effort even at levels 
below maximum (Bjorntrop & Rosmond, 2000; McMurray & Hackney, 2005). This is also 
confirmed by low values of lipid oxidation in DS group and may be related to lower VO2max 
for these subjects, and by free fatty acids values that remain high, suggesting that peripheral 
utilisation of lipids is insufficient when intensity and duration of the effort increases. 
Compared with controls, hormonal responses to exercise in young adults with trisomy 21 
were thus attenuated, which could explain cardiovascular and metabolic limitation of these 
subjects to continue muscular exercise (Bricout et al., 2008; Flore et al., 2008). The aim of 
these two studies was to analyse if hormonal responses could explain an exercise limitation 
in DS, and if it exist an oxidative stress in this population. DS is a risk factor for metabolic 
syndrome and cardiovascular disease. The greater oxidative stress described in DS can 
increase this risk owing to its potential deleterious effects on insulin sensitivity. We 
hypothesised that metabolic syndrome or its markers, at rest and during exercise, are more 
pronounced in young adults with DS. 
Fourteen young men with DS (mean age 22.5 ± 0.7 years) took part to the study. During a 
treadmill sub-maximal incremental test, blood samples were collected for determination of 
hormonal and metabolic variables.  
Compared to controls, DS individuals showed lower VO2max (60.8 ± 2.4 versus 44.4 ± 3.3 
ml.min-1.kg-1respectively; P < 0.05) but it was close to the predicted value (95 ± 6%). They 
presented a lower duration of sub-maximal incremental exercise (P<0.001).  
At rest, DS individuals showed greater catecholamine, insulin and leptin values (P<0.05), 
but lower testosteronemia and cortisolemia (P<0.05) compared to controls. During sub-
maximal incremental tests, catecholamine and cortisol did not increased, whereas the 
insulin concentration of DS individuals was significantly higher (P<0.01) compared to 
controls. Glycaemia increased significantly at the end of sub-maximal incremental test for 
controls but not for DS individuals (P<0.01). In DS participants, as expected, oxidative stress 
was greater than in controls (+ 15%; P<0.001) at rest and throughout the exercise protocol. 
Although a greater fat mass (DS: 19.9 ± 1.3%; controls: 13.5 ± 0.9%; P<0.001), and a lower 
insulin sensitivity (HOMA-IR DS: 1.09 ± 0.16; HOMA controls: 0.64 ± 0.13; P<0.05) was 
observed for DS participants, a metabolic syndrome could not be shown. Maximal fat-
oxidation rate was lower in DS participants (DS = 394.2 ± 69.9 versus controls = 486.1± 134.8 
mg.min-1; P <0.01) but it was in the normal range. 
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These endocrine and metabolic profiles at rest and during exercise may limit endurance 
performance in DS individuals. 
So now, the aim of our research team is to assess chronotropic adaptation to exercise in non 
obese young physically active adult males with DS and its relationships with exercise 
tolerance and catecholamine response. In a preliminary study, fourteen DS and healthy age-
matched controls initially performed a graded maximal exercise test. Chronotropic 
incompetence (CI) was characterised if less than 80% of the chronotropic reserve was 
achieved.  
Only four DS subjects (28%) had CI whereas none in controls. DS with CI showed exercise 
intolerance with HR peak and peak oxygen uptake lower than those without CI. Conversely, 
DS with CI had impaired epinephrine and norepinephrine responses to exercise. The 
association between CI, exercise intolerance and impaired catecholamine response in a 
subgroup of DS, indicate that biological effects of catecholamine are necessary for 
optimising acute exercise adaptations. Nevertheless, the results suggest that reduced 
chronotropic response and aerobic power in DS without CI are likely to be due to the 
metabolic consequences of fat mass excess and inherited oxidative stress rather than to 
impaired catecholamine drive. 
However, the results of that work are still being acquired and it will be necessary to obtain 
results on a more important number of subjects to confirm our current results.  
6. Interest of the promotion and guidance of an active lifestyle in populations 
with specific needs such as Down Syndrome  
Direct assessment of health 
There is no pharmacological treatment for trisomy 21. Nevertheless, the knowledge of 
physiological and biological parameters of trisomy 21 by means of studies based on 
protocols of effort is an original path that could bring: (1) load response adapted to the daily 
lives of subjects with trisomy 21, (2) results directly applicable to the health of these subjects 
(treatment of endocrine diseases, nutritional advice, and rehabilitation training ...). 
By promoting a physically active life, as it has been shown in various reports across the 
Atlantic (A Report of the Surgeon General. U.S. Department of Health & Human Services, 
1996) a reduction in health costs is logically expected for all categories of "persons with 
special needs”, usually victims of the adverse effects of inactivity. The qualitative 
accompanying aging people with disabilities, is an important goal for our wealthy societies. 
The basic criteria for this support which actually extends from childhood to old age, is 
provided by professionals who educate, guide and look after these populations. These 
professionals should benefit from the results of this completed investigation on the effects of 
physical activity. Indeed, while renewing their knowledge and professional practices, they 
should be able to provide better care, better quality of life and even better end of life for all 
the elderly, disabled or not. 
In addition, regular physical activity is widely recognised as a means of improving the 
health and the quality of life of people with disabilities. These benefits have already been 
demonstrated, at least temporarily. Over the last decade, the advanced educational media 
have helped give these people a more active lifestyle that has immediately impacted on their 
recognition and social integration. But as physical exercise is considered as a stress, 
questions remain as to the metabolic and hormonal adaptations of these DS subjects. 
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Similarly, long-term benefits of an active lifestyle, with a perspective of delaying the ageing 
of the person to maintain a certain level of mental and physical well-being, must be better 
identified. 
Propositions could be considered, and should aim at finding the best conditions (nature, 
intensity, frequency) of an intervention based on physical activity among this specific 
population. It seems likely that the physical training of people with trisomy 21 should be 
scheduled, monitored and controlled in order to derive benefits for their health and quality 
of life.  
In this context, Rimmer et al., (2004) have shown that a combined resistance and aerobic 
training program can improve physical fitness in this population; however, it remains 
unclear whether this transfers to improved performance on functional tasks of daily living.  
Persons with DS have also reduced muscle strength and muscular endurance compared 
with their peers without disability and also compared with their peers with an intellectual 
disability but without DS (Croce & Horvat, 1992). Muscle weakness can also impact the 
ability of DS subjects to perform everyday activities, such as walking, maintaining balance 
while standing, and achieving all the movements of daily life. Further, because their 
workplace activities typically emphasize physical rather than cognitive skills, decreased 
strength can negatively impact the vocational and social development of adults with DS in 
the workforce. It has been shown that resistance training can improve work productivity in 
individuals with intellectual disability (Croce & Horvat, 1992). It might be expected that 
adults with DS have difficulty taking part in or being motivated to continue with a 
progressive resistance exercise program. Compliance with a training program can be very 
variable depending on the intellectual disabilities. To obtain a positive impact, it is necessary 
that the training program appeared to be a safe intervention for people with DS. No major 
adverse events should be reported by the participants, their families, or the fitness trainers 
involved in the program, during or after the training sessions.  
To support the opinion that the activity is required in DS population, Heyne et al. (1997) have 
shown that the absence of a meaningful leisure program will foster maladaptive or aggressive 
behaviours. These authors point out the significance of leisure programs but also the 
importance of physical activities which will expand the social network, promote friendships 
and, introduce a sense of autonomy. Songster et al. (1997) reinforce this argument and 
emphasise that consistent training and sports competition in Special Olympics are essential to 
the physical, mental and social developments of young person with Down syndrome.  
7. Conclusion  
Children and young adults with Down syndrome have the opportunities to learn the 
different aspects of physical education and thus the means to become a physically educated 
person. They are capable of learning sports techniques, can progress, and participate in 
sports competition.  
Nevertheless, physical activities need to be carefully taught and chosen for their fitness 
benefit. It is necessary to encourage enough recreational activities to maintain a sufficient 
motivation, so physical educational programs for this specific population should include all 
activities to learn, to understand both kinaesthetically and cognitively movements and 
abilities. Finally, the physical activity becomes enjoyable, social, repeatable, valued for its 
own sake, and we contribute to the formation of autonomous adults, physically active and 
educated. 
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age FC rest FC peak VO2 peak SBP
Authors Review years bpm bpm ml/min/kg mmHg
Baynard et al., (2004) Arch. Phys. Med Rehabil. 20,8 +/- 0,9 71 +/- 3,4 161 +/- 5,3 27,4 +/- 1,8 nd
Baynard et al., (2008) M.S.S.E 25 +/- 2 nd 167 +/- nd 24  +/- nd nd
Bricout et al., (2008) J. NeuroEndocrinol. 22,5 +/- 0,7 57,7 +/- 3,7 180 +/- 2 44,2 +/- 3,04 116,0 +/- 2,8
Draheim et al., (2002) Mental Retard. 34,5 +/- 10,0 nd nd nd 111,4 +/- 13,6
Eberhard et al., (1989) J. Ment. Defic. Res. 14,8 +/- 2,2 67,1 +/- 12,6 123,6 +/- 19,7 47,6 +/- 8,1 107 +/- 14,6
Eberhard et al., (1997) Adapt. Phys. Activ. Quater. 17,5 +/- 1,7 nd 162,2 +/-   18,9 48 +/- 1 nd
Fernhall et al., (1996) M.S.S.E 26,7 +/- 5,9 nd 164 +/- 14,4 27,6 +/- 6,4 nd
Fernhall et al., (2003) J.A.P 23,8 +/- 1,8 66,4 +/- 4,6 154, +/- 4,2 18,1 +/- 1,6 112,2 +/- 6,6
Fernhall et al., (2005) Arch. Phys. Med Rehabil. 25,1 +/- 7,3 72,5 159 +/- 16,8 19,7 +/- 6,4 117,5  +/- nd
Fernhall et al., (2009) Am. J Cardiol. 24 +/- 7 nd 170 +/- 10 27,3 +/- 5,6 nd
Figueroa et al., (2005) Clin. Auton. Res. 27,8 +/- 8,1 76 +/- 3 nd nd 115 +/- 4
Guerra et al., (2003) Arch. Phys. Med Rehabil. 24,3 +/- 3,5 69,0 +/- 11,2 165,0 +/- 14,7 31,9 +/- 6,6 nd
Gouloupoulou et al. (2006) Am. J. Ment. Retard. 24 +/- 0,9 70 +/- 1,5 162 +/- 2,4 24,5 ++/- 1,0 nd
Hefferman et al., (2005) M.S.S.E 25 +/- 2,4 72 +/- nd nd nd 106,1 +/- 2,9
Iellamo et al., (2005) Am. J. Physiol. 26,3 +/- 2,3 nd nd nd 116,1 +/- 2,7
Mendonca et al., (2011) Arch. Phys. Med Rehabil. 36,5 +/- 5,5 69,6 +/- 12,2 167,6 +/- 19,1 31,7 +/- 7,9 nd
Mendonca et al., (2011) Res. Dev. Disabilities 34,9 +/- 1,1 71 +/- nd 171,5 +/- 4,9 30,4 +/- 2,1 nd
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CARDIOVASCULARA DATA
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Baynard et al., (2004) Arch. Phys. Med Rehabil. 20,8 +/- 0,9 1264,1 +/- 226,2 ms2 1418,1 +/- 268,6 ms2 1,81 +/- 0,42
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LF: low frequency power expressed in ms2 or ln ms2 or n.u (normalised units) 
HF: high frequency power; LF/HF ratio reflected the Autonomic Nervous System balance 
(sympathetic/parasympathetic).  
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Konings et al., (2001) Eur. J. Endocrinol. 1.5 to 13 nd 6.5 +/- 1.3 mU/L 14.3 to 18.5 pmol/L
TSH T3 T4 ENDOCRINE DATA age (years) Testosterone
 
TSH: thyroid stimulating hormone; T3: tri-iodothyronine; T4: thyroxine; nd : not determined, 
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age cortisol (rest) Epinephrine NorEpinephrine Epinephrine NorEpinephrine
Authors Review years nmol/L rest (pmol/mL) rest (pmol/mL) post ex (pmol/mL) post ex (pmol/mL)
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Eberhard et al., (1997) Adapt. Phys. Activ. Quater. Girls: 16.7 +/- 1.5 nd 0.4 +/- 0.3 0.63 +/- 0.25 0.78 +/- 0.3 6.9 +/- 1.6
ENDOCRINE DATA
 
TSH: thyroid stimulating hormone; T3: tri-iodothyronine; T4: thyroxine; nd : not determined, 
Table 4. Endocrine data. 
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1. Introduction 
Down syndrome (DS) is the most common genetic disorder with a prevalence that ranges 
from 1:700 to 1:100 live births and accounts for 25–30% of people with intellectual disability 
(Nadel, 1999; Rogers, Roizen, & Capone, 1996; Rondal, 1988, 1998; Rondal, Perera, & Nadel, 
1999). Trisomy 21, one of the three forms of DS, is caused by the presence of a third 
chromosome at band 21q22 of the long arm. The other two forms, namely translocation 21 
and mosaicism, account for only 6% of children with DS (Rogers et al., 1996). Recent medical 
advances suggest that over 300 genes are affected, making the genetic etiology of DS a 
complex mechanism that implicates gene interactions that are not clearly understood 
(Pennington, Moon, Edgin, Stedron, & Nadel, 2003; Antonarakis et al., 2004). The syndrome 
is characterized by specific phenotypic characteristics, health related problems, cognitive 
and language impairments, neuromotor dysfunction and early aging, often associated with 
increased prevalence of Alzheimer’s disease.  
Interest in the cognitive profile of DS has been robust during the past decades, with a large 
number of published studies discussing the atypical and unique profile of cognitive abilities 
in this population. Yet, there is no clear understanding of the cognitive profile of individuals 
with DS and how this differentiates from other forms of intellectual disability. The 
uniqueness of the cognitive make-up of individuals with DS will contribute to a better 
understanding of the specific strengths and impairments of this population, as well as to the 
development of more effective educational programs suitable for them. This chapter will 
focus on language and visuo-spatial abilities of individuals with DS from a cognitive 
neuroscience perspective. The chapter is organized in four parts. The first part discusses 
language abilities in individuals with DS, with particular emphasis on expressive and 
receptive vocabulary and grammar. In the second part, research in visuospatial abilities in 
individuals with DS is reviewed. The third part deals with the concept of atypical cerebral 
laterality (ACL) in DS individuals and, in particular, how ACL may affect their language 
and visuospatial abilities. Finally, the last part discusses the contribution of laterality 
research in understanding the unique pattern of cognitive abilities in DS. 
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2. Neurobiology of DS 
At birth, the total brain volume of individuals with DS is close to normal, although 
microscopically some changes have been observed as early as 22 weeks of gestation that 
become more obvious by 6 months of age (Nadel, 2003). This condition has been linked to 
neural density reduction in the cerebral cortex (Florez, 1992).  Indeed, the most affected area 
of the brain of individuals with DS is the cortex, both in neural density and in weaker neural 
synapses, caused by fewer dendritic spines. (Florez, 1992; also see Lubec & Engidawork, 
2002 for a review). Although, the reduced brain volume cannot be directly associated with 
the observed intellectual disability of this group, it is suspected that these abnormalities in 
the neural density of the cortex may contribute to the weak cognitive deficits associated with 
the syndrome (e.g., memory and attention). Shapiro and colleagues (1992) reported 
abnormal neuronal interactions between the frontal and parietal lobes of individuals with 
DS, suggesting the involvement of Broca’s area. More specific differences in the brain’s 
neuroanatomy of individuals with DS include reduced growth of the frontal lobes (Kesslak 
et al. 1994), narrowing of the superior temporal gyrus, smaller brain stem and cerebellum 
(Cole et al., 1993).  
Research using magnetic resonance imaging (MRI), comparing demented and non-
demented individuals with DS, indicates the presence of reduced volume of left 
hippocampus and amygdala in the former group (Pearlson et al., 1998). In a different MRI 
study, measuring hippocampal and amygdala volumes, non-demented individuals with DS 
exhibited smaller hippocampal size compared to age-matched typically developing controls, 
but there were no differences in amygdala volumes between the two groups (Pinter, Brown, 
Eliez, Schmitt, Capone, & Reiss, 2001). In their study, Pinter and colleagues (2001) confirmed 
that individuals with DS have smaller brain volumes, both in gray and white matter, smaller 
cerebellar volumes, and relatively larger subcortical gray matter volumes, both in parietal 
and temporal structures. Finally, Teipel and colleagues (2003) found decreased size of the 
corpus callosum in a group of non-demented individuals with DS, even when total brain 
volume was controlled for (Teipel et al., 2003). Thus, although the neuropathology of 
individuals with DS is widespread, particularly in older adults, it is also selectively affecting 
mainly cortical areas that are involved in higher cognitive processes.   
3. Cognitive profile of individuals with DS 
Individuals with DS demonstrate a unique cognitive profile of strengths and weaknesses 
that is characteristic to the syndrome. The general intellectual ability of individuals with DS 
ranges from mild to severe mental retardation, with a decline as they grow older (e.g., 
Hoddap & Zigler, 1990; Pennington, Moon, Edgin, Stedron, & Nadel, 2003). This decline, 
which begins early in adulthood, has been related to the gradual deterioration of several 
brain areas, such as the hippocampus and the cerebellum (Pennington et al., 2003). 
Alternatively, this decline has been linked to the increased prevalence of dementia in adults 
with DS (Takashima, Ieshima, Nakamura, & Becker, 1989). 
Hippocampal function that supports tasks that tap short-term and long-term memory are 
severely affected in individuals with DS, as opposed to those supported by prefrontal areas 
(e.g., executive functions) (Pennington et al., 2003). Explicit memory (verbal and non-verbal) 
is particularly weak when compared both to typically developing (TD) individuals matched 
for mental age, and non-Down syndrome individuals with intellectual disability (ID) 
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(Carlesimo, Marlota, & Vicari, 1997). These findings suggest that memory is 
disproportionally affected in DS due to the specific neurological abnormalities mentioned 
earlier (i.e., hippocampal dysfunction, reduced brain volume) (Lubec & Engidawork, 2002).  
Sustained attention has been also examined in infants with DS (Brown, Johnson, Paterson, 
Gilmore, Longhi, & Karmiloff-Smith, 2003). Results showed that infants with DS exhibit 
poor engagement and less duration in sustained attention than TD mental-age controls 
(Brown et al. 2003). These results are unlikely to reflect lack of motivation or task difficulty. 
In older individuals with DS, this condition has been associated with other dementia 
symptoms, such as lack of orientation (e.g., Granholm, Sanders, & Crnic, 2000).  
Language is the most extensively studied domain within the cognitive system in individuals 
with DS. Most authors agree that language is severely affected in these individuals, with 
expressive vocabulary, grammar and syntax being the weakest areas of function. Indeed, 
individuals with DS document an unusual disparity in performance in expressive and 
receptive vocabulary tasks, with the latter being more affected than the former. Particular 
emphasis has been placed in identifying the specific nature of the expressive language 
difficulties, their neural substrates, as well as the developmental changes throughout the life 
span.  
Grammar and syntax are disproportionally affected in individuals with DS as well. Spoken 
language is characterized by a systematic omission of tense-related grammatical morphemes 
that persists throughout development. Surprisingly, in most studies examining English-
speaking children with DS, regular past tense formation is more affected than irregular past 
tense formation, suggesting a difficulty with understanding and applying grammatical and 
syntactic rules, as opposed vocabulary entry and retrieval.   
Visuo-spatial abilities have been less extensively investigated in DS. Some authors propose 
that visuo-spatial working memory is relatively preserved compared to verbal working 
memory in DS individuals (e.g., Lanfranchi, Carretti, Spanò & Cornoldi, 2009).  In fact, they 
have often been characterized with relative strengths in visuo-spatial processing and poor 
verbal processing skills (Jarrold, Baddeley & Hewes, 1999; Klein & Mervis, 1999; Wang & 
Bellugi, 1994). The relative strength of visuo-spatial skills is supported by strong fine motor 
skills documented through the use of gestures in early development (Bilovsky & Share, 
1965). More specifically, it has been reported that children with DS are better at the 
construction subtests of the Stanford-Binet (e.g., block building, drawing line, copying, 
folding), compared to mental age controls, due to their strong visuo-motor abilities 
(Silverstein, Legutski, Friedman, and Takayama, 1982). Pueschel and collegues (1987) 
documented that young children with DS were better at figure closure and hand movement 
tasks, compared to verbal tasks (using the Kaufman Assessment Battery for Children), while 
TD children exhibited the reverse pattern of performance and children with IDs without DS 
exhibited equally weak performance in both tasks. 
Bellugi and colleagues (1994) proposed that individuals with DS are better at sustaining the 
global configuration of objects, as opposed to local forms, a pattern that is reversed in 
individuals with intellectual disability of different genetic origin. Similar findings have been 
reported in drawing, where individuals with DS tend to reproduce the global features of a 
stimulus and omit the local details of the object. This pattern of performance is often 
encountered in patients with left hemisphere damage, suggesting lateralized brain lesions in 
individuals with DS. However, MRI data do not exhibit asymmetrical damage in 
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2. Neurobiology of DS 
At birth, the total brain volume of individuals with DS is close to normal, although 
microscopically some changes have been observed as early as 22 weeks of gestation that 
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of the brain of individuals with DS is the cortex, both in neural density and in weaker neural 
synapses, caused by fewer dendritic spines. (Florez, 1992; also see Lubec & Engidawork, 
2002 for a review). Although, the reduced brain volume cannot be directly associated with 
the observed intellectual disability of this group, it is suspected that these abnormalities in 
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the syndrome (e.g., memory and attention). Shapiro and colleagues (1992) reported 
abnormal neuronal interactions between the frontal and parietal lobes of individuals with 
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et al. 1994), narrowing of the superior temporal gyrus, smaller brain stem and cerebellum 
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hippocampus and amygdala in the former group (Pearlson et al., 1998). In a different MRI 
study, measuring hippocampal and amygdala volumes, non-demented individuals with DS 
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Individuals with DS demonstrate a unique cognitive profile of strengths and weaknesses 
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Hoddap & Zigler, 1990; Pennington, Moon, Edgin, Stedron, & Nadel, 2003). This decline, 
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Hippocampal function that supports tasks that tap short-term and long-term memory are 
severely affected in individuals with DS, as opposed to those supported by prefrontal areas 
(e.g., executive functions) (Pennington et al., 2003). Explicit memory (verbal and non-verbal) 
is particularly weak when compared both to typically developing (TD) individuals matched 
for mental age, and non-Down syndrome individuals with intellectual disability (ID) 
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(Carlesimo, Marlota, & Vicari, 1997). These findings suggest that memory is 
disproportionally affected in DS due to the specific neurological abnormalities mentioned 
earlier (i.e., hippocampal dysfunction, reduced brain volume) (Lubec & Engidawork, 2002).  
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that visuo-spatial working memory is relatively preserved compared to verbal working 
memory in DS individuals (e.g., Lanfranchi, Carretti, Spanò & Cornoldi, 2009).  In fact, they 
have often been characterized with relative strengths in visuo-spatial processing and poor 
verbal processing skills (Jarrold, Baddeley & Hewes, 1999; Klein & Mervis, 1999; Wang & 
Bellugi, 1994). The relative strength of visuo-spatial skills is supported by strong fine motor 
skills documented through the use of gestures in early development (Bilovsky & Share, 
1965). More specifically, it has been reported that children with DS are better at the 
construction subtests of the Stanford-Binet (e.g., block building, drawing line, copying, 
folding), compared to mental age controls, due to their strong visuo-motor abilities 
(Silverstein, Legutski, Friedman, and Takayama, 1982). Pueschel and collegues (1987) 
documented that young children with DS were better at figure closure and hand movement 
tasks, compared to verbal tasks (using the Kaufman Assessment Battery for Children), while 
TD children exhibited the reverse pattern of performance and children with IDs without DS 
exhibited equally weak performance in both tasks. 
Bellugi and colleagues (1994) proposed that individuals with DS are better at sustaining the 
global configuration of objects, as opposed to local forms, a pattern that is reversed in 
individuals with intellectual disability of different genetic origin. Similar findings have been 
reported in drawing, where individuals with DS tend to reproduce the global features of a 
stimulus and omit the local details of the object. This pattern of performance is often 
encountered in patients with left hemisphere damage, suggesting lateralized brain lesions in 
individuals with DS. However, MRI data do not exhibit asymmetrical damage in 
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individuals with DS. This evidence supports the existence of an atypical functional 
lateralization in this clinical group (Jernigan & Bellugi, 1990). 
4. Language of individuals with DS 
One of the earlier studies on language of individuals with DS explored speech reproduction 
and observed weak expressive skills in this population (Dodd, 1975). During the same 
decade Gibson (1978) discussed the language production of individuals with DS during the 
first two years of life. He suggested that some aspects of language, particularly expression, 
fall behind their chronological age. Almost a decade later, Cardosa- Martins and colleagues 
(1985) found weaknesses in speech production in individuals with DS. Since then, it has 
been repeatedly documented that children with DS exhibit an unusual disparity between 
expressive and receptive language, compared to what would be expected, based on their 
mental age, with the latter being less affected than the former (e.g., Jenkins, 1993; Chapman, 
1997). This delay in expressive performance is evident from infancy, even prior to 
development of formal vocal speech. 
Likewise, it has been found that infant gesture development in DS population is delayed, 
compared to TD infants (e.g., Miller, 1992). Longitudinal studies examining one-to-two 
word formations, found that individuals with DS exhibit a delay in speech production up to 
18 months, with large individual variation that reached 19 months (e.g., Oliver and Buckley, 
1994). The “vocabulary spurt”, typically observed in TD 24-month old infants, was 
commonly absent in individuals with DS. As the syntax becomes more complex and the 
vocabulary for speech production more demanding, the discrepancies between DS and TD 
individuals become more pronounced (Miller, 1992).  
Receptive language and comprehension appear to be more advanced than expressive speech 
in DS adolescents (Chapman, Schwartz, & Kay-Raining Bird, 1991). However, some 
evidence suggests that comprehension declines with age in non-demented individuals with 
DS (Chapman, Hesketh, & Kistler, 2002). In our study, receptive and expressive vocabulary 
was investigated in DS and TD individuals matched for mental age (Ypsilanti, Grouios, 
Alevriadou & Tsapkini, 2005). Four subtests of the Test of Word Knowledge (TOWK) (Wiig 
& Secord, 1992) were used to assess naming pictures (expressive vocabulary), matching a 
spoken word to a picture among four semantically related detractors (receptive vocabulary), 
relational word knowledge and ability to provide definitions to orally presented words. We 
found no differences between the two groups in three of the four tasks of expressive and 
receptive vocabulary. The only reliable weakness of individuals with DS was evidenced in 
the word definitions subtest that demands complex syntactic constructions, requirement 
which is challenging for these individuals.   
Surprisingly, narrative production, which is closely related to expressive language and 
syntax, seems to be less affected in individuals with DS. Chapman, and colleagues (1998) 
compared the performance of 33 individuals with DS with two TD control groups matched 
for syntactic comprehension and for mean length of utterance (MLU), respectively, and 
failed to find reliable differences in number of episodes (stories) described by the three 
groups. Individuals with DS documented syntactic errors that included verb omissions, 
suggesting that narrative production may be weak due to syntactic deficits and not 
vocabulary restrictions.  
Grammatical word formation, particularly the omission of tense-related morphemes, is 
another area of difficulty for individuals with DS (e.g., Laws & Bishop, 2003). Regular past 
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tense formation is more affected than irregular in individuals with DS (Laws & Bishop; 
Eadie, Fey, Douglas, & Parsons, 2002). This peculiar finding suggests that irregular past 
tense formation resembles accessing vocabulary entries, which does not rely on 
understanding and applying grammatical rules (Pinter, 1991). This theorization has been 
subsequently supported by evidence indicating significant correlation between irregular 
past formation and vocabulary level in individuals with DS (Laws and Bishop, 2003). 
In summary, most published studies agree that expression is more affected than reception in 
individuals with DS (for a review see Ypsilanti & Grouios, 2008) and that phonological 
short-term memory may be mediating the performance on such tasks. This hypothesis is 
supported by research findings indicating that auditory short-term memory predicts early 
vocabulary entry in individuals with DS (Chapman & Hesketh, 2001). Several investigators 
have proposed that children with DS may exhibit difficulties in naming and sentence 
repetition tasks due to strong anatomical and functional deficiencies in the corpus callosum 
(e.g., Wang, Hesselink, Jernigan, Doherty, & Bellugi, 1992). Bunn et al. (2002) argued that if 
interhemispheric communication is necessary for picture naming before speech production, 
then deficiencies in the corpus callosum, such as those observed in individuals with DS, 
would influence performance on naming, but not on reading tasks. 
5. Visuospatial abilities in DS 
Studies on visuospatial abilities of individuals with DS reveal the existence of strengths and 
weaknesses within this domain. In particular, individuals with DS are stronger in 
visuomotor integration and visual memory, compared to spatial memory and spatial 
construction (Fidler, 2005). Visuospatial short-term memory was found to be relatively 
unaffected in individuals with DS (e.g., Jarrold & Baddeley, 1997). Bellugi and colleagues 
(1999) found a unique dissociation in the visuospatial abilities of individuals with DS and 
Williams Syndrome (WS) (a genetically linked disorder associated with intellectual 
disability). Individuals with DS tended to maintain a holistic strategy in drawing tasks, 
while those with WS matched for mental age, reproduced local features of the drawing 
objects (Bellugi, Lichtenberger, Mills, Galaburda, & Korenberg, 1999). Moreover, individuals 
with DS exhibited increased difficulty in depicting internal details of objects in block 
construction and integrating simple shapes. In the same study, a clear dissociation in 
global/local features of individuals with DS was illustrated using the Navon task, in which 
participants were asked to maintain the global or local form of letter stimuli. Individuals 
with DS were unable to reproduce the local details of the stimuli, maintaining only the 
global aspect of the presented letter. 
In another study, Bellugi and colleagues (2000) presented comparative data from drawings 
of individuals with DS and WS demonstrating that individuals with DS produce drawings 
conforming with gestalt rules (such as, closure and continuation) that lack detail, but are 
easily recognizable  (Bellugi, Lichtenberger, Jones, Lai, & St. George 2000). Interestingly, the 
two groups were equally weak in the block design subtest of the WISC-R (Wechsler, 1974). 
However, further analysis of the process of block design indicated that although 
erroneously, individuals with DS maintained the global configuration of the block 
arrangements, while individuals with WS exhibited a more local perspective in their 
arrangements (Bellugi et al., 1999). The characteristic profile of the visuospatial abilities of 
individuals with DS implicates the neural substrates supporting these processes that are 
ultimately linked to the chromosomal abnormality of the disorder and its unique 
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individuals with DS. This evidence supports the existence of an atypical functional 
lateralization in this clinical group (Jernigan & Bellugi, 1990). 
4. Language of individuals with DS 
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and observed weak expressive skills in this population (Dodd, 1975). During the same 
decade Gibson (1978) discussed the language production of individuals with DS during the 
first two years of life. He suggested that some aspects of language, particularly expression, 
fall behind their chronological age. Almost a decade later, Cardosa- Martins and colleagues 
(1985) found weaknesses in speech production in individuals with DS. Since then, it has 
been repeatedly documented that children with DS exhibit an unusual disparity between 
expressive and receptive language, compared to what would be expected, based on their 
mental age, with the latter being less affected than the former (e.g., Jenkins, 1993; Chapman, 
1997). This delay in expressive performance is evident from infancy, even prior to 
development of formal vocal speech. 
Likewise, it has been found that infant gesture development in DS population is delayed, 
compared to TD infants (e.g., Miller, 1992). Longitudinal studies examining one-to-two 
word formations, found that individuals with DS exhibit a delay in speech production up to 
18 months, with large individual variation that reached 19 months (e.g., Oliver and Buckley, 
1994). The “vocabulary spurt”, typically observed in TD 24-month old infants, was 
commonly absent in individuals with DS. As the syntax becomes more complex and the 
vocabulary for speech production more demanding, the discrepancies between DS and TD 
individuals become more pronounced (Miller, 1992).  
Receptive language and comprehension appear to be more advanced than expressive speech 
in DS adolescents (Chapman, Schwartz, & Kay-Raining Bird, 1991). However, some 
evidence suggests that comprehension declines with age in non-demented individuals with 
DS (Chapman, Hesketh, & Kistler, 2002). In our study, receptive and expressive vocabulary 
was investigated in DS and TD individuals matched for mental age (Ypsilanti, Grouios, 
Alevriadou & Tsapkini, 2005). Four subtests of the Test of Word Knowledge (TOWK) (Wiig 
& Secord, 1992) were used to assess naming pictures (expressive vocabulary), matching a 
spoken word to a picture among four semantically related detractors (receptive vocabulary), 
relational word knowledge and ability to provide definitions to orally presented words. We 
found no differences between the two groups in three of the four tasks of expressive and 
receptive vocabulary. The only reliable weakness of individuals with DS was evidenced in 
the word definitions subtest that demands complex syntactic constructions, requirement 
which is challenging for these individuals.   
Surprisingly, narrative production, which is closely related to expressive language and 
syntax, seems to be less affected in individuals with DS. Chapman, and colleagues (1998) 
compared the performance of 33 individuals with DS with two TD control groups matched 
for syntactic comprehension and for mean length of utterance (MLU), respectively, and 
failed to find reliable differences in number of episodes (stories) described by the three 
groups. Individuals with DS documented syntactic errors that included verb omissions, 
suggesting that narrative production may be weak due to syntactic deficits and not 
vocabulary restrictions.  
Grammatical word formation, particularly the omission of tense-related morphemes, is 
another area of difficulty for individuals with DS (e.g., Laws & Bishop, 2003). Regular past 
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tense formation is more affected than irregular in individuals with DS (Laws & Bishop; 
Eadie, Fey, Douglas, & Parsons, 2002). This peculiar finding suggests that irregular past 
tense formation resembles accessing vocabulary entries, which does not rely on 
understanding and applying grammatical rules (Pinter, 1991). This theorization has been 
subsequently supported by evidence indicating significant correlation between irregular 
past formation and vocabulary level in individuals with DS (Laws and Bishop, 2003). 
In summary, most published studies agree that expression is more affected than reception in 
individuals with DS (for a review see Ypsilanti & Grouios, 2008) and that phonological 
short-term memory may be mediating the performance on such tasks. This hypothesis is 
supported by research findings indicating that auditory short-term memory predicts early 
vocabulary entry in individuals with DS (Chapman & Hesketh, 2001). Several investigators 
have proposed that children with DS may exhibit difficulties in naming and sentence 
repetition tasks due to strong anatomical and functional deficiencies in the corpus callosum 
(e.g., Wang, Hesselink, Jernigan, Doherty, & Bellugi, 1992). Bunn et al. (2002) argued that if 
interhemispheric communication is necessary for picture naming before speech production, 
then deficiencies in the corpus callosum, such as those observed in individuals with DS, 
would influence performance on naming, but not on reading tasks. 
5. Visuospatial abilities in DS 
Studies on visuospatial abilities of individuals with DS reveal the existence of strengths and 
weaknesses within this domain. In particular, individuals with DS are stronger in 
visuomotor integration and visual memory, compared to spatial memory and spatial 
construction (Fidler, 2005). Visuospatial short-term memory was found to be relatively 
unaffected in individuals with DS (e.g., Jarrold & Baddeley, 1997). Bellugi and colleagues 
(1999) found a unique dissociation in the visuospatial abilities of individuals with DS and 
Williams Syndrome (WS) (a genetically linked disorder associated with intellectual 
disability). Individuals with DS tended to maintain a holistic strategy in drawing tasks, 
while those with WS matched for mental age, reproduced local features of the drawing 
objects (Bellugi, Lichtenberger, Mills, Galaburda, & Korenberg, 1999). Moreover, individuals 
with DS exhibited increased difficulty in depicting internal details of objects in block 
construction and integrating simple shapes. In the same study, a clear dissociation in 
global/local features of individuals with DS was illustrated using the Navon task, in which 
participants were asked to maintain the global or local form of letter stimuli. Individuals 
with DS were unable to reproduce the local details of the stimuli, maintaining only the 
global aspect of the presented letter. 
In another study, Bellugi and colleagues (2000) presented comparative data from drawings 
of individuals with DS and WS demonstrating that individuals with DS produce drawings 
conforming with gestalt rules (such as, closure and continuation) that lack detail, but are 
easily recognizable  (Bellugi, Lichtenberger, Jones, Lai, & St. George 2000). Interestingly, the 
two groups were equally weak in the block design subtest of the WISC-R (Wechsler, 1974). 
However, further analysis of the process of block design indicated that although 
erroneously, individuals with DS maintained the global configuration of the block 
arrangements, while individuals with WS exhibited a more local perspective in their 
arrangements (Bellugi et al., 1999). The characteristic profile of the visuospatial abilities of 
individuals with DS implicates the neural substrates supporting these processes that are 
ultimately linked to the chromosomal abnormality of the disorder and its unique 
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phenotype. This profile may also indicate variations in neuronal plasticity in different 
disorders with intellectual disability (Bellugi et al., 2000). 
6. Atypical cerebral laterality in individuals with DS  
Atypical cerebral laterality (ACL) has been associated with the cognitive deficits of 
individuals with intellectual disability since the early 1920s (Gordon, 1921). ACL refers to 
the reverse or weak or bilateral representation of language in the two cerebral hemispheres 
(Geschwind & Galaburda, 1985). The majority of right-handed individuals (97%) exhibit left-
hemisphere lateralization for language. Only about 60% of left-handed individuals exhibit 
left-hemisphere lateralization for language, 30% bilateral lateralization and 10% right-
hemisphere lateralization for language (Bishop, 1990). Geschwind & Behan (1982) termed 
atypical laterality any laterality pattern that differed from the “standard dominance pattern” 
(pp. 70). According to Geschwind & Galaburda (1985a; 1985b), atypical dominance may 
involve the inverse or weak dominance of three features; hand dominance, language 
dominance and visuospatial dominance. 
Several accounts have been put forward to explain the increased incidence of atypical 
laterality in individuals with neurodevelopmental disorders, which fall into four main 
categories: hormonal, genetic, pathological, and developmental. According to hormonal 
theories a number of exogenous and endogenous factors increase the secretion of prenatal 
testosterone in the fetus (Geschwind & Galaburda, 1987). This increment enhances the 
growth of the right cerebral hemisphere and inhibits that of the left cerebral hemisphere. In 
particular, their posterior regions, cortical areas tightly linked to intellectual disability and 
poor language development (Geschiwind & Galaburda, 1985a, 1985b, 1985c). This 
speculation has been repeatedly challenged during the past decades for its complexity (e.g., 
McManus & Bryden, 1991; McManus, Bryden & Bulman-Fleming, 1994; Annett, 1994; 
Previc, 1994), although the implication of testosterone levels in the establishment of cerebral 
lateralization remains well supported (e.g. Witleslon, 1985). For example, Witelson (1985, 
1989) suggested that larger callosal isthmus is related to increased left-handedness in TD 
individuals, resulting from less axonal loss in the corpus callosum during foetal 
development, which is influenced by prenatal testosterone levels. Specifically, decreased 
levels of prenatal testosterone may cause decreased axonal loss in the corpus callosum, 
causing increased bilateral representation of cognitive functions and enhanced prevalence of 
non-right-handedness (Witelson, 1989, 1991). 
Genetic theories argue that ACL results from genetic variation determined by a single gene 
(Annett, 1985; McManus & Bryden,1982). Individuals who are not carriers of this gene will 
exhibit random hand preference (right or left). Any pathology during development may 
inhibit the expression of the right-hand gene causing ACL (Annett & Alexander, 1996). 
Alternatively, Satz (1973) proposed that ACL may be the result of early brain damage in the 
left hemisphere, causing a mild dysfunction of the contralateral hand for motor activities, 
which in turn, forces a genetically right handed person to switch to non-right handedness. 
According to this account, individuals with ACL are “pathological” left handers, genetically 
programmed to become right handers, but brain pathology altered this biological 
expression. From a developmental perspective, ACL may be caused by an atypical 
maturational process in motor development that initiates from the trunk, followed by the 
shoulders and then the hands. If this maturational process is arrested, or lagged, it could 
cause increased randomness which would be documented by lack of hand preference (i.e., 
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ambiguous handedness) (Palmer, 1964). Bishop (1983; 1990) speculated that non right 
handedness is an indicator of an immature development of the motor system, caused by 
diffuse brain abnormalities in individuals with intellectual disability. 
The characteristic dissociation of language being disproportionately affected to visuospatial 
abilities in individuals with DS that cannot be accounted by the hearing impairments (Laws, 
2004) provides suspicion for the link between ACL and language problems in DS 
population. Indeed, an extensive review of the literature indicates that individuals with DS 
document an ACL pattern in speech perception and oral motor movements (e.g., Elliott & 
Weeks, 1993; Elliott, Weeks, & Chua, 1994; Heath & Elliott, 1999). 
In a typical dichotic listening paradigm, two different auditory verbal stimuli are 
simultaneously presented in each ear using headphones. The participant is asked to repeat the 
stimulus that was best heard. TD right-handed individuals document a right-ear advantage 
(REA) for speech stimuli, which is indicative of left hemisphere lateralization for speech 
perception. According to the original account, auditory information incoming from the right 
ear is predominately represented in the opposite hemisphere (i.e., the left hemisphere) due to 
anatomical contralateral auditory pathways and, thus, closer to the language centers of the 
same hemisphere (Kimura, 1961). In order for verbal stimuli incoming from the left ear to 
reach the left-hemisphere’s language centers, information crosses from the right to the left 
cerebral hemisphere via the corpus callosum, causing significant delays. In individuals with 
DS, a left-ear/right-cerebral hemisphere preference for speech sounds (Hartley, 1981; Pipe, 
1988), or no ear advantage (Sommer and Starkey, 1977; Tannock et al., 1984) has been 
observed, instead of the typical right-ear/left-cerebral hemisphere preference found in TD 
controls. Using dichotic listening tasks, Welsh, Elliot, and Simon (2003) verified this hypothesis 
with right-handed individuals with DS exhibiting a left-ear/right-cerebral hemisphere 
advantage for speech perception, unlike the right-ear/left-cerebral hemisphere laterality for 
speech perception typically observed in TD adults. Similar results were obtained in a Japanese 
study with individuals with DS (Shoji, Koizumi & Ozaki, 2008). 
Recently, Groen, Alku and Bishop (2008) used T-complex auditory event-related potentials 
to investigate whether individuals with DS show ACL, as reflected by atypical patterns of 
brain activity elicited by verbal and tone sounds presented in each ear. The relationship 
between atypical lateralization, language deficits and handedness was further explored.  
The laterality patterns of individuals with DS were significantly different, compared to TD 
individuals, confirming the existence of ACL for auditory processing in this population. 
However, this atypicality was not specific to verbal stimuli, but also to non-verbal stimuli, 
suggesting a more “generalized abnormality in auditory processing in individuals with DS” 
(Groen et al., 2008, p. 155).  
Overall, in line with behavioral studies of language lateralization in individual with DS, 
there is reasonable evidence for the existence of ACL in this group.   
Laterality studies indicate that individuals with DS exhibit increased non-right handedness, 
and inconsistent hand preference compared to healthy adults (Groen, Yasin, Laws, Barry & 
Bishop, 2008). This finding is in accordance with laterality studies examining handedness in 
other populations with intellectual disability of different etiology (e.g., Grouios, Sakadami, 
Poderi & Alevriadou, 1999).   
7. Discussion 
An overview of studies examining language and visuospatial abilities in individuals with 
DS suggests that there is a unique profile of cognitive abilities characteristic to the syndrome 
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phenotype. This profile may also indicate variations in neuronal plasticity in different 
disorders with intellectual disability (Bellugi et al., 2000). 
6. Atypical cerebral laterality in individuals with DS  
Atypical cerebral laterality (ACL) has been associated with the cognitive deficits of 
individuals with intellectual disability since the early 1920s (Gordon, 1921). ACL refers to 
the reverse or weak or bilateral representation of language in the two cerebral hemispheres 
(Geschwind & Galaburda, 1985). The majority of right-handed individuals (97%) exhibit left-
hemisphere lateralization for language. Only about 60% of left-handed individuals exhibit 
left-hemisphere lateralization for language, 30% bilateral lateralization and 10% right-
hemisphere lateralization for language (Bishop, 1990). Geschwind & Behan (1982) termed 
atypical laterality any laterality pattern that differed from the “standard dominance pattern” 
(pp. 70). According to Geschwind & Galaburda (1985a; 1985b), atypical dominance may 
involve the inverse or weak dominance of three features; hand dominance, language 
dominance and visuospatial dominance. 
Several accounts have been put forward to explain the increased incidence of atypical 
laterality in individuals with neurodevelopmental disorders, which fall into four main 
categories: hormonal, genetic, pathological, and developmental. According to hormonal 
theories a number of exogenous and endogenous factors increase the secretion of prenatal 
testosterone in the fetus (Geschwind & Galaburda, 1987). This increment enhances the 
growth of the right cerebral hemisphere and inhibits that of the left cerebral hemisphere. In 
particular, their posterior regions, cortical areas tightly linked to intellectual disability and 
poor language development (Geschiwind & Galaburda, 1985a, 1985b, 1985c). This 
speculation has been repeatedly challenged during the past decades for its complexity (e.g., 
McManus & Bryden, 1991; McManus, Bryden & Bulman-Fleming, 1994; Annett, 1994; 
Previc, 1994), although the implication of testosterone levels in the establishment of cerebral 
lateralization remains well supported (e.g. Witleslon, 1985). For example, Witelson (1985, 
1989) suggested that larger callosal isthmus is related to increased left-handedness in TD 
individuals, resulting from less axonal loss in the corpus callosum during foetal 
development, which is influenced by prenatal testosterone levels. Specifically, decreased 
levels of prenatal testosterone may cause decreased axonal loss in the corpus callosum, 
causing increased bilateral representation of cognitive functions and enhanced prevalence of 
non-right-handedness (Witelson, 1989, 1991). 
Genetic theories argue that ACL results from genetic variation determined by a single gene 
(Annett, 1985; McManus & Bryden,1982). Individuals who are not carriers of this gene will 
exhibit random hand preference (right or left). Any pathology during development may 
inhibit the expression of the right-hand gene causing ACL (Annett & Alexander, 1996). 
Alternatively, Satz (1973) proposed that ACL may be the result of early brain damage in the 
left hemisphere, causing a mild dysfunction of the contralateral hand for motor activities, 
which in turn, forces a genetically right handed person to switch to non-right handedness. 
According to this account, individuals with ACL are “pathological” left handers, genetically 
programmed to become right handers, but brain pathology altered this biological 
expression. From a developmental perspective, ACL may be caused by an atypical 
maturational process in motor development that initiates from the trunk, followed by the 
shoulders and then the hands. If this maturational process is arrested, or lagged, it could 
cause increased randomness which would be documented by lack of hand preference (i.e., 
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ambiguous handedness) (Palmer, 1964). Bishop (1983; 1990) speculated that non right 
handedness is an indicator of an immature development of the motor system, caused by 
diffuse brain abnormalities in individuals with intellectual disability. 
The characteristic dissociation of language being disproportionately affected to visuospatial 
abilities in individuals with DS that cannot be accounted by the hearing impairments (Laws, 
2004) provides suspicion for the link between ACL and language problems in DS 
population. Indeed, an extensive review of the literature indicates that individuals with DS 
document an ACL pattern in speech perception and oral motor movements (e.g., Elliott & 
Weeks, 1993; Elliott, Weeks, & Chua, 1994; Heath & Elliott, 1999). 
In a typical dichotic listening paradigm, two different auditory verbal stimuli are 
simultaneously presented in each ear using headphones. The participant is asked to repeat the 
stimulus that was best heard. TD right-handed individuals document a right-ear advantage 
(REA) for speech stimuli, which is indicative of left hemisphere lateralization for speech 
perception. According to the original account, auditory information incoming from the right 
ear is predominately represented in the opposite hemisphere (i.e., the left hemisphere) due to 
anatomical contralateral auditory pathways and, thus, closer to the language centers of the 
same hemisphere (Kimura, 1961). In order for verbal stimuli incoming from the left ear to 
reach the left-hemisphere’s language centers, information crosses from the right to the left 
cerebral hemisphere via the corpus callosum, causing significant delays. In individuals with 
DS, a left-ear/right-cerebral hemisphere preference for speech sounds (Hartley, 1981; Pipe, 
1988), or no ear advantage (Sommer and Starkey, 1977; Tannock et al., 1984) has been 
observed, instead of the typical right-ear/left-cerebral hemisphere preference found in TD 
controls. Using dichotic listening tasks, Welsh, Elliot, and Simon (2003) verified this hypothesis 
with right-handed individuals with DS exhibiting a left-ear/right-cerebral hemisphere 
advantage for speech perception, unlike the right-ear/left-cerebral hemisphere laterality for 
speech perception typically observed in TD adults. Similar results were obtained in a Japanese 
study with individuals with DS (Shoji, Koizumi & Ozaki, 2008). 
Recently, Groen, Alku and Bishop (2008) used T-complex auditory event-related potentials 
to investigate whether individuals with DS show ACL, as reflected by atypical patterns of 
brain activity elicited by verbal and tone sounds presented in each ear. The relationship 
between atypical lateralization, language deficits and handedness was further explored.  
The laterality patterns of individuals with DS were significantly different, compared to TD 
individuals, confirming the existence of ACL for auditory processing in this population. 
However, this atypicality was not specific to verbal stimuli, but also to non-verbal stimuli, 
suggesting a more “generalized abnormality in auditory processing in individuals with DS” 
(Groen et al., 2008, p. 155).  
Overall, in line with behavioral studies of language lateralization in individual with DS, 
there is reasonable evidence for the existence of ACL in this group.   
Laterality studies indicate that individuals with DS exhibit increased non-right handedness, 
and inconsistent hand preference compared to healthy adults (Groen, Yasin, Laws, Barry & 
Bishop, 2008). This finding is in accordance with laterality studies examining handedness in 
other populations with intellectual disability of different etiology (e.g., Grouios, Sakadami, 
Poderi & Alevriadou, 1999).   
7. Discussion 
An overview of studies examining language and visuospatial abilities in individuals with 
DS suggests that there is a unique profile of cognitive abilities characteristic to the syndrome 
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that cannot be explained by intellectual disability. Individuals with DS exhibit diverse levels 
of strengths and weaknesses in both cognitive domains. Namely, the deficits in language 
abilities usually exceed impairments in visualspatial abilities. Recent studies demonstrate a 
more complex neuropsychological profile in this population, suggesting that the 
dissociation between language and visuospatial abilities is too simplistic. Indeed, we 
presented research that indicates that there are strengths and weaknesses in the visuospatial 
domain and the level of performance rarely exceed that of TD individuals matched for 
mental age. Moreover, the strength in visuospatial ability may be an artifact of comparisons 
with another genetic syndrome with intellectual disability, namely WS.  
The brain abnormalities of individuals with DS result in a complex pattern of a behavioral 
phenotype that involves a number of interacting cognitive systems. It also implicates 
atypical lateralization of function reflected in the abnormal auditory perception for speech 
stimuli and increased incidence of non-right handedness. According to the neuronal 
network hypothesis, the cognitive deficits of individuals with intellectual disability are the 
result of weak connectivity of different areas of the cerebral cortex (Ramakers, 2002). If this 
holds true, then processing difficulties are not limited to cognitive systems, but also 
perceptual systems such as auditory pathways. Indeed, difficulties in perceptual 
organization have been correlated with severity of intellectual disability, which is consistent 
with the hypothesis of a more general deficit in information processing (Ramakers, 2002). 
Future research should investigate the development of language and visuospatial abilities 
longitudinally to provide information on when the divergence of these cognitive domains 
becomes apparent.  
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abilities usually exceed impairments in visualspatial abilities. Recent studies demonstrate a 
more complex neuropsychological profile in this population, suggesting that the 
dissociation between language and visuospatial abilities is too simplistic. Indeed, we 
presented research that indicates that there are strengths and weaknesses in the visuospatial 
domain and the level of performance rarely exceed that of TD individuals matched for 
mental age. Moreover, the strength in visuospatial ability may be an artifact of comparisons 
with another genetic syndrome with intellectual disability, namely WS.  
The brain abnormalities of individuals with DS result in a complex pattern of a behavioral 
phenotype that involves a number of interacting cognitive systems. It also implicates 
atypical lateralization of function reflected in the abnormal auditory perception for speech 
stimuli and increased incidence of non-right handedness. According to the neuronal 
network hypothesis, the cognitive deficits of individuals with intellectual disability are the 
result of weak connectivity of different areas of the cerebral cortex (Ramakers, 2002). If this 
holds true, then processing difficulties are not limited to cognitive systems, but also 
perceptual systems such as auditory pathways. Indeed, difficulties in perceptual 
organization have been correlated with severity of intellectual disability, which is consistent 
with the hypothesis of a more general deficit in information processing (Ramakers, 2002). 
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1. Introduction 
Chromosomal aberration is a phenomenon occurring relatively commonly in the 
development process. Chromosomal aberration is known to have various causes, and its 
frequency has been reported to vary particularly according to maternal age. Though 
different among reports, the frequency was around 0.6-0.8% in analysis with all childbirths1 
and around 2-3% in case childbirths were reclassified based on maternal age of 35.2 In 
addition, the frequency increased when the maternal age was relatively young, artificial 
insemination was used, etc.3 Spontaneous abortion related to such chromosomal aberrations 
occurs usually in the first trimester, and consequently, the prevalence of trisomy 21, 18 and 
13 decreases with the advance of gestational age.4 Chromosomal aberrations that can be 
found in prenatal diagnosis are largely divided into aneuploidy, structural aberration, 
mosaicism, uniparental disomy, small defect, etc., and additionally, there can be marker 
chromosomes. Marker chromosomes are observed in around one out of 1000 cases of 
chromosomal analysis, and are known to be related to old maternal age.5 It is reported that 
around 80% of marker chromosomes detected are new ones, and 13% of marker 
chromosomes are associated with physical abnormalities or cognitive disorders.6 
The frequency and type of chromosomal aberration are known to be different depending on 
the time of evaluation, population group under the analysis of structural chromosomal 
aberration, and the banding level of the laboratory performing cytogenetic evaluation.7 
Thus, it is increasingly important to conduct adequate prenatal genetic screening and 
analyze its results properly. Among chromosomal aberrations detected in pregnant women 
who received amniocentesis because of their age, 64% were trisomy (21% trisomy 21), 11% 
translocation, 17% sex chromosomal aberration, and 8% other types of chromosomal 
aberration.2 Thus, considering the increasing number of old age pregnancies in Korea, 
careful attention should to paid in analyzing the results of prenatal genetic tests. Thus, this 
study purposed to discuss how to analyze the results of maternal serum marker tests and 
sonography used in prenatal genetic evaluation.  
2. Maternal serum screening 
2.1 Alpha fetoprotein 
Brock and Sutcliffe 2 found in 1972 that the level of alpha fetoprotein in amniotic fluid 
increased when the fetus had a neural tube defect, and from the 1980s, the maternal serum 
alpha fetoprotein test began to be used for screening fetal anomalies in pregnant women. 
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Alpha fetoprotein, which is glycoprotein, is produced in the yolk sac in the early stage, and 
later in the fetal gastrointestinal tract and liver. A small portion of alpha fetoprotein in fetal 
serum may be discharged to urine and amniotic fluid, and it may diffuse through the fetal 
membrane and the placenta and enter maternal serum. Whereas the alpha fetoprotein level 
in fetal serum and amniotic fluid increases until 13 week and then decreases thereafter, the 
level in maternal serum increases continuously until 32 week because the size of the fetus 
keeps growing.8 Between 16-20 week of gestational age, the level of alpha fetoprotein in 
maternal serum is only around 1/100,000 of that in fetal serum. 
2.1.1 Analysis of serum alpha fetoprotein data 
As is known, the concentration of alpha fetoprotein in maternal serum or amniotic fluid is 
measured as a test for screening fetal neural tube defects. When the measurements of alpha 
fetoprotein are analyzed, we should be careful not to attach clinical importance to absolute 
values. It is because the test method of each laboratory or company may seem to have been 
stabilized by itself, but absolute values from the method are often different from those 
obtained by other laboratories or test methods. For this reason, the measurements of alpha 
fetoprotein are often reported as the multiples of the median (MoM). A median is the value 
in the middle when result values are put in order of size, so it can reduce errors and allow 
the comparative analysis of result values without being influenced by laboratory or test 
method.  
On the other hand, the measurements of alpha fetoprotein in maternal serum can be affected 
not only by multiple pregnancy and gestational age but also by maternal weight, diabetes, 
race, etc.9,10, so these factors should be confirmed before the analysis of such measurements. 
Because the absolute level of serum alpha fetoprotein rises along with gestational age8, 
underestimated gestational age is the most common cause of increased alpha fetoprotein 
concentration. In such a case, we can avoid unnecessary additional tests by correcting 
gestational age and recalculating the median. 
2.1.2 Causes of increased alpha fetoprotein in maternal serum 
Fetal anomalies  
The rise of the alpha fetoprotein level in maternal serum is often accompanied by fetal 
anomalies. This is not because of a special function of alpha fetoprotein but because fetal 
tissue leaks to amniotic fluid due to neural tube defect, abdominal wall defect, 
sacrococcygeal teratoma, cystic hygroma, skin defect, etc. and, as a result, an increasing 
amount of alpha fetoprotein flows into amniotic fluid and maternal serum11 or because 
alpha fetoprotein is not reabsorbed but discharged to urine due to fetal kidney anomaly.12  
In fetal neural tube defect, alpha fetoprotein exudes through exposed nervous tissue, so the 
level of alpha fetoprotein in maternal serum is relatively higher in spina bifida aperta or 
anencephaly than in spina bifida occulta. In most laboratories, those whose median alpha 
fetoprotein level in maternal serum is over 2.0-2.5 are classified into a high-risk group of 
fetal neural tube defect. When median 2.5 was used, spina bifida aperta was detected at a 
detection rate of 80% and the false positive rate was 3-4%.13  
The anomaly found second most commonly to neural tube defect in alpha-fetoprotein 
screening is abdominal wall defect. Particularly in case of gastroschisis, organs removed out 
of the abdominal cavity contact amniotic fluid directly, and therefore, the alpha fetoprotein 
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level tends to be higher than that in omphalocele.11 Maternal serum alpha fetoprotein 
screening detects around 85% of gastroschisis and around 50 % of omphalocele.11 
Placental abnormalities 
Because the concentration of alpha fetoprotein in fetal serum is 100,000 times higher than 
that in maternal serum8, even a small inflow of fetal blood increases the fetoprotein level in 
maternal serum rapidly. In case of chorioangioma in the placenta and hemangioma in the 
umbilical cord, fetal serum exudes into amniotic fluid and the maternal body due to mass 
bleeding14, and in case of placenta accreta, placental infarct, etc. as well, alpha fetoprotein 
increases in the same way.16 
2.2 Maternal serum test for aneuploidy screening 
2.2.1 Second trimester multiple marker screening test 
In 1984, Merkatz et al.16 found that the risk of Down syndrome was high when the level of 
serum alpha fetoprotein was low during the second trimester, but this finding alone was not 
sufficient for using alpha fetoprotein as an accurate Down syndrome marker.16 Later, double 
marker test that added human chorionic gonadotropin (hCG) test, and triple test that added 
also estriol (E3) to the double test were introduced as Down syndrome screening tests in the 
second trimester.18 Recently, quad test that added inhibin A was developed18 for higher 
accuracy of screening. The mean median (MoM) of each marker in trisomy 21 and 18 is 
presented in Table 1. There were large-scale prospective studies that compared accuracy 
among a number of multiple markers in the U.K. (Serum, Urine and Ultrasound Screening 
Study; SURUSS)19 and the U.S. (First and Second Trimester Evaluation of Risk for Fetal 
Anueploidy; FASTER),20 and in both studies the detection rate of quad markers was 
reported to be 81 %. Table 2 summarized the Down syndrome detection rates of multiple 
markers from the two studies. 
 
Aneuploidy AFP hCG uE3 Inhibin A 
Trisomy 21 0.74 * (↓) 2.05 * (↑) 0.70 * (↓) 2.548 * (↑) 
Trisomy 18 0.65** (↓) 0.32** (↓) 0.42** (↓) - 
AFP, α-fetoprotein; hCG, human chorionic gonadotropin; uE3, unconjugated estriol 
* Modified from the results of the FASTER trial 
** Modified from the results of Benn PA et al. Obstet Gyenecol 1999;93:707-11.  
Table 1. The mean MoM (multiples of the median) values for the second trimester maternal 
serum quad markers.  
 
  Detection rate at a 5% false-positive rate 
  SURUSS19 FASTER20 
Double markers AFP + hCG 66% - 
Triple markers AFP + hCG + uE3 74% 70% 
Quad markers AFP + hCG + uE3 + inhibin A 81% 81% 
AFP, α-fetoprotein; hCG, human chorionic gonadotropin; uE3, unconjugated estriol 
Table 2. The detection rate of second trimester serum markers for Down syndrome. 
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2.2.2 First trimester screening test 
Maternal serum triple marker test 
Among first trimester serum markers, pregnancy-associated plasma protein A (PAPP-A) 
and free β-hCG are known to have the highest discrimination for haploidy. In Down 
syndrome, the MoM of maternal serum PAPP-A is 0.38, decreasing by 60%, and that of free 
β-hCG is 1.83, increasing by around two times.21 Accordingly, both of the two markers are 
used in first trimester screening, and with this test, the Down syndrome detection rate is 60-
74% and the false positive rate is 5%.19,20 The detection rate is lower than that of the quad 
test in the second trimester but similar to that of the triple test. 
Nuchal translucency measuring  
The thickness of nuchal translucency in the first trimester is related to fetal haploidy, in 
particular, to Down syndrome, apart from maternal serum markers.22 Accordingly, the 
accuracy of screening can be enhanced through the first trimester combined test that 
measures the thickness of nuchal translucency in addition to serologic tests that measure 
PAPPA-A and free β-hCG.22 In the results of a meta-analysis with 209,603 subjects, the 
combined screening test showed a detection rate of 86% (84-88 95%, CI) with a false positive 
rate of 5.1% and Down syndrome was detected in 785 subjects.23 When only nuchal 
translucency was measured without serologic tests, the Down syndrome detection rate was 
77% with a false positive rate of 6.0%, so it was less accurate than the combined test. The 
positive predictive value of the combined screening test was 16.8 (16.3-17.4, 95% CI), which 
means that one out of 17 pregnancies with a positive result of the combined screening test is 
found to have a Down syndrome fetus.23 On the other hand, because PAPP-A decreases but 
free β-hCG increases for 11-14 weeks of pregnancy, the detection rate varies significantly 
according to gestational age.23 In the results of FASTER, the Down syndrome detection rate 
was 73% and the false positive rate was 1% in 11 weeks of pregnancy, but 67% and 5%, 
respectively, in 13 weeks, and based on this result the research reported that the accuracy of 
the combined test was highest at the gestational age of 11 weeks.20 However, it was reported 
that if second trimester screening would be performed additionally, it would be more 
efficient to have the combined test in 10 weeks of pregnancy.23 
2.2.3 First and second trimester integrated test 
Wald et al.24 proposed integrated test, which uses information on first and second trimester 
markers in sequence. They expected that if nuchal translucency and serum PAPP-A are 
measured in 10-13 weeks, and alpha fetoprotein, total hCG, estriol and inhibin A in 15-18 
weeks, Down syndrome can be detected at a rate of 94% with a false positive rate of 5%, or 
85% with a false positive rate of 1%.25 Accordingly, because Down syndrome can be 
screened with a false positive rate of 1%, it reduces the need of additional diagnoses such as 
amniocentesis, and prevents fetal death resulting from invasive examination. In the results 
of SURUSS19 and FASTER,20 the integrated test was most accurate as a Down syndrome 
screening test (Table 3). 
However, the integrated test has a number of shortcomings to be an alternative general 
screening test in prenatal examination. First, most of pregnant women who receive a 
screening test in the first trimester want the termination of pregnancy immediately if 
abnormalities are found in the fetus, and it is safer to terminate pregnancy in the first 
trimester. Second, it is hard to distinguish pregnant women who cannot be followed up after 
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first trimester serologic tests. In SURUSS 19 as well, 20% of pregnant women who had a first 
trimester test did not appear in the second trimester test. In such a case, there could be the 
legal risk of not telling the results of the first trimester test, so it was not an adequate 
alternative at present. Third, if the risk is unusually high in the results of the first trimester 
test the results are not provided until the second trimester, and this may raise an ethical 
issue. Thus, the integrated test can be the method of highest sensitivity and specificity if a 
pregnant woman receives prenatal examination from the beginning of pregnancy and takes 
both the first and second trimester screening tests, but is not adequate for those who want to 
get invasive chorionic villus sampling immediately based on the results of the first trimester 
screening test. 
 
 FASTER20 SURUSS19 







FPR of    : 
 75% 85% 95% 1% 5% 75% 85% 95% 1% 5% 
1st trimester           
NT only 8.1 20 55 54 68 12.9 25 55 33 60 
PAPP-A + f-βhCG 7.1 16 42 46 67 5.5 12.1 33 52 74 
Combined† 1.2 3.8 18 72 85 2.3 6.1 22 66 83 
1st + 2nd trimester:      .     
Serum integrated‡§ 1.2 3.6 15 70 86 0.8 2.7 12.5 77 90 
Full integrated§ 0.2 0.6 4.0 87 95 0.3 1.2 7.2 84 95 
2nd trimester           
Triple (AFP+hCG+E3) 7.0 14 32 45 69 2.9 7.1 22 51 74 
Quad (Triple+inhibin A) 3.1 7.3 22 60 81 2.6 6.1 18 63 83 
DR, detection rate; FPR, false positive rate; NT, nuchal translucency; PAPP-A, pregnancy associated 
plasma protein-A; f-βhCG free beta subunit of human chorionic gonadotropin; Quad, second trimester 
quadruple screen; AFP, alphafetoprotein; uE3, unconjugated estriol 
† Combined: NT, PAPP-A, and f-βhCG in the first trimester 
‡ Serum integrated: PAPP-A in the first trimester and quad screen in the second trimester 
§ Full integrated: NT and PAPP-A in the first trimester with quad screen in the second trimester 
Data from Rosen T et al. Semin Perinatol 2005;29:367-75. 
Table 3. Direct comparative data for the first and second trimester Down syndrome screens 
from the prospective FASTER and SURUSS trials. 
2.2.4 Alternatives to the integrated test 
Sequential screening 
If the result of the first trimester screening test is positive, chromosomal analysis is performed 
immediately and if the result is negative, the second trimester screening test is performed and 
if the result is positive, chromosomal analysis is performed. A characteristic of this method is 
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2.2.2 First trimester screening test 
Maternal serum triple marker test 
Among first trimester serum markers, pregnancy-associated plasma protein A (PAPP-A) 
and free β-hCG are known to have the highest discrimination for haploidy. In Down 
syndrome, the MoM of maternal serum PAPP-A is 0.38, decreasing by 60%, and that of free 
β-hCG is 1.83, increasing by around two times.21 Accordingly, both of the two markers are 
used in first trimester screening, and with this test, the Down syndrome detection rate is 60-
74% and the false positive rate is 5%.19,20 The detection rate is lower than that of the quad 
test in the second trimester but similar to that of the triple test. 
Nuchal translucency measuring  
The thickness of nuchal translucency in the first trimester is related to fetal haploidy, in 
particular, to Down syndrome, apart from maternal serum markers.22 Accordingly, the 
accuracy of screening can be enhanced through the first trimester combined test that 
measures the thickness of nuchal translucency in addition to serologic tests that measure 
PAPPA-A and free β-hCG.22 In the results of a meta-analysis with 209,603 subjects, the 
combined screening test showed a detection rate of 86% (84-88 95%, CI) with a false positive 
rate of 5.1% and Down syndrome was detected in 785 subjects.23 When only nuchal 
translucency was measured without serologic tests, the Down syndrome detection rate was 
77% with a false positive rate of 6.0%, so it was less accurate than the combined test. The 
positive predictive value of the combined screening test was 16.8 (16.3-17.4, 95% CI), which 
means that one out of 17 pregnancies with a positive result of the combined screening test is 
found to have a Down syndrome fetus.23 On the other hand, because PAPP-A decreases but 
free β-hCG increases for 11-14 weeks of pregnancy, the detection rate varies significantly 
according to gestational age.23 In the results of FASTER, the Down syndrome detection rate 
was 73% and the false positive rate was 1% in 11 weeks of pregnancy, but 67% and 5%, 
respectively, in 13 weeks, and based on this result the research reported that the accuracy of 
the combined test was highest at the gestational age of 11 weeks.20 However, it was reported 
that if second trimester screening would be performed additionally, it would be more 
efficient to have the combined test in 10 weeks of pregnancy.23 
2.2.3 First and second trimester integrated test 
Wald et al.24 proposed integrated test, which uses information on first and second trimester 
markers in sequence. They expected that if nuchal translucency and serum PAPP-A are 
measured in 10-13 weeks, and alpha fetoprotein, total hCG, estriol and inhibin A in 15-18 
weeks, Down syndrome can be detected at a rate of 94% with a false positive rate of 5%, or 
85% with a false positive rate of 1%.25 Accordingly, because Down syndrome can be 
screened with a false positive rate of 1%, it reduces the need of additional diagnoses such as 
amniocentesis, and prevents fetal death resulting from invasive examination. In the results 
of SURUSS19 and FASTER,20 the integrated test was most accurate as a Down syndrome 
screening test (Table 3). 
However, the integrated test has a number of shortcomings to be an alternative general 
screening test in prenatal examination. First, most of pregnant women who receive a 
screening test in the first trimester want the termination of pregnancy immediately if 
abnormalities are found in the fetus, and it is safer to terminate pregnancy in the first 
trimester. Second, it is hard to distinguish pregnant women who cannot be followed up after 
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first trimester serologic tests. In SURUSS 19 as well, 20% of pregnant women who had a first 
trimester test did not appear in the second trimester test. In such a case, there could be the 
legal risk of not telling the results of the first trimester test, so it was not an adequate 
alternative at present. Third, if the risk is unusually high in the results of the first trimester 
test the results are not provided until the second trimester, and this may raise an ethical 
issue. Thus, the integrated test can be the method of highest sensitivity and specificity if a 
pregnant woman receives prenatal examination from the beginning of pregnancy and takes 
both the first and second trimester screening tests, but is not adequate for those who want to 
get invasive chorionic villus sampling immediately based on the results of the first trimester 
screening test. 
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 75% 85% 95% 1% 5% 75% 85% 95% 1% 5% 
1st trimester           
NT only 8.1 20 55 54 68 12.9 25 55 33 60 
PAPP-A + f-βhCG 7.1 16 42 46 67 5.5 12.1 33 52 74 
Combined† 1.2 3.8 18 72 85 2.3 6.1 22 66 83 
1st + 2nd trimester:      .     
Serum integrated‡§ 1.2 3.6 15 70 86 0.8 2.7 12.5 77 90 
Full integrated§ 0.2 0.6 4.0 87 95 0.3 1.2 7.2 84 95 
2nd trimester           
Triple (AFP+hCG+E3) 7.0 14 32 45 69 2.9 7.1 22 51 74 
Quad (Triple+inhibin A) 3.1 7.3 22 60 81 2.6 6.1 18 63 83 
DR, detection rate; FPR, false positive rate; NT, nuchal translucency; PAPP-A, pregnancy associated 
plasma protein-A; f-βhCG free beta subunit of human chorionic gonadotropin; Quad, second trimester 
quadruple screen; AFP, alphafetoprotein; uE3, unconjugated estriol 
† Combined: NT, PAPP-A, and f-βhCG in the first trimester 
‡ Serum integrated: PAPP-A in the first trimester and quad screen in the second trimester 
§ Full integrated: NT and PAPP-A in the first trimester with quad screen in the second trimester 
Data from Rosen T et al. Semin Perinatol 2005;29:367-75. 
Table 3. Direct comparative data for the first and second trimester Down syndrome screens 
from the prospective FASTER and SURUSS trials. 
2.2.4 Alternatives to the integrated test 
Sequential screening 
If the result of the first trimester screening test is positive, chromosomal analysis is performed 
immediately and if the result is negative, the second trimester screening test is performed and 
if the result is positive, chromosomal analysis is performed. A characteristic of this method is 
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that the result of the first trimester screening test is provided to the pregnant woman and then 
the second trimester test is performed additionally. It can enhance the Down syndrome 
detection rate up to 98% but its false positive rate is also high as 17%.26 
Contingency screening 
If the first trimester screening test indicates high risk, chromosomal analysis is performed, 
and if the result indicates low risk no additional test is performed, but if it indicates 
moderate risk integrating screening is performed.27 
3. Genetic sonographic markers of aneuploidy 
Most of fetuses with chromosomal aberration have organs whose appearance is anomalous 
or abnormal, and such defects can be detected through prenatal sonography. A fetal 
structural anomaly may be caused by multiple factors, but it can be the result of 
chromosomal aberration. Therefore, if a fetal anomaly has been found, we should determine 
whether to perform cytogenetic analysis through amniocentesis after checking if other 
abnormalities accompany. Using genetic sonographic findings, we can detect pregnancies 
with high risk of aneuploidy at a sensitivity of 50-93%28, and the absence of genetic 
sonographic findings may be regarded as sure evidence for the low risk of haploidy. Genetic 
sonographic findings can be divided into major structural anomalies and minor anomalies. 
In particular, anomalies that are observed frequently also in normal fetuses and occasionally 
disappear with the advance of gestational age are called sonographic markers. It is generally 
accepted that a major anomaly is a sign of high risk of chromosomal aberration and thus 
chromosomal analysis is required, but it is still controversial whether additional tests are 
required when only a minor anomaly has been found. It is important to determine in 
consideration of the likelihood of chromosomal aberration on a case basis rather than 
applying a uniform rule to every case, and for this, we need to be familiar with the risk of 
chromosomal aberration and representative types of haploidy in connection to each genetic 
sonographic marker (Table 4).  
3.1 Major anomalies related to haploidy  
The characteristic and frequency of sonographic findings in fetuses with chromosomal 
aberration are various according to gestational age, and the detection of abnormal findings 
is affected by the reason of sonography, criteria for positive finding, the level of sonographic 
equipment, etc. Structural major anomalies are detected mostly by sonography in trisomy 13 
and 18, but are missed relatively often in trisomy 21. Table 5 summarized structural major 
anomalies detected commonly in pregnancies with trisomy 13, 18 and 21 and Turner 
syndrome. 
3.2 Sonographic markers related to haploidy  
The most common sonographic markers in the second trimester include nuchal thickening, 
hyperechoic bowel, short limbs, pyelectasia, echogenic intracardiac focus, and choroid 
plexus cysts. In general, the risk of chromosomal aberration is higher when the number of 
markers is large. Table 6 summarized the likelihood ratio of haploidy when each 
sonographic marker has occurred singly. The likelihood ratio was calculated by sensitivity / 
false positive rate, and if two or more sonographic markers have occurred together, the 
combined likelihood ratio is the product of their respective likelihood ratios.  
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Cystic hygroma 1/120 EU–1/6,000 B 60-75% 45X (80%),21,18,13,XXY 
Hydrops 1/1,500–4,000 B 30-80% 13,21,18,45X 
Hydrocephalus 3–8/10,000 LB 3-8% 13,18,triploidy 
Hydranencephaly 2/1,000 IA Minimal  
Holoprosencephaly 1/16,000 LB 40-60% 13,18,18p- 
Cardiac defect 7-9/100 LB 5-30% 21,18,13,22,8,9 
Diaphragmatic hernia 1/3,500–4,000 LB 20-25% 13,18,21,45X 
Omphalocele 1/5,800 LB 30-40% 13,18 
Gastroschisis 1/10,000–15,000 LB Minimal  
Duodenal atresia 1/10,000 LB 20-30% 21 
Bladder outlet obstruction 1-2/1,000 LB 20-25% 13,18 
Facial cleft 1/700 LB 1% 13,18, deletions 
Limb reduction 4-6/1,000 LB 8% 18 
Clubfoot 1.2/1,000 LB 20-30% 13,18, 4p-, 18q- 
Single umbilical artery 1% Minimal  
B, birth; EU, early ultrasonography; LB, livebirth; IA, infant autopsy. 
Data from Shipp TD, et al. Am J Obstet Gynecol 1998; 178: 600–2. and Nyberg DA and Crane JP. 
Chromosome abnormalities. In: Nyberg DA, et al. Diagnostic ultrasound of fetal anomalies: text and 
atlas. Chicago (IL): Year Book Medical; 1990. p. 676–724. 
Table 4. Aneuploidy risk of major structural fetal malformation. 
Aneuploidy Sonographic finding Aneuploidy Sonographic finding 




Face (midline defects, ocular 
abnormalities) 
Kidney(enlarged cystic kidneys)
IUGR with polyhydramnios 
Trisomy 21 Heart (septal defects) 
Abnormal fluid accumulation 
(thickened nuchal fold, cystic 
hygroma, fetal hydrops) 
Abdominal malformations 
IUGR with polyhydramnios 
Trisomy 18 Heart (VSD)
CNS (posterior fossa cyst, 
abnormal head shape, 
ventriculomegaly) 
Facial anomalies 
Choroid plexus cyst 
Abnormal fluid accumulation 
(thickened nuchal fold, cystic 
hygroma, fetal hydrops) 
Abdominal malformations 
IUGR with polyhydramnios 
Turner 
syndrome 
Heart (Coarctation of aorta) 
Abnormal fluid accumulation 
(increased nuchal 
translucency/ thickened 
nuchal fold, cystic hygroma, 
feta hydrops) 
Renal anomalies 
Short femur or humerus 
CNS, central nervous system; IUGR, intrauterine growth restriction; VSD, ventricular septal defect 
Table 5. Sonographic finding with high incidence in different fetal chromosomal 
abnormalities 
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that the result of the first trimester screening test is provided to the pregnant woman and then 
the second trimester test is performed additionally. It can enhance the Down syndrome 
detection rate up to 98% but its false positive rate is also high as 17%.26 
Contingency screening 
If the first trimester screening test indicates high risk, chromosomal analysis is performed, 
and if the result indicates low risk no additional test is performed, but if it indicates 
moderate risk integrating screening is performed.27 
3. Genetic sonographic markers of aneuploidy 
Most of fetuses with chromosomal aberration have organs whose appearance is anomalous 
or abnormal, and such defects can be detected through prenatal sonography. A fetal 
structural anomaly may be caused by multiple factors, but it can be the result of 
chromosomal aberration. Therefore, if a fetal anomaly has been found, we should determine 
whether to perform cytogenetic analysis through amniocentesis after checking if other 
abnormalities accompany. Using genetic sonographic findings, we can detect pregnancies 
with high risk of aneuploidy at a sensitivity of 50-93%28, and the absence of genetic 
sonographic findings may be regarded as sure evidence for the low risk of haploidy. Genetic 
sonographic findings can be divided into major structural anomalies and minor anomalies. 
In particular, anomalies that are observed frequently also in normal fetuses and occasionally 
disappear with the advance of gestational age are called sonographic markers. It is generally 
accepted that a major anomaly is a sign of high risk of chromosomal aberration and thus 
chromosomal analysis is required, but it is still controversial whether additional tests are 
required when only a minor anomaly has been found. It is important to determine in 
consideration of the likelihood of chromosomal aberration on a case basis rather than 
applying a uniform rule to every case, and for this, we need to be familiar with the risk of 
chromosomal aberration and representative types of haploidy in connection to each genetic 
sonographic marker (Table 4).  
3.1 Major anomalies related to haploidy  
The characteristic and frequency of sonographic findings in fetuses with chromosomal 
aberration are various according to gestational age, and the detection of abnormal findings 
is affected by the reason of sonography, criteria for positive finding, the level of sonographic 
equipment, etc. Structural major anomalies are detected mostly by sonography in trisomy 13 
and 18, but are missed relatively often in trisomy 21. Table 5 summarized structural major 
anomalies detected commonly in pregnancies with trisomy 13, 18 and 21 and Turner 
syndrome. 
3.2 Sonographic markers related to haploidy  
The most common sonographic markers in the second trimester include nuchal thickening, 
hyperechoic bowel, short limbs, pyelectasia, echogenic intracardiac focus, and choroid 
plexus cysts. In general, the risk of chromosomal aberration is higher when the number of 
markers is large. Table 6 summarized the likelihood ratio of haploidy when each 
sonographic marker has occurred singly. The likelihood ratio was calculated by sensitivity / 
false positive rate, and if two or more sonographic markers have occurred together, the 
combined likelihood ratio is the product of their respective likelihood ratios.  
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Cystic hygroma 1/120 EU–1/6,000 B 60-75% 45X (80%),21,18,13,XXY 
Hydrops 1/1,500–4,000 B 30-80% 13,21,18,45X 
Hydrocephalus 3–8/10,000 LB 3-8% 13,18,triploidy 
Hydranencephaly 2/1,000 IA Minimal  
Holoprosencephaly 1/16,000 LB 40-60% 13,18,18p- 
Cardiac defect 7-9/100 LB 5-30% 21,18,13,22,8,9 
Diaphragmatic hernia 1/3,500–4,000 LB 20-25% 13,18,21,45X 
Omphalocele 1/5,800 LB 30-40% 13,18 
Gastroschisis 1/10,000–15,000 LB Minimal  
Duodenal atresia 1/10,000 LB 20-30% 21 
Bladder outlet obstruction 1-2/1,000 LB 20-25% 13,18 
Facial cleft 1/700 LB 1% 13,18, deletions 
Limb reduction 4-6/1,000 LB 8% 18 
Clubfoot 1.2/1,000 LB 20-30% 13,18, 4p-, 18q- 
Single umbilical artery 1% Minimal  
B, birth; EU, early ultrasonography; LB, livebirth; IA, infant autopsy. 
Data from Shipp TD, et al. Am J Obstet Gynecol 1998; 178: 600–2. and Nyberg DA and Crane JP. 
Chromosome abnormalities. In: Nyberg DA, et al. Diagnostic ultrasound of fetal anomalies: text and 
atlas. Chicago (IL): Year Book Medical; 1990. p. 676–724. 
Table 4. Aneuploidy risk of major structural fetal malformation. 
Aneuploidy Sonographic finding Aneuploidy Sonographic finding 




Face (midline defects, ocular 
abnormalities) 
Kidney(enlarged cystic kidneys)
IUGR with polyhydramnios 
Trisomy 21 Heart (septal defects) 
Abnormal fluid accumulation 
(thickened nuchal fold, cystic 
hygroma, fetal hydrops) 
Abdominal malformations 
IUGR with polyhydramnios 
Trisomy 18 Heart (VSD)
CNS (posterior fossa cyst, 
abnormal head shape, 
ventriculomegaly) 
Facial anomalies 
Choroid plexus cyst 
Abnormal fluid accumulation 
(thickened nuchal fold, cystic 
hygroma, fetal hydrops) 
Abdominal malformations 
IUGR with polyhydramnios 
Turner 
syndrome 
Heart (Coarctation of aorta) 
Abnormal fluid accumulation 
(increased nuchal 
translucency/ thickened 
nuchal fold, cystic hygroma, 
feta hydrops) 
Renal anomalies 
Short femur or humerus 
CNS, central nervous system; IUGR, intrauterine growth restriction; VSD, ventricular septal defect 
Table 5. Sonographic finding with high incidence in different fetal chromosomal 
abnormalities 
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 Likelihood ratio (95% confidence interval) 
Sonographic marker Nyberg et al. Smith-Bindman et al. 
Nuchal thickening 11.0 (5.5-22.0) 17 (8-38) 
Hyperechoic bowel 6.7 (2.7-16.8) 6.1 (3.0-12.6) 
Short humerus 5.1 (1.6-16.5) 7.5 (4.7-12.0) 
Short femur 1.5 (0.8-2.8) 2.7 (1.2-6.0) 
Echogenic intracardiac focus 1.8 (1.0-3.0) 2.8 (1.5-5.5) 
Pyelectasis 1.5 (0.6-3.6) 1.9 (0.7-5.1) 
Normal ultrasound 0.36 - 
Data from Nyberg DA, et al Ultrasound Obstet Gynecol 1998; 12: 8-14. and  
Smith-Bindman R et al. JAMA. 2001; 285: 1044-55. 
Table 6. Likelihood ratio of sonographic soft marker for fetal aneuploidy 
3.2.1 Choroid plexus cysts 
Choroid plexus cyst is found relatively commonly during the second trimester, showing a 
prevalence of 0.3-3.6%.29 This type of cyst is known to be benign, disappearing 
spontaneously at the later stage of pregnancy without affecting the development of the 
fetus. As a sonographic marker of haploidy, choroid plexus cyst is found in 50% of fetuses 
with trisomy 1830 but most of the cases are accompanied by another anomaly, and it is 
reported that no particular prenatal care including chromosomal analysis is necessary if 
only isolated choroid plexus cysts are found.29  
3.2.2 Mild cerebral ventricular dilatation 
Mild cerebral ventricular dilatation, in which the diameter of the cerebral lateral ventricle is 
over 10-15 mm, is related to aneuploidy like trisomy 21.32 Bromley et al.32 reported that 12% 
of pregnancies with mild cerebral ventricular dilatation are related to abnormal karyotype 
(trisomy 18, 21). In addition, mild cerebral ventricular dilatation was observed in 4.3% of 
fetuses with trisomy 2133 and all of them had accompanying anomalies. It is known that the 
presence of cerebral ventricular dilatation alone does not increase the risk of chromosomal 
aberration. 
3.2.3 Nuchal thickening 
Excessive skin on the back neck is a characteristic finding of trisomy 21. It is observed in 
80% of neonates with trisomy 21 and can be found in other chromosomal aberrations 
(trisomy 13 and 18, 45X).34 Although the sensitivity and the false positive rate vary 
according to gestational age and criteria for positive value are different among institutions, 
its sensitivity for detecting chromosomal aberrations is generally within the range of 20-40%. 
3.2.4 Hyper-echoic bowel 
Hyper-echoic bowel is found in 0.5% of normal fetuses, but in fetuses with aneuploidy like 
trisomy 21, it is known to be observed more frequently and increase the risk 6-7 times 
higher.35 Assuming that the likelihood ratio of isolated hyper-echoic bowel is 6.7 and the 
total risk of Down syndrome in the entire population is one per 500, isolated echoic bowel is 
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expected to be related to the risk of Down syndrome in around 1-2% of the general 
population. Hyper-echoic bowel is also known to be related to ileus, congenital infection, 
and rarely to secondary meconium ileus in cystic fibrosis.36 
3.2.5 Skeletal abnormalities such as shortened limbs 
Shortened limbs are a characteristic observed in fetuses with trisomy 2137 and the length of 
shortened humerus seems to be a slightly more specific marker than the length of shortened 
femur. These results may be different according to gestational age, racial group, expected 
sex of the fetus, and used criteria. 
3.2.6 Echogenic intracardiac focus 
Echogenic intracardiac focus is a common finding in the second trimester. It is observed in 
3-4% of normal fetuses and disappears spontaneously in the third trimester.39 If the size of 
echogenic intracardiac focus is large or there are multiple of them, the risk of aneuploidy 
increases. Bromley et al.40 reported that the risk of aneuploidy is 2 times higher when 
echogenic intracardiac focuses are in the right ventricle or bilateral than when they are only 
in the left ventricle. 
4. Conclusions 
Chromosomal aberration is closely related to the in intrauterine fetal death and perinatal 
prevalence. However, amniocentesis and chorionic villus sampling used for prenatal 
diagnosis of haploidy are invasive methods, and the reported fetal loss rate resulting just 
from the examinations is around 1-2%. Accordingly, it is very important to screen those with 
high risk of chromosomal aberration before such invasive examinations. 
Serologic test of pregnant women for the screening of trisomy 18 and 21 is an important 
diagnostic process in prenatal care, and in particular, second trimester serum alpha 
fetoprotein is used as an important screening marker to detect anomalies such as fetal neural 
tube defect. If the concentration of alpha fetoprotein is over 2.5 MoM, sonography should be 
performed in order to detect neural tube defect and other problems. Recently, because 
sonography shows a high detection rate for neural tube defect, amniocentesis is used less 
frequently in diagnosing neural tube defect. 
The preferred type of serum screening test is various among countries and institutions. In 
general, the first trimester screening test is increasingly preferred, but second trimester 
screening is still used frequently at hospitals that cannot measure fetal nuchal translucency 
or perform chorionic villus sampling. The triple test has been used commonly as second 
trimester screening, but recently the use of the quad test, which adds inhibin A, is 
increasing. If both first and second trimester tests are performed, they can increase the 
detection rate of fetal anomalies, but because the two tests have to be applied at an interval 
of 3-4 weeks, it is quite important to provide an adequate explanation to the patient. The 
serum screening test can be performed in various ways depending on the combination of 
serum factors. Thus, rather than using a uniform test for every case, we need to understand 
the characteristic, detection rate and false positive rate of each test, and individualize the test 
for each case according to maternal age, sonographic findings, and compliance. 
In conclusion, in order to determine the risk of chromosomal aberration, we should analyze 
each case based on maternal age, nuchal fold thickness in the first trimester, the results of 
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 Likelihood ratio (95% confidence interval) 
Sonographic marker Nyberg et al. Smith-Bindman et al. 
Nuchal thickening 11.0 (5.5-22.0) 17 (8-38) 
Hyperechoic bowel 6.7 (2.7-16.8) 6.1 (3.0-12.6) 
Short humerus 5.1 (1.6-16.5) 7.5 (4.7-12.0) 
Short femur 1.5 (0.8-2.8) 2.7 (1.2-6.0) 
Echogenic intracardiac focus 1.8 (1.0-3.0) 2.8 (1.5-5.5) 
Pyelectasis 1.5 (0.6-3.6) 1.9 (0.7-5.1) 
Normal ultrasound 0.36 - 
Data from Nyberg DA, et al Ultrasound Obstet Gynecol 1998; 12: 8-14. and  
Smith-Bindman R et al. JAMA. 2001; 285: 1044-55. 
Table 6. Likelihood ratio of sonographic soft marker for fetal aneuploidy 
3.2.1 Choroid plexus cysts 
Choroid plexus cyst is found relatively commonly during the second trimester, showing a 
prevalence of 0.3-3.6%.29 This type of cyst is known to be benign, disappearing 
spontaneously at the later stage of pregnancy without affecting the development of the 
fetus. As a sonographic marker of haploidy, choroid plexus cyst is found in 50% of fetuses 
with trisomy 1830 but most of the cases are accompanied by another anomaly, and it is 
reported that no particular prenatal care including chromosomal analysis is necessary if 
only isolated choroid plexus cysts are found.29  
3.2.2 Mild cerebral ventricular dilatation 
Mild cerebral ventricular dilatation, in which the diameter of the cerebral lateral ventricle is 
over 10-15 mm, is related to aneuploidy like trisomy 21.32 Bromley et al.32 reported that 12% 
of pregnancies with mild cerebral ventricular dilatation are related to abnormal karyotype 
(trisomy 18, 21). In addition, mild cerebral ventricular dilatation was observed in 4.3% of 
fetuses with trisomy 2133 and all of them had accompanying anomalies. It is known that the 
presence of cerebral ventricular dilatation alone does not increase the risk of chromosomal 
aberration. 
3.2.3 Nuchal thickening 
Excessive skin on the back neck is a characteristic finding of trisomy 21. It is observed in 
80% of neonates with trisomy 21 and can be found in other chromosomal aberrations 
(trisomy 13 and 18, 45X).34 Although the sensitivity and the false positive rate vary 
according to gestational age and criteria for positive value are different among institutions, 
its sensitivity for detecting chromosomal aberrations is generally within the range of 20-40%. 
3.2.4 Hyper-echoic bowel 
Hyper-echoic bowel is found in 0.5% of normal fetuses, but in fetuses with aneuploidy like 
trisomy 21, it is known to be observed more frequently and increase the risk 6-7 times 
higher.35 Assuming that the likelihood ratio of isolated hyper-echoic bowel is 6.7 and the 
total risk of Down syndrome in the entire population is one per 500, isolated echoic bowel is 
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expected to be related to the risk of Down syndrome in around 1-2% of the general 
population. Hyper-echoic bowel is also known to be related to ileus, congenital infection, 
and rarely to secondary meconium ileus in cystic fibrosis.36 
3.2.5 Skeletal abnormalities such as shortened limbs 
Shortened limbs are a characteristic observed in fetuses with trisomy 2137 and the length of 
shortened humerus seems to be a slightly more specific marker than the length of shortened 
femur. These results may be different according to gestational age, racial group, expected 
sex of the fetus, and used criteria. 
3.2.6 Echogenic intracardiac focus 
Echogenic intracardiac focus is a common finding in the second trimester. It is observed in 
3-4% of normal fetuses and disappears spontaneously in the third trimester.39 If the size of 
echogenic intracardiac focus is large or there are multiple of them, the risk of aneuploidy 
increases. Bromley et al.40 reported that the risk of aneuploidy is 2 times higher when 
echogenic intracardiac focuses are in the right ventricle or bilateral than when they are only 
in the left ventricle. 
4. Conclusions 
Chromosomal aberration is closely related to the in intrauterine fetal death and perinatal 
prevalence. However, amniocentesis and chorionic villus sampling used for prenatal 
diagnosis of haploidy are invasive methods, and the reported fetal loss rate resulting just 
from the examinations is around 1-2%. Accordingly, it is very important to screen those with 
high risk of chromosomal aberration before such invasive examinations. 
Serologic test of pregnant women for the screening of trisomy 18 and 21 is an important 
diagnostic process in prenatal care, and in particular, second trimester serum alpha 
fetoprotein is used as an important screening marker to detect anomalies such as fetal neural 
tube defect. If the concentration of alpha fetoprotein is over 2.5 MoM, sonography should be 
performed in order to detect neural tube defect and other problems. Recently, because 
sonography shows a high detection rate for neural tube defect, amniocentesis is used less 
frequently in diagnosing neural tube defect. 
The preferred type of serum screening test is various among countries and institutions. In 
general, the first trimester screening test is increasingly preferred, but second trimester 
screening is still used frequently at hospitals that cannot measure fetal nuchal translucency 
or perform chorionic villus sampling. The triple test has been used commonly as second 
trimester screening, but recently the use of the quad test, which adds inhibin A, is 
increasing. If both first and second trimester tests are performed, they can increase the 
detection rate of fetal anomalies, but because the two tests have to be applied at an interval 
of 3-4 weeks, it is quite important to provide an adequate explanation to the patient. The 
serum screening test can be performed in various ways depending on the combination of 
serum factors. Thus, rather than using a uniform test for every case, we need to understand 
the characteristic, detection rate and false positive rate of each test, and individualize the test 
for each case according to maternal age, sonographic findings, and compliance. 
In conclusion, in order to determine the risk of chromosomal aberration, we should analyze 
each case based on maternal age, nuchal fold thickness in the first trimester, the results of 
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maternal serum screening in the first or second trimester, and sonographic findings in the 
second trimester. Through this approach, we may reduce the number of unnecessary 
chromosomal analyses, lower the fetal loss rate resulting from invasive examination, and 
enhance the accuracy of screening for fetal chromosomal aberrations.  
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maternal serum screening in the first or second trimester, and sonographic findings in the 
second trimester. Through this approach, we may reduce the number of unnecessary 
chromosomal analyses, lower the fetal loss rate resulting from invasive examination, and 
enhance the accuracy of screening for fetal chromosomal aberrations.  
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1. Introduction 
Screening programs play a significant role in the assessment of fetal chromosomal defects 
and provide the appropriate prenatal counseling and diagnostic tests.  
Every pregnant woman has a risk that her fetus might be affected by trisomy 21. At the 
beginning of the 1980's the screening based on a woman's age was introduced. With the cut-
off age of 35 years, 5% of the pregnant women population were classified as "high-risk". 
However, only 30% of fetuses with trisomy 21 were detected in this group while the 
majority of trisomy 21 babies were born to mothers from the "low-risk" group. 
Later, biochemical screening tests in the second trimester became widely used. The test is 
based on the concentration of various fetoplacental markers in the maternal circulation: 
alpha-fetoprotein (AFP), unconjugated estriol (uE3), human chorionic gonadotropin (hCG) 
and inhibin-A. This method of screening is proved to be more effective than maternal age 
alone and at the same rate of invasive testing (about 5%) it can identify about 50 to 70% of 
the fetuses with trisomy 21 (Nicolaides KH 2004). 
In the 1990's screening tests were moved to the first trimester. The woman's age was first 
combined with sonographic measurement of fetal nuchal translucency and fetal heart rate. 
Later sonographic screening was upgraded by the measurement of maternal serum free β-
human chorionic gonadotropin (β-hCG) and pregnancy-associated plasma protein-A 
(PAPP-A) (Wright D et al, 2008; Kagan KO et al, 2008). Fetal nuchal translucency screening 
identifies 75 to 80% of fetuses with trisomy 21 at a false positive rate of 5%. 
In the last 10 years, several additional first trimester sonographic markers have been 
described (nasal bone, tricuspid flow, ductus venosus flow) which improve the detection 
rate of chromosomal abnormalities and reduce the false positive rate. At a risk cut-off of 1 in 
100, the detection rate of trisomy 21 is about 95% at a false positive rate of 2.5%.  
The ability to achieve reliable measurements and evaluation of sonographic markers 
depends on an appropriate training of sonographers, adherence to a standard ultrasound 
technique in order to achieve uniformity of results among different operators (Nicolaides 
KH 2011). Health professionals undertaking the first trimester scan have to be adequately 
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1. Introduction 
Screening programs play a significant role in the assessment of fetal chromosomal defects 
and provide the appropriate prenatal counseling and diagnostic tests.  
Every pregnant woman has a risk that her fetus might be affected by trisomy 21. At the 
beginning of the 1980's the screening based on a woman's age was introduced. With the cut-
off age of 35 years, 5% of the pregnant women population were classified as "high-risk". 
However, only 30% of fetuses with trisomy 21 were detected in this group while the 
majority of trisomy 21 babies were born to mothers from the "low-risk" group. 
Later, biochemical screening tests in the second trimester became widely used. The test is 
based on the concentration of various fetoplacental markers in the maternal circulation: 
alpha-fetoprotein (AFP), unconjugated estriol (uE3), human chorionic gonadotropin (hCG) 
and inhibin-A. This method of screening is proved to be more effective than maternal age 
alone and at the same rate of invasive testing (about 5%) it can identify about 50 to 70% of 
the fetuses with trisomy 21 (Nicolaides KH 2004). 
In the 1990's screening tests were moved to the first trimester. The woman's age was first 
combined with sonographic measurement of fetal nuchal translucency and fetal heart rate. 
Later sonographic screening was upgraded by the measurement of maternal serum free β-
human chorionic gonadotropin (β-hCG) and pregnancy-associated plasma protein-A 
(PAPP-A) (Wright D et al, 2008; Kagan KO et al, 2008). Fetal nuchal translucency screening 
identifies 75 to 80% of fetuses with trisomy 21 at a false positive rate of 5%. 
In the last 10 years, several additional first trimester sonographic markers have been 
described (nasal bone, tricuspid flow, ductus venosus flow) which improve the detection 
rate of chromosomal abnormalities and reduce the false positive rate. At a risk cut-off of 1 in 
100, the detection rate of trisomy 21 is about 95% at a false positive rate of 2.5%.  
The ability to achieve reliable measurements and evaluation of sonographic markers 
depends on an appropriate training of sonographers, adherence to a standard ultrasound 
technique in order to achieve uniformity of results among different operators (Nicolaides 
KH 2011). Health professionals undertaking the first trimester scan have to be adequately 
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trained and their results have to be subjected to an audit. The Fetal Medicine Foundation 
(FMF) has introduced a process of training and certification to help establish high standards 
of scanning on an international basis (www.fetalmedicine.com). 
1.1 Nuchal translucency 
Nuchal translucency (NT) is the assessment of the amount of fluid behind the neck of the 
fetus, also known as the nuchal fold. An anechoic space is visible and measurable 
sonographically in all fetuses between the 11th and 14th weeks of pregnancy (Figure 1). 
Underlying pathophysiological mechanisms for nuchal fluid collection include cardiac 
dysfunction, venous congestion in the head and neck, altered composition of the 
extracellular matrix, failure of lymphatic drainage, fetal anemia or hypoproteinemia and 
congenital infection (Nicolaides KH 2004). Accumulation of nuchal fluid decreases after the 
14th week. Enlarged NT helps us to identify the high-risk fetuses for trisomy 21 and other 
chromosomal abnormalities (Nicolaides KH et al, 1992; Nicolaides KH et al, 1994). 
NT is evaluated in fetuses with crown-rump length (CRL) range from 45 to 84 mm. The scan 
may be performed transabdominally but in some cases transvaginal approach may be 
beneficial. During the measurement, the fetus lies in a neutral position, with the head in line 
with the spine (www.fetalmedicine.com). The assessment of the NT is obtained in a mid-
sagittal view of the fetal profile. The measurements are taken with the inner border of the 
horizontal line and callipers are placed on the line that defines the NT thickness. Normally, 
NT increases with the CRL.  
 
 
Fig. 1. Measurement of nuchal translucency behind the neck of the fetus. 
1.2 Nasal bone 
The nasal root depth is abnormally short in 50% of trisomy 21 cases (Cicero S et al, 2003). 
Sonographic studies at the 15th to 22nd weeks of gestation reported that about 65% of trisomy 
21 fetuses had an absent or abnormally short nasal bone. The fetal nasal bone can be 
visualized between the 11th and 14th weeks of gestation, when CRL is between 45 and 84 
mm. The assessment of the nasal bone should be obtained in a mid-sagittal view of the fetal 
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profile (Figure 2). The image of the nose includes three lines. The top line represents the 
nasal skin, in continuity with the skin is the tip of the nose, and the bottom line represents 
the nasal bone which is thicker and more echogenic. 
 
 
Fig. 2. Assessment of the nasal bone in a mid-sagittal view of the fetal profile. 
2. Sonographic screening for trisomy 21 by maternal age, nuchal 
translucency and fetal nasal bone 
The best performance of first trimester screening is achieved by a combination of maternal 
age, serum biochemical testing and multiple sonographic markers. But Doppler assessment 
of tricuspid and ductus venosus flow can be time consuming and it requires properly 
trained sonographers. As a first stage policy the assessment only by maternal age, nuchal 
translucency and fetal nasal bone, without biochemical testing, has some advantages 
(Nicolaides KH 2011). Beside the examination of fetal anatomy which leads to early 
diagnosis of many abnormalities in all pregnancies, the major advantage is the reduction in 
the cost of screening.  The measurement of biochemical markers is undertaken only in the 
subgroup with positive first stage screening results. 
Our study reports the results of the first trimester trisomy 21 risk assessment by a 
combination of maternal age, sonographic measurement of fetal NT thickness and 
assessment of fetal nasal bone in unselected pregnancies in Slovenia.  
3. Subjects and methods 
The study included all pregnant women appointed for the first trimester ultrasound 
screening examination at a single outpatient clinic between January 4, 2005 and April 30, 
2010. Before the screening they all received counseling by their level one gynaecologists and 
an information leaflet about the ultrasound examination and the aim of screening.  
At the time of the visit, they gave details about their demographic characteristics and 
medical history, which were entered into the computer database. The examinations were 
carried out by two experienced sonographers, certified by the Fetal Medicine Foundation 
Certificate of Competence in the 11th to 14th weeks scan. 
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trained and their results have to be subjected to an audit. The Fetal Medicine Foundation 
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with the spine (www.fetalmedicine.com). The assessment of the NT is obtained in a mid-
sagittal view of the fetal profile. The measurements are taken with the inner border of the 
horizontal line and callipers are placed on the line that defines the NT thickness. Normally, 
NT increases with the CRL.  
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In the majority of the cases the examination was performed transabdominally within 20 
minutes. In less than 1% of the cases a transvaginal ultrasound examination had to be 
carried out.  
In the fetal CRL less than 45 mm, the pregnant woman was given a new appointment, while 
in the fetal CRL more than 83 mm, only a detailed ultrasound scan was performed and the 
pregnant woman received further information about the possibility of the second trimester 
biochemical test. 
For the examinations we used 2-5 MHz and 3.7-9.3 MHz transducers GE Healthcare 
Voluson 730 Pro, Milwaukee, USA, and 4–6 MHz, 4–7 MHz, 5–9 MHz and 7–9 MHz 
transducers Acuson S2000, Siemens Medical Solutions, Mountain View CA, USA. 
Only singleton pregnancies with live fetus from the 11th to 14th weeks of gestation with the 
CRL of 45-83 mm were included in the further analysis. Pregnancy outcomes were obtained 
from the participating women, referred by level one gynecologists and paediatricians. 
Karyotype results were reported by the three cytogenetic laboratories. 
3.2 Statistical methods 
Risks were calculated according to the FMF program, following the FMF guidelines 
(Snijders RJM et al, 1999; www.fetalmedicine.com). The distribution of maternal age of the 
examined women was compared to the age distribution in the pregnant population in 
Slovenia for the time interval 2005-2010 (www.stat.si).  
We calculated the sensitivity, false positive rate, positive predictive value and negative 
predictive value for a cut-off risk of 1 in 300.  We accompanied the most important results 
with a 95% confidence interval. The balance between the false positive rate and the detection 
rate was studied and the trends were inspected graphically. The cut-off risk that would 
yield 5% false positives was calculated for trisomy 21.  
Additionally, the expected numbers for the Slovene population were estimated by 
weighting the values of each woman according to the frequency of her age in the Slovene 
population.  
4. Results 
4.1 Study population 
A total of 13,535 pregnant women were offered first trimester screening for detecting fetal 
chromosomal abnormalities at a single outpatient clinic between January 4, 2005 and April 
30, 2010.  
The sample represented unselected population of pregnant women of Caucasian ethnic 
origin. Twin pregnancies (3.6% of the cases, 486 of 13,535) were excluded. All further 
analyses included 13,049 women with singleton pregnancies. 
4.2 Age distribution 
The average maternal age (at the time of screening) was 29 years (range 11 to 47, SD=3.9) 
with a distribution as shown in the Figure 3 (black columns). When compared to the age 
distribution in the pregnant population in 2005-2010 in Slovenia, the average maternal age 
was the same - 28.9 years (Figure 3, red columns). The pregnant population however varied 
more, in particular there was a larger proportion of women aged 36 and more in the Slovene 
pregnant population (10.2%) as compared to only 3.6% in our sample. The sample on the 
other hand included a considerably larger percent of the women between 26 and 30 (47.9% 
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compared to 40.6%). Only 2.5% were 37 and older compared to the 7.2% in the population of 
Slovene pregnant women. 
 
 
Fig. 3. Age distribution comparison at screening; Slovene population (red columns), our 
sample of unselected population of pregnant women (black columns). 
4.3 The screening results 
The average gestation was 12 weeks 4 days (range 11 weeks 1 day to 14 weeks 0 days). The 
average fetal CRL was 63.2 mm (range 45 to 83 mm). And the average NT thickness was 1.7 
mm (range 0.9 to 13.4 mm).  
The distribution of NT for fetal CRL in normal pregnancies and pregnancies with fetuses 
affected by chromosomal abnormalities is shown in Figure 4. The NT was above the 95th 
centile of the normal range for the CRL in 75% (15 of 20) of trisomy 21 pregnancies and in 
64% (16 of 25) pregnancies with other chromosomal abnormalities. 
At the time of testing in 3% of all pregnancies (394 of 13,049) the estimated risk for trisomy 21 
was 1 in 300 or higher, considering the calculation based on FMF program. Three hundred and 
sixty cases (2.8%) turned out to be false positive. At the invasive testing, chromosomal 
abnormalities were identified in 8.6% of high risk cases (34 of 394), which represents one case 
of fetal chromosomal abnormality detected per 12 invasive diagnostic procedures. 
4.4 Detection rate 
We detected 34 out of 45 cases with chromosomal abnormalities (75.6%), diagnosed 
prenatally or postnatally. 
Trisomy 21 was detected in 20 cases (Figure 4). Among women with an estimated risk of 1 in 
300 or higher there were 17 cases of trisomy 21. The detection rate for trisomy 21 was 85% 
(17 out of 20), the 95% confidence interval for the detection rate was [69.4, 100]. The positive 
predictive value for the trisomy 21 was 4.3% (17 of 394); and the negative predictive value 
was 99.98% (12,652 of 12,655). 
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compared to 40.6%). Only 2.5% were 37 and older compared to the 7.2% in the population of 
Slovene pregnant women. 
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Fig. 4. Distribution of NT (in mm) with respect to CRL (in mm) in our sample. The curves 
present the 5th, 50th and 95th centiles. 
Other chromosomal abnormalities were diagnosed in 25 cases (Figure 4). Among women 
with an estimated risk of 1 in 300 or higher there were 17 cases of other chromosomal 
abnormalities. The detection rate was 68% (17 out of 25). The 95% confidence interval for the 
detection rate was [49.7, 86.3]. The positive predictive value for the other chromosomal 
abnormalities was 4.3% (17 of 394); and the negative predictive value was 99.94% (12,647 of 
12,655). 
The diagnosed chromosomal abnormalities and their frequencies are presented in Table 1. 
The assessment of nasal bone was performed in 98.5%of the cases (12,847 out of 13,049). In 
12 cases nasal bone was absent (0.1%), and in 3 out of those 12 cases (25%), the chromosomal 
abnormality was detected. 
 
Karyotype No. 
Trisomy 21 20 
Trisomy 18 10 
Trisomy 13 2 
45,X (Turner syndrome) 3 
47,XXY 2 
Mosaic structure 3 
Unbalanced structural rearrangements 5 
Total 45 
Table 1. Chromosomal abnormalities in fetuses and newborns in our sample of 13,049 
women with singleton pregnancies. 
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4.5 The risk threshold 
The risk values of the undetected cases of trisomy 21 were as follows: 1 in 1979, 6365, 7435; 
for other chromosomal abnormalities they were 1 in 493, 872, 1102, 1279, 2016, 2180, 3816, 
6731. 
It was thus clear that a less conservative limit for probability threshold (for example 1 in 
500) would not yield different detection rate in case of trisomy 21, but would rather improve 
the detection of other chromosomal abnormalities.  
These changes are explored in Figure 5, which shows how detection rate would change by 
changing the risk threshold. The black curve shows how detection rate of trisomy 21 
changes by changing the risk threshold (value 200 implies probability threshold set at 
1/200). The red curve represents the same information for other chromosomal 
abnormalities. The numbers above the points indicate the percentage of false positives that 
would occur in our sample at that threshold. 
 
 
Fig. 5. Detection rate of trisomy 21 (black curve) and other chromosomal abnormalities (red 
curve) with respect to the risk threshold set (value 200 implies probability threshold set at 
1/200). The numbers above the points give the false positive rate.  
Inversely, Figure 6 shows the detection rate with respect to the percentage of false positives, 
the numbers above the points indicate the risk threshold (value 200 implies threshold 
1/200). 
4.6 Prediction for the Slovene population 
Since the age distribution in our sample was different from the age distribution in the 
Slovene pregnant women population, we can expect all the above results to be slightly 
different. In particular, the rate of false positives can be expected to change. Figure 7 gives 
the false positive rate in our sample with respect to calendar year and compares it to the 
predicted false positive rate in the Slovene pregnant women population.  
 




Fig. 4. Distribution of NT (in mm) with respect to CRL (in mm) in our sample. The curves 
present the 5th, 50th and 95th centiles. 
Other chromosomal abnormalities were diagnosed in 25 cases (Figure 4). Among women 
with an estimated risk of 1 in 300 or higher there were 17 cases of other chromosomal 
abnormalities. The detection rate was 68% (17 out of 25). The 95% confidence interval for the 
detection rate was [49.7, 86.3]. The positive predictive value for the other chromosomal 
abnormalities was 4.3% (17 of 394); and the negative predictive value was 99.94% (12,647 of 
12,655). 
The diagnosed chromosomal abnormalities and their frequencies are presented in Table 1. 
The assessment of nasal bone was performed in 98.5%of the cases (12,847 out of 13,049). In 
12 cases nasal bone was absent (0.1%), and in 3 out of those 12 cases (25%), the chromosomal 
abnormality was detected. 
 
Karyotype No. 
Trisomy 21 20 
Trisomy 18 10 
Trisomy 13 2 
45,X (Turner syndrome) 3 
47,XXY 2 
Mosaic structure 3 
Unbalanced structural rearrangements 5 
Total 45 
Table 1. Chromosomal abnormalities in fetuses and newborns in our sample of 13,049 
women with singleton pregnancies. 
First Trimester Screening for Trisomy 21 by Maternal Age,  
Nuchal Translucency and Fetal Nasal Bone in Unselected Pregnancies 
 
307 
4.5 The risk threshold 
The risk values of the undetected cases of trisomy 21 were as follows: 1 in 1979, 6365, 7435; 
for other chromosomal abnormalities they were 1 in 493, 872, 1102, 1279, 2016, 2180, 3816, 
6731. 
It was thus clear that a less conservative limit for probability threshold (for example 1 in 
500) would not yield different detection rate in case of trisomy 21, but would rather improve 
the detection of other chromosomal abnormalities.  
These changes are explored in Figure 5, which shows how detection rate would change by 
changing the risk threshold. The black curve shows how detection rate of trisomy 21 
changes by changing the risk threshold (value 200 implies probability threshold set at 
1/200). The red curve represents the same information for other chromosomal 
abnormalities. The numbers above the points indicate the percentage of false positives that 
would occur in our sample at that threshold. 
 
 
Fig. 5. Detection rate of trisomy 21 (black curve) and other chromosomal abnormalities (red 
curve) with respect to the risk threshold set (value 200 implies probability threshold set at 
1/200). The numbers above the points give the false positive rate.  
Inversely, Figure 6 shows the detection rate with respect to the percentage of false positives, 
the numbers above the points indicate the risk threshold (value 200 implies threshold 
1/200). 
4.6 Prediction for the Slovene population 
Since the age distribution in our sample was different from the age distribution in the 
Slovene pregnant women population, we can expect all the above results to be slightly 
different. In particular, the rate of false positives can be expected to change. Figure 7 gives 
the false positive rate in our sample with respect to calendar year and compares it to the 
predicted false positive rate in the Slovene pregnant women population.  
 
Genetics and Etiology of Down Syndrome 
 
308 




Fig. 6. Detection rate of trisomy 21 (black curve) and other chromosomal abnormalities (red 
curve) with respect to the false positive rate. The numbers above the points give the risk 
threshold (value 200 implies probability threshold set at 1/200).  
 
 
Fig. 7. The percentage of false positives in our sample (gray columns) and the predicted false 
positive rate in the Slovene pregnant women population (white columns) with respect to 
calendar year. 
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Fig. 8. The risk threshold that would result in a 5% false positive rate with respect to 
calendar year. 
 
Fig. 9. Detection rate of trisomy 21 (black curve) and other chromosomal abnormalities (red 
curve) with respect to the risk threshold set (value 200 implies probability threshold set at 
1/200) - prediction for the Slovene population. The numbers above the points give the false 
positive rate. 
 
Genetics and Etiology of Down Syndrome 
 
308 




Fig. 6. Detection rate of trisomy 21 (black curve) and other chromosomal abnormalities (red 
curve) with respect to the false positive rate. The numbers above the points give the risk 
threshold (value 200 implies probability threshold set at 1/200).  
 
 
Fig. 7. The percentage of false positives in our sample (gray columns) and the predicted false 
positive rate in the Slovene pregnant women population (white columns) with respect to 
calendar year. 
First Trimester Screening for Trisomy 21 by Maternal Age,  




Fig. 8. The risk threshold that would result in a 5% false positive rate with respect to 
calendar year. 
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The retrospective study of the  first trimester screening for trisomy 21 in 5-year period from 
2005 to 2010 by a combination of maternal age, sonographic measurement of fetal NT 
thickness and assessment of the fetal nasal bone represented a detection rate of 85% at a 
false positive rate of 2.8%. 
5.1 Detection rate 
The findings of many studies suggest that effective first trimester screening for trisomy 21 
can be provided only by the combination of maternal age and measurement of fetal NT 
(Pajkrt E et al, 1998; Economides DL et al, 1998; Bindra R et al, 2002; Liu SS et al, 2004; 
Rozenberg P et al, 2006; Westin M et al, 2006; Czuba B et al., 2007; Kagan KO et al, 2010). At 
a risk cut-off of 1 in 100, the detection rate of trisomy 21 is about 75%, at a false positive rate 
of about 2%.  
The detection can be improved to 85% by the additional assessment of the fetal nasal bone 
and even more by the Doppler assessment of blood flow across the tricuspid valve or blood 
flow in the ductus venosus, which increased the detection rate to about 95% at a false 
positive rate of 2.5% (Kagan KO et al, 2010). The disadvantage of the Doppler assessment of 
tricuspid and ductus venosus flow is that it is time consuming and it requires appropriately 
trained sonographers (Nicolaides KH 2011). 
 
 
Fig. 10. Detection rate of trisomy 21 (black curve) and other abnormalities (red curve) with 
respect to the false positive rate - prediction for the Slovene population. The numbers above 
the points give the risk threshold (value 200 implies probability threshold set at 1/200). 
By the measurement of fetal NT thickness and the assessment of the fetal nasal bone we 
were able to achieve the expected results at a risk cut-off of 1 in 300. In our sample the 
relationship between the false positive rate and the detection rate was proved to be in line 
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with the prediction from the Nicolaides study (Nicolaides KH 2011) and highly comparable 
to other reports (Prefumo F et al, 2006; Kagan KO et al, 2010). 
Choosing sonographic assessment rather than biochemical testing as a first stage policy has 
a few advantages. In all sonographically screened pregnancies in addition to chromosomal 
markers, fetal anatomy is observed and both provide early diagnosis of many major 
abnormalities, not just in the subgroup with a positive first stage biochemical screening 
results (Nicolaides KH 2011). Further measurements of maternal serum free β-hCG and 
PAPP-A can be limited only to high risk subgroup.  
5.2 Prediction for the Slovene population 
But the trend of ageing the population of pregnant women is noticed and the false positive 
rate at the risk cut-off 1 in 300 is changing almost linearly with time (Figure 7).  
Allowing ourselves 5% false positive rate in the population, we could lower the risk limit. 
But, as our detection rate is more than adequate according to FMF guidelines, at the moment 
we have no reason to actually change it, and we believe that any such change should also be 
weighted against the risk of pregnancy loss due to invasive testing. 
Our calculations show that the FMF recommendations about the risk limit cannot be directly 
translated to our specific population distribution. We believe the limit that ensures a 5% 
false positive rate is constantly changing and could be adjusted within each country. To 
accurate the changing, the weighting could be performed using a large data set, preferably 
the data set on which the FMF algorithm was developed, using the respective population 
maternal age distribution. The only assumption needed for such estimation would be, that 
conditional on the maternal age, the NT and CRL distributions do not vary among the 
countries, which we believe is an assumption we can safely make.  
6. Conclusion 
The 11th to 14th weeks scan includes confirmation of the viability of the fetus, accurate 
dating of the pregnancy, and an early diagnosis of multiple pregnancies and identification 
of chorionicity. 
Effective screening for trisomy 21 can be achieved in the first trimester of pregnancy by a 
combination of maternal age, sonographic measurement of fetal NT thickness and 
assessment of fetal nasal bone, with detection rate of 85% at a false positive rate of less than 
3%. 
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respect to the false positive rate - prediction for the Slovene population. The numbers above 
the points give the risk threshold (value 200 implies probability threshold set at 1/200). 
By the measurement of fetal NT thickness and the assessment of the fetal nasal bone we 
were able to achieve the expected results at a risk cut-off of 1 in 300. In our sample the 
relationship between the false positive rate and the detection rate was proved to be in line 
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with the prediction from the Nicolaides study (Nicolaides KH 2011) and highly comparable 
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6. Conclusion 
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1. Introduction  
Molecular composition of pregnant women blood plasma/serum is an indispensable tool 
for biochemists in the field of routine prenatal diagnostics aimed at the detection of the most 
common aneuploidies.  
Predictive power of some biochemical markers respectively their sum is an important guide 
for the assessment of the status of the fetus and pregnancy.  
But the diagnostic potential of maternal plasma is much broader.  
Fragmented and apoptically degraded fetal cells and nucleic acid molecules, which 
overcame the placental (feto-maternal) barrier and got under the influence of the immune 
system of the mother, offer other options for molecular biologists.  
Some of them will focus on the clarification of rules between the quantity of fetal molecules 
and pathology of the placenta and the fetus others are engaged in direct diagnostic potential.   
In the maternal blood circulation can be detected fetal genetic material of a different 
integrity ranging from the nuclear DNA of living cells through fetal apoptically partially 
degraded molecules more or less packed in nucleoides to completely fragmented DNA 
molecules  mostly of size between 100 - 400 bp. Cell free fetal (cff) mRNA molecules  from 
trophoblast are also presented in detectable concentration in maternal plasma. 
While the presence of fetal cells in maternal circulation is quite rare (1 fetal cell in 1 million 
maternal cells), the quantity of cffDNA molecules in plasma is considerably higher (typically 
3 % - 6 %).   
2. Source and transport of cff nucleic acid molecules into maternal plasma 
The ways in which cffDNA forms and how gets into the maternal circulation, are not yet 
fully clarified. There are several hypotheses on the origin of cff DNA. 
The main source of free DNA appears to be a placenta (Wataganara & Bianchi, 2004). Most 
likely the cff DNA forms by disintegration of placental cells and the direct transition to the 
maternal circulation.  
Another possibility is that the placenta functions as an mediator of transition for DNA 
circulating in the fetal blood circuit into maternal tissues.  
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In this case, there should be a two-way traffic, however, the amount of analyzed fetal DNA 
in maternal plasma is much greater than the amount of free maternal DNA in umbilical 
plasma in childbirth (Sekizawa et al., 2003). It is indicative of an unequal transfer of free 
DNA from fetus to the mother. Another source of fetal molecules may be fetal hematopoietic 
cells which get into the maternal circulation (Bianchi, 2004). The fetal DNA is apoptically 
released into maternal plasma due to the effect of maternal immune system (Pertl et al., 
2000). Apoptotic fetal cells were found in detectable concentrations also directly in the 
plasma (Van Wijk et al., 2000). Apoptosis proven in maternal plasma (Sekizawa et al., 2003) 
or in cord blood (Hristoskova et al., 2001) suggests that this mechanism could be an 
important source of fetal material. Another hypothesis assumes a simple diffusion of shorter 
DNA molecules from the amniotic fluid through placenta or membranes into maternal 
circulation. This DNA then comes from various fetal tissues. 
Cff DNA was also demonstrated in the maternal plasma even before feto-maternal 
circulation establishment. This means that the DNA could be of the trofoblastic origin 
(Bianchi et al., 2004).   In general, it could be assumed that cff DNA in maternal circulation is 
of different origin but its large portion likely comes from the trophoblastic placental tissue. 
The transfer of fetal molecules through the feto-maternal barrier is continuous during 
pregnancy and after the delivery they are quickly eliminated from plasma (16 min halftime 
of degradation (Lo et al., 1999).  
Free fetal RNA allows non-invasive prenatal profiling of gene expression and offers a 
number of research and diagnostic applications on the basis of easily detectable mRNA 
transcripts from placentally expressed genes in maternal plasma (Ng et al., 2003).  
Considering serious degradation as a result of the activities of the ribonucleases, the stability 
of mRNA molecules in fetal free plasma is surprising. Plasma RNA molecules are much 
more stable than isolated and purified RNA molecules. Mechanisms that protect the 
circulating free fetal RNA are not fully clarified at present time. However their conjunction 
with the sub cellular particles could prevent their degradation (Hasselmann et al., 2001).  
They can form complexes with proteins, lipids, lipoproteins, phospholipids bound to the 
DNA in nucleosomes or within protected apoptotic corpuscles or other vesicular structures 
(Halicka et al., 2000; Hasselmann et al., 2001; Tsui et al., 2002; Sisko et al., 2001).   
The stability of placental mRNA molecules in maternal plasma is a promising assumption 
that fetal markers at the level of mRNA will be clinically useful.  
It could be useful for prenatal detection of some pregnancy pathologies, including pre-
eclampsia and certain chromosomal aneuploidies (Ng et al., 2004).    
3. Placental trophoblast and trisomy 21 
Trophoblast with chromosome 21 trisomy  shows disturbed both cell fusion and  formation 
of syncytiotrofoblast (ST) (Frendo et al., 2000b; Massin et al., 2001). An activation of caspases 
is necessary for formation of ST in early stage of differentiation (Huppertz and Kingdom, 
2004). If ST is inadequate, the individual trophoblastic cells with trisomy 21 could continue 
on in the cascade of apoptic events and release more fragmented cff DNA than disomic 
trophoblastic cells. Another possible cause for the release of larger amounts of fetal 
molecules in pregnancy with trisomy 21 is a continuation of trophoblastic cells in the 
improper proliferation, without initiating events leading to the formation of ST. In this case 
maternal immune system would regulate the division by increased degradation of fetal 
cells. 
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4. Fragmentation profile of cffDNA 
Publications, relating to the characterization of the DNA fragments in the plasma, are aimed 
to the level of fragmentation of fetal molecules related to the maternal ones in the course of 
pregnancy. For pregnant women were described in plasma longer fragments in comparison 
with non-pregnant women (Chan et al., 2004).  
Real-time PCR is the most commonly used procedure for the analysis of fetal DNA 
fragments in present time (Alberry et al., 2009; Ariga et al., 2001; Lo et al., 1998). Honda et al. 
(2002) described the sensitivity of the detection of fetal DNA for this method and 
determined it at 5,38 copies/ml of the peripheral blood. 
Molecules of fetal origin are more degraded and shorter than the maternal and their size is 
approximately in the range from 100 bp - to 700 bp. (Zhong et al., 2000; Koide et al., 2005). 
Fragments above 1 kb belong mostly to the mother (Li et al., 2004). 
We have evaluated fragment analysis using three methods (capillary electrophoresis of STR 
loci, capillary electrophoresis and Real-time PCR of gonozomal sequences) from two 
different perspectives. The first relied on direct analysis of the size of fractions and the 
second assessed PCR efficiency with respect to the size of amplified DNA molecules 
(Vodicka et al., 2010).  
Direct detection of fetal molecules has confirmed a large heterogeneity in the individual 
fractions both by capillary electrophoresis and Real-time PCR.   
A direct dependency of fetal molecules on the week of pregnancy has been suggested only 
in the size fraction of 500 - 760 bp. Regression modeling at STR and gonozomal analyses was 
the most accurate in the pD system, where the size of molecules ranged from 395 bp to  
440 bp. Statistical significance of regression declined towards the smaller molecules.  
The fragment size was 200 bp to 223 bp in the D21S1446 system and 157-188 bp in D21S1435.  
Regression analysis was inconclusive in the AMELY (molecule size 109 bp). 
If we compare analysis of the size of fractions to the results of the effectiveness of the STR 
and gonozomal analyses (Vodicka et al., 2008a), where was demonstrated statistically 
significant increase of fetal molecules in all 3 STR systems, we found out that it was 
confirmed an interesting trend, which indicates an increase in the larger fetal molecules 
during pregnancy while the number of smaller molecules of fetal origin does not change.   
In the case of quantification using SRY probe, whose length is 64 bp it was observed even 
reverse trend and the number of amplified molecules in 150-300 bp fraction was in indirect 
relation to the week of gestation.  
The tendency has decreased for larger fractions and in total plasma the trend has stopped 
even slightly reversed.  
On the basis of these observations, we can therefore assume the most sensitive detection of 
fetal material using short probes. But these probes are not much suitable for quantitative 
analysis.  Fractions from 400 bp above are the most appropriate for the assessment of the 
amount of fetal material, although in these fractions the relative amount of fetal DNA is less. 
The importance of this study resides in decision-making, whether, from a diagnostic point 
of view, it is more important a detection of fetal molecules or their quantification (Vodicka 
et al., 2010). 
5. The extraction of cffDNA/RNA from maternal peripheral blood 
5.1 CffDNA isolation procedures 
An essential precondition for the success of all subsequent procedures is a sufficient yield, 
reproducibility and the purity of the isolated plasma cffDNA.  Isolation procedures are most 
 
Genetics and Etiology of Down Syndrome 
 
314 
In this case, there should be a two-way traffic, however, the amount of analyzed fetal DNA 
in maternal plasma is much greater than the amount of free maternal DNA in umbilical 
plasma in childbirth (Sekizawa et al., 2003). It is indicative of an unequal transfer of free 
DNA from fetus to the mother. Another source of fetal molecules may be fetal hematopoietic 
cells which get into the maternal circulation (Bianchi, 2004). The fetal DNA is apoptically 
released into maternal plasma due to the effect of maternal immune system (Pertl et al., 
2000). Apoptotic fetal cells were found in detectable concentrations also directly in the 
plasma (Van Wijk et al., 2000). Apoptosis proven in maternal plasma (Sekizawa et al., 2003) 
or in cord blood (Hristoskova et al., 2001) suggests that this mechanism could be an 
important source of fetal material. Another hypothesis assumes a simple diffusion of shorter 
DNA molecules from the amniotic fluid through placenta or membranes into maternal 
circulation. This DNA then comes from various fetal tissues. 
Cff DNA was also demonstrated in the maternal plasma even before feto-maternal 
circulation establishment. This means that the DNA could be of the trofoblastic origin 
(Bianchi et al., 2004).   In general, it could be assumed that cff DNA in maternal circulation is 
of different origin but its large portion likely comes from the trophoblastic placental tissue. 
The transfer of fetal molecules through the feto-maternal barrier is continuous during 
pregnancy and after the delivery they are quickly eliminated from plasma (16 min halftime 
of degradation (Lo et al., 1999).  
Free fetal RNA allows non-invasive prenatal profiling of gene expression and offers a 
number of research and diagnostic applications on the basis of easily detectable mRNA 
transcripts from placentally expressed genes in maternal plasma (Ng et al., 2003).  
Considering serious degradation as a result of the activities of the ribonucleases, the stability 
of mRNA molecules in fetal free plasma is surprising. Plasma RNA molecules are much 
more stable than isolated and purified RNA molecules. Mechanisms that protect the 
circulating free fetal RNA are not fully clarified at present time. However their conjunction 
with the sub cellular particles could prevent their degradation (Hasselmann et al., 2001).  
They can form complexes with proteins, lipids, lipoproteins, phospholipids bound to the 
DNA in nucleosomes or within protected apoptotic corpuscles or other vesicular structures 
(Halicka et al., 2000; Hasselmann et al., 2001; Tsui et al., 2002; Sisko et al., 2001).   
The stability of placental mRNA molecules in maternal plasma is a promising assumption 
that fetal markers at the level of mRNA will be clinically useful.  
It could be useful for prenatal detection of some pregnancy pathologies, including pre-
eclampsia and certain chromosomal aneuploidies (Ng et al., 2004).    
3. Placental trophoblast and trisomy 21 
Trophoblast with chromosome 21 trisomy  shows disturbed both cell fusion and  formation 
of syncytiotrofoblast (ST) (Frendo et al., 2000b; Massin et al., 2001). An activation of caspases 
is necessary for formation of ST in early stage of differentiation (Huppertz and Kingdom, 
2004). If ST is inadequate, the individual trophoblastic cells with trisomy 21 could continue 
on in the cascade of apoptic events and release more fragmented cff DNA than disomic 
trophoblastic cells. Another possible cause for the release of larger amounts of fetal 
molecules in pregnancy with trisomy 21 is a continuation of trophoblastic cells in the 
improper proliferation, without initiating events leading to the formation of ST. In this case 
maternal immune system would regulate the division by increased degradation of fetal 
cells. 
 
Noninvasive Prenatal Nucleic Acid Diagnostics of Down Syndrome 
 
315 
4. Fragmentation profile of cffDNA 
Publications, relating to the characterization of the DNA fragments in the plasma, are aimed 
to the level of fragmentation of fetal molecules related to the maternal ones in the course of 
pregnancy. For pregnant women were described in plasma longer fragments in comparison 
with non-pregnant women (Chan et al., 2004).  
Real-time PCR is the most commonly used procedure for the analysis of fetal DNA 
fragments in present time (Alberry et al., 2009; Ariga et al., 2001; Lo et al., 1998). Honda et al. 
(2002) described the sensitivity of the detection of fetal DNA for this method and 
determined it at 5,38 copies/ml of the peripheral blood. 
Molecules of fetal origin are more degraded and shorter than the maternal and their size is 
approximately in the range from 100 bp - to 700 bp. (Zhong et al., 2000; Koide et al., 2005). 
Fragments above 1 kb belong mostly to the mother (Li et al., 2004). 
We have evaluated fragment analysis using three methods (capillary electrophoresis of STR 
loci, capillary electrophoresis and Real-time PCR of gonozomal sequences) from two 
different perspectives. The first relied on direct analysis of the size of fractions and the 
second assessed PCR efficiency with respect to the size of amplified DNA molecules 
(Vodicka et al., 2010).  
Direct detection of fetal molecules has confirmed a large heterogeneity in the individual 
fractions both by capillary electrophoresis and Real-time PCR.   
A direct dependency of fetal molecules on the week of pregnancy has been suggested only 
in the size fraction of 500 - 760 bp. Regression modeling at STR and gonozomal analyses was 
the most accurate in the pD system, where the size of molecules ranged from 395 bp to  
440 bp. Statistical significance of regression declined towards the smaller molecules.  
The fragment size was 200 bp to 223 bp in the D21S1446 system and 157-188 bp in D21S1435.  
Regression analysis was inconclusive in the AMELY (molecule size 109 bp). 
If we compare analysis of the size of fractions to the results of the effectiveness of the STR 
and gonozomal analyses (Vodicka et al., 2008a), where was demonstrated statistically 
significant increase of fetal molecules in all 3 STR systems, we found out that it was 
confirmed an interesting trend, which indicates an increase in the larger fetal molecules 
during pregnancy while the number of smaller molecules of fetal origin does not change.   
In the case of quantification using SRY probe, whose length is 64 bp it was observed even 
reverse trend and the number of amplified molecules in 150-300 bp fraction was in indirect 
relation to the week of gestation.  
The tendency has decreased for larger fractions and in total plasma the trend has stopped 
even slightly reversed.  
On the basis of these observations, we can therefore assume the most sensitive detection of 
fetal material using short probes. But these probes are not much suitable for quantitative 
analysis.  Fractions from 400 bp above are the most appropriate for the assessment of the 
amount of fetal material, although in these fractions the relative amount of fetal DNA is less. 
The importance of this study resides in decision-making, whether, from a diagnostic point 
of view, it is more important a detection of fetal molecules or their quantification (Vodicka 
et al., 2010). 
5. The extraction of cffDNA/RNA from maternal peripheral blood 
5.1 CffDNA isolation procedures 
An essential precondition for the success of all subsequent procedures is a sufficient yield, 
reproducibility and the purity of the isolated plasma cffDNA.  Isolation procedures are most 
 
Genetics and Etiology of Down Syndrome 
 
316 
often based on double centrifugation and subsequent binding (adsorption) of DNA 
molecules on a silica surface of membrane or magnetic particles.  
5.1.1 Isolation by binding to a silica-gel membrane 
The adsorption on silica surface is one of the most common techniques which is able to 
capture free fragmented DNA.  
Silicate polymer in the presence of chaotropic salts (e.g. sodium iodide or guanidine 
thiocyanate) specifically binds to the DNA molecule on the surface of silicon dioxide 
(usually specially prepared glass) and in the presence of water or other elution reagent, 
which has a very low content of salt, this molecule releases from its surface.  
High specificity of the link between DNA molecule and silicate material is useful in 
eliminating other extracellular substances.   
5.1.2 Isolation by binding to the magnetic particles 
Methods based on the (para) magnetic particles (MPs) are other approach to the cffDNA 
isolation. MPs are particles of size from 5 nm to 100 µm, consisting of a metal core, it is 
usually γ-Fe2O3 (maghemit) or Fe3O4 (magnetite) but could be also for example Au.  
The core is coated with a layer that has specifically prepared surface for binding the 
molecules that we want to isolate.  
The size of the MPs can be adapted according to the molecules which we are isolating: 5-50 
nm proteins; 20-450 nm nucleic acids; 10-100 µm viruses.  
MPs respond to the external magnetic field and are capable to bind different bioreaktive 
molecules, because of their affinity to the modified surface, directly from the biological 
material. The isolation is then as follows.  
MPs are added to the sample where bind with the targeted molecule. Modified MPs are then 
attracted by magnet to the wall of the tube and the remaining solution with non-bind 
substances is removed.  
The MPs with joined molecules are subsequently washed and released in added solution.  
Bound molecules are separated from the MPs by some physical-chemical step (denaturing 
or change in pH).  
This way we obtain targeted molecules which could be afterward analyzed (Húska et al., 
2008).    
5.1.3 Comparison of silica-gel to magentic particles methods 
Both above mentioned isolation procedures were tested in our workplace.   
For a comparison, cff DNA (male fetus)  was measured and quantified both by Real-time 
PCR in SRY locus and by quantitative fluorescent (QF) PCR and capillary electrophoresis 
separation  in AMELY locus in  38 samples from the 1st and 38 samples from the 2nd 
trimester. While the concentrations of total DNA measured spectrophotometrically were 
similar there were substantial differences in yield of cffDNA between tested DNA extraction 
methods (graph 1,2).  
Isolation based on the separation of magnetic particles had significantly lower recovery 
compared with the amount of cffDNA extracted by binding on the silicate membrane. 
According to our current findings "silica membrane" based method seemed to be clearly 
more suitable for isolation of cffDNA from the plasma of pregnant women.  
DNA extraction using magnetic particles should present a simple way how relatively easily 
and without contamination obtained the cffDNA.  
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Graph 2. Comparison of silica gel and magnetic particles isolation effectiveness by capillary 
electrophoresis quantification  
However, for the isolation of short fragments of cffDNA this method did not work, although 
the manufacturer declares, that it should be able to detect the DNA molecules of the size 
from 50 bp to 1,5 kb. Low efficiency of cffDNA capture can be caused by strong bond of free 
fragmented fetal DNA on magnetic particles, or by contraries, by weaker bond of these 
fragments on magnetic particles and their wash out during isolation.  
To explain this, we re-isolated unbound DNA from supernatant. The subsequent 
quantification by capillary electrophoresis has demonstrated again only the maternal 
sequences, which suggests a stronger link of fragmented fetal DNA on magnetic particles.   
If cffDNA was succsessfully  detected by both methods, the amount of DNA has correlated 
to each other (Graph 3). 
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Graph 3. Correlation of the results of free fetal DNA quantification by capillary 
electrophoresis and real-time PCR (RT-PCR). The Y axis shows the Relative fluorescence 
units (RFU) obtained from capillary electrophoresis, X axis shows the fluorescence scanned 
in Real time system. 
5.2 Cff mRNA isolation procedures 
To maintain integrity of obtained free fetal RNA, it is important to use isolation techniques 
which have minimum isolation steps, are quick and contain RNA stabilizers.  
Currently there are no commercially produced kits standardized for isolation of free fetal 
RNA directly from maternal plasma, but there are available kits specialized for isolation of 
viral RNA, which could be, with little modification, applied to the isolation of free fetal 
RNA.  
Double centrifugation in cooled centrifuge or ultra centrifugation is necessary for separation 
of cellular component of blood prior to the isolation of free fetal RNA. 
The combination of viral RNA Kit and vacuum pumps seems to be an optimal system for 
obtaining free fetal RNA in the highest possible quantity and the quality, with minimal risk 
of contamination during isolation, unlike centrifugation steps. Microfilters can be used to 
increase the concentration of free fetal RNA. 
6. The use of cff DNA for diagnostic purposes 
The resolution of the fetal genotype and precise quantification of cffDNA are crucial for 
diagnostic purposes.  
6.1 Noninvasive fetal sex determination by cffDNA 
So far, the most common and relatively simple for the analysis of fetal DNA was the use of Y 
specific sequences from male fetuses.  
These sequences can be quantified by methods of Real-time PCR and QF PCR. 
The methodology for fetal sex detection in maternal plasma is already relatively well 
developed and reliable (Lo et al., 1998; Honda et al., 2002; Wei et al., 2001; Zhong et al., 2000, 
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Our quick and simplify fetal sex detection is based on refined QF PCR. We tested 475 DNA 
samples isolated from maternal plasma in different weeks of pregnancy ranging from 4th 
w.g. to 37th w.g. Y chromosomal sequences in AMELY were tested and quantify by 
comparison to AMELX using capillary electrophoresis.  
The method is able to distinguish even less than 1 % of Y chromosomal sequences of 
artificial mixtures. Fetal sex was detected with 4.05 % of false positivity and 7.15 % of false 
negativity (Vodicka et al., 2008).   
The methodology has very high detection sensitivity, which is comparable with a sensitivity 
of real-time PCR methodology (Sekizawa et al., 2001; Honda et al., 2002).  
Possible contamination of the samples during collection and in the course of the isolation 
procedure is the main cause of false-positive detection of the male sex. 
Minimization of any contamination is fundamental in sensitive DNA analyses in which it is 
necessary to capture the genotype in quantities of about 5%.   
Mistakes in determination of male fetus (false-negative results) come mostly from early 
stages of pregnancy, when the concentration of cffDNA is still very low, so rather than non-
compliance could be assessed these results as missing fetal DNA. 
Capillary electrophoresis has proven to be uniquely able to capture even 1 % genotype 
artificial admixture.  
The result of examinations of our group of pregnant women can be considered very 
satisfactory. The methodology is prepared for practical use, however, further improvement 
of isolation robustness and following laboratory procedures may increase specificity, 
sensitivity, and the yield of fetal DNA. 
6.2 Noninvasive RHD genotyping by cffDNA 
RHD genotype of the fetus can be identified from maternal plasma already at the beginning 
of pregnancy using molecular analysis of cffDNA.  
Clinical significance of determination of fetal RhD status is dual:  
1. Noninvasive fetal RHD determination from peripheral blood of Rh- alloimmunized 
pregnant women at the beginning of pregnancy allows to determine the fetuses which 
are really threatened by development of hemolytic disease of fetus and newborn. 
2. If anti-D antibodies are not present at the beginning of pregnancy, RhD negative 
woman should be provided with anti-D immunoglobulin during pregnancy in 
sufficient dosage for each potentially sensitizing events including completion of 
antepartal prophylaxis at 28th week of gestation. Potentially sensitizing event means 
any situation in which may occur intersection of RhD positive fetal erythrocytes to the 
mother's blood, and subsequent development of the RhD alloimmunization (chorionic 
villus sampling, amniocentesis, cordocentesis, another intervention of the prenatal 
diagnosis and fetal therapy, obstetric hemorrhage in the 2nd and 3rd trimester, 
intrauterine death of fetus). Prevention of RhD alloimmunization should be provided to 
RhD negative pregnant woman by delivery of anti-D immunoglobulin in sufficient 
dosage in all above-mentioned cases. The administration of anti-d immunoglobulin is 
necessary if the fetus is RhD-positive, on the contrary, if the fetus is RhD negative, the 
pregnant woman is not threatened by the development of the RhD alloimmunization 
and administration of anti-D immunoglobulin is not necessary.  
RHD genotyping of cffDNA is most often done using Taq man Real time PCR with probes 
from exone 7, 10, 4 or 5. System of negative and positive PCR control in addition to internal 
 





























Corelation of cff DNA quantity between capillary electrophoresis















Graph 3. Correlation of the results of free fetal DNA quantification by capillary 
electrophoresis and real-time PCR (RT-PCR). The Y axis shows the Relative fluorescence 
units (RFU) obtained from capillary electrophoresis, X axis shows the fluorescence scanned 
in Real time system. 
5.2 Cff mRNA isolation procedures 
To maintain integrity of obtained free fetal RNA, it is important to use isolation techniques 
which have minimum isolation steps, are quick and contain RNA stabilizers.  
Currently there are no commercially produced kits standardized for isolation of free fetal 
RNA directly from maternal plasma, but there are available kits specialized for isolation of 
viral RNA, which could be, with little modification, applied to the isolation of free fetal 
RNA.  
Double centrifugation in cooled centrifuge or ultra centrifugation is necessary for separation 
of cellular component of blood prior to the isolation of free fetal RNA. 
The combination of viral RNA Kit and vacuum pumps seems to be an optimal system for 
obtaining free fetal RNA in the highest possible quantity and the quality, with minimal risk 
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So far, the most common and relatively simple for the analysis of fetal DNA was the use of Y 
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Our quick and simplify fetal sex detection is based on refined QF PCR. We tested 475 DNA 
samples isolated from maternal plasma in different weeks of pregnancy ranging from 4th 
w.g. to 37th w.g. Y chromosomal sequences in AMELY were tested and quantify by 
comparison to AMELX using capillary electrophoresis.  
The method is able to distinguish even less than 1 % of Y chromosomal sequences of 
artificial mixtures. Fetal sex was detected with 4.05 % of false positivity and 7.15 % of false 
negativity (Vodicka et al., 2008).   
The methodology has very high detection sensitivity, which is comparable with a sensitivity 
of real-time PCR methodology (Sekizawa et al., 2001; Honda et al., 2002).  
Possible contamination of the samples during collection and in the course of the isolation 
procedure is the main cause of false-positive detection of the male sex. 
Minimization of any contamination is fundamental in sensitive DNA analyses in which it is 
necessary to capture the genotype in quantities of about 5%.   
Mistakes in determination of male fetus (false-negative results) come mostly from early 
stages of pregnancy, when the concentration of cffDNA is still very low, so rather than non-
compliance could be assessed these results as missing fetal DNA. 
Capillary electrophoresis has proven to be uniquely able to capture even 1 % genotype 
artificial admixture.  
The result of examinations of our group of pregnant women can be considered very 
satisfactory. The methodology is prepared for practical use, however, further improvement 
of isolation robustness and following laboratory procedures may increase specificity, 
sensitivity, and the yield of fetal DNA. 
6.2 Noninvasive RHD genotyping by cffDNA 
RHD genotype of the fetus can be identified from maternal plasma already at the beginning 
of pregnancy using molecular analysis of cffDNA.  
Clinical significance of determination of fetal RhD status is dual:  
1. Noninvasive fetal RHD determination from peripheral blood of Rh- alloimmunized 
pregnant women at the beginning of pregnancy allows to determine the fetuses which 
are really threatened by development of hemolytic disease of fetus and newborn. 
2. If anti-D antibodies are not present at the beginning of pregnancy, RhD negative 
woman should be provided with anti-D immunoglobulin during pregnancy in 
sufficient dosage for each potentially sensitizing events including completion of 
antepartal prophylaxis at 28th week of gestation. Potentially sensitizing event means 
any situation in which may occur intersection of RhD positive fetal erythrocytes to the 
mother's blood, and subsequent development of the RhD alloimmunization (chorionic 
villus sampling, amniocentesis, cordocentesis, another intervention of the prenatal 
diagnosis and fetal therapy, obstetric hemorrhage in the 2nd and 3rd trimester, 
intrauterine death of fetus). Prevention of RhD alloimmunization should be provided to 
RhD negative pregnant woman by delivery of anti-D immunoglobulin in sufficient 
dosage in all above-mentioned cases. The administration of anti-d immunoglobulin is 
necessary if the fetus is RhD-positive, on the contrary, if the fetus is RhD negative, the 
pregnant woman is not threatened by the development of the RhD alloimmunization 
and administration of anti-D immunoglobulin is not necessary.  
RHD genotyping of cffDNA is most often done using Taq man Real time PCR with probes 
from exone 7, 10, 4 or 5. System of negative and positive PCR control in addition to internal 
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control of PCR amplification is necessary for the reliability of detection considering great 
sensitivity of the method. At the same time, you must have created calibration quantitative 
profile for exact specification of detection limit of RhD positivity.  
6.3 Noninvasive cffDNA analysis of monogenic inherited diseases 
CffDNA can be also used for examination of monogenic inherited diseases.   
Many genetic abnormalities, for example autosomal dominant myotonic dystrophy 
(Amicucci et al., 2000), Huntington's disease (Gonzalez-Gonzalez et al., 2003) or gene 
mutations such as achondroplasia (Saito et al., 2000) has already been examined from 
cffDNA. Furthermore, it is possible to detect some autosomal recessive diseases, such as 
cystic fibrosis (Gonzalez-Gonzalez et al., 2002) or β-talasemia (Chiu et al., 2002). 
7. Cff nucleic acid quantitation for noninvasive Down syndrome diagnostics 
Targeted molecular analysis of fetal aneuploidy with maternal plasma utilization is more 
complicated and applicable differentiation of maternal and fetal genotypes within the 
desired chromosome brings with it many challenges.  
Considering differences between the quantity of total cffDNA and cfDNA, in the fetuses 
with Down syndrome (DS) pathology can be observed a greater quantity of cffDNA 
compared to the physiological pregnancies (Vodicka et al, 2008a).  
The total amount of cffDNA cannot be considered as unambiguous marker due to large 
variation in the amount of cffDNA in physiological pregnancies and, rather, it is possible to 
include it to the system of ultrasound and biochemical markers.  
Direct examination of the loci responsible for the DS brings a substantial improvement of 
the diagnosis. Currently, there are several approaches or their combinations respectively, 
aimed to unambiguous resolution of pathological fetus with the DS. 
7.1 Noninvasive cffDNA diagnostics of Down syndrome using genotype differences 
between paternal and maternal genotypes 
DS analyses and quantifications of cffDNA are based on the resolution of paternal from 
maternal genotypes. The fetus must be always heterozygous for the monitored loci. 
Previous genotyping of the parents is therefore important for the selection of appropriate 
markers. 
Targeted resolution assumes a sufficient number of reliable analyzable markers of paternal 
(fetal) origin on chromosome 21 and at the same time a sufficient number of reliable markers 
outside the chromosome 21.   
The genotype of the fetus can be distinguished by means of DNA sequence variation using 
male specific sequences for male fetus, short tandem repeats (STR) or single nucleotide 
polymorphisms (SNP).   
For the estimation of the relative amounts of cffDNA originating in chromosome 21 it is 
necessary to choose a strategy that combines the creation of sensitive and accurate 
calibration standards for each marker and reciprocal measuring of cffDNA amount from the 
locus on chromosome 21 and cffDNA quantity from autosomal locus or locus on 
chromosome Y respectively.    
If the measurement is accurate enough, then the amount of cffDNA of chromosome 21 
related to the quantity of the cffDNA locus outside the chromosome 21 should differ in the 
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case of trisomy 21 from disomy 21. It is clearly distinguishable in the case of trisomy of 
paternal origin, where the extra chromosome comes from the father.   
The methodology of quantitative calculations for STR loci on chromosome 21, where was 
mainly taken into account the relative length of alleles and preferential amplification of the 
shorter alleles has been developed at our department.  
In pregnancies with trisomy 21, it was found statistically more cffDNA for systems in which 
the length of PCR products ranged mostly between 200 bp - 400 bp (Vodicka et al., 2008).  
In total six genes that are specifically expressed in trofoblastic tissues (placenta) has been 
selected for quantification and genotyping on the DNA level in loci responsible for Down 
syndrome and for reference SNP genotyping (Böhmova et al. 2010). 
These genes are DSCR4, KRTAP26-1, PLAC4, PLAC1, PAPPA and PSG11 of them DSCR4, 
KRTAP26-1 and PLAC4 are localized on chromosome 21 in the area responsible for Down 
syndrome. In total 12 SNPs were selected for genotyping in these genes.  
Balanced allelic frequency for particular SNP alleles reported in the database of the NCBI 
website was the criterion for the SNP selection. For individual SNP variants have been 
defined TaqMan probes. Individual genotypes were identified initially by sequencing of the 
SNP regions for 30 randomly selected maternal DNA samples. Subsequently TaqMan Real 
Time PCR optimization and calibration was carried out.  
Quantifiler kit (Applied Biosystems) has been used for verification of the quality of the 
dilutive series of calibration standards. The quantification itself was carried out on 240 DNA 
samples isolated from plasma of pregnant women in the 1st and 2nd   trimester.  
Heterozygozity in particular SNP ranged from 14 % to 55 % and the probability of 
appropriate genotypes capture for each SNP was stated in the range from 12 % to 28 %. 
Sensitivity of minor genotype capture depends on fluorescence background of non-
specifically hybridized probe.  
Taqman SNP probes were able to capture as low as 1 percent of artificial genotypic mixture 
and by the most sensitive systems we have detected 0,22 % artificial genotypic mixture.  
R2 values were in the range of 0,995 to 0,999 and the inclination (angular coefficient) 
assessing the effectiveness of the PCR (tendency around the values of -3.3 shows the 
optimum, 100% PCR amplification) from -3.2 to -3.6. All standard calibration curves were 
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Picture 1. Quantity assessment of cffDNA using calibration curve in SNP1 of PAPPA 
Cff DNA was analyzed only for the detectable genotypes. The detection ability ranged from 
11.8 % to 100 %. The amount of cffDNA was very variable (from about 0.02 ng to 13 ng 
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control of PCR amplification is necessary for the reliability of detection considering great 
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profile for exact specification of detection limit of RhD positivity.  
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The total amount of cffDNA cannot be considered as unambiguous marker due to large 
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aimed to unambiguous resolution of pathological fetus with the DS. 
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DS analyses and quantifications of cffDNA are based on the resolution of paternal from 
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Previous genotyping of the parents is therefore important for the selection of appropriate 
markers. 
Targeted resolution assumes a sufficient number of reliable analyzable markers of paternal 
(fetal) origin on chromosome 21 and at the same time a sufficient number of reliable markers 
outside the chromosome 21.   
The genotype of the fetus can be distinguished by means of DNA sequence variation using 
male specific sequences for male fetus, short tandem repeats (STR) or single nucleotide 
polymorphisms (SNP).   
For the estimation of the relative amounts of cffDNA originating in chromosome 21 it is 
necessary to choose a strategy that combines the creation of sensitive and accurate 
calibration standards for each marker and reciprocal measuring of cffDNA amount from the 
locus on chromosome 21 and cffDNA quantity from autosomal locus or locus on 
chromosome Y respectively.    
If the measurement is accurate enough, then the amount of cffDNA of chromosome 21 
related to the quantity of the cffDNA locus outside the chromosome 21 should differ in the 
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case of trisomy 21 from disomy 21. It is clearly distinguishable in the case of trisomy of 
paternal origin, where the extra chromosome comes from the father.   
The methodology of quantitative calculations for STR loci on chromosome 21, where was 
mainly taken into account the relative length of alleles and preferential amplification of the 
shorter alleles has been developed at our department.  
In pregnancies with trisomy 21, it was found statistically more cffDNA for systems in which 
the length of PCR products ranged mostly between 200 bp - 400 bp (Vodicka et al., 2008).  
In total six genes that are specifically expressed in trofoblastic tissues (placenta) has been 
selected for quantification and genotyping on the DNA level in loci responsible for Down 
syndrome and for reference SNP genotyping (Böhmova et al. 2010). 
These genes are DSCR4, KRTAP26-1, PLAC4, PLAC1, PAPPA and PSG11 of them DSCR4, 
KRTAP26-1 and PLAC4 are localized on chromosome 21 in the area responsible for Down 
syndrome. In total 12 SNPs were selected for genotyping in these genes.  
Balanced allelic frequency for particular SNP alleles reported in the database of the NCBI 
website was the criterion for the SNP selection. For individual SNP variants have been 
defined TaqMan probes. Individual genotypes were identified initially by sequencing of the 
SNP regions for 30 randomly selected maternal DNA samples. Subsequently TaqMan Real 
Time PCR optimization and calibration was carried out.  
Quantifiler kit (Applied Biosystems) has been used for verification of the quality of the 
dilutive series of calibration standards. The quantification itself was carried out on 240 DNA 
samples isolated from plasma of pregnant women in the 1st and 2nd   trimester.  
Heterozygozity in particular SNP ranged from 14 % to 55 % and the probability of 
appropriate genotypes capture for each SNP was stated in the range from 12 % to 28 %. 
Sensitivity of minor genotype capture depends on fluorescence background of non-
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Taqman SNP probes were able to capture as low as 1 percent of artificial genotypic mixture 
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cffDNA in 200 ul of the plasma).  All 12 selected SNP are able to detect cffDNA with the 
desired probability. Parameters of the calibration curve are suitable for the precise 
quantification of cffDNA (Picture 1) (Böhmova et al., 2010).    
7.2 Noninvasive cff mRNA analysis for Down syndrome diagnostics 
Placental tissue is ontogenetically much unrelated to blood cells and may express other 
genes whose expression is missing in maternal blood cells. The first work, which confirmed 
the RNA of fetal origin, was published in 2000 (Poon et al., 2000). 
Using microarray technology in the maternal plasma have been detected RNA markers 
whose expression is specific to the placenta (Tsui et al., 2004). The same approach was used 
in the study, which described the cff mRNA transcribed from gene PLAC4 (placenta-specific 
4), which is located on chromosome 21.  
On the basis of the assumption of uniform batch theory (3 alleles of PLAC4 gene, without 
allele-specific preferential transcription, express 1/3 more mRNA than 2 alleles) quantitative 
detection of disomic and trizomic dose was developed. With the use of the SNP in the 
heterozygous state in the gene coding for the PLAC4  there were detected disomic fetus 
ratio 1: 1 and trizomic ratio  2: 1 with 90% of the diagnostic sensitivity and 96.5% specificity 
of trisomy 21 capture by mass spectrometry technique (Lo et al., 2007a). 
The disadvantage of this method is relatively labour-intensive preparation of high-quality 
and reproducible matrix for mass spectrophotometry RNA analysis. Another limiting factor 
is the real amount of cff mRNA molecules in the isolate from plasma, which could affect the 
evenness of distribution of mRNA molecules transcribed from individual alleles. Only 
sufficient number of SNPs can assure desired heterozygozity. Therefore it is necessary to 
test and introduce new mRNA SNP markers (Go et al., 2007; Yang et al., 2008). 
Another approach of measuring allelic SNP ratios in cff mRNA has been tested using digital 
PCR. It is based on the assumption that, in the PCR reaction is either 1 or no molecule of 
cDNA. PCR is carried out in parallel in many hundreds to thousands of mixtures. According 
to the number of positive responses, you can estimate an initial number of cff RNA 
molecules with a particular SNP and by measuring of the ratios between the SNP from RNA 
derived from chromosome 21 and another autosome, you can detect chromosome 21 
trisomy with high sensitivity (Lo et al., 2007b). 
7.3 Noninvasive Down syndrome diagnostics by cffDNA epigenetic detection and 
quantification 
Methodology relies on different methylation of maternal and fetal or placental sequence. 
Sequences, which are subject to methylation are on principle situated in CpG islands of 
promoter areas. These islets may regulate the transcription of the gene by variable degree of 
methylation. In different tissues there are promoters of genes whose expression is tissue 
specific, and which are methylated differently, and specifically for the type of tissue.  
Different fetal (placental) and maternal methylation of regions on chromosome 21 were 
tracked for the purposes of Down Syndrome non-invasive prenatal diagnostics.  Different 
methylation showed 22 out of 114 assessed genomic regions on this chromosome (Chim et 
al., 2008).  
This relatively large number of methylation specific fetal DNA sequences offers a promising 
source of prenatal biomarkers independent on maternal and fetal genotype.  
Large loss of genetic material (90 %) in the course of DNA modification, based on cytosine 
deamination using bisulphite, is a disadvantage of this epigenetic way of examination. 
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The modification procedure, somewhat laborious, in addition increases the risk of 
contamination.  Additional distortion of results could be due to heterogeneous methylation 
of CpG islands.  
Some laboratories are trying to test methods that would eliminate the a forementioned 
shortcomings (Chan et al., 2006; Tong et al., 2007). 
Digital methyl sensitive PCR, methyl sensitive HRM and, probably, massive parallel DNA 
sequencing are the most promising prospective technologies for precise quantification of 
epialleles. 
7.4 Combination of genetic/epigenetic/cff mRNA methods  
To increase the diagnostic sensitivity it is possible to combine methodological approaches, 
based on cffDNA, cff mRNA and hyper/hypomethylated placental DNA.  
Tong et al (2010) published the epigenetic quantification of hypermethylated placental DNA 
from chromosome 21 (locus HLCS) using digital PCR and compared it to the male specific 
genetic marker of the Y chromosome.    
The relative quantities of the epigenetic marker were shown to be increased for fetus with 
trisomy 21 compared to disomic fetus. This approach is very sensitive even for the DS 
diagnosis in the first trimester.  
It will be appropriate to use different paternal genetic polymorphic markers at the level of 
the SNP or STR instead of male specific genetic marker.  
To increase the reliability of resolution of trisomy 21 from disomy 21 is also possible to 
perform relative quantification of cffDNA/cff mRNA using exonal SNP of chromosome 21 
and exonal SNP from the reference autosome. 
8. Tasks for future 
For the successful development of high accurate detection of DS and other frequent 
trisomies it is necessary to attend to the following tasks:  
- Choice of isolation procedures for plasmatic DNA fragments length of which 
corresponds to the fetal molecules. 
- Protection of plasmatic molecules from the disintegration of maternal lymphocytes.  
- Prevention of free plasmatic fetal RNA degradation. 
- Loss minimization during modification of hyper/hypomethylated DNA. 
- Provision of sufficient number of reliable genetic and epigenetic fetal markers.  
- More sensitive optimization of calibration and quantification for HRM, Real time PCR 
and QF PCR. 
- Introduction of automation of digital PCR and digital HRM for quantification of 
CffDNA/cff mRNA/modified cffDNA. 
9. Conclusion 
Almost 15 years have passed since the first work, which pointed to the presence of the cff 
DNA in maternal plasma of pregnant women (Lo et al., 1997). 
Since then many authors gradually contributed more and more theoretical and 
methodological knowledge. 
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cffDNA in 200 ul of the plasma).  All 12 selected SNP are able to detect cffDNA with the 
desired probability. Parameters of the calibration curve are suitable for the precise 
quantification of cffDNA (Picture 1) (Böhmova et al., 2010).    
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the RNA of fetal origin, was published in 2000 (Poon et al., 2000). 
Using microarray technology in the maternal plasma have been detected RNA markers 
whose expression is specific to the placenta (Tsui et al., 2004). The same approach was used 
in the study, which described the cff mRNA transcribed from gene PLAC4 (placenta-specific 
4), which is located on chromosome 21.  
On the basis of the assumption of uniform batch theory (3 alleles of PLAC4 gene, without 
allele-specific preferential transcription, express 1/3 more mRNA than 2 alleles) quantitative 
detection of disomic and trizomic dose was developed. With the use of the SNP in the 
heterozygous state in the gene coding for the PLAC4  there were detected disomic fetus 
ratio 1: 1 and trizomic ratio  2: 1 with 90% of the diagnostic sensitivity and 96.5% specificity 
of trisomy 21 capture by mass spectrometry technique (Lo et al., 2007a). 
The disadvantage of this method is relatively labour-intensive preparation of high-quality 
and reproducible matrix for mass spectrophotometry RNA analysis. Another limiting factor 
is the real amount of cff mRNA molecules in the isolate from plasma, which could affect the 
evenness of distribution of mRNA molecules transcribed from individual alleles. Only 
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cDNA. PCR is carried out in parallel in many hundreds to thousands of mixtures. According 
to the number of positive responses, you can estimate an initial number of cff RNA 
molecules with a particular SNP and by measuring of the ratios between the SNP from RNA 
derived from chromosome 21 and another autosome, you can detect chromosome 21 
trisomy with high sensitivity (Lo et al., 2007b). 
7.3 Noninvasive Down syndrome diagnostics by cffDNA epigenetic detection and 
quantification 
Methodology relies on different methylation of maternal and fetal or placental sequence. 
Sequences, which are subject to methylation are on principle situated in CpG islands of 
promoter areas. These islets may regulate the transcription of the gene by variable degree of 
methylation. In different tissues there are promoters of genes whose expression is tissue 
specific, and which are methylated differently, and specifically for the type of tissue.  
Different fetal (placental) and maternal methylation of regions on chromosome 21 were 
tracked for the purposes of Down Syndrome non-invasive prenatal diagnostics.  Different 
methylation showed 22 out of 114 assessed genomic regions on this chromosome (Chim et 
al., 2008).  
This relatively large number of methylation specific fetal DNA sequences offers a promising 
source of prenatal biomarkers independent on maternal and fetal genotype.  
Large loss of genetic material (90 %) in the course of DNA modification, based on cytosine 
deamination using bisulphite, is a disadvantage of this epigenetic way of examination. 
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The modification procedure, somewhat laborious, in addition increases the risk of 
contamination.  Additional distortion of results could be due to heterogeneous methylation 
of CpG islands.  
Some laboratories are trying to test methods that would eliminate the a forementioned 
shortcomings (Chan et al., 2006; Tong et al., 2007). 
Digital methyl sensitive PCR, methyl sensitive HRM and, probably, massive parallel DNA 
sequencing are the most promising prospective technologies for precise quantification of 
epialleles. 
7.4 Combination of genetic/epigenetic/cff mRNA methods  
To increase the diagnostic sensitivity it is possible to combine methodological approaches, 
based on cffDNA, cff mRNA and hyper/hypomethylated placental DNA.  
Tong et al (2010) published the epigenetic quantification of hypermethylated placental DNA 
from chromosome 21 (locus HLCS) using digital PCR and compared it to the male specific 
genetic marker of the Y chromosome.    
The relative quantities of the epigenetic marker were shown to be increased for fetus with 
trisomy 21 compared to disomic fetus. This approach is very sensitive even for the DS 
diagnosis in the first trimester.  
It will be appropriate to use different paternal genetic polymorphic markers at the level of 
the SNP or STR instead of male specific genetic marker.  
To increase the reliability of resolution of trisomy 21 from disomy 21 is also possible to 
perform relative quantification of cffDNA/cff mRNA using exonal SNP of chromosome 21 
and exonal SNP from the reference autosome. 
8. Tasks for future 
For the successful development of high accurate detection of DS and other frequent 
trisomies it is necessary to attend to the following tasks:  
- Choice of isolation procedures for plasmatic DNA fragments length of which 
corresponds to the fetal molecules. 
- Protection of plasmatic molecules from the disintegration of maternal lymphocytes.  
- Prevention of free plasmatic fetal RNA degradation. 
- Loss minimization during modification of hyper/hypomethylated DNA. 
- Provision of sufficient number of reliable genetic and epigenetic fetal markers.  
- More sensitive optimization of calibration and quantification for HRM, Real time PCR 
and QF PCR. 
- Introduction of automation of digital PCR and digital HRM for quantification of 
CffDNA/cff mRNA/modified cffDNA. 
9. Conclusion 
Almost 15 years have passed since the first work, which pointed to the presence of the cff 
DNA in maternal plasma of pregnant women (Lo et al., 1997). 
Since then many authors gradually contributed more and more theoretical and 
methodological knowledge. 
 
Genetics and Etiology of Down Syndrome 
 
324 
Nowadays, also thanks to introduction of new and more robust technologies we can boldly 
predict that direct clinical outcome of this multi-year effort of noninvasive prenatal 
diagnostics  of Down Syndrome will be feasible in very near future. 
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